[
    {
        "index": "DDI-DrugBank.d0.s1.p0",
        "sentence": "Pharmacokinetic studies indicate that administration of @DRUG$ or @DRUG$ does not affect the pharmacokinetics of acamprosate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d0.s1.p1",
        "sentence": "Pharmacokinetic studies indicate that administration of @DRUG$ or diazepam does not affect the pharmacokinetics of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d0.s1.p2",
        "sentence": "Pharmacokinetic studies indicate that administration of disulfiram or @DRUG$ does not affect the pharmacokinetics of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d100.s0.p0",
        "sentence": "Increased nephrotoxicity has been reported following concomitant administration of @DRUG$ and @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d103.s0.p0",
        "sentence": "@DRUG$: Aerosol @DRUG$ of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using formoterol.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d103.s0.p1",
        "sentence": "@DRUG$: Aerosol bronchodilators of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d103.s0.p2",
        "sentence": "Short-Acting beta2-agonists: Aerosol @DRUG$ of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d104.s1.p0",
        "sentence": "Other @DRUG$ should be used with caution in patients taking @DRUG$, since the effects may be additive.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d106.s0.p0",
        "sentence": "A 30 to 45% increase in AUC and Cmax of @DRUG$ was observed with concomitant administration of @DRUG$ twice daily.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d106.s4.p0",
        "sentence": "Coadministration of @DRUG$ with @DRUG$ or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d106.s4.p1",
        "sentence": "Coadministration of @DRUG$ with phenytoin or any known CYP3A4 inducer should be avoided and alternative @DRUG$ therapy should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d106.s4.p2",
        "sentence": "Coadministration of SULAR with @DRUG$ or any known CYP3A4 inducer should be avoided and alternative @DRUG$ therapy should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d106.s5.p0",
        "sentence": "Pharmacokinetic interactions between @DRUG$ and @DRUG$ (atenolol, propranolol) were variable and not significant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d106.s5.p1",
        "sentence": "Pharmacokinetic interactions between @DRUG$ and beta-blockers (@DRUG$, propranolol) were variable and not significant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d106.s5.p2",
        "sentence": "Pharmacokinetic interactions between @DRUG$ and beta-blockers (atenolol, @DRUG$) were variable and not significant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d106.s5.p3",
        "sentence": "Pharmacokinetic interactions between nisoldipine and @DRUG$ (@DRUG$, propranolol) were variable and not significant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d106.s5.p4",
        "sentence": "Pharmacokinetic interactions between nisoldipine and @DRUG$ (atenolol, @DRUG$) were variable and not significant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d106.s5.p5",
        "sentence": "Pharmacokinetic interactions between nisoldipine and beta-blockers (@DRUG$, @DRUG$) were variable and not significant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d106.s6.p0",
        "sentence": "@DRUG$ attenuated the heart rate increase following administration of immediate release @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d106.s8.p0",
        "sentence": "@DRUG$ at 648 mg bid decreased the bioavailability (AUC) of @DRUG$ by 26%, but not the peak concentration.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d107.s12.p0",
        "sentence": "Agents Increasing Serum Potassium: @DRUG$ and @DRUG$ IV attenuate potassium loss caused by thiazide-type diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d107.s12.p1",
        "sentence": "Agents Increasing Serum Potassium: @DRUG$ and enalapril IV attenuate potassium loss caused by @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d107.s12.p2",
        "sentence": "Agents Increasing Serum Potassium: Enalapril and @DRUG$ IV attenuate potassium loss caused by @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d107.s17.p0",
        "sentence": "It is recommended that serum @DRUG$ levels be monitored frequently if @DRUG$ is administered concomitantly with lithium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d107.s17.p1",
        "sentence": "It is recommended that serum @DRUG$ levels be monitored frequently if enalapril is administered concomitantly with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d107.s17.p2",
        "sentence": "It is recommended that serum lithium levels be monitored frequently if @DRUG$ is administered concomitantly with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d108.s1.p0",
        "sentence": "In a single study, rats given high intraperitoneal doses of an @DRUG$ plus @DRUG$ experienced severe toxicity, including convulsions and death.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d108.s2.p0",
        "sentence": "Concomitant use of @DRUG$ and other @DRUG$ is generally not recommended because of possible potentiating effects.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d109.s0.p0",
        "sentence": "@DRUG$/@DRUG$, Macrolides, Including Erythromycin",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d109.s0.p1",
        "sentence": "@DRUG$/Itraconazole, @DRUG$, Including Erythromycin",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d109.s0.p2",
        "sentence": "@DRUG$/Itraconazole, Macrolides, Including @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d109.s0.p3",
        "sentence": "Ketoconazole/@DRUG$, @DRUG$, Including Erythromycin",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d109.s0.p4",
        "sentence": "Ketoconazole/@DRUG$, Macrolides, Including @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d109.s0.p5",
        "sentence": "Ketoconazole/Itraconazole, @DRUG$, Including @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d11.s0.p0",
        "sentence": "Drug-Drug Interactions @DRUG$ - @DRUG$ should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d11.s0.p1",
        "sentence": "Drug-Drug Interactions @DRUG$ - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) @DRUG$ (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d11.s0.p2",
        "sentence": "Drug-Drug Interactions @DRUG$ - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other @DRUG$) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d11.s0.p3",
        "sentence": "Drug-Drug Interactions @DRUG$ - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of @DRUG$ on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d11.s0.p4",
        "sentence": "Drug-Drug Interactions Albuterol - @DRUG$ should be administered with caution to patients being treated with systemically-administered (oral or intravenous) @DRUG$ (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d11.s0.p5",
        "sentence": "Drug-Drug Interactions Albuterol - @DRUG$ should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other @DRUG$) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d11.s0.p6",
        "sentence": "Drug-Drug Interactions Albuterol - @DRUG$ should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of @DRUG$ on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d11.s0.p7",
        "sentence": "Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) @DRUG$ (or other @DRUG$) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d11.s0.p8",
        "sentence": "Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) @DRUG$ (or other beta2 agonists) because the action of @DRUG$ on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d11.s0.p9",
        "sentence": "Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other @DRUG$) because the action of @DRUG$ on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d110.s5.p0",
        "sentence": "Therefore, @DRUG$ should not be used in any condition in which a @DRUG$ is being employed.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d113.s3.p0",
        "sentence": "The urinary excretion of @DRUG$ is unaffected by @DRUG$, indicating no change in meclofenamate sodium absorption.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d113.s3.p1",
        "sentence": "The urinary excretion of @DRUG$ is unaffected by aspirin, indicating no change in @DRUG$ absorption.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d113.s3.p2",
        "sentence": "The urinary excretion of meclofenamate sodium is unaffected by @DRUG$, indicating no change in @DRUG$ absorption.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d113.s6.p0",
        "sentence": "@DRUG$: The concurrent administration of @DRUG$ does not affect the bioavailability of meclofenamate sodium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d113.s6.p1",
        "sentence": "@DRUG$: The concurrent administration of propoxyphene hydrochloride does not affect the bioavailability of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d113.s6.p2",
        "sentence": "Propoxyphene: The concurrent administration of @DRUG$ does not affect the bioavailability of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d113.s7.p0",
        "sentence": "@DRUG$: Concomitant administration of @DRUG$s does not interfere with absorption of meclofenamate sodium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d113.s7.p1",
        "sentence": "@DRUG$: Concomitant administration of aluminum and @DRUG$s does not interfere with absorption of meclofenamate sodium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d113.s7.p2",
        "sentence": "@DRUG$: Concomitant administration of aluminum and magnesium hydroxides does not interfere with absorption of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d113.s7.p3",
        "sentence": "Antacids: Concomitant administration of @DRUG-DRUG$s does not interfere with absorption of meclofenamate sodium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d113.s7.p4",
        "sentence": "Antacids: Concomitant administration of @DRUG$s does not interfere with absorption of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d113.s7.p5",
        "sentence": "Antacids: Concomitant administration of aluminum and @DRUG$s does not interfere with absorption of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d115.s16.p0",
        "sentence": "Systemic exposure to @DRUG$ is expected to be increased when coadministered with @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d115.s3.p0",
        "sentence": "Drugs that may decrease @DRUG$ plasma concentrations: Substances that are inducers of CYP3A4 activity may increase metabolism and decrease @DRUG$ plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d115.s8.p0",
        "sentence": "Drugs that may have their plasma concentration altered by @DRUG$ @DRUG$ increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d115.s8.p1",
        "sentence": "Drugs that may have their plasma concentration altered by @DRUG$ Gleevec increases the mean cmax and AUC of @DRUG$ (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d115.s8.p2",
        "sentence": "Drugs that may have their plasma concentration altered by @DRUG$ Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d115.s8.p3",
        "sentence": "Drugs that may have their plasma concentration altered by Gleevec @DRUG$ increases the mean cmax and AUC of @DRUG$ (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d115.s8.p4",
        "sentence": "Drugs that may have their plasma concentration altered by Gleevec @DRUG$ increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d115.s8.p5",
        "sentence": "Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of @DRUG$ (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d119.s2.p0",
        "sentence": "@DRUG$    Prolonged action of @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d12.s8.p0",
        "sentence": "While it is not known whether this interaction occurs with @DRUG$ other than @DRUG$, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d12.s8.p1",
        "sentence": "While it is not known whether this interaction occurs with @DRUG$ other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of @DRUG$ alone, including clofibrate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d12.s8.p2",
        "sentence": "While it is not known whether this interaction occurs with @DRUG$ other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d12.s8.p3",
        "sentence": "While it is not known whether this interaction occurs with fibrates other than @DRUG$, myopathy and rhabdomyolysis have occasionally been associated with the use of @DRUG$ alone, including clofibrate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d12.s8.p4",
        "sentence": "While it is not known whether this interaction occurs with fibrates other than @DRUG$, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d12.s8.p5",
        "sentence": "While it is not known whether this interaction occurs with fibrates other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of @DRUG$ alone, including @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d122.s1.p0",
        "sentence": "Renal function should be carefully monitored, especially if higher dosages of the @DRUG$ are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d123.s0.p0",
        "sentence": "Some @DRUG$, including @DRUG$, have also been shown to interfere with the metabolism of caffeine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d123.s0.p1",
        "sentence": "Some @DRUG$, including ciprofloxacin, have also been shown to interfere with the metabolism of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d123.s0.p2",
        "sentence": "Some quinolones, including @DRUG$, have also been shown to interfere with the metabolism of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d123.s2.p0",
        "sentence": "Some @DRUG$, including @DRUG$, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d123.s2.p1",
        "sentence": "Some @DRUG$, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving @DRUG$ concomitantly.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d123.s2.p2",
        "sentence": "Some quinolones, including @DRUG$, have been associated with transient elevations in serum creatinine in patients receiving @DRUG$ concomitantly.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d124.s12.p0",
        "sentence": "Drugs That Should Not Be Coadministered With @DRUG$/@DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d124.s22.p0",
        "sentence": "@DRUG$: @DRUG$, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d124.s22.p1",
        "sentence": "@DRUG$: lovastatin, @DRUG$ WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d124.s22.p2",
        "sentence": "HMG-CoA Reductase Inhibitors: @DRUG$, @DRUG$ WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d124.s28.p0",
        "sentence": "Since @DRUG$ is coadministered with @DRUG$, the ritonavir label should be reviewed for additional drugs that should not be coadministered.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d124.s28.p1",
        "sentence": "Since @DRUG$ is coadministered with ritonavir, the @DRUG$ label should be reviewed for additional drugs that should not be coadministered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d124.s28.p2",
        "sentence": "Since INVIRASE is coadministered with @DRUG$, the @DRUG$ label should be reviewed for additional drugs that should not be coadministered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d124.s3.p0",
        "sentence": "Because @DRUG$ is coadministered, prescribers should also refer to the prescribing information for @DRUG$ regarding drug interactions associated with this agent.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d128.s0.p0",
        "sentence": "May interact with wthionamide (@DRUG$) and @DRUG$ (Nydrazid).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d128.s0.p1",
        "sentence": "May interact with wthionamide (@DRUG$) and isoniazid (@DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d128.s0.p2",
        "sentence": "May interact with wthionamide (Trecator-SC) and @DRUG$ (@DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d129.s3.p0",
        "sentence": "In diabetic patients, the metabolic effects of @DRUG$ may decrease blood glucose and therefore, @DRUG$ requirements.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d131.s0.p0",
        "sentence": "The @DRUG$, including @DRUG$, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s0.p1",
        "sentence": "The @DRUG$, including alprazolam, produce additive CNS depressant effects when co-administered with other @DRUG$, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d131.s0.p2",
        "sentence": "The @DRUG$, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, @DRUG$, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d131.s0.p3",
        "sentence": "The @DRUG$, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, @DRUG$, ethanol, and other drugs which themselves produce CNS depression.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d131.s0.p4",
        "sentence": "The @DRUG$, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, @DRUG$, and other drugs which themselves produce CNS depression.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d131.s0.p5",
        "sentence": "The benzodiazepines, including @DRUG$, produce additive CNS depressant effects when co-administered with other @DRUG$, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d131.s0.p6",
        "sentence": "The benzodiazepines, including @DRUG$, produce additive CNS depressant effects when co-administered with other psychotropic medications, @DRUG$, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d131.s0.p7",
        "sentence": "The benzodiazepines, including @DRUG$, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, @DRUG$, ethanol, and other drugs which themselves produce CNS depression.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d131.s0.p8",
        "sentence": "The benzodiazepines, including @DRUG$, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, @DRUG$, and other drugs which themselves produce CNS depression.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d131.s0.p9",
        "sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other @DRUG$, @DRUG$, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s0.p10",
        "sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other @DRUG$, anticonvulsants, @DRUG$, ethanol, and other drugs which themselves produce CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s0.p11",
        "sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other @DRUG$, anticonvulsants, antihistaminics, @DRUG$, and other drugs which themselves produce CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s0.p12",
        "sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, @DRUG$, @DRUG$, ethanol, and other drugs which themselves produce CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s0.p13",
        "sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, @DRUG$, antihistaminics, @DRUG$, and other drugs which themselves produce CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s0.p14",
        "sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, @DRUG$, @DRUG$, and other drugs which themselves produce CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s7.p0",
        "sentence": "Coadministration of oral @DRUG$ increased the maximum plasma concentration of @DRUG$ by 18%, decreased clearance by 22%, and increased half-life by 29%.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p0",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p1",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p2",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p3",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p4",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p5",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p6",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p7",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p8",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p9",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p10",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p11",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p12",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p13",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p14",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p15",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p16",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p17",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p18",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p19",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p20",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p21",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p22",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p23",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p24",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p25",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p26",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p27",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p28",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p29",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p30",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p31",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p32",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p33",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p34",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p35",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p36",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p37",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p38",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p39",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p40",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p41",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p42",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p43",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p44",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p45",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p46",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p47",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p48",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p49",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p50",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p51",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p52",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p53",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p54",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p55",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p56",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p57",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p58",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p59",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p60",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p61",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p62",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p63",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p64",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p65",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p66",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p67",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p68",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p69",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p70",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p71",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p72",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p73",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p74",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p75",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as @DRUG$ and clarithromycin, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p76",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and @DRUG$, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d131.s8.p77",
        "sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and @DRUG$, and grapefruit juice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s0.p0",
        "sentence": "Oral @DRUG$: In some normal volunteers, the concomitant administration of @DRUG$ and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s0.p1",
        "sentence": "Oral @DRUG$: In some normal volunteers, the concomitant administration of diflunisal and @DRUG$, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s0.p2",
        "sentence": "Oral @DRUG$: In some normal volunteers, the concomitant administration of diflunisal and warfarin, @DRUG$, or phenprocoumon resulted in prolongation of prothrombin time.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s0.p3",
        "sentence": "Oral @DRUG$: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or @DRUG$ resulted in prolongation of prothrombin time.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s0.p4",
        "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of @DRUG$ and @DRUG$, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d132.s0.p5",
        "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of @DRUG$ and warfarin, @DRUG$, or phenprocoumon resulted in prolongation of prothrombin time.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d132.s0.p6",
        "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of @DRUG$ and warfarin, acenocoumarol, or @DRUG$ resulted in prolongation of prothrombin time.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d132.s0.p7",
        "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and @DRUG$, @DRUG$, or phenprocoumon resulted in prolongation of prothrombin time.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s0.p8",
        "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and @DRUG$, acenocoumarol, or @DRUG$ resulted in prolongation of prothrombin time.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s0.p9",
        "sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, @DRUG$, or @DRUG$ resulted in prolongation of prothrombin time.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s12.p0",
        "sentence": "@DRUG$ had no effect on plasma levels of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s13.p0",
        "sentence": "Since @DRUG$ in high doses has been associated with hepatotoxicity, concomitant administration of @DRUG$ and acetaminophen should be used cautiously, with careful monitoring of patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s13.p1",
        "sentence": "Since @DRUG$ in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and @DRUG$ should be used cautiously, with careful monitoring of patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s13.p2",
        "sentence": "Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of @DRUG$ and @DRUG$ should be used cautiously, with careful monitoring of patients.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d132.s14.p0",
        "sentence": "Concomitant administration of @DRUG$ and @DRUG$ in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d132.s14.p1",
        "sentence": "Concomitant administration of @DRUG$ and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of @DRUG$/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s14.p2",
        "sentence": "Concomitant administration of @DRUG$ and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/@DRUG$) resulted in greater gastrointestinal toxicity than when either drug was administered alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s14.p3",
        "sentence": "Concomitant administration of diflunisal and @DRUG$ in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of @DRUG$/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s14.p4",
        "sentence": "Concomitant administration of diflunisal and @DRUG$ in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/@DRUG$) resulted in greater gastrointestinal toxicity than when either drug was administered alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s14.p5",
        "sentence": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of @DRUG$/@DRUG$) resulted in greater gastrointestinal toxicity than when either drug was administered alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s7.p0",
        "sentence": "@DRUG$: In normal volunteers, the concomitant administration of @DRUG$ and furosemide had no effect on the diuretic activity of furosemide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s7.p1",
        "sentence": "@DRUG$: In normal volunteers, the concomitant administration of diflunisal and @DRUG$ had no effect on the diuretic activity of furosemide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s7.p2",
        "sentence": "@DRUG$: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s7.p3",
        "sentence": "Furosemide: In normal volunteers, the concomitant administration of @DRUG$ and @DRUG$ had no effect on the diuretic activity of furosemide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s7.p4",
        "sentence": "Furosemide: In normal volunteers, the concomitant administration of @DRUG$ and furosemide had no effect on the diuretic activity of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d132.s7.p5",
        "sentence": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and @DRUG$ had no effect on the diuretic activity of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d133.s2.p0",
        "sentence": "Excessive neuromuscular weakness may be exacerbated by administration of another @DRUG$ prior to the resolution of the effects of a previously administered @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d137.s1.p0",
        "sentence": "Sublingual @DRUG$ may be taken if necessary for the control of acute angina attacks during @DRUG$ therapy.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d137.s7.p0",
        "sentence": "Oral @DRUG$: @DRUG$ has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d137.s7.p1",
        "sentence": "Oral @DRUG$: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for @DRUG$ or oral hypoglycemic agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d137.s7.p2",
        "sentence": "Oral @DRUG$: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d137.s7.p3",
        "sentence": "Oral Hypoglycemics: @DRUG$ has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for @DRUG$ or oral hypoglycemic agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d137.s7.p4",
        "sentence": "Oral Hypoglycemics: @DRUG$ has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d137.s7.p5",
        "sentence": "Oral Hypoglycemics: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for @DRUG$ or oral @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p0",
        "sentence": "Although specific drug interaction studies have not been conducted with @DRUG$, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p1",
        "sentence": "Although specific drug interaction studies have not been conducted with @DRUG$, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, sedatives, or anesthetics) should be considered.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p2",
        "sentence": "Although specific drug interaction studies have not been conducted with @DRUG$, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, sedatives, or anesthetics) should be considered.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p3",
        "sentence": "Although specific drug interaction studies have not been conducted with @DRUG$, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, @DRUG$, sedatives, or anesthetics) should be considered.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p4",
        "sentence": "Although specific drug interaction studies have not been conducted with @DRUG$, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, @DRUG$, or anesthetics) should be considered.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p5",
        "sentence": "Although specific drug interaction studies have not been conducted with @DRUG$, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or @DRUG$) should be considered.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p6",
        "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with @DRUG$ (@DRUG$, barbiturates, opiates, sedatives, or anesthetics) should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p7",
        "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, @DRUG$, opiates, sedatives, or anesthetics) should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p8",
        "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, @DRUG$, sedatives, or anesthetics) should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p9",
        "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, @DRUG$, or anesthetics) should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p10",
        "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, sedatives, or @DRUG$) should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p11",
        "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, @DRUG$, opiates, sedatives, or anesthetics) should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p12",
        "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, @DRUG$, sedatives, or anesthetics) should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p13",
        "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, @DRUG$, or anesthetics) should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p14",
        "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, sedatives, or @DRUG$) should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p15",
        "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, @DRUG$, sedatives, or anesthetics) should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p16",
        "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, @DRUG$, or anesthetics) should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p17",
        "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, sedatives, or @DRUG$) should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p18",
        "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, @DRUG$, @DRUG$, or anesthetics) should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p19",
        "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, @DRUG$, sedatives, or @DRUG$) should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s0.p20",
        "sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, @DRUG$, or @DRUG$) should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s2.p0",
        "sentence": "Caution in using concomitant drugs such as @DRUG$ (ophthalmic and systemic), @DRUG$ and/or cardiac glycosides is advised.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s2.p1",
        "sentence": "Caution in using concomitant drugs such as @DRUG$ (ophthalmic and systemic), anti-hypertensives and/or @DRUG$ is advised.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d138.s2.p2",
        "sentence": "Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), @DRUG$ and/or @DRUG$ is advised.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d14.s0.p0",
        "sentence": "The vasodilating effects of @DRUG$ may be additive with those of other @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d14.s2.p0",
        "sentence": "Marked symptomatic orthostatic hypotension has been reported when @DRUG$ and organic @DRUG$ were used in combination.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d140.s1.p0",
        "sentence": "@DRUG$: When @DRUG$ and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d140.s1.p1",
        "sentence": "@DRUG$: When atorvastatin and @DRUG$ suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d140.s1.p2",
        "sentence": "@DRUG$: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of @DRUG$ decreased approximately 35%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d140.s1.p3",
        "sentence": "Antacid: When @DRUG$ and @DRUG$ suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d140.s1.p4",
        "sentence": "Antacid: When @DRUG$ and Maalox TC suspension were coadministered, plasma concentrations of @DRUG$ decreased approximately 35%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d140.s1.p5",
        "sentence": "Antacid: When atorvastatin and @DRUG$ suspension were coadministered, plasma concentrations of @DRUG$ decreased approximately 35%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s0.p0",
        "sentence": "@DRUG$, @DRUG$, Niacin (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s0.p1",
        "sentence": "@DRUG$, Fibric Acid Derivatives, @DRUG$ (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s0.p2",
        "sentence": "@DRUG$, Fibric Acid Derivatives, Niacin (@DRUG$, Erythromycin, Azole Antifungals: Skeletal Muscle.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s0.p3",
        "sentence": "@DRUG$, Fibric Acid Derivatives, Niacin (Nicotinic Acid, @DRUG$, Azole Antifungals: Skeletal Muscle.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s0.p4",
        "sentence": "@DRUG$, Fibric Acid Derivatives, Niacin (Nicotinic Acid, Erythromycin, @DRUG$: Skeletal Muscle.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s0.p5",
        "sentence": "Immunosuppressive Drugs, @DRUG$, @DRUG$ (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s0.p6",
        "sentence": "Immunosuppressive Drugs, @DRUG$, Niacin (@DRUG$, Erythromycin, Azole Antifungals: Skeletal Muscle.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s0.p7",
        "sentence": "Immunosuppressive Drugs, @DRUG$, Niacin (Nicotinic Acid, @DRUG$, Azole Antifungals: Skeletal Muscle.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s0.p8",
        "sentence": "Immunosuppressive Drugs, @DRUG$, Niacin (Nicotinic Acid, Erythromycin, @DRUG$: Skeletal Muscle.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s0.p9",
        "sentence": "Immunosuppressive Drugs, Fibric Acid Derivatives, @DRUG$ (@DRUG$, Erythromycin, Azole Antifungals: Skeletal Muscle.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s0.p10",
        "sentence": "Immunosuppressive Drugs, Fibric Acid Derivatives, @DRUG$ (Nicotinic Acid, @DRUG$, Azole Antifungals: Skeletal Muscle.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s0.p11",
        "sentence": "Immunosuppressive Drugs, Fibric Acid Derivatives, @DRUG$ (Nicotinic Acid, Erythromycin, @DRUG$: Skeletal Muscle.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s0.p12",
        "sentence": "Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (@DRUG$, @DRUG$, Azole Antifungals: Skeletal Muscle.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s0.p13",
        "sentence": "Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (@DRUG$, Erythromycin, @DRUG$: Skeletal Muscle.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s0.p14",
        "sentence": "Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (Nicotinic Acid, @DRUG$, @DRUG$: Skeletal Muscle.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s2.p0",
        "sentence": "@DRUG$: @DRUG$ plasma concentrations were not affected by co-administration of cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s2.p1",
        "sentence": "@DRUG$: Cerivastatin plasma concentrations were not affected by co-administration of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s2.p2",
        "sentence": "CIMETlDINE: @DRUG$ plasma concentrations were not affected by co-administration of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s3.p0",
        "sentence": "@DRUG$: The influence of the bile-acidsequestering agent @DRUG$ on the pharmacokinetits of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s3.p1",
        "sentence": "@DRUG$: The influence of the bile-acidsequestering agent cholestyramine on the pharmacokinetits of @DRUG$ was evaluated in 12 healthy males in 2 separate randomized crossover studies.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s3.p2",
        "sentence": "CHOLESTYRAMINE: The influence of the bile-acidsequestering agent @DRUG$ on the pharmacokinetits of @DRUG$ was evaluated in 12 healthy males in 2 separate randomized crossover studies.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d141.s8.p0",
        "sentence": "@DRUG$ plasma concentrations were also not affected by co-administration of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s10.p0",
        "sentence": "A case report of one patient taking @DRUG$ 200 mg and @DRUG$ 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d143.s10.p1",
        "sentence": "A case report of one patient taking @DRUG$ 200 mg and indinavir 800 mg three times a day resulted in increases in @DRUG$ concentrations from 0.9 mg/L to 1.3 mg/L.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s10.p2",
        "sentence": "A case report of one patient taking amiodarone 200 mg and @DRUG$ 800 mg three times a day resulted in increases in @DRUG$ concentrations from 0.9 mg/L to 1.3 mg/L.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s14.p0",
        "sentence": "@DRUG$: @DRUG$ inhibits CYP3A4 and can increase serum amiodarone levels.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d143.s14.p1",
        "sentence": "@DRUG$: Cimetidine inhibits CYP3A4 and can increase serum @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s14.p2",
        "sentence": "Histamine H2 antagonists: @DRUG$ inhibits CYP3A4 and can increase serum @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s17.p0",
        "sentence": "This information should be considered when changing from intravenous @DRUG$ to oral @DRUG$ .",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s20.p0",
        "sentence": "Reported examples of this interaction include the following: @DRUG$s: @DRUG$ (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s20.p1",
        "sentence": "Reported examples of this interaction include the following: @DRUG$s: Cyclosporine (@DRUG$ substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s20.p2",
        "sentence": "Reported examples of this interaction include the following: @DRUG$s: Cyclosporine (CYP3A4 substrate) administered in combination with oral @DRUG$ has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s20.p3",
        "sentence": "Reported examples of this interaction include the following: @DRUG$s: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of @DRUG$ resulting in elevated creatinine, despite reduction in dose of cyclosporine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s20.p4",
        "sentence": "Reported examples of this interaction include the following: @DRUG$s: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s20.p5",
        "sentence": "Reported examples of this interaction include the following: Immunosuppressives: @DRUG$ (@DRUG$ substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s20.p6",
        "sentence": "Reported examples of this interaction include the following: Immunosuppressives: @DRUG$ (CYP3A4 substrate) administered in combination with oral @DRUG$ has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s20.p7",
        "sentence": "Reported examples of this interaction include the following: Immunosuppressives: @DRUG$ (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of @DRUG$ resulting in elevated creatinine, despite reduction in dose of cyclosporine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s20.p8",
        "sentence": "Reported examples of this interaction include the following: Immunosuppressives: @DRUG$ (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s20.p9",
        "sentence": "Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (@DRUG$ substrate) administered in combination with oral @DRUG$ has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s20.p10",
        "sentence": "Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (@DRUG$ substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of @DRUG$ resulting in elevated creatinine, despite reduction in dose of cyclosporine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s20.p11",
        "sentence": "Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (@DRUG$ substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s20.p12",
        "sentence": "Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral @DRUG$ has been reported to produce persistently elevated plasma concentrations of @DRUG$ resulting in elevated creatinine, despite reduction in dose of cyclosporine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s20.p13",
        "sentence": "Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral @DRUG$ has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s20.p14",
        "sentence": "Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of @DRUG$ resulting in elevated creatinine, despite reduction in dose of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s23.p0",
        "sentence": "@DRUG$ taken concomitantly with @DRUG$ increases the serum digoxin concentration by 70% after one day.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s23.p1",
        "sentence": "@DRUG$ taken concomitantly with digoxin increases the serum @DRUG$ concentration by 70% after one day.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s23.p2",
        "sentence": "Amiodarone taken concomitantly with @DRUG$ increases the serum @DRUG$ concentration by 70% after one day.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s40.p0",
        "sentence": "In @DRUG$-treated patients who require additional @DRUG$ therapy, the initial dose of such agents should be approximately half of the usual recommended dose.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s47.p0",
        "sentence": "Reported examples of this interaction include the following: @DRUG$: @DRUG$ is a potent inducer of CYP3A4.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s47.p1",
        "sentence": "Reported examples of this interaction include the following: @DRUG$: Rifampin is a potent inducer of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d143.s47.p2",
        "sentence": "Reported examples of this interaction include the following: Antibiotics: @DRUG$ is a potent inducer of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d146.s1.p0",
        "sentence": "The action of @DRUG$ is potentiated by @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d148.s0.p0",
        "sentence": "@DRUG$: Since @DRUG$ is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d148.s0.p1",
        "sentence": "@DRUG$: Since heparin is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d148.s0.p2",
        "sentence": "@DRUG$: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of @DRUG$ and heparin is unlikely for this indication.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d148.s0.p3",
        "sentence": "@DRUG$: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and @DRUG$ is unlikely for this indication.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d148.s0.p4",
        "sentence": "Heparin: Since @DRUG$ is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d148.s0.p5",
        "sentence": "Heparin: Since @DRUG$ is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of @DRUG$ and heparin is unlikely for this indication.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d148.s0.p6",
        "sentence": "Heparin: Since @DRUG$ is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and @DRUG$ is unlikely for this indication.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d148.s0.p7",
        "sentence": "Heparin: Since heparin is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of @DRUG$ and heparin is unlikely for this indication.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d148.s0.p8",
        "sentence": "Heparin: Since heparin is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of Argatroban and @DRUG$ is unlikely for this indication.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d148.s0.p9",
        "sentence": "Heparin: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of @DRUG$ and @DRUG$ is unlikely for this indication.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d148.s5.p0",
        "sentence": "@DRUG$: The safety and effectiveness of @DRUG$ with thrombolytic agents have not been established.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d148.s5.p1",
        "sentence": "@DRUG$: The safety and effectiveness of Argatroban with @DRUG$ have not been established.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d148.s5.p2",
        "sentence": "Thrombolytic agents: The safety and effectiveness of @DRUG$ with @DRUG$ have not been established.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d150.s0.p0",
        "sentence": "@DRUG$ may have life-threatening interactions with @DRUG$.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d151.s3.p0",
        "sentence": "@DRUG$ may enhance the toxicity of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d154.s1.p0",
        "sentence": "Although the mechanism of interaction between @DRUG$ and @DRUG$ is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d154.s1.p1",
        "sentence": "Although the mechanism of interaction between @DRUG$ and aspirin is not totally known, enzyme induction and displacement of @DRUG$ from plasma albumin binding sites are possibilities.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d154.s1.p2",
        "sentence": "Although the mechanism of interaction between fenoprofen and @DRUG$ is not totally known, enzyme induction and displacement of @DRUG$ from plasma albumin binding sites are possibilities.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d157.s1.p0",
        "sentence": "(See CLINICAL PHARMACOLOGY) Coadministration of @DRUG$ and @DRUG$ 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d157.s1.p1",
        "sentence": "(See CLINICAL PHARMACOLOGY) Coadministration of @DRUG$ and tamoxifen 20 mg daily resulted in a reduction of @DRUG$ plasma levels by 38% on average.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d157.s1.p2",
        "sentence": "(See CLINICAL PHARMACOLOGY) Coadministration of Femara and @DRUG$ 20 mg daily resulted in a reduction of @DRUG$ plasma levels by 38% on average.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d158.s16.p0",
        "sentence": "@DRUG$: @DRUG$ potentiate the analgesic effect of meperidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d158.s16.p1",
        "sentence": "@DRUG$: Amphetamines potentiate the analgesic effect of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d158.s16.p2",
        "sentence": "Meperidine: @DRUG$ potentiate the analgesic effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d158.s19.p0",
        "sentence": "@DRUG$: @DRUG$ may delay intestinal absorption of phenobarbital;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d158.s19.p1",
        "sentence": "@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d158.s19.p2",
        "sentence": "Phenobarbital: @DRUG$ may delay intestinal absorption of @DRUG$;",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d158.s23.p0",
        "sentence": "@DRUG$: In cases of @DRUG$ overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d158.s23.p1",
        "sentence": "@DRUG$: In cases of propoxyphene overdosage, @DRUG$ CNS stimulation is potentiated and fatal convulsions can occur.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d158.s23.p2",
        "sentence": "Propoxyphene: In cases of @DRUG$ overdosage, @DRUG$ CNS stimulation is potentiated and fatal convulsions can occur.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d158.s4.p0",
        "sentence": "@DRUG$ with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d158.s4.p1",
        "sentence": "@DRUG$ with desipramine or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d158.s4.p2",
        "sentence": "@DRUG$ with desipramine or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d158.s4.p3",
        "sentence": "@DRUG$ with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d158.s4.p4",
        "sentence": "d-amphetamine with @DRUG$ or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d158.s4.p5",
        "sentence": "d-amphetamine with @DRUG$ or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d158.s4.p6",
        "sentence": "d-amphetamine with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d158.s4.p7",
        "sentence": "d-amphetamine with desipramine or @DRUG$ and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d158.s4.p8",
        "sentence": "d-amphetamine with desipramine or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d158.s4.p9",
        "sentence": "d-amphetamine with desipramine or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of @DRUG$ in the brain;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d16.s2.p0",
        "sentence": "Since @DRUG$ may raise the serum uric acid level, dosage adjustment of @DRUG$ may be necessary",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d160.s0.p0",
        "sentence": "The results of a study of coadministration of @DRUG$ (50 mg/kg) with an @DRUG$ containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d160.s0.p1",
        "sentence": "The results of a study of coadministration of @DRUG$ (50 mg/kg) with an aluminum hydroxide containing @DRUG$ to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d160.s0.p2",
        "sentence": "The results of a study of coadministration of @DRUG$ (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of @DRUG$ of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d160.s0.p3",
        "sentence": "The results of a study of coadministration of @DRUG$ (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of @DRUG$ may be reduced by these antacid products.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d160.s0.p4",
        "sentence": "The results of a study of coadministration of @DRUG$ (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d160.s0.p5",
        "sentence": "The results of a study of coadministration of ethambutol (50 mg/kg) with an @DRUG$ containing @DRUG$ to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d160.s0.p6",
        "sentence": "The results of a study of coadministration of ethambutol (50 mg/kg) with an @DRUG$ containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of @DRUG$ of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d160.s0.p7",
        "sentence": "The results of a study of coadministration of ethambutol (50 mg/kg) with an @DRUG$ containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of @DRUG$ may be reduced by these antacid products.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d160.s0.p8",
        "sentence": "The results of a study of coadministration of ethambutol (50 mg/kg) with an @DRUG$ containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d160.s0.p9",
        "sentence": "The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing @DRUG$ to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of @DRUG$ of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d160.s0.p10",
        "sentence": "The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing @DRUG$ to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of @DRUG$ may be reduced by these antacid products.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d160.s0.p11",
        "sentence": "The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing @DRUG$ to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d160.s0.p12",
        "sentence": "The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of @DRUG$ of approximately 20% and 13%, respectively, suggesting that the oral absorption of @DRUG$ may be reduced by these antacid products.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d160.s0.p13",
        "sentence": "The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of @DRUG$ of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d160.s0.p14",
        "sentence": "The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of @DRUG$ may be reduced by these @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d162.s6.p0",
        "sentence": "@DRUG$, @DRUG$: intensified electrolyte depletion, particularly hypokalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d163.s10.p0",
        "sentence": "@DRUG$: @DRUG$ has not been shown to alter the pharmacokinetics of phenytoin in a study in seven healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d163.s10.p1",
        "sentence": "@DRUG$: Accutane has not been shown to alter the pharmacokinetics of @DRUG$ in a study in seven healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d163.s10.p2",
        "sentence": "Phenytoin: @DRUG$ has not been shown to alter the pharmacokinetics of @DRUG$ in a study in seven healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d165.s11.p0",
        "sentence": "Coadministration of @DRUG$ with oral @DRUG$ or triazolam has resulted in elevated plasma concentrations of the latter two drugs.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d165.s11.p1",
        "sentence": "Coadministration of @DRUG$ with oral midazolam or @DRUG$ has resulted in elevated plasma concentrations of the latter two drugs.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d165.s11.p2",
        "sentence": "Coadministration of Itraconazole with oral @DRUG$ or @DRUG$ has resulted in elevated plasma concentrations of the latter two drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d165.s16.p0",
        "sentence": "@DRUG$, @DRUG$ and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d165.s16.p1",
        "sentence": "@DRUG$, tacrolimus and @DRUG$ concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d165.s16.p2",
        "sentence": "@DRUG$, tacrolimus and digoxin concentrations should be monitored at the initiation of @DRUG$ therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d165.s16.p3",
        "sentence": "Cyclosporine, @DRUG$ and @DRUG$ concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d165.s16.p4",
        "sentence": "Cyclosporine, @DRUG$ and digoxin concentrations should be monitored at the initiation of @DRUG$ therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d165.s16.p5",
        "sentence": "Cyclosporine, tacrolimus and @DRUG$ concentrations should be monitored at the initiation of @DRUG$ therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d165.s21.p0",
        "sentence": "therefore, plasma concentrations of @DRUG$ should also be monitored when it is given concurrently with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d165.s25.p0",
        "sentence": "@DRUG$ plasma concentrations should be monitored when @DRUG$ and isoniazid are coadministered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d165.s25.p1",
        "sentence": "@DRUG$ plasma concentrations should be monitored when Itraconazole and @DRUG$ are coadministered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d165.s25.p2",
        "sentence": "Itraconazole plasma concentrations should be monitored when @DRUG$ and @DRUG$ are coadministered.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d165.s31.p0",
        "sentence": "The results from a study in which eight HIV-infected individuals were treated with @DRUG$, 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of @DRUG$ were not affected during concomitant administration of Itraconazole, 100 mg b.i.d.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d165.s31.p1",
        "sentence": "The results from a study in which eight HIV-infected individuals were treated with @DRUG$, 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of zidovudine were not affected during concomitant administration of @DRUG$, 100 mg b.i.d.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d165.s31.p2",
        "sentence": "The results from a study in which eight HIV-infected individuals were treated with zidovudine, 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of @DRUG$ were not affected during concomitant administration of @DRUG$, 100 mg b.i.d.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d165.s9.p0",
        "sentence": "In vitro data suggest that @DRUG$ also markedly inhibits the biotransformation system mainly responsible for the metabolism of @DRUG$;",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d166.s0.p0",
        "sentence": "@DRUG$ has been found to temporarily raise serum concentrations of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p0",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general @DRUG$, local @DRUG$ like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p1",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general @DRUG$, local anesthetics like @DRUG$, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p2",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general @DRUG$, local anesthetics like lidocaine, @DRUG$, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p3",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general @DRUG$, local anesthetics like lidocaine, procaine, @DRUG$, metaclopramide, lithium carbonate, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p4",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general @DRUG$, local anesthetics like lidocaine, procaine, beta-blockers, @DRUG$, lithium carbonate, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p5",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general @DRUG$, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, @DRUG$, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p6",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general @DRUG$, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p7",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local @DRUG$ like @DRUG$, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p8",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local @DRUG$ like lidocaine, @DRUG$, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p9",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local @DRUG$ like lidocaine, procaine, @DRUG$, metaclopramide, lithium carbonate, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p10",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local @DRUG$ like lidocaine, procaine, beta-blockers, @DRUG$, lithium carbonate, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p11",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local @DRUG$ like lidocaine, procaine, beta-blockers, metaclopramide, @DRUG$, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p12",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local @DRUG$ like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p13",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like @DRUG$, @DRUG$, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p14",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like @DRUG$, procaine, @DRUG$, metaclopramide, lithium carbonate, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p15",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like @DRUG$, procaine, beta-blockers, @DRUG$, lithium carbonate, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p16",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like @DRUG$, procaine, beta-blockers, metaclopramide, @DRUG$, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p17",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like @DRUG$, procaine, beta-blockers, metaclopramide, lithium carbonate, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p18",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, @DRUG$, @DRUG$, metaclopramide, lithium carbonate, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p19",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, @DRUG$, beta-blockers, @DRUG$, lithium carbonate, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p20",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, @DRUG$, beta-blockers, metaclopramide, @DRUG$, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p21",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, @DRUG$, beta-blockers, metaclopramide, lithium carbonate, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p22",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, @DRUG$, @DRUG$, lithium carbonate, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p23",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, @DRUG$, metaclopramide, @DRUG$, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p24",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, @DRUG$, metaclopramide, lithium carbonate, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p25",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, @DRUG$, @DRUG$, and terbutaline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p26",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, @DRUG$, lithium carbonate, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d167.s2.p27",
        "sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, @DRUG$, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d169.s0.p0",
        "sentence": "Results from human in vitro metabolism studies and nonclinical studies show that @DRUG$  (@DRUG$) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that lenalidomide is not likely to cause or be subject to P450-based metabolic drug interactions in man.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d169.s0.p1",
        "sentence": "Results from human in vitro metabolism studies and nonclinical studies show that @DRUG$  (lenalidomide) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that @DRUG$ is not likely to cause or be subject to P450-based metabolic drug interactions in man.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d169.s0.p2",
        "sentence": "Results from human in vitro metabolism studies and nonclinical studies show that REVLIMID  (@DRUG$) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that @DRUG$ is not likely to cause or be subject to P450-based metabolic drug interactions in man.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d169.s1.p0",
        "sentence": "Co-administration of multiple doses of 10 mg of @DRUG$ had no effect on the single dose pharmacokinetics of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d169.s1.p1",
        "sentence": "Co-administration of multiple doses of 10 mg of @DRUG$ had no effect on the single dose pharmacokinetics of R- and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d169.s1.p2",
        "sentence": "Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of @DRUG-DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d17.s21.p0",
        "sentence": "(Concurrent use with @DRUG$ is not recommended, as they may provoke @DRUG$ toxicity because of reduced renal clearance.)",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d17.s28.p0",
        "sentence": "(@DRUG$ may decrease arterial responsiveness to @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d17.s9.p0",
        "sentence": "@DRUG$ or @DRUG$ or Corticotropin (ACTH)",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d17.s9.p1",
        "sentence": "@DRUG$ or Corticosteroids or @DRUG$ (ACTH)",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d17.s9.p2",
        "sentence": "@DRUG$ or Corticosteroids or Corticotropin (@DRUG$)",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d17.s9.p3",
        "sentence": "Amphotericin B or @DRUG$ or @DRUG$ (ACTH)",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d17.s9.p4",
        "sentence": "Amphotericin B or @DRUG$ or Corticotropin (@DRUG$)",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d17.s9.p5",
        "sentence": "Amphotericin B or Corticosteroids or @DRUG$ (@DRUG$)",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p0",
        "sentence": "The concomitant use of transdermal @DRUG$ with @DRUG$ or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p1",
        "sentence": "The concomitant use of transdermal @DRUG$ with ritonavir or other potent 3A4 inhibitors such as @DRUG$, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p2",
        "sentence": "The concomitant use of transdermal @DRUG$ with ritonavir or other potent 3A4 inhibitors such as ketoconazole, @DRUG$, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p3",
        "sentence": "The concomitant use of transdermal @DRUG$ with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, @DRUG$, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p4",
        "sentence": "The concomitant use of transdermal @DRUG$ with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, @DRUG$, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p5",
        "sentence": "The concomitant use of transdermal @DRUG$ with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, @DRUG$, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p6",
        "sentence": "The concomitant use of transdermal @DRUG$ with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in @DRUG$ plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p7",
        "sentence": "The concomitant use of transdermal fentanyl with @DRUG$ or other potent 3A4 inhibitors such as @DRUG$, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p8",
        "sentence": "The concomitant use of transdermal fentanyl with @DRUG$ or other potent 3A4 inhibitors such as ketoconazole, @DRUG$, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p9",
        "sentence": "The concomitant use of transdermal fentanyl with @DRUG$ or other potent 3A4 inhibitors such as ketoconazole, itraconazole, @DRUG$, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p10",
        "sentence": "The concomitant use of transdermal fentanyl with @DRUG$ or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, @DRUG$, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p11",
        "sentence": "The concomitant use of transdermal fentanyl with @DRUG$ or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, @DRUG$, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p12",
        "sentence": "The concomitant use of transdermal fentanyl with @DRUG$ or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in @DRUG$ plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p13",
        "sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as @DRUG$, @DRUG$, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p14",
        "sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as @DRUG$, itraconazole, @DRUG$, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p15",
        "sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as @DRUG$, itraconazole, troleandomycin, @DRUG$, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p16",
        "sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as @DRUG$, itraconazole, troleandomycin, clarithromycin, @DRUG$, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p17",
        "sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as @DRUG$, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in @DRUG$ plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p18",
        "sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, @DRUG$, @DRUG$, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p19",
        "sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, @DRUG$, troleandomycin, @DRUG$, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p20",
        "sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, @DRUG$, troleandomycin, clarithromycin, @DRUG$, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p21",
        "sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, @DRUG$, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in @DRUG$ plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p22",
        "sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, @DRUG$, @DRUG$, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p23",
        "sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, @DRUG$, clarithromycin, @DRUG$, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p24",
        "sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, @DRUG$, clarithromycin, nelfinavir, and nefazadone may result in an increase in @DRUG$ plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p25",
        "sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, @DRUG$, @DRUG$, and nefazadone may result in an increase in fentanyl plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p26",
        "sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, @DRUG$, nelfinavir, and nefazadone may result in an increase in @DRUG$ plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d170.s2.p27",
        "sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, @DRUG$, and nefazadone may result in an increase in @DRUG$ plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s10.p0",
        "sentence": "This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d172.s13.p0",
        "sentence": "@DRUG$: @DRUG$ can be used with low dose aspirin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s13.p1",
        "sentence": "@DRUG$: CELEBREX can be used with low dose @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s13.p2",
        "sentence": "Aspirin: @DRUG$ can be used with low dose @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d172.s15.p0",
        "sentence": "Because of its lack of platelet effects, @DRUG$ is not a substitute for @DRUG$ for cardiovascular prophylaxis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s18.p0",
        "sentence": "@DRUG$ should be introduced at the lowest recommended dose in patients receiving @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d172.s7.p0",
        "sentence": "Experience with @DRUG$ (@DRUG$) suggests the potential for interactions with furosemide and ACE inhibitors.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s7.p1",
        "sentence": "Experience with @DRUG$ (NSAIDs) suggests the potential for interactions with @DRUG$ and ACE inhibitors.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d172.s7.p2",
        "sentence": "Experience with @DRUG$ (NSAIDs) suggests the potential for interactions with furosemide and @DRUG$.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d172.s7.p3",
        "sentence": "Experience with nonsteroidal anti-inflammatory drugs (@DRUG$) suggests the potential for interactions with @DRUG$ and ACE inhibitors.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d172.s7.p4",
        "sentence": "Experience with nonsteroidal anti-inflammatory drugs (@DRUG$) suggests the potential for interactions with furosemide and @DRUG$.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d172.s7.p5",
        "sentence": "Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with @DRUG$ and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p0",
        "sentence": "The effects @DRUG$ on the pharmacokinetics and/or pharmacodynamics of @DRUG$, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p1",
        "sentence": "The effects @DRUG$ on the pharmacokinetics and/or pharmacodynamics of glyburide, @DRUG$, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p2",
        "sentence": "The effects @DRUG$ on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, @DRUG$, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p3",
        "sentence": "The effects @DRUG$ on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, @DRUG$, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p4",
        "sentence": "The effects @DRUG$ on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, @DRUG$, and warfarin have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p5",
        "sentence": "The effects @DRUG$ on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, tolbutamide, and @DRUG$ have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p6",
        "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of @DRUG$, @DRUG$, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p7",
        "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of @DRUG$, ketoconazole, @DRUG$, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p8",
        "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of @DRUG$, ketoconazole, methotrexate, @DRUG$, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p9",
        "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of @DRUG$, ketoconazole, methotrexate, phenytoin, @DRUG$, and warfarin have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p10",
        "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of @DRUG$, ketoconazole, methotrexate, phenytoin, tolbutamide, and @DRUG$ have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p11",
        "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, @DRUG$, @DRUG$, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p12",
        "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, @DRUG$, methotrexate, @DRUG$, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p13",
        "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, @DRUG$, methotrexate, phenytoin, @DRUG$, and warfarin have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p14",
        "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, @DRUG$, methotrexate, phenytoin, tolbutamide, and @DRUG$ have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p15",
        "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, @DRUG$, @DRUG$, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p16",
        "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, @DRUG$, phenytoin, @DRUG$, and warfarin have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p17",
        "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, @DRUG$, phenytoin, tolbutamide, and @DRUG$ have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p18",
        "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, @DRUG$, @DRUG$, and warfarin have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p19",
        "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, @DRUG$, tolbutamide, and @DRUG$ have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d172.s8.p20",
        "sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, @DRUG$, and @DRUG$ have been studied in vivo and clinically important interactions have not been found.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d174.s1.p0",
        "sentence": "Caution should be exercised when administering @DRUG$ with @DRUG$ since interactions have been seen with other NSAIDs.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d174.s1.p1",
        "sentence": "Caution should be exercised when administering @DRUG$ with warfarin since interactions have been seen with other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d174.s1.p2",
        "sentence": "Caution should be exercised when administering nabumetone with @DRUG$ since interactions have been seen with other @DRUG$.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d174.s2.p0",
        "sentence": "Concomitant administration of an @DRUG$-containing @DRUG$ had no significant effect in the bioavailability of 6MNA.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d174.s2.p1",
        "sentence": "Concomitant administration of an @DRUG$-containing antacid had no significant effect in the bioavailability of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d174.s2.p2",
        "sentence": "Concomitant administration of an aluminum-containing @DRUG$ had no significant effect in the bioavailability of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s10.p0",
        "sentence": "Agents Affecting Sympathetic Activity The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving @DRUG$ alone or with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s12.p0",
        "sentence": "@DRUG$ add some further antihypertensive effect to @DRUG$, but the overall response is less than additive.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d175.s14.p0",
        "sentence": "@DRUG$ such as @DRUG$, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s14.p1",
        "sentence": "@DRUG$ such as spironolactone, @DRUG$, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s14.p2",
        "sentence": "@DRUG$ such as spironolactone, triamterene, or @DRUG$, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s14.p3",
        "sentence": "@DRUG$ such as spironolactone, triamterene, or amiloride, or @DRUG$ supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s14.p4",
        "sentence": "Potassium-sparing diuretics such as @DRUG$, @DRUG$, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s14.p5",
        "sentence": "Potassium-sparing diuretics such as @DRUG$, triamterene, or @DRUG$, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s14.p6",
        "sentence": "Potassium-sparing diuretics such as @DRUG$, triamterene, or amiloride, or @DRUG$ supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s14.p7",
        "sentence": "Potassium-sparing diuretics such as spironolactone, @DRUG$, or @DRUG$, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s14.p8",
        "sentence": "Potassium-sparing diuretics such as spironolactone, @DRUG$, or amiloride, or @DRUG$ supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s14.p9",
        "sentence": "Potassium-sparing diuretics such as spironolactone, triamterene, or @DRUG$, or @DRUG$ supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s22.p0",
        "sentence": "@DRUG$: @DRUG$ administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s22.p1",
        "sentence": "@DRUG$: Furosemide administered concurrently with @DRUG$ does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s22.p2",
        "sentence": "@DRUG$: Furosemide administered concurrently with captopril does not alter the pharmacokinetics of @DRUG$ in renally impaired hypertensive patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s22.p3",
        "sentence": "Loop Diuretics: @DRUG$ administered concurrently with @DRUG$ does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s22.p4",
        "sentence": "Loop Diuretics: @DRUG$ administered concurrently with captopril does not alter the pharmacokinetics of @DRUG$ in renally impaired hypertensive patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s22.p5",
        "sentence": "Loop Diuretics: Furosemide administered concurrently with @DRUG$ does not alter the pharmacokinetics of @DRUG$ in renally impaired hypertensive patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d175.s8.p0",
        "sentence": "Agents Causing Renin Release @DRUG$'s effect will be augmented by @DRUG$ that cause renin release.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p0",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, @DRUG$, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p1",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p2",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, @DRUG$, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p3",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, hydrochlorothiazide, @DRUG$, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p4",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p5",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p6",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p7",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p8",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p9",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p10",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p11",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, @DRUG$, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p12",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, hydrochlorothiazide, @DRUG$, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p13",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p14",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p15",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p16",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p17",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p18",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p19",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, @DRUG$, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p20",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, @DRUG$, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p21",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p22",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p23",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p24",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p25",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p26",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p27",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, @DRUG$, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p28",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, cimetidine, @DRUG$, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p29",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, cimetidine, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p30",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, cimetidine, metoclopramide, propantheline, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p31",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, cimetidine, metoclopramide, propantheline, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p32",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p33",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p34",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, @DRUG$, @DRUG$, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p35",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, @DRUG$, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p36",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, @DRUG$, metoclopramide, propantheline, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p37",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, @DRUG$, metoclopramide, propantheline, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p38",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, @DRUG$, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p39",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, @DRUG$, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p40",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, @DRUG$, @DRUG$, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p41",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p42",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p43",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p44",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p45",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p46",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p47",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p48",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p49",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, @DRUG$, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p50",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, @DRUG$, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p51",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p52",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and @DRUG$, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p53",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s12.p54",
        "sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of @DRUG$ with any one of these drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s13.p0",
        "sentence": "In a study with concomitant administration of @DRUG$ and @DRUG$, the bioavailability of unbound fosinoprilat was not altered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s13.p1",
        "sentence": "In a study with concomitant administration of @DRUG$ and fosinopril sodium, the bioavailability of unbound @DRUG$ was not altered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s13.p2",
        "sentence": "In a study with concomitant administration of aspirin and @DRUG$, the bioavailability of unbound @DRUG$ was not altered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s4.p0",
        "sentence": "@DRUG$ (@DRUG$, amiloride,triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s4.p1",
        "sentence": "@DRUG$ (spironolactone, @DRUG$,triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s4.p2",
        "sentence": "@DRUG$ (spironolactone, amiloride,@DRUG$, and others) or potassium supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s4.p3",
        "sentence": "@DRUG$ (spironolactone, amiloride,triamterene, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s4.p4",
        "sentence": "Potassium-sparing diuretics (@DRUG$, @DRUG$,triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s4.p5",
        "sentence": "Potassium-sparing diuretics (@DRUG$, amiloride,@DRUG$, and others) or potassium supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s4.p6",
        "sentence": "Potassium-sparing diuretics (@DRUG$, amiloride,triamterene, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s4.p7",
        "sentence": "Potassium-sparing diuretics (spironolactone, @DRUG$,@DRUG$, and others) or potassium supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s4.p8",
        "sentence": "Potassium-sparing diuretics (spironolactone, @DRUG$,triamterene, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s4.p9",
        "sentence": "Potassium-sparing diuretics (spironolactone, amiloride,@DRUG$, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s6.p0",
        "sentence": "@DRUG$: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s6.p1",
        "sentence": "@DRUG$: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s6.p2",
        "sentence": "@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with lithium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s6.p3",
        "sentence": "@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s6.p4",
        "sentence": "Lithium: Increased serum @DRUG$ levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s6.p5",
        "sentence": "Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with lithium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s6.p6",
        "sentence": "Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s6.p7",
        "sentence": "Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving @DRUG$ during therapy with lithium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s6.p8",
        "sentence": "Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d176.s6.p9",
        "sentence": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d178.s13.p0",
        "sentence": "Coadministration of gly-buride and @DRUG$ did not result in any changes in either @DRUG$ pharmacokinetics or pharmaco-dynamics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s18.p0",
        "sentence": "- @DRUG$ (e.g., @DRUG$) (with long-term, high-dose use) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s2.p0",
        "sentence": "- @DRUG$ (e.g., @DRUG$) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p0",
        "sentence": "- @DRUG$ (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p1",
        "sentence": "- @DRUG$ (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p2",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p3",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p4",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p5",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p6",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p7",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p8",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p9",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p10",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p11",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p12",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p13",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p14",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p15",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p16",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p17",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p18",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p19",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p20",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p21",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p22",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p23",
        "sentence": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p24",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p25",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p26",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p27",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p28",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p29",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p30",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p31",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p32",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p33",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p34",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p35",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p36",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p37",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p38",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p39",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p40",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p41",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p42",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p43",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p44",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p45",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p46",
        "sentence": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p47",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p48",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p49",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p50",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p51",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p52",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p53",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p54",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p55",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p56",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p57",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p58",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p59",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p60",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p61",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p62",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p63",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p64",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p65",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p66",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p67",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p68",
        "sentence": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p69",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p70",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p71",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p72",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p73",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p74",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p75",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p76",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p77",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p78",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p79",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p80",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p81",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p82",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p83",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p84",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p85",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p86",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p87",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p88",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p89",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p90",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p91",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p92",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p93",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p94",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p95",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p96",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p97",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p98",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p99",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p100",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p101",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p102",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p103",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p104",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p105",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p106",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p107",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p108",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p109",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p110",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p111",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p112",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p113",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p114",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p115",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p116",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p117",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p118",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p119",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p120",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p121",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p122",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p123",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p124",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p125",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p126",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p127",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p128",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p129",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p130",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p131",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p132",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p133",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p134",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p135",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p136",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p137",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p138",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p139",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p140",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p141",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p142",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p143",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p144",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p145",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p146",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p147",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p148",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p149",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p150",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p151",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p152",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p153",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p154",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p155",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p156",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p157",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p158",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p159",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p160",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p161",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p162",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p163",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p164",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p165",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p166",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p167",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p168",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p169",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p170",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p171",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p172",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p173",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p174",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p175",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p176",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p177",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p178",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p179",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p180",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p181",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p182",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p183",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p184",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p185",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p186",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p187",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p188",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p189",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p190",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p191",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p192",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p193",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p194",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p195",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p196",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p197",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p198",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p199",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p200",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p201",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p202",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p203",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p204",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p205",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p206",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p207",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p208",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p209",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p210",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p211",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p212",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p213",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p214",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p215",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p216",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p217",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p218",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p219",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p220",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p221",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p222",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p223",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p224",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p225",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p226",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p227",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p228",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p229",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p230",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p231",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p232",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p233",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p234",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p235",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p236",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p237",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p238",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p239",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p240",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p241",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p242",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p243",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p244",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p245",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p246",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p247",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p248",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p249",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p250",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p251",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p252",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p253",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p254",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p255",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p256",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p257",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p258",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p259",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p260",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p261",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p262",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p263",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p264",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p265",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p266",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p267",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p268",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p269",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p270",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p271",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p272",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p273",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p274",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p275",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p276",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p277",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p278",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p279",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p280",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p281",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p282",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p283",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p284",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p285",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p286",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p287",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p288",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p289",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p290",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p291",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p292",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p293",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p294",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p295",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p296",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p297",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], @DRUG$ [e.g., Temaril]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p298",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s21.p299",
        "sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., @DRUG$]) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s23.p0",
        "sentence": "- @DRUG$ (e.g., @DRUG$) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the liver",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s23.p1",
        "sentence": "- @DRUG$ (e.g., Depakene) Use of @DRUG$ with these medicines may increase the chance of side effects affecting the liver",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s23.p2",
        "sentence": "- Valproic acid (e.g., @DRUG$) Use of @DRUG$ with these medicines may increase the chance of side effects affecting the liver",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s29.p0",
        "sentence": "- @DRUG$ (e.g., @DRUG$) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s34.p0",
        "sentence": "- @DRUG$ (@DRUG$s) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s35.p0",
        "sentence": "- @DRUG$ (e.g., @DRUG$) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s39.p0",
        "sentence": "- @DRUG$ (e.g., @DRUG$) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s39.p1",
        "sentence": "- @DRUG$ (e.g., Aldomet) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s39.p2",
        "sentence": "- @DRUG$ (e.g., Aldomet) Use of methyldopa with @DRUG$ may increase the chance of side effects affecting the liver and/or the blood",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s39.p3",
        "sentence": "- Methyldopa (e.g., @DRUG$) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s39.p4",
        "sentence": "- Methyldopa (e.g., @DRUG$) Use of methyldopa with @DRUG$ may increase the chance of side effects affecting the liver and/or the blood",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s39.p5",
        "sentence": "- Methyldopa (e.g., Aldomet) Use of @DRUG$ with @DRUG$ may increase the chance of side effects affecting the liver and/or the blood",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d179.s40.p0",
        "sentence": "- @DRUG$ (e.g., @DRUG$) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s40.p1",
        "sentence": "- @DRUG$ (e.g., Dilantin) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s40.p2",
        "sentence": "- @DRUG$ (e.g., Dilantin) Use of phenytoin with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of phenytoin",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s40.p3",
        "sentence": "- @DRUG$ (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s40.p4",
        "sentence": "- Phenytoin (e.g., @DRUG$) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s40.p5",
        "sentence": "- Phenytoin (e.g., @DRUG$) Use of phenytoin with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of phenytoin",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s40.p6",
        "sentence": "- Phenytoin (e.g., @DRUG$) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s40.p7",
        "sentence": "- Phenytoin (e.g., Dilantin) Use of @DRUG$ with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of phenytoin",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d179.s40.p8",
        "sentence": "- Phenytoin (e.g., Dilantin) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s40.p9",
        "sentence": "- Phenytoin (e.g., Dilantin) Use of phenytoin with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d179.s7.p0",
        "sentence": "- @DRUG$ (e.g., @DRUG$) or",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d18.s0.p0",
        "sentence": "Tablets: The @DRUG$, including @DRUG$, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d18.s0.p1",
        "sentence": "Tablets: The @DRUG$, including lorazepam, produce CNS-depressant effects when administered with such medications as @DRUG$ or alcohol.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d18.s0.p2",
        "sentence": "Tablets: The @DRUG$, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d18.s0.p3",
        "sentence": "Tablets: The benzodiazepines, including @DRUG$, produce CNS-depressant effects when administered with such medications as @DRUG$ or alcohol.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d18.s0.p4",
        "sentence": "Tablets: The benzodiazepines, including @DRUG$, produce CNS-depressant effects when administered with such medications as barbiturates or @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d18.s0.p5",
        "sentence": "Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as @DRUG$ or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d181.s0.p0",
        "sentence": "@DRUG$ or other @DRUG$ (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d181.s0.p1",
        "sentence": "@DRUG$ or other oxytocics (concurrent use with @DRUG$ may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d181.s0.p2",
        "sentence": "Oxytocin or other @DRUG$ (concurrent use with @DRUG$ may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p0",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p1",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p2",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p3",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p4",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p5",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p6",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p7",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p8",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p9",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p10",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p11",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p12",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p13",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p14",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p15",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p16",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p17",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p18",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p19",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p20",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p21",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p22",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p23",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p24",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p25",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p26",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p27",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p28",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p29",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p30",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p31",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p32",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p33",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p34",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p35",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p36",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p37",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p38",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p39",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p40",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p41",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p42",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p43",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p44",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p45",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p46",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p47",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p48",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p49",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p50",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p51",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p52",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p53",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p54",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p55",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p56",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p57",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p58",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p59",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p60",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p61",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p62",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p63",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p64",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p65",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p66",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p67",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p68",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p69",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p70",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p71",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p72",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p73",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p74",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p75",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p76",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p77",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p78",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p79",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p80",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p81",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p82",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p83",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p84",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p85",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p86",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p87",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p88",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p89",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d184.s0.p90",
        "sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d185.s4.p0",
        "sentence": "Certain concomitant medications (such as @DRUG$, @DRUG$, St.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d185.s6.p0",
        "sentence": "With oral @DRUG$ treatment, @DRUG$ such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d185.s6.p1",
        "sentence": "With oral @DRUG$ treatment, folic acid antagonists such as @DRUG$ have been noted to possibly increase the likelihood of hematologic reactions",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d185.s6.p2",
        "sentence": "With oral dapsone treatment, @DRUG$ such as @DRUG$ have been noted to possibly increase the likelihood of hematologic reactions",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d186.s1.p0",
        "sentence": "A causal relationship between these events and the concomitant administration of @DRUG$ and @DRUG$ has not been established;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d186.s4.p0",
        "sentence": "In a study of 12 schizophrenic patients coadministered oral @DRUG$ and @DRUG$, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d186.s4.p1",
        "sentence": "In a study of 12 schizophrenic patients coadministered oral @DRUG$ and rifampin, plasma @DRUG$ levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d186.s4.p2",
        "sentence": "In a study of 12 schizophrenic patients coadministered oral haloperidol and @DRUG$, plasma @DRUG$ levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d186.s5.p0",
        "sentence": "In 5 other schizophrenic patients treated with oral @DRUG$ and @DRUG$, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d186.s5.p1",
        "sentence": "In 5 other schizophrenic patients treated with oral @DRUG$ and rifampin, discontinuation of @DRUG$ produced a mean 3.3-fold increase in haloperidol concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d186.s5.p2",
        "sentence": "In 5 other schizophrenic patients treated with oral @DRUG$ and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in @DRUG$ concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d186.s5.p3",
        "sentence": "In 5 other schizophrenic patients treated with oral haloperidol and @DRUG$, discontinuation of @DRUG$ produced a mean 3.3-fold increase in haloperidol concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d186.s5.p4",
        "sentence": "In 5 other schizophrenic patients treated with oral haloperidol and @DRUG$, discontinuation of rifampin produced a mean 3.3-fold increase in @DRUG$ concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d186.s5.p5",
        "sentence": "In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of @DRUG$ produced a mean 3.3-fold increase in @DRUG$ concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d186.s6.p0",
        "sentence": "Thus, careful monitoring of clinical status is warranted when @DRUG$ is administered or discontinued in @DRUG$-treated patients.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d187.s13.p0",
        "sentence": "@DRUG$: A recent case study has shown a possible increase in the plasma level of @DRUG$ when co administered with isoniazid.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d187.s13.p1",
        "sentence": "@DRUG$: A recent case study has shown a possible increase in the plasma level of valproate when co administered with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d187.s13.p2",
        "sentence": "Valproate: A recent case study has shown a possible increase in the plasma level of @DRUG$ when co administered with @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d187.s8.p0",
        "sentence": "@DRUG$: Potential interaction of @DRUG$ and Isoniazid may exist.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d187.s8.p1",
        "sentence": "@DRUG$: Potential interaction of Ketoconazole and @DRUG$ may exist.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d187.s8.p2",
        "sentence": "Ketoconazole: Potential interaction of @DRUG$ and @DRUG$ may exist.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d187.s9.p0",
        "sentence": "@DRUG$: @DRUG$ may increase serum levels of phenytoin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d187.s9.p1",
        "sentence": "@DRUG$: Isoniazid may increase serum levels of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d187.s9.p2",
        "sentence": "Phenytoin: @DRUG$ may increase serum levels of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d188.s1.p0",
        "sentence": "Data from a randomized trial of @DRUG$ and @DRUG$ plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d188.s1.p1",
        "sentence": "Data from a randomized trial of @DRUG$ and cisplatin plus or minus @DRUG$ in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d188.s1.p2",
        "sentence": "Data from a randomized trial of @DRUG$ and cisplatin plus or minus pyridoxine in ovarian cancer indicated that @DRUG$ significantly reduced neurotoxicity;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d188.s1.p3",
        "sentence": "Data from a randomized trial of HEXALEN and @DRUG$ plus or minus @DRUG$ in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d188.s1.p4",
        "sentence": "Data from a randomized trial of HEXALEN and @DRUG$ plus or minus pyridoxine in ovarian cancer indicated that @DRUG$ significantly reduced neurotoxicity;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d188.s1.p5",
        "sentence": "Data from a randomized trial of HEXALEN and cisplatin plus or minus @DRUG$ in ovarian cancer indicated that @DRUG$ significantly reduced neurotoxicity;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d19.s7.p0",
        "sentence": "Patients taking @DRUG$ when @DRUG$ is given should be observed for the appearance of unsteady gait or marked changes in mental status;",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d190.s2.p0",
        "sentence": "Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose @DRUG$ (@DRUG$ up to 15,000 units/day) or prophylactic doses of low molecular weight heparins as indicated in the prescribing information for the specific products.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d190.s2.p1",
        "sentence": "Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose @DRUG$ (unfractionated heparin up to 15,000 units/day) or prophylactic doses of @DRUG$ as indicated in the prescribing information for the specific products.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d190.s2.p2",
        "sentence": "Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose heparin (@DRUG$ up to 15,000 units/day) or prophylactic doses of @DRUG$ as indicated in the prescribing information for the specific products.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d190.s3.p0",
        "sentence": "Concomitant use of prophylactic low dose @DRUG$ did not appear to affect safety, however, its effects on the efficacy of @DRUG$ have not been evaluated in an adequate and well-controlled clinical trial.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d191.s1.p0",
        "sentence": "@DRUG$ enhance the renal toxicity of @DRUG$ in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d191.s1.p1",
        "sentence": "@DRUG$ enhance the renal toxicity of edetate calcium disodium in animals. 7 @DRUG$ interferes with the action of zinc insulin preparations by chelating the zinc. 7",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d191.s1.p2",
        "sentence": "@DRUG$ enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of @DRUG$ preparations by chelating the zinc. 7",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d191.s1.p3",
        "sentence": "@DRUG$ enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the @DRUG$. 7",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d191.s1.p4",
        "sentence": "Steroids enhance the renal toxicity of @DRUG$ in animals. 7 @DRUG$ interferes with the action of zinc insulin preparations by chelating the zinc. 7",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d191.s1.p5",
        "sentence": "Steroids enhance the renal toxicity of @DRUG$ in animals. 7 Edetate calcium disodium interferes with the action of @DRUG$ preparations by chelating the zinc. 7",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d191.s1.p6",
        "sentence": "Steroids enhance the renal toxicity of @DRUG$ in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the @DRUG$. 7",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d191.s1.p7",
        "sentence": "Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 @DRUG$ interferes with the action of @DRUG$ preparations by chelating the zinc. 7",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d191.s1.p8",
        "sentence": "Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 @DRUG$ interferes with the action of zinc insulin preparations by chelating the @DRUG$. 7",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d191.s1.p9",
        "sentence": "Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of @DRUG$ preparations by chelating the @DRUG$. 7",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p0",
        "sentence": "@DRUG$ can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p1",
        "sentence": "@DRUG$ can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p2",
        "sentence": "@DRUG$ can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p3",
        "sentence": "@DRUG$ can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p4",
        "sentence": "@DRUG$ can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p5",
        "sentence": "@DRUG$ can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p6",
        "sentence": "@DRUG$ can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p7",
        "sentence": "@DRUG$ can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p8",
        "sentence": "Dexbrompheniramine can interact with @DRUG$ or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p9",
        "sentence": "Dexbrompheniramine can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p10",
        "sentence": "Dexbrompheniramine can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p11",
        "sentence": "Dexbrompheniramine can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p12",
        "sentence": "Dexbrompheniramine can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p13",
        "sentence": "Dexbrompheniramine can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p14",
        "sentence": "Dexbrompheniramine can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p15",
        "sentence": "Dexbrompheniramine can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p16",
        "sentence": "Dexbrompheniramine can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p17",
        "sentence": "Dexbrompheniramine can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p18",
        "sentence": "Dexbrompheniramine can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p19",
        "sentence": "Dexbrompheniramine can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p20",
        "sentence": "Dexbrompheniramine can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p21",
        "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p22",
        "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p23",
        "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p24",
        "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p25",
        "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p26",
        "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p27",
        "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p28",
        "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p29",
        "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p30",
        "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p31",
        "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p32",
        "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p33",
        "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p34",
        "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d192.s0.p35",
        "sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d193.s0.p0",
        "sentence": "A drug interaction study was performed in which @DRUG$ was administered in combination with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d195.s7.p0",
        "sentence": "Based on clinical and pharmacokinetic results from the ATAC trial, @DRUG$ should not be administered with @DRUG$ (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d195.s8.p0",
        "sentence": "Co-administration of @DRUG$ and @DRUG$ resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d195.s8.p1",
        "sentence": "Co-administration of @DRUG$ and tamoxifen resulted in a reduction of @DRUG$ plasma levels by 27% compared with those achieved with anastrozole alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d195.s8.p2",
        "sentence": "Co-administration of @DRUG$ and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with @DRUG$ alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d195.s8.p3",
        "sentence": "Co-administration of anastrozole and @DRUG$ resulted in a reduction of @DRUG$ plasma levels by 27% compared with those achieved with anastrozole alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d195.s8.p4",
        "sentence": "Co-administration of anastrozole and @DRUG$ resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with @DRUG$ alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d195.s8.p5",
        "sentence": "Co-administration of anastrozole and tamoxifen resulted in a reduction of @DRUG$ plasma levels by 27% compared with those achieved with @DRUG$ alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d196.s36.p0",
        "sentence": "@DRUG$ contains @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d196.s4.p0",
        "sentence": "Nucleoside Analogues @DRUG$ Co-administration of @DRUG$ and didanosine is not recommended.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d196.s4.p1",
        "sentence": "Nucleoside Analogues @DRUG$ Co-administration of COPEGUS and @DRUG$ is not recommended.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d196.s4.p2",
        "sentence": "Nucleoside Analogues Didanosine Co-administration of @DRUG$ and @DRUG$ is not recommended.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d196.s41.p0",
        "sentence": "@DRUG$ and @DRUG$ are excreted by the kidney, and the risk of toxic reactions to this therapy may be greater in patients with impaired renal function.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d196.s43.p0",
        "sentence": "@DRUG$ should be used with caution in patients with creatinine clearance  50 mL/min and @DRUG$ should not be administered to patients with creatinine clearance  50 mL/min",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p0",
        "sentence": "@DRUG$/@DRUG$/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p1",
        "sentence": "@DRUG$/Sedatives/@DRUG$/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p2",
        "sentence": "@DRUG$/Sedatives/Hypnotics/@DRUG$: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p3",
        "sentence": "@DRUG$/Sedatives/Hypnotics/Opioids: Co-administration of @DRUG$ with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p4",
        "sentence": "@DRUG$/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with @DRUG$, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p5",
        "sentence": "@DRUG$/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, @DRUG$, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p6",
        "sentence": "@DRUG$/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, @DRUG$, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p7",
        "sentence": "@DRUG$/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and @DRUG$ is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p8",
        "sentence": "Anesthetics/@DRUG$/@DRUG$/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p9",
        "sentence": "Anesthetics/@DRUG$/Hypnotics/@DRUG$: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p10",
        "sentence": "Anesthetics/@DRUG$/Hypnotics/Opioids: Co-administration of @DRUG$ with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p11",
        "sentence": "Anesthetics/@DRUG$/Hypnotics/Opioids: Co-administration of PRECEDEX with @DRUG$, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p12",
        "sentence": "Anesthetics/@DRUG$/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, @DRUG$, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p13",
        "sentence": "Anesthetics/@DRUG$/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, @DRUG$, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p14",
        "sentence": "Anesthetics/@DRUG$/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and @DRUG$ is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p15",
        "sentence": "Anesthetics/Sedatives/@DRUG$/@DRUG$: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p16",
        "sentence": "Anesthetics/Sedatives/@DRUG$/Opioids: Co-administration of @DRUG$ with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p17",
        "sentence": "Anesthetics/Sedatives/@DRUG$/Opioids: Co-administration of PRECEDEX with @DRUG$, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p18",
        "sentence": "Anesthetics/Sedatives/@DRUG$/Opioids: Co-administration of PRECEDEX with anesthetics, @DRUG$, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p19",
        "sentence": "Anesthetics/Sedatives/@DRUG$/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, @DRUG$, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p20",
        "sentence": "Anesthetics/Sedatives/@DRUG$/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and @DRUG$ is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p21",
        "sentence": "Anesthetics/Sedatives/Hypnotics/@DRUG$: Co-administration of @DRUG$ with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p22",
        "sentence": "Anesthetics/Sedatives/Hypnotics/@DRUG$: Co-administration of PRECEDEX with @DRUG$, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p23",
        "sentence": "Anesthetics/Sedatives/Hypnotics/@DRUG$: Co-administration of PRECEDEX with anesthetics, @DRUG$, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p24",
        "sentence": "Anesthetics/Sedatives/Hypnotics/@DRUG$: Co-administration of PRECEDEX with anesthetics, sedatives, @DRUG$, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p25",
        "sentence": "Anesthetics/Sedatives/Hypnotics/@DRUG$: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and @DRUG$ is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p26",
        "sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of @DRUG$ with @DRUG$, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p27",
        "sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of @DRUG$ with anesthetics, @DRUG$, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p28",
        "sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of @DRUG$ with anesthetics, sedatives, @DRUG$, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p29",
        "sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of @DRUG$ with anesthetics, sedatives, hypnotics, and @DRUG$ is likely to lead to an enhancement of effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p30",
        "sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with @DRUG$, @DRUG$, hypnotics, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p31",
        "sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with @DRUG$, sedatives, @DRUG$, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p32",
        "sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with @DRUG$, sedatives, hypnotics, and @DRUG$ is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p33",
        "sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, @DRUG$, @DRUG$, and opioids is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p34",
        "sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, @DRUG$, hypnotics, and @DRUG$ is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s1.p35",
        "sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, @DRUG$, and @DRUG$ is likely to lead to an enhancement of effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s4.p0",
        "sentence": "However, due to possible pharmacodynamic interactions, when co-administered with @DRUG$, a reduction in dosage of @DRUG$ on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s4.p1",
        "sentence": "However, due to possible pharmacodynamic interactions, when co-administered with @DRUG$, a reduction in dosage of PRECEDEX on the concomitant @DRUG$, sedative, hypnotic or opioid may be required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s4.p2",
        "sentence": "However, due to possible pharmacodynamic interactions, when co-administered with @DRUG$, a reduction in dosage of PRECEDEX on the concomitant anesthetic, @DRUG$, hypnotic or opioid may be required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s4.p3",
        "sentence": "However, due to possible pharmacodynamic interactions, when co-administered with @DRUG$, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, @DRUG$ or opioid may be required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s4.p4",
        "sentence": "However, due to possible pharmacodynamic interactions, when co-administered with @DRUG$, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or @DRUG$ may be required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s4.p5",
        "sentence": "However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of @DRUG$ on the concomitant @DRUG$, sedative, hypnotic or opioid may be required.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d197.s4.p6",
        "sentence": "However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of @DRUG$ on the concomitant anesthetic, @DRUG$, hypnotic or opioid may be required.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d197.s4.p7",
        "sentence": "However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of @DRUG$ on the concomitant anesthetic, sedative, @DRUG$ or opioid may be required.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d197.s4.p8",
        "sentence": "However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of @DRUG$ on the concomitant anesthetic, sedative, hypnotic or @DRUG$ may be required.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d197.s4.p9",
        "sentence": "However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant @DRUG$, @DRUG$, hypnotic or opioid may be required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s4.p10",
        "sentence": "However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant @DRUG$, sedative, @DRUG$ or opioid may be required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s4.p11",
        "sentence": "However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant @DRUG$, sedative, hypnotic or @DRUG$ may be required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s4.p12",
        "sentence": "However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, @DRUG$, @DRUG$ or opioid may be required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s4.p13",
        "sentence": "However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, @DRUG$, hypnotic or @DRUG$ may be required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s4.p14",
        "sentence": "However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, @DRUG$ or @DRUG$ may be required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s5.p0",
        "sentence": "@DRUG$: In one study of 10 healthy volunteers, administration of @DRUG$ for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s5.p1",
        "sentence": "@DRUG$: In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with @DRUG$ administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d197.s5.p2",
        "sentence": "Neuromuscular Blockers: In one study of 10 healthy volunteers, administration of @DRUG$ for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with @DRUG$ administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d198.s14.p0",
        "sentence": "@DRUG$ significantly prolonged the half-life of @DRUG$ to 26 hours.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d198.s15.p0",
        "sentence": "Consequently, it is recommended not to exceed a single 2.5 mg @DRUG$ dose in a 72-hour period when used in combination with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d198.s22.p0",
        "sentence": "In vivo studies: @DRUG$: The blood pressure lowering effects of sublingual @DRUG$ (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d198.s22.p1",
        "sentence": "In vivo studies: @DRUG$: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after @DRUG$ and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d198.s22.p2",
        "sentence": "In vivo studies: @DRUG$: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of @DRUG$ in healthy middle-aged subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d198.s22.p3",
        "sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual @DRUG$ (0.4 mg) taken 1 and 4 hours after @DRUG$ and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d198.s22.p4",
        "sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual @DRUG$ (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of @DRUG$ in healthy middle-aged subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d198.s22.p5",
        "sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after @DRUG$ and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of @DRUG$ in healthy middle-aged subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d198.s24.p0",
        "sentence": "Potentiation of the hypotensive effects of @DRUG$ for patients with ischemic heart disease has not been evaluated, and concomitant use of @DRUG$ and nitrates is contraindicated.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d198.s24.p1",
        "sentence": "Potentiation of the hypotensive effects of @DRUG$ for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and @DRUG$ is contraindicated.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d198.s24.p2",
        "sentence": "Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of @DRUG$ and @DRUG$ is contraindicated.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d198.s31.p0",
        "sentence": "When @DRUG$ dosing was separated from @DRUG$ 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d198.s31.p1",
        "sentence": "When @DRUG$ dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of @DRUG$ experienced a decrease in standing systolic blood pressure below 85 mm Hg.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d198.s31.p2",
        "sentence": "When Vardenafil dosing was separated from @DRUG$ 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of @DRUG$ experienced a decrease in standing systolic blood pressure below 85 mm Hg.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d198.s34.p0",
        "sentence": "The administration of lower doses of @DRUG$ with @DRUG$ has not been completely evaluated to determine if they can be safely administered together.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d198.s37.p0",
        "sentence": "Upon administration of 10 mg of @DRUG$ with 800 mg TID @DRUG$, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d198.s37.p1",
        "sentence": "Upon administration of 10 mg of @DRUG$ with 800 mg TID indinavir, the Cmax and AUC of @DRUG$ were reduced by 40% and 30%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d198.s37.p2",
        "sentence": "Upon administration of 10 mg of Vardenafil with 800 mg TID @DRUG$, the Cmax and AUC of @DRUG$ were reduced by 40% and 30%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d198.s5.p0",
        "sentence": "@DRUG$ (500 mg t.i.d) produced a 4-fold increase in @DRUG$ AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d198.s5.p1",
        "sentence": "@DRUG$ (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with @DRUG$ 5 mg in healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d198.s5.p2",
        "sentence": "Erythromycin (500 mg t.i.d) produced a 4-fold increase in @DRUG$ AUC and a 3-fold increase in Cmax when co-administered with @DRUG$ 5 mg in healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d199.s0.p0",
        "sentence": "@DRUG$: When coadministered with @DRUG$, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d199.s0.p1",
        "sentence": "@DRUG$: When coadministered with MONUROL, @DRUG$, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d199.s0.p2",
        "sentence": "@DRUG$: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d199.s0.p3",
        "sentence": "Metoclopramide: When coadministered with @DRUG$, @DRUG$, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d199.s0.p4",
        "sentence": "Metoclopramide: When coadministered with @DRUG$, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d199.s0.p5",
        "sentence": "Metoclopramide: When coadministered with MONUROL, @DRUG$, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d199.s2.p0",
        "sentence": "@DRUG$: @DRUG$ does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d199.s2.p1",
        "sentence": "@DRUG$: Cimetidine does not affect the pharmacokinetics of @DRUG$ when coadministered with MONUROL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d199.s2.p2",
        "sentence": "@DRUG$: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d199.s2.p3",
        "sentence": "Cimetidine: @DRUG$ does not affect the pharmacokinetics of @DRUG$ when coadministered with MONUROL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d199.s2.p4",
        "sentence": "Cimetidine: @DRUG$ does not affect the pharmacokinetics of fosfomycin when coadministered with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d199.s2.p5",
        "sentence": "Cimetidine: Cimetidine does not affect the pharmacokinetics of @DRUG$ when coadministered with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s1.p0",
        "sentence": "A pharmacokinetic study evaluating the administration of a single dose of @DRUG$ 100 mg with @DRUG$ 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d20.s1.p1",
        "sentence": "A pharmacokinetic study evaluating the administration of a single dose of @DRUG$ 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of @DRUG$ and a 5.4-fold increase in AUC of eplerenone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s1.p2",
        "sentence": "A pharmacokinetic study evaluating the administration of a single dose of @DRUG$ 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s1.p3",
        "sentence": "A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with @DRUG$ 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of @DRUG$ and a 5.4-fold increase in AUC of eplerenone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s1.p4",
        "sentence": "A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with @DRUG$ 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s1.p5",
        "sentence": "A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of @DRUG$ and a 5.4-fold increase in AUC of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s12.p0",
        "sentence": "Therefore, when @DRUG$ and @DRUG$ are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d20.s3.p0",
        "sentence": "Administration of @DRUG$ with other CYP3A4 inhibitors (e.g., @DRUG$ 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d20.s3.p1",
        "sentence": "Administration of @DRUG$ with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, @DRUG$ 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d20.s3.p2",
        "sentence": "Administration of @DRUG$ with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, @DRUG$ 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d20.s3.p3",
        "sentence": "Administration of @DRUG$ with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, @DRUG$ 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d20.s3.p4",
        "sentence": "Administration of @DRUG$ with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of @DRUG$ ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s3.p5",
        "sentence": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., @DRUG$ 500 mg BID, @DRUG$ 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s3.p6",
        "sentence": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., @DRUG$ 500 mg BID, verapamil 240 mg QD, @DRUG$ 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s3.p7",
        "sentence": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., @DRUG$ 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, @DRUG$ 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s3.p8",
        "sentence": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., @DRUG$ 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of @DRUG$ ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s3.p9",
        "sentence": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, @DRUG$ 240 mg QD, @DRUG$ 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s3.p10",
        "sentence": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, @DRUG$ 240 mg QD, saquinavir 1200 mg TID, @DRUG$ 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s3.p11",
        "sentence": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, @DRUG$ 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of @DRUG$ ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s3.p12",
        "sentence": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, @DRUG$ 1200 mg TID, @DRUG$ 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s3.p13",
        "sentence": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, @DRUG$ 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of @DRUG$ ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s3.p14",
        "sentence": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, @DRUG$ 200 mg QD) resulted in increases in Cmax of @DRUG$ ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s5.p0",
        "sentence": "Rates of patients with maximum potassium levels  5.5 mEq/L were similar regardless of the use of @DRUG$/@DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s7.p0",
        "sentence": "In a study in diabetics with microalbuminuria @DRUG$ 200 mg combined with the @DRUG$ enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s7.p1",
        "sentence": "In a study in diabetics with microalbuminuria @DRUG$ 200 mg combined with the ACE inhibitor @DRUG$ 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d20.s7.p2",
        "sentence": "In a study in diabetics with microalbuminuria @DRUG$ 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on @DRUG$ alone to 38%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s7.p3",
        "sentence": "In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the @DRUG$ @DRUG$ 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s7.p4",
        "sentence": "In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the @DRUG$ enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on @DRUG$ alone to 38%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d20.s7.p5",
        "sentence": "In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor @DRUG$ 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on @DRUG$ alone to 38%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s12.p0",
        "sentence": "Such individuals are referred to as  poor metabolizers  of drugs such as @DRUG$, @DRUG$, and the tricyclic antidepressants.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s12.p1",
        "sentence": "Such individuals are referred to as  poor metabolizers  of drugs such as @DRUG$, dextromethorphan, and the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s12.p2",
        "sentence": "Such individuals are referred to as  poor metabolizers  of drugs such as debrisoquin, @DRUG$, and the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s15.p0",
        "sentence": "Concomitant use of @DRUG$ with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the @DRUG$ or the other drug.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p0",
        "sentence": "Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p1",
        "sentence": "Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other antidepressants, @DRUG$, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p2",
        "sentence": "Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p3",
        "sentence": "Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and @DRUG$ (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p4",
        "sentence": "Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, @DRUG$, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p5",
        "sentence": "Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, @DRUG$, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p6",
        "sentence": "Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and @DRUG$), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p7",
        "sentence": "Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p8",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, @DRUG$, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p9",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p10",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, carbamazepine, and @DRUG$ (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p11",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, @DRUG$, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p12",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, @DRUG$, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p13",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and @DRUG$), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p14",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p15",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, @DRUG$, @DRUG$, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p16",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, @DRUG$, carbamazepine, and @DRUG$ (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p17",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, @DRUG$, carbamazepine, and Type 1C antiarrhythmics (eg, @DRUG$, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p18",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, @DRUG$, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, @DRUG$, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p19",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, @DRUG$, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and @DRUG$), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p20",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, @DRUG$, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p21",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, @DRUG$, and @DRUG$ (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p22",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (eg, @DRUG$, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p23",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (eg, propafenone, @DRUG$, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p24",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and @DRUG$), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p25",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p26",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and @DRUG$ (eg, @DRUG$, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p27",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and @DRUG$ (eg, propafenone, @DRUG$, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p28",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and @DRUG$ (eg, propafenone, flecainide, and @DRUG$), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p29",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and @DRUG$ (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p30",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, @DRUG$, @DRUG$, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p31",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, @DRUG$, flecainide, and @DRUG$), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p32",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, @DRUG$, flecainide, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p33",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, @DRUG$, and @DRUG$), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p34",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, @DRUG$, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s16.p35",
        "sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and @DRUG$), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d202.s4.p0",
        "sentence": "The therapeutic efficacy of @DRUG$ may be compromised in these patients when @DRUG$ is discontinued.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d204.s0.p0",
        "sentence": "When administered concurrently, the following drugs may interact with @DRUG$: @DRUG$, general: exaggeration of the hypotension induced by general anesthetics.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d204.s0.p1",
        "sentence": "When administered concurrently, the following drugs may interact with @DRUG$: Anesthetics, general: exaggeration of the hypotension induced by general @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d204.s0.p2",
        "sentence": "When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: @DRUG$, general: exaggeration of the hypotension induced by general @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d204.s1.p0",
        "sentence": "@DRUG$ (oral agents and @DRUG$): hypoglycemia or hyperglycemia;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p0",
        "sentence": "Since @DRUG$ (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p1",
        "sentence": "Since @DRUG$ (ethosuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p2",
        "sentence": "Since @DRUG$ (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, @DRUG$ may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p3",
        "sentence": "Since @DRUG$ (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate @DRUG$ serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p4",
        "sentence": "Since @DRUG$ (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and @DRUG$ has been reported to both increase and decrease ethosuximide levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p5",
        "sentence": "Since @DRUG$ (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease @DRUG$ levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p6",
        "sentence": "Since Zarontin (@DRUG$) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p7",
        "sentence": "Since Zarontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, @DRUG$ may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p8",
        "sentence": "Since Zarontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate @DRUG$ serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p9",
        "sentence": "Since Zarontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and @DRUG$ has been reported to both increase and decrease ethosuximide levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p10",
        "sentence": "Since Zarontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease @DRUG$ levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p11",
        "sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg, @DRUG$ may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p12",
        "sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate @DRUG$ serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p13",
        "sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and @DRUG$ has been reported to both increase and decrease ethosuximide levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p14",
        "sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease @DRUG$ levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p15",
        "sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, @DRUG$ may elevate @DRUG$ serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p16",
        "sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, @DRUG$ may elevate phenytoin serum levels and @DRUG$ has been reported to both increase and decrease ethosuximide levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p17",
        "sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, @DRUG$ may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease @DRUG$ levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p18",
        "sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate @DRUG$ serum levels and @DRUG$ has been reported to both increase and decrease ethosuximide levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p19",
        "sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate @DRUG$ serum levels and valproic acid has been reported to both increase and decrease @DRUG$ levels).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d205.s0.p20",
        "sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and @DRUG$ has been reported to both increase and decrease @DRUG$ levels).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d206.s0.p0",
        "sentence": "Results of preliminary studies in humans and rats suggest that nonabsorbable @DRUG$ given concurrently with @DRUG$ may inhibit the desired lactulose-induced drop in colonic pH.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d206.s0.p1",
        "sentence": "Results of preliminary studies in humans and rats suggest that nonabsorbable @DRUG$ given concurrently with lactulose may inhibit the desired @DRUG$-induced drop in colonic pH.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d206.s0.p2",
        "sentence": "Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with @DRUG$ may inhibit the desired @DRUG$-induced drop in colonic pH.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d207.s1.p0",
        "sentence": "In patients receiving a potent CYP3A4 inducer such as @DRUG$ or @DRUG$, a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d207.s8.p0",
        "sentence": "Phase II clinical trial data, where @DRUG$ and @DRUG$ have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d207.s8.p1",
        "sentence": "Phase II clinical trial data, where @DRUG$ and vinorelbine have been used concomitantly, indicate that @DRUG$ may exacerbate the neutropenic effect of vinorelbine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d207.s8.p2",
        "sentence": "Phase II clinical trial data, where @DRUG$ and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d207.s8.p3",
        "sentence": "Phase II clinical trial data, where IRESSA and @DRUG$ have been used concomitantly, indicate that @DRUG$ may exacerbate the neutropenic effect of vinorelbine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d207.s8.p4",
        "sentence": "Phase II clinical trial data, where IRESSA and @DRUG$ have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d207.s8.p5",
        "sentence": "Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that @DRUG$ may exacerbate the neutropenic effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d21.s0.p0",
        "sentence": "Tissue culture and animal studies indicate that @DRUG$ can diminish or abolish the effect of @DRUG$ on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d21.s0.p1",
        "sentence": "Tissue culture and animal studies indicate that @DRUG$ can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on @DRUG$ activity persists as long as plasma asparagine levels are suppressed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d21.s0.p2",
        "sentence": "Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of @DRUG$ on malignant cells.14 This effect on @DRUG$ activity persists as long as plasma asparagine levels are suppressed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s10.p0",
        "sentence": "@DRUG$: Co-administration with high doses of @DRUG$ [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s10.p1",
        "sentence": "@DRUG$: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of @DRUG$ by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s10.p2",
        "sentence": "Cimetidine: Co-administration with high doses of @DRUG$ [800 mg twice daily] increased the Cmax of @DRUG$ by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d210.s13.p0",
        "sentence": "@DRUG$: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and thiazides in some patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s13.p1",
        "sentence": "@DRUG$: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s13.p2",
        "sentence": "@DRUG$: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s13.p3",
        "sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d210.s13.p4",
        "sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d210.s13.p5",
        "sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s15.p0",
        "sentence": "@DRUG$: @DRUG$ 400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s15.p1",
        "sentence": "@DRUG$: Ketoconazole 400 mg daily did not have any clinically important effect on the pharmacokinetics of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s15.p2",
        "sentence": "Ketoconazole: @DRUG$ 400 mg daily did not have any clinically important effect on the pharmacokinetics of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s18.p0",
        "sentence": "Thus, when @DRUG$ and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d210.s18.p1",
        "sentence": "Thus, when @DRUG$ and lithium are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s18.p2",
        "sentence": "Thus, when VIOXX and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s19.p0",
        "sentence": "@DRUG$ @DRUG$ 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s19.p1",
        "sentence": "@DRUG$ VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of @DRUG$ as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s19.p2",
        "sentence": "@DRUG$ VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly @DRUG$ doses of 7.5 to 20 mg for rheumatoid arthritis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s19.p3",
        "sentence": "Methotrexate @DRUG$ 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of @DRUG$ as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s19.p4",
        "sentence": "Methotrexate @DRUG$ 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly @DRUG$ doses of 7.5 to 20 mg for rheumatoid arthritis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s19.p5",
        "sentence": "Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of @DRUG$ as measured by AUC0-24hr in patients receiving single weekly @DRUG$ doses of 7.5 to 20 mg for rheumatoid arthritis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s21.p0",
        "sentence": "At 24 hours postdose, a similar proportion of patients treated with @DRUG$ alone (94%) and subsequently treated with @DRUG$ co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s21.p1",
        "sentence": "At 24 hours postdose, a similar proportion of patients treated with @DRUG$ alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of @DRUG$ (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s21.p2",
        "sentence": "At 24 hours postdose, a similar proportion of patients treated with @DRUG$ alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had @DRUG$ plasma concentrations below the measurable limit (5 ng/mL).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s21.p3",
        "sentence": "At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with @DRUG$ co-administered with 75 mg of @DRUG$ (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d210.s21.p4",
        "sentence": "At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with @DRUG$ co-administered with 75 mg of rofecoxib (88%) had @DRUG$ plasma concentrations below the measurable limit (5 ng/mL).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s21.p5",
        "sentence": "At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of @DRUG$ (88%) had @DRUG$ plasma concentrations below the measurable limit (5 ng/mL).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s23.p0",
        "sentence": "Oral @DRUG$ @DRUG$ did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s23.p1",
        "sentence": "Oral @DRUG$ Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ and norethindrone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s23.p2",
        "sentence": "Oral @DRUG$ Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s23.p3",
        "sentence": "Oral Contraceptives @DRUG$ did not have any clinically important effect on the pharmacokinetics of @DRUG$ and norethindrone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s23.p4",
        "sentence": "Oral Contraceptives @DRUG$ did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s23.p5",
        "sentence": "Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s27.p0",
        "sentence": "@DRUG$ @DRUG$ 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s27.p1",
        "sentence": "@DRUG$ VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma @DRUG$ concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s27.p2",
        "sentence": "@DRUG$ VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s27.p3",
        "sentence": "Theophylline @DRUG$ 12.5, 25, and 50 mg administered once daily for 7 days increased plasma @DRUG$ concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d210.s27.p4",
        "sentence": "Theophylline @DRUG$ 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s27.p5",
        "sentence": "Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma @DRUG$ concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d210.s9.p0",
        "sentence": "Prospective, long-term studies on concomitant administration of @DRUG$ and @DRUG$ have not been conducted.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d212.s7.p0",
        "sentence": "Pharmacokinetics of @DRUG$ were also not affected by @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d213.s1.p0",
        "sentence": "Serum concentration of @DRUG$ and @DRUG$ may increase when patients take antithyroid agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d213.s1.p1",
        "sentence": "Serum concentration of @DRUG$ and digitoxin may increase when patients take @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d213.s1.p2",
        "sentence": "Serum concentration of digoxin and @DRUG$ may increase when patients take @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d213.s3.p0",
        "sentence": "@DRUG$ may decrease thyroidal uptake of @DRUG$, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d213.s3.p1",
        "sentence": "@DRUG$ may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d213.s3.p2",
        "sentence": "Antithyroid agents may decrease thyroidal uptake of @DRUG$, a rebound in uptake may occur up to 5 days after sudden withdrawal of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d215.s0.p0",
        "sentence": "Caution should be observed when @DRUG$ is coadministered with other @DRUG$, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d215.s0.p1",
        "sentence": "Caution should be observed when @DRUG$ is coadministered with other opioids, @DRUG$, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d215.s0.p2",
        "sentence": "Caution should be observed when @DRUG$ is coadministered with other opioids, sedatives, @DRUG$, or anesthetics, as these agents may increase respiratory and circulatory depression.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d215.s0.p3",
        "sentence": "Caution should be observed when @DRUG$ is coadministered with other opioids, sedatives, phenothiazines, or @DRUG$, as these agents may increase respiratory and circulatory depression.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d215.s0.p4",
        "sentence": "Caution should be observed when anileridine is coadministered with other @DRUG$, @DRUG$, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d215.s0.p5",
        "sentence": "Caution should be observed when anileridine is coadministered with other @DRUG$, sedatives, @DRUG$, or anesthetics, as these agents may increase respiratory and circulatory depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d215.s0.p6",
        "sentence": "Caution should be observed when anileridine is coadministered with other @DRUG$, sedatives, phenothiazines, or @DRUG$, as these agents may increase respiratory and circulatory depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d215.s0.p7",
        "sentence": "Caution should be observed when anileridine is coadministered with other opioids, @DRUG$, @DRUG$, or anesthetics, as these agents may increase respiratory and circulatory depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d215.s0.p8",
        "sentence": "Caution should be observed when anileridine is coadministered with other opioids, @DRUG$, phenothiazines, or @DRUG$, as these agents may increase respiratory and circulatory depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d215.s0.p9",
        "sentence": "Caution should be observed when anileridine is coadministered with other opioids, sedatives, @DRUG$, or @DRUG$, as these agents may increase respiratory and circulatory depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d216.s0.p0",
        "sentence": "CNS-Active Drugs @DRUG$ An additive effect on psychomotor performance was seen with coadministration of @DRUG$ and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d216.s0.p1",
        "sentence": "CNS-Active Drugs @DRUG$ An additive effect on psychomotor performance was seen with coadministration of eszopiclone and @DRUG$ 0.70 g/kg for up to 4 hours after ethanol administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d216.s0.p2",
        "sentence": "CNS-Active Drugs @DRUG$ An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after @DRUG$ administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d216.s0.p3",
        "sentence": "CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of @DRUG$ and @DRUG$ 0.70 g/kg for up to 4 hours after ethanol administration.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d216.s0.p4",
        "sentence": "CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of @DRUG$ and ethanol 0.70 g/kg for up to 4 hours after @DRUG$ administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d216.s0.p5",
        "sentence": "CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and @DRUG$ 0.70 g/kg for up to 4 hours after @DRUG$ administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d217.s12.p0",
        "sentence": "@DRUG$ (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d217.s12.p1",
        "sentence": "@DRUG$ (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d217.s12.p2",
        "sentence": "@DRUG$ (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d217.s12.p3",
        "sentence": "Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d217.s12.p4",
        "sentence": "Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d217.s12.p5",
        "sentence": "Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because these products may interfere with absorption resulting in lower serum and urine levels of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d217.s13.p0",
        "sentence": "Some @DRUG$ have also been shown to interfere with the metabolism of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d217.s2.p0",
        "sentence": "Therefore, monitoring of @DRUG$ plasma levels should be considered and dosage of @DRUG$ adjusted as required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d217.s7.p0",
        "sentence": "The concomitant administration of @DRUG$ including @DRUG$ with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d217.s7.p1",
        "sentence": "The concomitant administration of @DRUG$ including norfloxacin with @DRUG$ (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d217.s7.p2",
        "sentence": "The concomitant administration of @DRUG$ including norfloxacin with glyburide (a @DRUG$) has, on rare occasions, resulted in severe hypoglycemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d217.s7.p3",
        "sentence": "The concomitant administration of quinolones including @DRUG$ with @DRUG$ (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d217.s7.p4",
        "sentence": "The concomitant administration of quinolones including @DRUG$ with glyburide (a @DRUG$) has, on rare occasions, resulted in severe hypoglycemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d217.s7.p5",
        "sentence": "The concomitant administration of quinolones including norfloxacin with @DRUG$ (a @DRUG$) has, on rare occasions, resulted in severe hypoglycemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d217.s9.p0",
        "sentence": "Diminished urinary excretion of @DRUG$ has been reported during the concomitant administration of @DRUG$ and norfloxacin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d217.s9.p1",
        "sentence": "Diminished urinary excretion of @DRUG$ has been reported during the concomitant administration of probenecid and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d217.s9.p2",
        "sentence": "Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of @DRUG$ and @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d219.s18.p0",
        "sentence": "Thus, when @DRUG$ and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d219.s18.p1",
        "sentence": "Thus, when @DRUG$ and lithium are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d219.s18.p2",
        "sentence": "Thus, when NSAIDs and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d219.s2.p0",
        "sentence": "@DRUG$: The concomitant administration of @DRUG$ has no apparent effect on the extent of absorption of Lodine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d219.s2.p1",
        "sentence": "@DRUG$: The concomitant administration of antacids has no apparent effect on the extent of absorption of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d219.s2.p2",
        "sentence": "Antacids: The concomitant administration of @DRUG$ has no apparent effect on the extent of absorption of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d219.s20.p0",
        "sentence": "Although in vivo studies have not been done to see if @DRUG$ clearance is changed by coadministration of @DRUG$, it is not recommended that they be coadministered.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d219.s26.p0",
        "sentence": "However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in @DRUG$-treated patients receiving concomitant @DRUG$ therapy.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d219.s6.p0",
        "sentence": "however, as with other @DRUG$, concomitant administration of @DRUG$ and aspirin is not generally recommended because of the potential of increased adverse effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d219.s6.p1",
        "sentence": "however, as with other @DRUG$, concomitant administration of Lodine and @DRUG$ is not generally recommended because of the potential of increased adverse effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d219.s6.p2",
        "sentence": "however, as with other NSAIDs, concomitant administration of @DRUG$ and @DRUG$ is not generally recommended because of the potential of increased adverse effects.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d220.s1.p0",
        "sentence": "There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a @DRUG$ (@DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p0",
        "sentence": "In patients taking an @DRUG$ (eg, @DRUG$, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p1",
        "sentence": "In patients taking an @DRUG$ (eg, valproic acid, @DRUG$, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p2",
        "sentence": "In patients taking an @DRUG$ (eg, valproic acid, carbamazepine, @DRUG$ or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p3",
        "sentence": "In patients taking an @DRUG$ (eg, valproic acid, carbamazepine, phenobarbital or @DRUG$), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p4",
        "sentence": "In patients taking an @DRUG$ (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of @DRUG$ may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p5",
        "sentence": "In patients taking an @DRUG$ (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p6",
        "sentence": "In patients taking an anticonvulsant (eg, @DRUG$, @DRUG$, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p7",
        "sentence": "In patients taking an anticonvulsant (eg, @DRUG$, carbamazepine, @DRUG$ or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p8",
        "sentence": "In patients taking an anticonvulsant (eg, @DRUG$, carbamazepine, phenobarbital or @DRUG$), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p9",
        "sentence": "In patients taking an anticonvulsant (eg, @DRUG$, carbamazepine, phenobarbital or phenytoin), the concomitant use of @DRUG$ may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p10",
        "sentence": "In patients taking an anticonvulsant (eg, @DRUG$, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p11",
        "sentence": "In patients taking an anticonvulsant (eg, valproic acid, @DRUG$, @DRUG$ or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p12",
        "sentence": "In patients taking an anticonvulsant (eg, valproic acid, @DRUG$, phenobarbital or @DRUG$), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p13",
        "sentence": "In patients taking an anticonvulsant (eg, valproic acid, @DRUG$, phenobarbital or phenytoin), the concomitant use of @DRUG$ may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p14",
        "sentence": "In patients taking an anticonvulsant (eg, valproic acid, @DRUG$, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p15",
        "sentence": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, @DRUG$ or @DRUG$), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p16",
        "sentence": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, @DRUG$ or phenytoin), the concomitant use of @DRUG$ may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p17",
        "sentence": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, @DRUG$ or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p18",
        "sentence": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or @DRUG$), the concomitant use of @DRUG$ may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p19",
        "sentence": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or @DRUG$), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s11.p20",
        "sentence": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of @DRUG$ may reduce seizure control by lowering the plasma levels of the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d220.s4.p0",
        "sentence": "Because of the danger of a potentially fatal prolongation of the QTc interval, @DRUG$ must not be given simultaneously with or subsequent to @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d221.s1.p0",
        "sentence": "Simultaneous use of @DRUG$ or @DRUG$ should be avoided.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d222.s0.p0",
        "sentence": "When @DRUG$ and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d222.s0.p1",
        "sentence": "When @DRUG$ and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because pralidoxime may potentiate the effect of atropine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d222.s0.p2",
        "sentence": "When @DRUG$ and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because @DRUG$ may potentiate the effect of atropine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d222.s0.p3",
        "sentence": "When @DRUG$ and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d222.s0.p4",
        "sentence": "When atropine and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because pralidoxime may potentiate the effect of atropine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d222.s0.p5",
        "sentence": "When atropine and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because @DRUG$ may potentiate the effect of atropine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d222.s0.p6",
        "sentence": "When atropine and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d222.s0.p7",
        "sentence": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because @DRUG$ may potentiate the effect of atropine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d222.s0.p8",
        "sentence": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because pralidoxime may potentiate the effect of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d222.s0.p9",
        "sentence": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because @DRUG$ may potentiate the effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d223.s16.p0",
        "sentence": "Inhibitors or substrates of CYP2D6 (i.e., @DRUG$, @DRUG$ [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s16.p1",
        "sentence": "Inhibitors or substrates of CYP2D6 (i.e., @DRUG$, selective serotonin reuptake inhibitors [@DRUG$]) may increase the plasma concentration of doxepin when administered concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s16.p2",
        "sentence": "Inhibitors or substrates of CYP2D6 (i.e., @DRUG$, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of @DRUG$ when administered concomitantly.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d223.s16.p3",
        "sentence": "Inhibitors or substrates of CYP2D6 (i.e., quinidine, @DRUG$ [@DRUG$]) may increase the plasma concentration of doxepin when administered concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s16.p4",
        "sentence": "Inhibitors or substrates of CYP2D6 (i.e., quinidine, @DRUG$ [SSRIs]) may increase the plasma concentration of @DRUG$ when administered concomitantly.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d223.s16.p5",
        "sentence": "Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [@DRUG$]) may increase the plasma concentration of @DRUG$ when administered concomitantly.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d223.s25.p0",
        "sentence": "In patients who have been reported to be well controlled on @DRUG$ receiving concurrent @DRUG$ therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s25.p1",
        "sentence": "In patients who have been reported to be well controlled on @DRUG$ receiving concurrent cimetidine therapy, discontinuation of @DRUG$ has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s25.p2",
        "sentence": "In patients who have been reported to be well controlled on @DRUG$ receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum @DRUG$ levels and compromise their therapeutic effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s25.p3",
        "sentence": "In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent @DRUG$ therapy, discontinuation of @DRUG$ has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s25.p4",
        "sentence": "In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent @DRUG$ therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum @DRUG$ levels and compromise their therapeutic effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s25.p5",
        "sentence": "In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of @DRUG$ has been reported to decrease established steady-state serum @DRUG$ levels and compromise their therapeutic effects.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d223.s26.p0",
        "sentence": "@DRUG$: It should be borne in mind that @DRUG$ ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s26.p1",
        "sentence": "@DRUG$: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional @DRUG$ overdosage.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s26.p2",
        "sentence": "Alcohol: It should be borne in mind that @DRUG$ ingestion may increase the danger inherent in any intentional or unintentional @DRUG$ overdosage.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d223.s7.p0",
        "sentence": "@DRUG$) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s7.p1",
        "sentence": "@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s7.p2",
        "sentence": "@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ propafenone and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s7.p3",
        "sentence": "@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s7.p4",
        "sentence": "@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s7.p5",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, @DRUG$, and the Type 1C antiarrhythmics propafenone and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s7.p6",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the @DRUG$ propafenone and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s7.p7",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s7.p8",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics propafenone and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s7.p9",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the @DRUG$ propafenone and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s7.p10",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics @DRUG$ and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s7.p11",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s7.p12",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ @DRUG$ and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s7.p13",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ propafenone and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d223.s7.p14",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d224.s8.p0",
        "sentence": "Since @DRUG$ may reduce pulse and blood pressure, caution in using drugs such as @DRUG$ (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d224.s8.p1",
        "sentence": "Since @DRUG$ may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), @DRUG$, and cardiac glycosides is advised.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d224.s8.p2",
        "sentence": "Since @DRUG$ may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and @DRUG$ is advised.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d224.s8.p3",
        "sentence": "Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as @DRUG$ (ophthalmic and systemic), @DRUG$, and cardiac glycosides is advised.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d224.s8.p4",
        "sentence": "Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as @DRUG$ (ophthalmic and systemic), antihypertensives, and @DRUG$ is advised.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d224.s8.p5",
        "sentence": "Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), @DRUG$, and @DRUG$ is advised.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p0",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p1",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p2",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p3",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p4",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p5",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p6",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p7",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p8",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p9",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p10",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p11",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p12",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p13",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p14",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p15",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p16",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p17",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p18",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p19",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p20",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p21",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p22",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p23",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p24",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, @DRUG$, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p25",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, @DRUG$, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p26",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p27",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p28",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p29",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p30",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, @DRUG$, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p31",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p32",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p33",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p34",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p35",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p36",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p37",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p38",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p39",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p40",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, @DRUG$, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p41",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p42",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, @DRUG$, and beta adrenergic blocking agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p43",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s0.p44",
        "sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d225.s11.p0",
        "sentence": "The effect of concomitant administration of @DRUG$ and @DRUG$ has been demonstrated in a placebo-controlled crossover study in normal volunteers.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d231.s10.p0",
        "sentence": "Tablets Simultaneous administration of @DRUG$ and @DRUG$ tablets may reduce the natriuretic and antihypertensive effects of furosemide.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d231.s10.p1",
        "sentence": "Tablets Simultaneous administration of @DRUG$ and furosemide tablets may reduce the natriuretic and antihypertensive effects of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d231.s10.p2",
        "sentence": "Tablets Simultaneous administration of sucralfate and @DRUG$ tablets may reduce the natriuretic and antihypertensive effects of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d231.s12.p0",
        "sentence": "The intake of @DRUG$ and @DRUG$ should be separated by at least two hours.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d231.s13.p0",
        "sentence": "Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of @DRUG$ and @DRUG$ temporarily reduced creatinine clearance in patients with chronic renal insufficiency.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d231.s15.p0",
        "sentence": "Literature reports indicate that coadministration of @DRUG$ may reduce the natriuretic and antihypertensive effects of @DRUG$ in some patients by inhibiting prostaglandin synthesis.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d234.s11.p0",
        "sentence": "An adequate period of observation must be provided for any patient in whom either @DRUG$ (such as @DRUG$) or large doses of short-acting benzodiazepines (such as  10 mg of midazolam) have been used.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d234.s11.p1",
        "sentence": "An adequate period of observation must be provided for any patient in whom either @DRUG$ (such as diazepam) or large doses of @DRUG$ (such as  10 mg of midazolam) have been used.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d234.s11.p2",
        "sentence": "An adequate period of observation must be provided for any patient in whom either @DRUG$ (such as diazepam) or large doses of short-acting benzodiazepines (such as  10 mg of @DRUG$) have been used.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d234.s11.p3",
        "sentence": "An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as @DRUG$) or large doses of @DRUG$ (such as  10 mg of midazolam) have been used.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d234.s11.p4",
        "sentence": "An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as @DRUG$) or large doses of short-acting benzodiazepines (such as  10 mg of @DRUG$) have been used.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d234.s11.p5",
        "sentence": "An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as diazepam) or large doses of @DRUG$ (such as  10 mg of @DRUG$) have been used.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d235.s2.p0",
        "sentence": "Increased toxicity (CNS depression): @DRUG$, @DRUG$, tricyclic antidepressants, phenothiazines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d235.s2.p1",
        "sentence": "Increased toxicity (CNS depression): @DRUG$, MAO inhibitors, @DRUG$, phenothiazines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d235.s2.p2",
        "sentence": "Increased toxicity (CNS depression): @DRUG$, MAO inhibitors, tricyclic antidepressants, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d235.s2.p3",
        "sentence": "Increased toxicity (CNS depression): CNS depressants, @DRUG$, @DRUG$, phenothiazines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d235.s2.p4",
        "sentence": "Increased toxicity (CNS depression): CNS depressants, @DRUG$, tricyclic antidepressants, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d235.s2.p5",
        "sentence": "Increased toxicity (CNS depression): CNS depressants, MAO inhibitors, @DRUG$, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s10.p0",
        "sentence": "@DRUG$: @DRUG$, as well as a metabolite of furazolidone, slow amphetamine metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s10.p1",
        "sentence": "@DRUG$: MAOI antidepressants, as well as a metabolite of @DRUG$, slow amphetamine metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s10.p2",
        "sentence": "@DRUG$: MAOI antidepressants, as well as a metabolite of furazolidone, slow @DRUG$ metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s10.p3",
        "sentence": "MAO inhibitors: @DRUG$, as well as a metabolite of @DRUG$, slow amphetamine metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s10.p4",
        "sentence": "MAO inhibitors: @DRUG$, as well as a metabolite of furazolidone, slow @DRUG$ metabolism.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d236.s10.p5",
        "sentence": "MAO inhibitors: MAOI antidepressants, as well as a metabolite of @DRUG$, slow @DRUG$ metabolism.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d236.s14.p0",
        "sentence": "@DRUG$: @DRUG$ may counteract the sedative effect of antihistamines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s14.p1",
        "sentence": "@DRUG$: Amphetamines may counteract the sedative effect of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s14.p2",
        "sentence": "Antihistamines: @DRUG$ may counteract the sedative effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d236.s16.p0",
        "sentence": "@DRUG$: @DRUG$ blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s16.p1",
        "sentence": "@DRUG$: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of @DRUG$, and can be used to treat amphetamine poisoning.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s16.p2",
        "sentence": "@DRUG$: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat @DRUG$ poisoning.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s16.p3",
        "sentence": "Chlorpromazine: @DRUG$ blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of @DRUG$, and can be used to treat amphetamine poisoning.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d236.s16.p4",
        "sentence": "Chlorpromazine: @DRUG$ blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat @DRUG$ poisoning.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s16.p5",
        "sentence": "Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of @DRUG$, and can be used to treat @DRUG$ poisoning.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s23.p0",
        "sentence": "@DRUG$: @DRUG$ may delay intestinal absorption of phenobarbital;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s23.p1",
        "sentence": "@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s23.p2",
        "sentence": "Phenobarbital: @DRUG$ may delay intestinal absorption of @DRUG$;",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d236.s27.p0",
        "sentence": "@DRUG$: In cases of @DRUG$ overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s27.p1",
        "sentence": "@DRUG$: In cases of propoxyphene overdosage, @DRUG$ CNS stimulation is potentiated and fatal convulsions can occur.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d236.s27.p2",
        "sentence": "Propoxyphene: In cases of @DRUG$ overdosage, @DRUG$ CNS stimulation is potentiated and fatal convulsions can occur.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d237.s1.p0",
        "sentence": "In some cases where serious ventricular arrhythmias, QT prolongation, and torsades de pointes have occurred when @DRUG$ was taken in conjunction with one of the cytochrome P450 3A4 inhibitors, elevated blood @DRUG$ levels were noted at the time of the QT prolongation.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s12.p0",
        "sentence": "@DRUG$: In vitro data indicate that @DRUG$ and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s12.p1",
        "sentence": "@DRUG$: In vitro data indicate that indinavir and @DRUG$ markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s12.p2",
        "sentence": "@DRUG$: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of @DRUG$ which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s12.p3",
        "sentence": "@DRUG$: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s12.p4",
        "sentence": "Protease Inhibitors: In vitro data indicate that @DRUG$ and @DRUG$ markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s12.p5",
        "sentence": "Protease Inhibitors: In vitro data indicate that @DRUG$ and ritonavir markedly inhibit the metabolism of @DRUG$ which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d237.s12.p6",
        "sentence": "Protease Inhibitors: In vitro data indicate that @DRUG$ and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s12.p7",
        "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and @DRUG$ markedly inhibit the metabolism of @DRUG$ which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d237.s12.p8",
        "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and @DRUG$ markedly inhibit the metabolism of cisapride which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s12.p9",
        "sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of @DRUG$ which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s13.p0",
        "sentence": "Other: Coadministration of grapefruit juice with @DRUG$ increases the bioavailability of @DRUG$ and concomitant use should be avoided.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s14.p0",
        "sentence": "@DRUG$ should not be used concomitantly with other drugs known to prolong the QT interval: certain @DRUG$, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d237.s14.p1",
        "sentence": "@DRUG$ should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as @DRUG$ and procainamide) and Class III (such as sotalol);",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d237.s14.p2",
        "sentence": "@DRUG$ should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and @DRUG$) and Class III (such as sotalol);",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d237.s14.p3",
        "sentence": "@DRUG$ should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as @DRUG$);",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d237.s14.p4",
        "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain @DRUG$, including those of Class IA (such as @DRUG$ and procainamide) and Class III (such as sotalol);",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s14.p5",
        "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain @DRUG$, including those of Class IA (such as quinidine and @DRUG$) and Class III (such as sotalol);",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s14.p6",
        "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain @DRUG$, including those of Class IA (such as quinidine and procainamide) and Class III (such as @DRUG$);",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s14.p7",
        "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as @DRUG$ and @DRUG$) and Class III (such as sotalol);",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s14.p8",
        "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as @DRUG$ and procainamide) and Class III (such as @DRUG$);",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s14.p9",
        "sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and @DRUG$) and Class III (such as @DRUG$);",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s16.p0",
        "sentence": "certain @DRUG$ (such as @DRUG$);",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s3.p0",
        "sentence": "@DRUG$: Concurrent administration of certain @DRUG$, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s3.p1",
        "sentence": "@DRUG$: Concurrent administration of certain anticholinergic compounds, such as @DRUG$ and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s3.p2",
        "sentence": "@DRUG$: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and @DRUG$, would be expected to compromise the beneficial effects of cisapride.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s3.p3",
        "sentence": "@DRUG$: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s3.p4",
        "sentence": "Anticholinergics: Concurrent administration of certain @DRUG$, such as @DRUG$ and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s3.p5",
        "sentence": "Anticholinergics: Concurrent administration of certain @DRUG$, such as belladonna alkaloids and @DRUG$, would be expected to compromise the beneficial effects of cisapride.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s3.p6",
        "sentence": "Anticholinergics: Concurrent administration of certain @DRUG$, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d237.s3.p7",
        "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as @DRUG$ and @DRUG$, would be expected to compromise the beneficial effects of cisapride.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s3.p8",
        "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as @DRUG$ and dicyclomine, would be expected to compromise the beneficial effects of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d237.s3.p9",
        "sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and @DRUG$, would be expected to compromise the beneficial effects of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d237.s4.p0",
        "sentence": "@DRUG$ (Oral): In patients receiving oral @DRUG$, the coagulation times were increased in some cases.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d237.s9.p0",
        "sentence": "A study in 14 normal male and female volunteers suggests that coadministration of @DRUG$ and @DRUG$ can result in prolongation of the QT interval on the ECG.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d238.s19.p0",
        "sentence": "Nevertheless, caution is indicated in the co-administration of @DRUG$ with any of the @DRUG$ and also in switching from one class to the other.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d238.s20.p0",
        "sentence": "Of particular importance, sufficient time must elapse before initiating @DRUG$treatment in a patient being withdrawn from @DRUG$, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d238.s23.p0",
        "sentence": "It is desirable to monitor @DRUG$plasma levels whenever an agent of the @DRUG$ including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d238.s23.p1",
        "sentence": "It is desirable to monitor @DRUG$plasma levels whenever an agent of the tricyclic antidepressant class including @DRUG$ is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d238.s23.p2",
        "sentence": "It is desirable to monitor TCAplasma levels whenever an agent of the @DRUG$ including @DRUG$ is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d238.s24.p0",
        "sentence": "Because @DRUG$ is highly bound to serum protein, the administration of @DRUG$ to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d238.s24.p1",
        "sentence": "Because @DRUG$ is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., @DRUG$, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d238.s24.p2",
        "sentence": "Because @DRUG$ is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, @DRUG$) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d238.s24.p3",
        "sentence": "Because Anafranil is highly bound to serum protein, the administration of @DRUG$ to patients taking other drugs that are highly bound to protein (e.g., @DRUG$, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d238.s24.p4",
        "sentence": "Because Anafranil is highly bound to serum protein, the administration of @DRUG$ to patients taking other drugs that are highly bound to protein (e.g., warfarin, @DRUG$) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d238.s24.p5",
        "sentence": "Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., @DRUG$, @DRUG$) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d238.s4.p0",
        "sentence": "Several @DRUG$ have been reported to block the pharmacologic effects of @DRUG$, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d238.s4.p1",
        "sentence": "Several @DRUG$ have been reported to block the pharmacologic effects of guanethidine, @DRUG$, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d238.s4.p2",
        "sentence": "Several @DRUG$ have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with @DRUG$ because of its structural similarity to other tricyclic antidepressants.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d238.s4.p3",
        "sentence": "Several @DRUG$ have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d238.s4.p4",
        "sentence": "Several tricyclic antidepressants have been reported to block the pharmacologic effects of @DRUG$, @DRUG$, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d238.s4.p5",
        "sentence": "Several tricyclic antidepressants have been reported to block the pharmacologic effects of @DRUG$, clonidine, or similar agents, and such an effect may be anticipated with @DRUG$ because of its structural similarity to other tricyclic antidepressants.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d238.s4.p6",
        "sentence": "Several tricyclic antidepressants have been reported to block the pharmacologic effects of @DRUG$, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d238.s4.p7",
        "sentence": "Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, @DRUG$, or similar agents, and such an effect may be anticipated with @DRUG$ because of its structural similarity to other tricyclic antidepressants.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d238.s4.p8",
        "sentence": "Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, @DRUG$, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d238.s4.p9",
        "sentence": "Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with @DRUG$ because of its structural similarity to other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d238.s5.p0",
        "sentence": "The plasma concentration of @DRUG$ has been reported to be increased by the concomitant administration of @DRUG$;",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d240.s1.p0",
        "sentence": "It may also interact with @DRUG$ or other @DRUG$ or MAOIs, which may intensify the anticholinergic action.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d240.s1.p1",
        "sentence": "It may also interact with @DRUG$ or other anticholinergic drugs or @DRUG$, which may intensify the anticholinergic action.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d240.s1.p2",
        "sentence": "It may also interact with amantadine or other @DRUG$ or @DRUG$, which may intensify the anticholinergic action.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d241.s2.p0",
        "sentence": "However, patients receiving infusions of @DRUG$ in clinical trials were maintained on @DRUG$ without evidence of increased bleeding.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d242.s1.p0",
        "sentence": "However, the systemic administration of some @DRUG$ has been shown to elevate plasma concentrations of @DRUG$, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d242.s1.p1",
        "sentence": "However, the systemic administration of some @DRUG$ has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of @DRUG$, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d242.s1.p2",
        "sentence": "However, the systemic administration of some @DRUG$ has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral @DRUG$ warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d242.s1.p3",
        "sentence": "However, the systemic administration of some @DRUG$ has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant @DRUG$ and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d242.s1.p4",
        "sentence": "However, the systemic administration of some @DRUG$ has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic @DRUG$ concomitantly.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d242.s1.p5",
        "sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of @DRUG$, interfere with the metabolism of @DRUG$, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d242.s1.p6",
        "sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of @DRUG$, interfere with the metabolism of caffeine, and enhance the effects of the oral @DRUG$ warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d242.s1.p7",
        "sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of @DRUG$, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant @DRUG$ and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d242.s1.p8",
        "sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of @DRUG$, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic @DRUG$ concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d242.s1.p9",
        "sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of @DRUG$, and enhance the effects of the oral @DRUG$ warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d242.s1.p10",
        "sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of @DRUG$, and enhance the effects of the oral anticoagulant @DRUG$ and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d242.s1.p11",
        "sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of @DRUG$, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic @DRUG$ concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d242.s1.p12",
        "sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral @DRUG$ @DRUG$ and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d242.s1.p13",
        "sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral @DRUG$ warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic @DRUG$ concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d242.s1.p14",
        "sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant @DRUG$ and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic @DRUG$ concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p0",
        "sentence": "Concurrent use of @DRUG$ with @DRUG$ (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p1",
        "sentence": "Concurrent use of @DRUG$ with central nervous system depressants (e.g., @DRUG$, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p2",
        "sentence": "Concurrent use of @DRUG$ with central nervous system depressants (e.g., alcohol, @DRUG$, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p3",
        "sentence": "Concurrent use of @DRUG$ with central nervous system depressants (e.g., alcohol, barbiturates, @DRUG$, and antihistamines) may result in increased central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p4",
        "sentence": "Concurrent use of @DRUG$ with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and @DRUG$) may result in increased central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p5",
        "sentence": "Concurrent use of @DRUG$ with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased @DRUG$ effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p6",
        "sentence": "Concurrent use of butorphanol with @DRUG$ (e.g., @DRUG$, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p7",
        "sentence": "Concurrent use of butorphanol with @DRUG$ (e.g., alcohol, @DRUG$, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p8",
        "sentence": "Concurrent use of butorphanol with @DRUG$ (e.g., alcohol, barbiturates, @DRUG$, and antihistamines) may result in increased central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p9",
        "sentence": "Concurrent use of butorphanol with @DRUG$ (e.g., alcohol, barbiturates, tranquilizers, and @DRUG$) may result in increased central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p10",
        "sentence": "Concurrent use of butorphanol with @DRUG$ (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased @DRUG$ effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p11",
        "sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., @DRUG$, @DRUG$, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p12",
        "sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., @DRUG$, barbiturates, @DRUG$, and antihistamines) may result in increased central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p13",
        "sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., @DRUG$, barbiturates, tranquilizers, and @DRUG$) may result in increased central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p14",
        "sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., @DRUG$, barbiturates, tranquilizers, and antihistamines) may result in increased @DRUG$ effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p15",
        "sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, @DRUG$, @DRUG$, and antihistamines) may result in increased central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p16",
        "sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, @DRUG$, tranquilizers, and @DRUG$) may result in increased central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p17",
        "sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, @DRUG$, tranquilizers, and antihistamines) may result in increased @DRUG$ effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p18",
        "sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, @DRUG$, and @DRUG$) may result in increased central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p19",
        "sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, @DRUG$, and antihistamines) may result in increased @DRUG$ effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s0.p20",
        "sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and @DRUG$) may result in increased @DRUG$ effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s13.p0",
        "sentence": "The fraction of @DRUG$ absorbed is unaffected by the concomitant administration of a @DRUG$ (oxymetazoline), but the rate of absorption is decreased.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s13.p1",
        "sentence": "The fraction of @DRUG$ absorbed is unaffected by the concomitant administration of a nasal vasoconstrictor (@DRUG$), but the rate of absorption is decreased.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s13.p2",
        "sentence": "The fraction of STADOL NS absorbed is unaffected by the concomitant administration of a @DRUG$ (@DRUG$), but the rate of absorption is decreased.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s7.p0",
        "sentence": "These results suggest that the analgesic effect of @DRUG$ may be diminished when it is administered shortly after @DRUG$ nasal spray, but by 30 minutes any such reduction in effect should be minimal.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d246.s8.p0",
        "sentence": "The safety of using @DRUG$ and @DRUG$ (sumatriptan) Nasal Spray during the same episode of migraine has not been established.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s8.p1",
        "sentence": "The safety of using @DRUG$ and IMITREX (@DRUG$) Nasal Spray during the same episode of migraine has not been established.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d246.s8.p2",
        "sentence": "The safety of using STADOL NS and @DRUG$ (@DRUG$) Nasal Spray during the same episode of migraine has not been established.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d249.s10.p0",
        "sentence": "Oral @DRUG$: @DRUG$ does not alter glucose metabolism in normal subjects nor does it alter the effects of oral hypoglycemic agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d249.s10.p1",
        "sentence": "Oral @DRUG$: Diclofenac does not alter glucose metabolism in normal subjects nor does it alter the effects of oral @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d249.s10.p2",
        "sentence": "Oral Hypoglycemics: @DRUG$ does not alter glucose metabolism in normal subjects nor does it alter the effects of oral @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d250.s0.p0",
        "sentence": "Certain other @DRUG$ (@DRUG$ and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d250.s0.p1",
        "sentence": "Certain other @DRUG$ (aminoglycosides and @DRUG$) have also been reported to interfere with the nerve transmission at the neuromuscular junction.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d250.s0.p2",
        "sentence": "Certain other antibiotics (@DRUG$ and @DRUG$) have also been reported to interfere with the nerve transmission at the neuromuscular junction.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d250.s3.p0",
        "sentence": "@DRUG$ may enhance the nephrotoxicity of @DRUG$ Parenteral.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d250.s4.p0",
        "sentence": "The concomitant use of @DRUG$ and @DRUG$ Parenteral should be avoided.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d252.s4.p0",
        "sentence": "The concomitant use of @DRUG$ with @DRUG$ and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d252.s4.p1",
        "sentence": "The concomitant use of @DRUG$ with digitalis and @DRUG$s may have additive effects on prolonging atrioventricular conduction time.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d252.s4.p2",
        "sentence": "The concomitant use of beta-adrenergic blocking agents with @DRUG$ and @DRUG$s may have additive effects on prolonging atrioventricular conduction time.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p0",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p1",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p2",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p3",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p4",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p5",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p6",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p7",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p8",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p9",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p10",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p11",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p12",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p13",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p14",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p15",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p16",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p17",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p18",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p19",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p20",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p21",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p22",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p23",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p24",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p25",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p26",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p27",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p28",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p29",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p30",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p31",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p32",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p33",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p34",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p35",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p36",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p37",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p38",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p39",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p40",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p41",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p42",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p43",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p44",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p45",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p46",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p47",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p48",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p49",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p50",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p51",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p52",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p53",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p54",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p55",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p56",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p57",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p58",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p59",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p60",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p61",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p62",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p63",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p64",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p65",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p66",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p67",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p68",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p69",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p70",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p71",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p72",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p73",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p74",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p75",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p76",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d257.s0.p77",
        "sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and @DRUG$) may result in additive central nervous system depressant effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d258.s12.p0",
        "sentence": "There does not appear to be an increase in adverse events in subjects who received oral @DRUG$ and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p0",
        "sentence": "@DRUG$ : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p1",
        "sentence": "@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p2",
        "sentence": "@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p3",
        "sentence": "@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p4",
        "sentence": "@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p5",
        "sentence": "@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p6",
        "sentence": "@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p7",
        "sentence": "@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p8",
        "sentence": "@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p9",
        "sentence": "@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p10",
        "sentence": "@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p11",
        "sentence": "@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p12",
        "sentence": "@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p13",
        "sentence": "@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p14",
        "sentence": "@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p15",
        "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p16",
        "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p17",
        "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p18",
        "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p19",
        "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p20",
        "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p21",
        "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p22",
        "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p23",
        "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p24",
        "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p25",
        "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p26",
        "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p27",
        "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p28",
        "sentence": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p29",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p30",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p31",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p32",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p33",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p34",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p35",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p36",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p37",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p38",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p39",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p40",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p41",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p42",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p43",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p44",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p45",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p46",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p47",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p48",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p49",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p50",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p51",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p52",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p53",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p54",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p55",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p56",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p57",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p58",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p59",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p60",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p61",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p62",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p63",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p64",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p65",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p66",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p67",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p68",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p69",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p70",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p71",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p72",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p73",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p74",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p75",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p76",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p77",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p78",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p79",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p80",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p81",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p82",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p83",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p84",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p85",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p86",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p87",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p88",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p89",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p90",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p91",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p92",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p93",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p94",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p95",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p96",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p97",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p98",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p99",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p100",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p101",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p102",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p103",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p104",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p105",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p106",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p107",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p108",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p109",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p110",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p111",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, @DRUG$ agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p112",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p113",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p114",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, @DRUG$ agents, theophylline, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p115",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p116",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p117",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, @DRUG$, and zidovudine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p118",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s0.p119",
        "sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s2.p0",
        "sentence": "@DRUG$ should either be temporarily discontinued or decreased by 50% when coadministered with @DRUG$ on the day of VISTIDE infusion.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d260.s2.p1",
        "sentence": "@DRUG$ should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of @DRUG$ infusion.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d260.s2.p2",
        "sentence": "Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with @DRUG$ on the day of @DRUG$ infusion.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s1.p0",
        "sentence": "@DRUG$ also has no significant effect on the intracellular phosphorylation of @DRUG$, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d263.s14.p0",
        "sentence": "Concomitant use of @DRUG$ with @DRUG$ is not recommended.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p0",
        "sentence": "@DRUG$, @DRUG$, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p1",
        "sentence": "@DRUG$, Foscarnet, and @DRUG$: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p2",
        "sentence": "@DRUG$, Foscarnet, and Aminoglycosides: Drugs such as @DRUG$, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p3",
        "sentence": "@DRUG$, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, @DRUG$, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p4",
        "sentence": "@DRUG$, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and @DRUG$ may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p5",
        "sentence": "@DRUG$, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other @DRUG$-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p6",
        "sentence": "@DRUG$, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of @DRUG$ (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p7",
        "sentence": "Amphotericin, @DRUG$, and @DRUG$: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p8",
        "sentence": "Amphotericin, @DRUG$, and Aminoglycosides: Drugs such as @DRUG$, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p9",
        "sentence": "Amphotericin, @DRUG$, and Aminoglycosides: Drugs such as amphotericin, @DRUG$, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p10",
        "sentence": "Amphotericin, @DRUG$, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and @DRUG$ may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p11",
        "sentence": "Amphotericin, @DRUG$, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other @DRUG$-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p12",
        "sentence": "Amphotericin, @DRUG$, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of @DRUG$ (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p13",
        "sentence": "Amphotericin, Foscarnet, and @DRUG$: Drugs such as @DRUG$, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p14",
        "sentence": "Amphotericin, Foscarnet, and @DRUG$: Drugs such as amphotericin, @DRUG$, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p15",
        "sentence": "Amphotericin, Foscarnet, and @DRUG$: Drugs such as amphotericin, foscarnet, and @DRUG$ may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p16",
        "sentence": "Amphotericin, Foscarnet, and @DRUG$: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other @DRUG$-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p17",
        "sentence": "Amphotericin, Foscarnet, and @DRUG$: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of @DRUG$ (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p18",
        "sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as @DRUG$, @DRUG$, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p19",
        "sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as @DRUG$, foscarnet, and @DRUG$ may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p20",
        "sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as @DRUG$, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other @DRUG$-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p21",
        "sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as @DRUG$, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of @DRUG$ (thereby raising systemic exposure).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p22",
        "sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, @DRUG$, and @DRUG$ may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p23",
        "sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, @DRUG$, and aminoglycosides may increase the risk of developing peripheral neuropathy or other @DRUG$-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p24",
        "sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, @DRUG$, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of @DRUG$ (thereby raising systemic exposure).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p25",
        "sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and @DRUG$ may increase the risk of developing peripheral neuropathy or other @DRUG$-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p26",
        "sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and @DRUG$ may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of @DRUG$ (thereby raising systemic exposure).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d263.s18.p27",
        "sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other @DRUG$-associated adverse events by interfering with the renal clearance of @DRUG$ (thereby raising systemic exposure).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s20.p0",
        "sentence": "@DRUG$ or @DRUG$: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s20.p1",
        "sentence": "@DRUG$ or Cimetidine: Concomitant administration of @DRUG$ or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s20.p2",
        "sentence": "@DRUG$ or Cimetidine: Concomitant administration of probenecid or @DRUG$ decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s20.p3",
        "sentence": "@DRUG$ or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of @DRUG$, most likely by inhibition of renal tubular secretion of zalcitabine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s20.p4",
        "sentence": "@DRUG$ or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s20.p5",
        "sentence": "Probenecid or @DRUG$: Concomitant administration of @DRUG$ or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s20.p6",
        "sentence": "Probenecid or @DRUG$: Concomitant administration of probenecid or @DRUG$ decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s20.p7",
        "sentence": "Probenecid or @DRUG$: Concomitant administration of probenecid or cimetidine decreases the elimination of @DRUG$, most likely by inhibition of renal tubular secretion of zalcitabine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s20.p8",
        "sentence": "Probenecid or @DRUG$: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s20.p9",
        "sentence": "Probenecid or Cimetidine: Concomitant administration of @DRUG$ or @DRUG$ decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s20.p10",
        "sentence": "Probenecid or Cimetidine: Concomitant administration of @DRUG$ or cimetidine decreases the elimination of @DRUG$, most likely by inhibition of renal tubular secretion of zalcitabine.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d263.s20.p11",
        "sentence": "Probenecid or Cimetidine: Concomitant administration of @DRUG$ or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s20.p12",
        "sentence": "Probenecid or Cimetidine: Concomitant administration of probenecid or @DRUG$ decreases the elimination of @DRUG$, most likely by inhibition of renal tubular secretion of zalcitabine.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d263.s20.p13",
        "sentence": "Probenecid or Cimetidine: Concomitant administration of probenecid or @DRUG$ decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s20.p14",
        "sentence": "Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of @DRUG$, most likely by inhibition of renal tubular secretion of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s5.p0",
        "sentence": "@DRUG$ inhibited @DRUG$ phosphorylation at high concentration ratios (10 and 100);",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d263.s7.p0",
        "sentence": "These in vitro studies suggest that concomitant administration of @DRUG$ and @DRUG$ in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d263.s7.p1",
        "sentence": "These in vitro studies suggest that concomitant administration of @DRUG$ and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated @DRUG$, which may lead to a decreased antiretroviral effect of zalcitabine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s7.p2",
        "sentence": "These in vitro studies suggest that concomitant administration of @DRUG$ and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased @DRUG$ effect of zalcitabine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s7.p3",
        "sentence": "These in vitro studies suggest that concomitant administration of @DRUG$ and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s7.p4",
        "sentence": "These in vitro studies suggest that concomitant administration of zalcitabine and @DRUG$ in humans may result in sub-therapeutic concentrations of active phosphorylated @DRUG$, which may lead to a decreased antiretroviral effect of zalcitabine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s7.p5",
        "sentence": "These in vitro studies suggest that concomitant administration of zalcitabine and @DRUG$ in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased @DRUG$ effect of zalcitabine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s7.p6",
        "sentence": "These in vitro studies suggest that concomitant administration of zalcitabine and @DRUG$ in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s7.p7",
        "sentence": "These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated @DRUG$, which may lead to a decreased @DRUG$ effect of zalcitabine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s7.p8",
        "sentence": "These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated @DRUG$, which may lead to a decreased antiretroviral effect of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s7.p9",
        "sentence": "These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased @DRUG$ effect of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d263.s9.p0",
        "sentence": "Concomitant use of @DRUG$ and @DRUG$ is not recommended.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d265.s0.p0",
        "sentence": "@DRUG$ may add to or potentiate the action of other @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d265.s7.p0",
        "sentence": "@DRUG$ and related drugs may increase the responsiveness to @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d267.s2.p0",
        "sentence": "There are no clinical data on concomitant use of @DRUG$ and other nondepolarizing @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d267.s3.p0",
        "sentence": "@DRUG$, @DRUG$, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d267.s3.p1",
        "sentence": "@DRUG$, enflurane, and @DRUG$ decrease the ED50 of NUROMAX by 30% to 45%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d267.s3.p2",
        "sentence": "@DRUG$, enflurane, and halothane decrease the ED50 of @DRUG$ by 30% to 45%.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d267.s3.p3",
        "sentence": "Isoflurane, @DRUG$, and @DRUG$ decrease the ED50 of NUROMAX by 30% to 45%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d267.s3.p4",
        "sentence": "Isoflurane, @DRUG$, and halothane decrease the ED50 of @DRUG$ by 30% to 45%.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d267.s3.p5",
        "sentence": "Isoflurane, enflurane, and @DRUG$ decrease the ED50 of @DRUG$ by 30% to 45%.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d269.s10.p0",
        "sentence": "Due to wide interindividual variability in the dose adjustment required, it is recommended that @DRUG$ concentrations be monitored closely after initiation of @DRUG$ therapy and that the dose of cyclosporine be adjusted as appropriate.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d269.s10.p1",
        "sentence": "Due to wide interindividual variability in the dose adjustment required, it is recommended that @DRUG$ concentrations be monitored closely after initiation of carvedilol therapy and that the dose of @DRUG$ be adjusted as appropriate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d269.s10.p2",
        "sentence": "Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of @DRUG$ therapy and that the dose of @DRUG$ be adjusted as appropriate.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d269.s13.p0",
        "sentence": "Therefore, increased monitoring of @DRUG$ is recommended when initiating, adjusting, or discontinuing @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d269.s17.p0",
        "sentence": "As with other @DRUG$, if @DRUG$ is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d269.s17.p1",
        "sentence": "As with other @DRUG$, if COREG is to be administered orally with @DRUG$ of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d269.s17.p2",
        "sentence": "As with other @DRUG$, if COREG is to be administered orally with calcium channel blockers of the @DRUG$ or diltiazem type, it is recommended that ECG and blood pressure be monitored.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d269.s17.p3",
        "sentence": "As with other @DRUG$, if COREG is to be administered orally with calcium channel blockers of the verapamil or @DRUG$ type, it is recommended that ECG and blood pressure be monitored.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d269.s17.p4",
        "sentence": "As with other agents with b-blocking properties, if @DRUG$ is to be administered orally with @DRUG$ of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d269.s17.p5",
        "sentence": "As with other agents with b-blocking properties, if @DRUG$ is to be administered orally with calcium channel blockers of the @DRUG$ or diltiazem type, it is recommended that ECG and blood pressure be monitored.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d269.s17.p6",
        "sentence": "As with other agents with b-blocking properties, if @DRUG$ is to be administered orally with calcium channel blockers of the verapamil or @DRUG$ type, it is recommended that ECG and blood pressure be monitored.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d269.s17.p7",
        "sentence": "As with other agents with b-blocking properties, if COREG is to be administered orally with @DRUG$ of the @DRUG$ or diltiazem type, it is recommended that ECG and blood pressure be monitored.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d269.s17.p8",
        "sentence": "As with other agents with b-blocking properties, if COREG is to be administered orally with @DRUG$ of the verapamil or @DRUG$ type, it is recommended that ECG and blood pressure be monitored.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d269.s17.p9",
        "sentence": "As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the @DRUG$ or @DRUG$ type, it is recommended that ECG and blood pressure be monitored.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d269.s5.p0",
        "sentence": "When concomitant treatment with @DRUG$ and @DRUG$ is to be terminated, the b-blocking agent should be discontinued first.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d269.s5.p1",
        "sentence": "When concomitant treatment with @DRUG$ and clonidine is to be terminated, the @DRUG$ should be discontinued first.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d269.s5.p2",
        "sentence": "When concomitant treatment with agents with b-blocking properties and @DRUG$ is to be terminated, the @DRUG$ should be discontinued first.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d269.s7.p0",
        "sentence": "@DRUG$: Modest increases in mean trough @DRUG$ concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d269.s7.p1",
        "sentence": "@DRUG$: Modest increases in mean trough cyclosporine concentrations were observed following initiation of @DRUG$ treatment in 21 renal transplant patients suffering from chronic vascular rejection.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d269.s7.p2",
        "sentence": "Cyclosporine: Modest increases in mean trough @DRUG$ concentrations were observed following initiation of @DRUG$ treatment in 21 renal transplant patients suffering from chronic vascular rejection.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d27.s2.p0",
        "sentence": "However, in clinical studies the consequences of concomitant @DRUG$ on the pharmacodynamics of @DRUG$ were negligible.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s18.p0",
        "sentence": "@DRUG$ exposure was significantly decreased by @DRUG$;",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d270.s20.p0",
        "sentence": "Alternatives to @DRUG$,such as @DRUG$, should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s25.p0",
        "sentence": "@DRUG$ @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s26.p0",
        "sentence": "Oral @DRUG$ and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking @DRUG$, since nevirapinemay lower the plasma levels of thesemedications.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d270.s36.p0",
        "sentence": "@DRUG$ and @DRUG$ should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d270.s36.p1",
        "sentence": "@DRUG$ and ketoconazole should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy of the drug.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s36.p2",
        "sentence": "Nevirapine and @DRUG$ should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy of the drug.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s42.p0",
        "sentence": "@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s42.p1",
        "sentence": "@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. @DRUG$ maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s42.p2",
        "sentence": "@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s42.p3",
        "sentence": "@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s42.p4",
        "sentence": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. @DRUG$ maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s42.p5",
        "sentence": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. Methadone maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s42.p6",
        "sentence": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s42.p7",
        "sentence": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. @DRUG$ maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d270.s42.p8",
        "sentence": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. @DRUG$ maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s42.p9",
        "sentence": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s45.p0",
        "sentence": "The appropriate dose for @DRUG$ incombination with @DRUG$, with respectto safety and efficacy, has not been established.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s75.p0",
        "sentence": "@DRUG$, @DRUG$, sirolimus",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s75.p1",
        "sentence": "@DRUG$, tacrolimus, @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d270.s75.p2",
        "sentence": "Cyclosporin, @DRUG$, @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d272.s1.p0",
        "sentence": "@DRUG$ may interact with @DRUG$, butyrophenones, and certain other agents.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d272.s1.p1",
        "sentence": "@DRUG$ may interact with dopamine antagonists, @DRUG$, and certain other agents.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d272.s1.p2",
        "sentence": "Bromocriptine mesylate may interact with @DRUG$, @DRUG$, and certain other agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d273.s0.p0",
        "sentence": "Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between @DRUG$ and other @DRUG$ have not been determined.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p0",
        "sentence": "There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p1",
        "sentence": "There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p2",
        "sentence": "There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p3",
        "sentence": "There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p4",
        "sentence": "There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p5",
        "sentence": "There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p6",
        "sentence": "There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p7",
        "sentence": "There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p8",
        "sentence": "There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p9",
        "sentence": "There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p10",
        "sentence": "There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p11",
        "sentence": "There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p12",
        "sentence": "There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p13",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p14",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p15",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p16",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p17",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p18",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p19",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p20",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p21",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p22",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p23",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p24",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p25",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p26",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p27",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p28",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p29",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p30",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p31",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p32",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p33",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p34",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p35",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p36",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p37",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p38",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p39",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p40",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p41",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p42",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p43",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p44",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p45",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p46",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p47",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p48",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p49",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p50",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p51",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p52",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p53",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p54",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p55",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p56",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p57",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p58",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p59",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p60",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p61",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p62",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p63",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p64",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p65",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p66",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p67",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p68",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p69",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p70",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p71",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p72",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p73",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p74",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p75",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p76",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p77",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p78",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, @DRUG$, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p79",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p80",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p81",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, @DRUG$, potassium chloride, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p82",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, @DRUG$, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p83",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, @DRUG$, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p84",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p85",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, @DRUG$, folic acid, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p86",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, @DRUG$, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p87",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p88",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, @DRUG$, and acetaminophen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p89",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d274.s3.p90",
        "sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d276.s1.p0",
        "sentence": "The mechanism for this interaction probably is adsorption of @DRUG$ onto the surface of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d276.s3.p0",
        "sentence": "The resulting increase in @DRUG$ serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s1.p0",
        "sentence": "@DRUG$, @DRUG$ and carbamazepine are ge nerally classified as enzyme inducers;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s1.p1",
        "sentence": "@DRUG$, phenobarbital and @DRUG$ are ge nerally classified as enzyme inducers;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s1.p2",
        "sentence": "Phenytoin, @DRUG$ and @DRUG$ are ge nerally classified as enzyme inducers;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s10.p0",
        "sentence": "Effects of other Antiepilepsy Drugs (@DRUG$) on @DRUG$ : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s10.p1",
        "sentence": "Effects of other Antiepilepsy Drugs (@DRUG$) on GABITRIL : @DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s10.p2",
        "sentence": "Effects of other Antiepilepsy Drugs (@DRUG$) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s10.p3",
        "sentence": "Effects of other Antiepilepsy Drugs (@DRUG$) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s10.p4",
        "sentence": "Effects of other Antiepilepsy Drugs (@DRUG$) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s10.p5",
        "sentence": "Effects of other Antiepilepsy Drugs (AEDs) on @DRUG$ : @DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s10.p6",
        "sentence": "Effects of other Antiepilepsy Drugs (AEDs) on @DRUG$ : Carbamazepine: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s10.p7",
        "sentence": "Effects of other Antiepilepsy Drugs (AEDs) on @DRUG$ : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s10.p8",
        "sentence": "Effects of other Antiepilepsy Drugs (AEDs) on @DRUG$ : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s10.p9",
        "sentence": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : @DRUG$: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s10.p10",
        "sentence": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : @DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s10.p11",
        "sentence": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : @DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s10.p12",
        "sentence": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d277.s10.p13",
        "sentence": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s10.p14",
        "sentence": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s12.p0",
        "sentence": "@DRUG$ (@DRUG$): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s12.p1",
        "sentence": "@DRUG$ (Primidone): Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s12.p2",
        "sentence": "@DRUG$ (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ (primidone) with or without other enzyme-inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s12.p3",
        "sentence": "@DRUG$ (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (@DRUG$) with or without other enzyme-inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s12.p4",
        "sentence": "@DRUG$ (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s12.p5",
        "sentence": "Phenobarbital (@DRUG$): Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s12.p6",
        "sentence": "Phenobarbital (@DRUG$): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ (primidone) with or without other enzyme-inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s12.p7",
        "sentence": "Phenobarbital (@DRUG$): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (@DRUG$) with or without other enzyme-inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s12.p8",
        "sentence": "Phenobarbital (@DRUG$): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s12.p9",
        "sentence": "Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking @DRUG$ (primidone) with or without other enzyme-inducing AEDs.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d277.s12.p10",
        "sentence": "Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking phenobarbital (@DRUG$) with or without other enzyme-inducing AEDs.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d277.s12.p11",
        "sentence": "Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s12.p12",
        "sentence": "Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ (@DRUG$) with or without other enzyme-inducing AEDs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s12.p13",
        "sentence": "Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ (primidone) with or without other enzyme-inducing @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s12.p14",
        "sentence": "Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (@DRUG$) with or without other enzyme-inducing @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s19.p0",
        "sentence": "@DRUG$: Concomitant administration of @DRUG$ did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s19.p1",
        "sentence": "@DRUG$: Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of @DRUG$ or the mean daily trough serum level of digoxin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s19.p2",
        "sentence": "@DRUG$: Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s19.p3",
        "sentence": "Digoxin: Concomitant administration of @DRUG$ did not affect the steady-state pharmacokinetics of @DRUG$ or the mean daily trough serum level of digoxin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s19.p4",
        "sentence": "Digoxin: Concomitant administration of @DRUG$ did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s19.p5",
        "sentence": "Digoxin: Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of @DRUG$ or the mean daily trough serum level of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s20.p0",
        "sentence": "@DRUG$ or @DRUG$: No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and tiagabine (10 mg) when given together as a single dose.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s20.p1",
        "sentence": "@DRUG$ or Triazolam: No significant differences were observed in the pharmacokinetics of @DRUG$ (0.125 mg) and tiagabine (10 mg) when given together as a single dose.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s20.p2",
        "sentence": "@DRUG$ or Triazolam: No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and @DRUG$ (10 mg) when given together as a single dose.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s20.p3",
        "sentence": "Ethanol or @DRUG$: No significant differences were observed in the pharmacokinetics of @DRUG$ (0.125 mg) and tiagabine (10 mg) when given together as a single dose.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s20.p4",
        "sentence": "Ethanol or @DRUG$: No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and @DRUG$ (10 mg) when given together as a single dose.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s20.p5",
        "sentence": "Ethanol or Triazolam: No significant differences were observed in the pharmacokinetics of @DRUG$ (0.125 mg) and @DRUG$ (10 mg) when given together as a single dose.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s22.p0",
        "sentence": "@DRUG$ has shown no clinically important potentiation of the pharmacodynamic effects of triazo lam or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s23.p0",
        "sentence": "Because of the possible additive effects of drugs that may depress the nervous system, @DRUG$ or @DRUG$ should be used cautiously in combination with tiagabine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s23.p1",
        "sentence": "Because of the possible additive effects of drugs that may depress the nervous system, @DRUG$ or triazolam should be used cautiously in combination with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d277.s23.p2",
        "sentence": "Because of the possible additive effects of drugs that may depress the nervous system, ethanol or @DRUG$ should be used cautiously in combination with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d277.s25.p0",
        "sentence": "@DRUG$ : @DRUG$ pharmacokinetics were not significantly different before and after tiagabine multiple-dose regimens.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s25.p1",
        "sentence": "@DRUG$ : Antipyrine pharmacokinetics were not significantly different before and after @DRUG$ multiple-dose regimens.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s25.p2",
        "sentence": "Antipyrine : @DRUG$ pharmacokinetics were not significantly different before and after @DRUG$ multiple-dose regimens.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s3.p0",
        "sentence": "@DRUG$ is considered to be a non-enzyme inducing @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s8.p0",
        "sentence": "@DRUG$ or @DRUG$ : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s8.p1",
        "sentence": "@DRUG$ or Primidone : No formal pharmacokinetic studies have been performed examining the addition of @DRUG$ to regimens containing phenobarbital or primidone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s8.p2",
        "sentence": "@DRUG$ or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing @DRUG$ or primidone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s8.p3",
        "sentence": "@DRUG$ or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s8.p4",
        "sentence": "Phenobarbital or @DRUG$ : No formal pharmacokinetic studies have been performed examining the addition of @DRUG$ to regimens containing phenobarbital or primidone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s8.p5",
        "sentence": "Phenobarbital or @DRUG$ : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing @DRUG$ or primidone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s8.p6",
        "sentence": "Phenobarbital or @DRUG$ : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s8.p7",
        "sentence": "Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of @DRUG$ to regimens containing @DRUG$ or primidone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s8.p8",
        "sentence": "Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of @DRUG$ to regimens containing phenobarbital or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d277.s8.p9",
        "sentence": "Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing @DRUG$ or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d279.s0.p0",
        "sentence": "The adverse effects of @DRUG$, such as myelosuppression and diarrhea, would be expected to be exacerbated by other @DRUG$ having similar adverse effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d279.s11.p0",
        "sentence": "In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by @DRUG$, the physician may wish to withhold @DRUG$ during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d279.s11.p1",
        "sentence": "In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by @DRUG$, the physician may wish to withhold diuretics during dosing with @DRUG$ and, certainly, during periods of active vomiting or diarrhea.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d279.s11.p2",
        "sentence": "In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold @DRUG$ during dosing with @DRUG$ and, certainly, during periods of active vomiting or diarrhea.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d28.s3.p0",
        "sentence": "However, 10 patients who switched from therapy with @DRUG$ to @DRUG$  did not report any serious and unexpected adverse reactions thought to be related to treatment.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d281.s0.p0",
        "sentence": "@DRUG$ may decrease renal tubular secretion of @DRUG$ when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d281.s0.p1",
        "sentence": "@DRUG$ may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged @DRUG$ blood levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d281.s0.p2",
        "sentence": "Probenecid may decrease renal tubular secretion of @DRUG$ when used concurrently, resulting in increased and more prolonged @DRUG$ blood levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d283.s14.p0",
        "sentence": "A single dose of @DRUG$ had no clinically important effect on the pharmacokinetics of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d283.s16.p0",
        "sentence": "The @DRUG$ Cmax values were not significantly affected by @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d283.s3.p0",
        "sentence": "@DRUG$: The combined use of @DRUG$ and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d283.s3.p1",
        "sentence": "@DRUG$: The combined use of TRICOR and @DRUG$ should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d283.s3.p2",
        "sentence": "HMG-CoA reductase inhibitors: The combined use of @DRUG$ and @DRUG$ should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d284.s3.p0",
        "sentence": "Concomitant treatment with @DRUG$ (@DRUG$, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d284.s3.p1",
        "sentence": "Concomitant treatment with @DRUG$ (aminophylline, @DRUG$), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d284.s3.p2",
        "sentence": "Concomitant treatment with @DRUG$ (aminophylline, theophylline), @DRUG$, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d284.s3.p3",
        "sentence": "Concomitant treatment with @DRUG$ (aminophylline, theophylline), steroids, or @DRUG$ may potentiate any hypokalemic effect of adrenergic agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d284.s3.p4",
        "sentence": "Concomitant treatment with @DRUG$ (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d284.s3.p5",
        "sentence": "Concomitant treatment with methylxanthines (@DRUG$, @DRUG$), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d284.s3.p6",
        "sentence": "Concomitant treatment with methylxanthines (@DRUG$, theophylline), @DRUG$, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d284.s3.p7",
        "sentence": "Concomitant treatment with methylxanthines (@DRUG$, theophylline), steroids, or @DRUG$ may potentiate any hypokalemic effect of adrenergic agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d284.s3.p8",
        "sentence": "Concomitant treatment with methylxanthines (@DRUG$, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d284.s3.p9",
        "sentence": "Concomitant treatment with methylxanthines (aminophylline, @DRUG$), @DRUG$, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d284.s3.p10",
        "sentence": "Concomitant treatment with methylxanthines (aminophylline, @DRUG$), steroids, or @DRUG$ may potentiate any hypokalemic effect of adrenergic agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d284.s3.p11",
        "sentence": "Concomitant treatment with methylxanthines (aminophylline, @DRUG$), steroids, or diuretics may potentiate any hypokalemic effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d284.s3.p12",
        "sentence": "Concomitant treatment with methylxanthines (aminophylline, theophylline), @DRUG$, or @DRUG$ may potentiate any hypokalemic effect of adrenergic agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d284.s3.p13",
        "sentence": "Concomitant treatment with methylxanthines (aminophylline, theophylline), @DRUG$, or diuretics may potentiate any hypokalemic effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d284.s3.p14",
        "sentence": "Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or @DRUG$ may potentiate any hypokalemic effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d284.s5.p0",
        "sentence": "Although the clinical significance of these effects is not known, caution is advised in the co-administration of @DRUG$ with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d284.s6.p0",
        "sentence": "@DRUG$, as with other @DRUG$, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d284.s6.p1",
        "sentence": "@DRUG$, as with other beta2-agonists, should be administered with extreme caution to patients being treated with @DRUG$, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d284.s6.p2",
        "sentence": "@DRUG$, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, @DRUG$, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d284.s6.p3",
        "sentence": "@DRUG$, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d284.s6.p4",
        "sentence": "BROVANA, as with other @DRUG$, should be administered with extreme caution to patients being treated with @DRUG$, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d284.s6.p5",
        "sentence": "BROVANA, as with other @DRUG$, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, @DRUG$, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d284.s6.p6",
        "sentence": "BROVANA, as with other @DRUG$, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d284.s6.p7",
        "sentence": "BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with @DRUG$, @DRUG$, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d284.s6.p8",
        "sentence": "BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with @DRUG$, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d284.s6.p9",
        "sentence": "BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, @DRUG$, or drugs known to prolong the QTc interval because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d286.s0.p0",
        "sentence": "@DRUG$ may increase the action of @DRUG$, amphetamines, procainamide, and quinidine.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d286.s0.p1",
        "sentence": "@DRUG$ may increase the action of tricyclics, @DRUG$, procainamide, and quinidine.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d286.s0.p2",
        "sentence": "@DRUG$ may increase the action of tricyclics, amphetamines, @DRUG$, and quinidine.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d286.s0.p3",
        "sentence": "@DRUG$ may increase the action of tricyclics, amphetamines, procainamide, and @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d286.s0.p4",
        "sentence": "Ethoxzolamide may increase the action of @DRUG$, @DRUG$, procainamide, and quinidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d286.s0.p5",
        "sentence": "Ethoxzolamide may increase the action of @DRUG$, amphetamines, @DRUG$, and quinidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d286.s0.p6",
        "sentence": "Ethoxzolamide may increase the action of @DRUG$, amphetamines, procainamide, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d286.s0.p7",
        "sentence": "Ethoxzolamide may increase the action of tricyclics, @DRUG$, @DRUG$, and quinidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d286.s0.p8",
        "sentence": "Ethoxzolamide may increase the action of tricyclics, @DRUG$, procainamide, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d286.s0.p9",
        "sentence": "Ethoxzolamide may increase the action of tricyclics, amphetamines, @DRUG$, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d286.s2.p0",
        "sentence": "Coadministration of @DRUG$ with other @DRUG$, amphotericin B, and corticosteroids may cause hypokalemia.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d286.s2.p1",
        "sentence": "Coadministration of @DRUG$ with other diuretics, @DRUG$, and corticosteroids may cause hypokalemia.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d286.s2.p2",
        "sentence": "Coadministration of @DRUG$ with other diuretics, amphotericin B, and @DRUG$ may cause hypokalemia.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d286.s2.p3",
        "sentence": "Coadministration of ethoxzolamide with other @DRUG$, @DRUG$, and corticosteroids may cause hypokalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d286.s2.p4",
        "sentence": "Coadministration of ethoxzolamide with other @DRUG$, amphotericin B, and @DRUG$ may cause hypokalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d286.s2.p5",
        "sentence": "Coadministration of ethoxzolamide with other diuretics, @DRUG$, and @DRUG$ may cause hypokalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d288.s1.p0",
        "sentence": "Pharmacokinetic data from these patients demonstrated a decrease in @DRUG$ clearance of approximately 33% when @DRUG$ was administered following cisplatin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d288.s1.p1",
        "sentence": "Pharmacokinetic data from these patients demonstrated a decrease in @DRUG$ clearance of approximately 33% when TAXOL was administered following @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d288.s1.p2",
        "sentence": "Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when @DRUG$ was administered following @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d289.s13.p0",
        "sentence": "Co-administration of @DRUG$ decreased the plasma concentrations of @DRUG$ (a CYP3A4 substrate) by approximately 50%.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d289.s14.p0",
        "sentence": "@DRUG$: Co-administration of @DRUG$ and bosentan has not been studied in man.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s14.p1",
        "sentence": "@DRUG$: Co-administration of tacrolimus and @DRUG$ has not been studied in man.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s14.p2",
        "sentence": "Tacrolimus: Co-administration of @DRUG$ and @DRUG$ has not been studied in man.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s15.p0",
        "sentence": "Co-administration of @DRUG$ and @DRUG$ resulted in markedly increased plasma concentrations of bosentan in animals.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d289.s15.p1",
        "sentence": "Co-administration of @DRUG$ and bosentan resulted in markedly increased plasma concentrations of @DRUG$ in animals.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s15.p2",
        "sentence": "Co-administration of tacrolimus and @DRUG$ resulted in markedly increased plasma concentrations of @DRUG$ in animals.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s21.p0",
        "sentence": "@DRUG$ is also expected to reduce plasma concentrations of other oral @DRUG$ that are predominantly metabolized by CYP2C9 or CYP3A4.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d289.s23.p0",
        "sentence": "@DRUG$: Co-administration of @DRUG$ 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s23.p1",
        "sentence": "@DRUG$: Co-administration of bosentan 125 mg b.i.d. and @DRUG$, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s23.p2",
        "sentence": "@DRUG$: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of @DRUG$ by approximately 2-fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s23.p3",
        "sentence": "Ketoconazole: Co-administration of @DRUG$ 125 mg b.i.d. and @DRUG$, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d289.s23.p4",
        "sentence": "Ketoconazole: Co-administration of @DRUG$ 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of @DRUG$ by approximately 2-fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s23.p5",
        "sentence": "Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and @DRUG$, a potent CYP3A4 inhibitor, increased the plasma concentrations of @DRUG$ by approximately 2-fold.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s25.p0",
        "sentence": "@DRUG$ and Other @DRUG$: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s25.p1",
        "sentence": "@DRUG$ and Other Statins: Co-administration of @DRUG$ decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s25.p2",
        "sentence": "@DRUG$ and Other Statins: Co-administration of bosentan decreased the plasma concentrations of @DRUG$ (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s25.p3",
        "sentence": "Simvastatin and Other @DRUG$: Co-administration of @DRUG$ decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s25.p4",
        "sentence": "Simvastatin and Other @DRUG$: Co-administration of bosentan decreased the plasma concentrations of @DRUG$ (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s25.p5",
        "sentence": "Simvastatin and Other Statins: Co-administration of @DRUG$ decreased the plasma concentrations of @DRUG$ (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d289.s30.p0",
        "sentence": "@DRUG$: Co-administration of @DRUG$ 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s30.p1",
        "sentence": "@DRUG$: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both @DRUG$ (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s30.p2",
        "sentence": "@DRUG$: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and @DRUG$ (a CYP3A4 substrate) by 29 and 38%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s30.p3",
        "sentence": "Warfarin: Co-administration of @DRUG$ 500 mg b.i.d. for 6 days decreased the plasma concentrations of both @DRUG$ (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d289.s30.p4",
        "sentence": "Warfarin: Co-administration of @DRUG$ 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and @DRUG$ (a CYP3A4 substrate) by 29 and 38%, respectively.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d289.s30.p5",
        "sentence": "Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both @DRUG$ (a CYP2C9 substrate) and @DRUG$ (a CYP3A4 substrate) by 29 and 38%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s31.p0",
        "sentence": "Clinical experience with concomitant administration of @DRUG$ and @DRUG$ in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s31.p1",
        "sentence": "Clinical experience with concomitant administration of @DRUG$ and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or @DRUG$ dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s31.p2",
        "sentence": "Clinical experience with concomitant administration of @DRUG$ and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the @DRUG$ dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s31.p3",
        "sentence": "Clinical experience with concomitant administration of @DRUG$ and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s31.p4",
        "sentence": "Clinical experience with concomitant administration of bosentan and @DRUG$ in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or @DRUG$ dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s31.p5",
        "sentence": "Clinical experience with concomitant administration of bosentan and @DRUG$ in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the @DRUG$ dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s31.p6",
        "sentence": "Clinical experience with concomitant administration of bosentan and @DRUG$ in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s31.p7",
        "sentence": "Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or @DRUG$ dose (baseline vs. end of the clinical studies), and the need to change the @DRUG$ dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s31.p8",
        "sentence": "Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or @DRUG$ dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s31.p9",
        "sentence": "Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the @DRUG$ dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d289.s8.p0",
        "sentence": "Therefore, @DRUG$, including oral, injectable, transdermal, and implantable forms, may not be reliable when @DRUG$ is co-administered.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d29.s13.p0",
        "sentence": "Coadministration of oral @DRUG$, @DRUG$, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d29.s13.p1",
        "sentence": "Coadministration of oral @DRUG$, diazepam, @DRUG$, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d29.s13.p2",
        "sentence": "Coadministration of oral @DRUG$, diazepam, phenytoin, or @DRUG$ did not seem to change the pharmacokinetic profile of esomeprazole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d29.s13.p3",
        "sentence": "Coadministration of oral @DRUG$, diazepam, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d29.s13.p4",
        "sentence": "Coadministration of oral contraceptives, @DRUG$, @DRUG$, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d29.s13.p5",
        "sentence": "Coadministration of oral contraceptives, @DRUG$, phenytoin, or @DRUG$ did not seem to change the pharmacokinetic profile of esomeprazole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d29.s13.p6",
        "sentence": "Coadministration of oral contraceptives, @DRUG$, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d29.s13.p7",
        "sentence": "Coadministration of oral contraceptives, diazepam, @DRUG$, or @DRUG$ did not seem to change the pharmacokinetic profile of esomeprazole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d29.s13.p8",
        "sentence": "Coadministration of oral contraceptives, diazepam, @DRUG$, or quinidine did not seem to change the pharmacokinetic profile of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d29.s13.p9",
        "sentence": "Coadministration of oral contraceptives, diazepam, phenytoin, or @DRUG$ did not seem to change the pharmacokinetic profile of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d29.s4.p0",
        "sentence": "Post-marketing reports of changes in prothrombin measures have been received among patients on concomitant @DRUG$ and @DRUG$ therapy.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d29.s7.p0",
        "sentence": "@DRUG$ may potentially interfere with CYP2C19, the major @DRUG$ metabolizing enzyme.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d291.s0.p0",
        "sentence": "When @DRUG$ or @DRUG$ is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d291.s0.p1",
        "sentence": "When @DRUG$ or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - @DRUG$ and Bezalip retard may enhance the action of anticoagulants of the coumarin type.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d291.s0.p2",
        "sentence": "When @DRUG$ or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and @DRUG$ may enhance the action of anticoagulants of the coumarin type.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d291.s0.p3",
        "sentence": "When @DRUG$ or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d291.s0.p4",
        "sentence": "When Bezalip or @DRUG$ is used at the same time as other medicines or substances the following interactions must be taken into account: - @DRUG$ and Bezalip retard may enhance the action of anticoagulants of the coumarin type.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d291.s0.p5",
        "sentence": "When Bezalip or @DRUG$ is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and @DRUG$ may enhance the action of anticoagulants of the coumarin type.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d291.s0.p6",
        "sentence": "When Bezalip or @DRUG$ is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d291.s0.p7",
        "sentence": "When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - @DRUG$ and @DRUG$ may enhance the action of anticoagulants of the coumarin type.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d291.s0.p8",
        "sentence": "When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - @DRUG$ and Bezalip retard may enhance the action of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d291.s0.p9",
        "sentence": "When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and @DRUG$ may enhance the action of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d295.s1.p0",
        "sentence": "Coadministration of @DRUG$ with @DRUG$, adefovir dipivoxil,or tenofovir disoproxil fumarate did not result in significant drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d295.s1.p1",
        "sentence": "Coadministration of @DRUG$ with lamivudine, @DRUG$,or tenofovir disoproxil fumarate did not result in significant drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d295.s1.p2",
        "sentence": "Coadministration of @DRUG$ with lamivudine, adefovir dipivoxil,or @DRUG$ did not result in significant drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d295.s1.p3",
        "sentence": "Coadministration of entecavir with @DRUG$, @DRUG$,or tenofovir disoproxil fumarate did not result in significant drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d295.s1.p4",
        "sentence": "Coadministration of entecavir with @DRUG$, adefovir dipivoxil,or @DRUG$ did not result in significant drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d295.s1.p5",
        "sentence": "Coadministration of entecavir with lamivudine, @DRUG$,or @DRUG$ did not result in significant drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d295.s2.p0",
        "sentence": "The effects of coadministration of @DRUG$ with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when @DRUG$ is coadministered with such drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d297.s5.p0",
        "sentence": "There is insufficient experience to assess the safety and efficacy of @DRUG$ administered concurrently with @DRUG$, and therefore such use is not recommended.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d299.s5.p0",
        "sentence": "@DRUG$: The pharmacokinetics of @DRUG$ were not affected by coadministration of propranolol.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d299.s5.p1",
        "sentence": "@DRUG$: The pharmacokinetics of almotriptan were not affected by coadministration of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d299.s5.p2",
        "sentence": "Propanolol: The pharmacokinetics of @DRUG$ were not affected by coadministration of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d299.s7.p0",
        "sentence": "If concomitant treatment with @DRUG$ and an @DRUG$ is clinically warranted, appropriate observation of the patient is advised.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p0",
        "sentence": "@DRUG$, @DRUG$, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p1",
        "sentence": "@DRUG$, Digoxin, @DRUG$, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p2",
        "sentence": "@DRUG$, Digoxin, Salicylate, and @DRUG$ The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p3",
        "sentence": "@DRUG$, Digoxin, Salicylate, and Heparin The in vitro binding of @DRUG$ to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p4",
        "sentence": "@DRUG$, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by @DRUG$ (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p5",
        "sentence": "@DRUG$, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when @DRUG$ plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p6",
        "sentence": "Warfarin, @DRUG$, @DRUG$, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p7",
        "sentence": "Warfarin, @DRUG$, Salicylate, and @DRUG$ The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p8",
        "sentence": "Warfarin, @DRUG$, Salicylate, and Heparin The in vitro binding of @DRUG$ to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p9",
        "sentence": "Warfarin, @DRUG$, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by @DRUG$ (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p10",
        "sentence": "Warfarin, @DRUG$, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when @DRUG$ plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p11",
        "sentence": "Warfarin, Digoxin, @DRUG$, and @DRUG$ The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p12",
        "sentence": "Warfarin, Digoxin, @DRUG$, and Heparin The in vitro binding of @DRUG$ to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p13",
        "sentence": "Warfarin, Digoxin, @DRUG$, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by @DRUG$ (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p14",
        "sentence": "Warfarin, Digoxin, @DRUG$, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when @DRUG$ plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p15",
        "sentence": "Warfarin, Digoxin, Salicylate, and @DRUG$ The in vitro binding of @DRUG$ to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p16",
        "sentence": "Warfarin, Digoxin, Salicylate, and @DRUG$ The in vitro binding of warfarin to plasma proteins is only slightly reduced by @DRUG$ (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p17",
        "sentence": "Warfarin, Digoxin, Salicylate, and @DRUG$ The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when @DRUG$ plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p18",
        "sentence": "Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of @DRUG$ to plasma proteins is only slightly reduced by @DRUG$ (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p19",
        "sentence": "Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of @DRUG$ to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when @DRUG$ plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s1.p20",
        "sentence": "Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by @DRUG$ (99.5% control vs 99.3%) when @DRUG$ plasma concentrations reach 5 to10 m g/mL.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s10.p0",
        "sentence": "Therefore, concomitant use of @DRUG$ and @DRUG$ is contraindicated.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d3.s13.p0",
        "sentence": "@DRUG$: Concomitant administration of @DRUG$ and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s13.p1",
        "sentence": "@DRUG$: Concomitant administration of methotrexate and some @DRUG$ has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s13.p2",
        "sentence": "@DRUG$: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of @DRUG$, enhancing the toxicity of methotrexate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s13.p3",
        "sentence": "@DRUG$: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s13.p4",
        "sentence": "Methotrexate: Concomitant administration of @DRUG$ and some @DRUG$ has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d3.s13.p5",
        "sentence": "Methotrexate: Concomitant administration of @DRUG$ and some NSAIDs has been reported to reduce the clearance of @DRUG$, enhancing the toxicity of methotrexate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s13.p6",
        "sentence": "Methotrexate: Concomitant administration of @DRUG$ and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s13.p7",
        "sentence": "Methotrexate: Concomitant administration of methotrexate and some @DRUG$ has been reported to reduce the clearance of @DRUG$, enhancing the toxicity of methotrexate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s13.p8",
        "sentence": "Methotrexate: Concomitant administration of methotrexate and some @DRUG$ has been reported to reduce the clearance of methotrexate, enhancing the toxicity of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s13.p9",
        "sentence": "Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of @DRUG$, enhancing the toxicity of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s18.p0",
        "sentence": "@DRUG$: Sporadic cases of seizures have been reported during concomitant use of @DRUG$ and antiepileptic drugs (phenytoin, carbamazepine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s18.p1",
        "sentence": "@DRUG$: Sporadic cases of seizures have been reported during concomitant use of TORADOL and @DRUG$ (phenytoin, carbamazepine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s18.p2",
        "sentence": "@DRUG$: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (@DRUG$, carbamazepine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s18.p3",
        "sentence": "@DRUG$: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s18.p4",
        "sentence": "Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of @DRUG$ and @DRUG$ (phenytoin, carbamazepine).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d3.s18.p5",
        "sentence": "Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of @DRUG$ and antiepileptic drugs (@DRUG$, carbamazepine).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d3.s18.p6",
        "sentence": "Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of @DRUG$ and antiepileptic drugs (phenytoin, @DRUG$).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d3.s18.p7",
        "sentence": "Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and @DRUG$ (@DRUG$, carbamazepine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s18.p8",
        "sentence": "Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and @DRUG$ (phenytoin, @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s18.p9",
        "sentence": "Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (@DRUG$, @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s21.p0",
        "sentence": "Do not mix @DRUG$ and @DRUG$ in the same syringe.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s9.p0",
        "sentence": "@DRUG$: Concomitant administration of @DRUG$ ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s9.p1",
        "sentence": "@DRUG$: Concomitant administration of TORADOL ORAL and @DRUG$ resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s9.p2",
        "sentence": "@DRUG$: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of @DRUG$ and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s9.p3",
        "sentence": "@DRUG$: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in @DRUG$ plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s9.p4",
        "sentence": "Probenecid: Concomitant administration of @DRUG$ ORAL and @DRUG$ resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d3.s9.p5",
        "sentence": "Probenecid: Concomitant administration of @DRUG$ ORAL and probenecid resulted in decreased clearance of @DRUG$ and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s9.p6",
        "sentence": "Probenecid: Concomitant administration of @DRUG$ ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in @DRUG$ plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s9.p7",
        "sentence": "Probenecid: Concomitant administration of TORADOL ORAL and @DRUG$ resulted in decreased clearance of @DRUG$ and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s9.p8",
        "sentence": "Probenecid: Concomitant administration of TORADOL ORAL and @DRUG$ resulted in decreased clearance of ketorolac and significant increases in @DRUG$ plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d3.s9.p9",
        "sentence": "Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of @DRUG$ and significant increases in @DRUG$ plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d30.s1.p0",
        "sentence": "@DRUG$, an inducer of drug metabolism, decreased the concentrations of @DRUG$ and its active metabolite.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d30.s8.p0",
        "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of @DRUG$ (e.g., @DRUG$, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d30.s8.p1",
        "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of @DRUG$ (e.g., spironolactone, @DRUG$, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d30.s8.p2",
        "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of @DRUG$ (e.g., spironolactone, triamterene, @DRUG$), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d30.s8.p3",
        "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of @DRUG$ (e.g., spironolactone, triamterene, amiloride), @DRUG$ supplements, or salt substitutes containing potassium may lead to increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d30.s8.p4",
        "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., @DRUG$, @DRUG$, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d30.s8.p5",
        "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., @DRUG$, triamterene, @DRUG$), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d30.s8.p6",
        "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., @DRUG$, triamterene, amiloride), @DRUG$ supplements, or salt substitutes containing potassium may lead to increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d30.s8.p7",
        "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, @DRUG$, @DRUG$), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d30.s8.p8",
        "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, @DRUG$, amiloride), @DRUG$ supplements, or salt substitutes containing potassium may lead to increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d30.s8.p9",
        "sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, @DRUG$), @DRUG$ supplements, or salt substitutes containing potassium may lead to increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d30.s9.p0",
        "sentence": "As with other @DRUG$, the antihypertensive effect of @DRUG$ may be blunted by the non-steroidal anti-inflammatory drug indomethacin",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d30.s9.p1",
        "sentence": "As with other @DRUG$, the antihypertensive effect of losartan may be blunted by the @DRUG$ indomethacin",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d30.s9.p2",
        "sentence": "As with other @DRUG$, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d30.s9.p3",
        "sentence": "As with other antihypertensive agents, the antihypertensive effect of @DRUG$ may be blunted by the @DRUG$ indomethacin",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d30.s9.p4",
        "sentence": "As with other antihypertensive agents, the antihypertensive effect of @DRUG$ may be blunted by the non-steroidal anti-inflammatory drug @DRUG$",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d30.s9.p5",
        "sentence": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the @DRUG$ @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d305.s3.p0",
        "sentence": "Binding to plasma proteins is reduced by @DRUG$ and clotibrate and increased by @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d305.s5.p0",
        "sentence": "The combination of therapeutic doses of intravenous @DRUG$ and @DRUG$ in halothane a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d305.s5.p1",
        "sentence": "The combination of therapeutic doses of intravenous @DRUG$ and verapamil in @DRUG$ a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d305.s5.p2",
        "sentence": "The combination of therapeutic doses of intravenous dantrolene sodium and @DRUG$ in @DRUG$ a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d305.s6.p0",
        "sentence": "It is recommended that the combination of intravenous @DRUG$ and @DRUG$, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d305.s6.p1",
        "sentence": "It is recommended that the combination of intravenous @DRUG$ and calcium channel blockers, such as @DRUG$, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d305.s6.p2",
        "sentence": "It is recommended that the combination of intravenous dantrolene sodium and @DRUG$, such as @DRUG$, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d307.s45.p0",
        "sentence": "@DRUG$s: After repeated co-administration of @DRUG$, the AUC of felodipine was lowered by 28% [90% CI: 20-33].",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d307.s45.p1",
        "sentence": "@DRUG$s: After repeated co-administration of Trileptal, the AUC of @DRUG$ was lowered by 28% [90% CI: 20-33].",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d307.s45.p2",
        "sentence": "Calcium Antagonists: After repeated co-administration of @DRUG$, the AUC of @DRUG$ was lowered by 28% [90% CI: 20-33].",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d307.s46.p0",
        "sentence": "@DRUG$ produced a decrease of 20% [90% CI: 18-27] of the plasma levels of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d307.s48.p0",
        "sentence": "Results with @DRUG$ wshow no evidence of interaction with either single or repeated doses of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d307.s7.p0",
        "sentence": "Increases of 22% with @DRUG$ and 47% with @DRUG$ were observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d308.s0.p0",
        "sentence": "THE POTENTIATING ACTION OF @DRUG$ MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH @DRUG$ SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d308.s0.p1",
        "sentence": "THE POTENTIATING ACTION OF @DRUG$ MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS @DRUG$, NON-NARCOTIC ANALGESICS AND BARBITURATES.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d308.s0.p2",
        "sentence": "THE POTENTIATING ACTION OF @DRUG$ MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, @DRUG$ AND BARBITURATES.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d308.s0.p3",
        "sentence": "THE POTENTIATING ACTION OF @DRUG$ MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d308.s0.p4",
        "sentence": "THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH @DRUG$ SUCH AS @DRUG$, NON-NARCOTIC ANALGESICS AND BARBITURATES.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d308.s0.p5",
        "sentence": "THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH @DRUG$ SUCH AS NARCOTICS, @DRUG$ AND BARBITURATES.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d308.s0.p6",
        "sentence": "THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH @DRUG$ SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d308.s0.p7",
        "sentence": "THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS @DRUG$, @DRUG$ AND BARBITURATES.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d308.s0.p8",
        "sentence": "THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS @DRUG$, NON-NARCOTIC ANALGESICS AND @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d308.s0.p9",
        "sentence": "THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, @DRUG$ AND @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d309.s1.p0",
        "sentence": "Patients receiving @DRUG$ should be advised against the concurrent use of other @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d309.s2.p0",
        "sentence": "@DRUG$ prolong and intensify the anticholinergic effects of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d31.s0.p0",
        "sentence": "@DRUG$ should be used with caution in patients receiving @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d31.s6.p0",
        "sentence": "@DRUG$, @DRUG$, and nadolol (low hepatic clearance or no first-pass metabolism) are unlikely to be affected.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d31.s6.p1",
        "sentence": "@DRUG$, atenolol, and @DRUG$ (low hepatic clearance or no first-pass metabolism) are unlikely to be affected.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d31.s6.p2",
        "sentence": "Acebutolol, @DRUG$, and @DRUG$ (low hepatic clearance or no first-pass metabolism) are unlikely to be affected.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d310.s4.p0",
        "sentence": "This effect may be mediated by the known inhibition of hepatic cytochrome P- 450 by @DRUG$, which could decrease first pass metabolism of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d312.s2.p0",
        "sentence": "@DRUG$ concentrations were similar in patients receiving bolus-IFL alone and in combination with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s1.p0",
        "sentence": "@DRUG$ injection and potassium-depleting agents: When @DRUG$ are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s1.p1",
        "sentence": "@DRUG$ injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., @DRUG$, diuretics), patients should be observed closely for development of hypokalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s1.p2",
        "sentence": "@DRUG$ injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, @DRUG$), patients should be observed closely for development of hypokalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s1.p3",
        "sentence": "Amphotericin B injection and potassium-depleting agents: When @DRUG$ are administered concomitantly with potassium-depleting agents (e.g., @DRUG$, diuretics), patients should be observed closely for development of hypokalemia.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d314.s1.p4",
        "sentence": "Amphotericin B injection and potassium-depleting agents: When @DRUG$ are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, @DRUG$), patients should be observed closely for development of hypokalemia.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d314.s1.p5",
        "sentence": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., @DRUG$, @DRUG$), patients should be observed closely for development of hypokalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s10.p0",
        "sentence": "@DRUG$: @DRUG$ may increase the clearance of corticosteroids.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s10.p1",
        "sentence": "@DRUG$: Cholestyramine may increase the clearance of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s10.p2",
        "sentence": "Cholestyramine: @DRUG$ may increase the clearance of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d314.s15.p0",
        "sentence": "@DRUG$: Patients on @DRUG$ may be at increased risk of arrhythmias due to hypokalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s22.p0",
        "sentence": "@DRUG$: @DRUG$ has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s22.p1",
        "sentence": "@DRUG$: Ketoconazole has been reported to decrease the metabolism of certain @DRUG$ by up to 60%, leading to increased risk of corticosteroid side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s22.p2",
        "sentence": "@DRUG$: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of @DRUG$ side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s22.p3",
        "sentence": "Ketoconazole: @DRUG$ has been reported to decrease the metabolism of certain @DRUG$ by up to 60%, leading to increased risk of corticosteroid side effects.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d314.s22.p4",
        "sentence": "Ketoconazole: @DRUG$ has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of @DRUG$ side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s22.p5",
        "sentence": "Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain @DRUG$ by up to 60%, leading to increased risk of @DRUG$ side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s24.p0",
        "sentence": "@DRUG$ (@DRUG$): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s24.p1",
        "sentence": "@DRUG$ (NSAIDS): Concomitant use of @DRUG$ (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s24.p2",
        "sentence": "@DRUG$ (NSAIDS): Concomitant use of aspirin (or other @DRUG$) and corticosteroids increases the risk of gastrointestinal side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s24.p3",
        "sentence": "@DRUG$ (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and @DRUG$ increases the risk of gastrointestinal side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s24.p4",
        "sentence": "Nonsteroidal anti-inflammatory agents (@DRUG$): Concomitant use of @DRUG$ (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s24.p5",
        "sentence": "Nonsteroidal anti-inflammatory agents (@DRUG$): Concomitant use of aspirin (or other @DRUG$) and corticosteroids increases the risk of gastrointestinal side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s24.p6",
        "sentence": "Nonsteroidal anti-inflammatory agents (@DRUG$): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and @DRUG$ increases the risk of gastrointestinal side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s24.p7",
        "sentence": "Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of @DRUG$ (or other @DRUG$) and corticosteroids increases the risk of gastrointestinal side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s24.p8",
        "sentence": "Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of @DRUG$ (or other nonsteroidal antiinflammatory agents) and @DRUG$ increases the risk of gastrointestinal side effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d314.s24.p9",
        "sentence": "Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other @DRUG$) and @DRUG$ increases the risk of gastrointestinal side effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d314.s32.p0",
        "sentence": "Routine administration of @DRUG$ or toxoids should be deferred until @DRUG$ therapy is discontinued if possible.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d314.s5.p0",
        "sentence": "If possible, @DRUG$ should be withdrawn at least 24 hours before initiating @DRUG$ therapy.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d314.s6.p0",
        "sentence": "@DRUG$, oral: Co-administration of @DRUG$ and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s6.p1",
        "sentence": "@DRUG$, oral: Co-administration of corticosteroids and @DRUG$ usually results in inhibition of response to warfarin, although there have been some conflicting reports.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s6.p2",
        "sentence": "@DRUG$, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to @DRUG$, although there have been some conflicting reports.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s6.p3",
        "sentence": "Anticoagulants, oral: Co-administration of @DRUG$ and @DRUG$ usually results in inhibition of response to warfarin, although there have been some conflicting reports.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d314.s6.p4",
        "sentence": "Anticoagulants, oral: Co-administration of @DRUG$ and warfarin usually results in inhibition of response to @DRUG$, although there have been some conflicting reports.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d314.s6.p5",
        "sentence": "Anticoagulants, oral: Co-administration of corticosteroids and @DRUG$ usually results in inhibition of response to @DRUG$, although there have been some conflicting reports.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d315.s0.p0",
        "sentence": "@DRUG$: Coadministration of @DRUG$, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d315.s0.p1",
        "sentence": "@DRUG$: Coadministration of digoxin, a P-glycoprotein substrate, with oral @DRUG$ resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d315.s0.p2",
        "sentence": "@DRUG$: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in @DRUG$ Cmax and AUC values.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d315.s0.p3",
        "sentence": "Digoxin: Coadministration of @DRUG$, a P-glycoprotein substrate, with oral @DRUG$ resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d315.s0.p4",
        "sentence": "Digoxin: Coadministration of @DRUG$, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in @DRUG$ Cmax and AUC values.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d315.s0.p5",
        "sentence": "Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral @DRUG$ resulted in a reduction in clearance and an increase in @DRUG$ Cmax and AUC values.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s1.p0",
        "sentence": "Co-administration of CYP3A4 inhibitors (eg, @DRUG$, @DRUG$, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s1.p1",
        "sentence": "Co-administration of CYP3A4 inhibitors (eg, @DRUG$, itraconazole, @DRUG$, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s1.p2",
        "sentence": "Co-administration of CYP3A4 inhibitors (eg, @DRUG$, itraconazole, erythromycin, grapefruit juice, @DRUG$) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s1.p3",
        "sentence": "Co-administration of CYP3A4 inhibitors (eg, @DRUG$, itraconazole, erythromycin, grapefruit juice, cimetidine) with @DRUG$ may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s1.p4",
        "sentence": "Co-administration of CYP3A4 inhibitors (eg, @DRUG$, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of @DRUG$, either due to an increase in bioavailability or due to a decrease in metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s1.p5",
        "sentence": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, @DRUG$, @DRUG$, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s1.p6",
        "sentence": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, @DRUG$, erythromycin, grapefruit juice, @DRUG$) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s1.p7",
        "sentence": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, @DRUG$, erythromycin, grapefruit juice, cimetidine) with @DRUG$ may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s1.p8",
        "sentence": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, @DRUG$, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of @DRUG$, either due to an increase in bioavailability or due to a decrease in metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s1.p9",
        "sentence": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, @DRUG$, grapefruit juice, @DRUG$) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s1.p10",
        "sentence": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, @DRUG$, grapefruit juice, cimetidine) with @DRUG$ may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s1.p11",
        "sentence": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, @DRUG$, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of @DRUG$, either due to an increase in bioavailability or due to a decrease in metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s1.p12",
        "sentence": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, @DRUG$) with @DRUG$ may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s1.p13",
        "sentence": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, @DRUG$) with felodipine may lead to several- fold increases in the plasma levels of @DRUG$, either due to an increase in bioavailability or due to a decrease in metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s1.p14",
        "sentence": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with @DRUG$ may lead to several- fold increases in the plasma levels of @DRUG$, either due to an increase in bioavailability or due to a decrease in metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s12.p0",
        "sentence": "In controlled clinical trials, however, @DRUG$ including @DRUG$ were concurrently administered with felodipine and were well tolerated.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s12.p1",
        "sentence": "In controlled clinical trials, however, @DRUG$ including metoprolol were concurrently administered with @DRUG$ and were well tolerated.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s12.p2",
        "sentence": "In controlled clinical trials, however, beta blockers including @DRUG$ were concurrently administered with @DRUG$ and were well tolerated.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s14.p0",
        "sentence": "@DRUG$: In a pharmacokinetic study, maximum plasma concentrations of @DRUG$ were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s14.p1",
        "sentence": "@DRUG$: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term @DRUG$ therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s14.p2",
        "sentence": "@DRUG$: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, @DRUG$, carbamazepine, or phenobarbital) than in healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s14.p3",
        "sentence": "@DRUG$: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, @DRUG$, or phenobarbital) than in healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s14.p4",
        "sentence": "@DRUG$: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or @DRUG$) than in healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s14.p5",
        "sentence": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of @DRUG$ were considerably lower in epileptic patients on long-term @DRUG$ therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d316.s14.p6",
        "sentence": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of @DRUG$ were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, @DRUG$, carbamazepine, or phenobarbital) than in healthy volunteers.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d316.s14.p7",
        "sentence": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of @DRUG$ were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, @DRUG$, or phenobarbital) than in healthy volunteers.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d316.s14.p8",
        "sentence": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of @DRUG$ were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or @DRUG$) than in healthy volunteers.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d316.s14.p9",
        "sentence": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term @DRUG$ therapy (eg, @DRUG$, carbamazepine, or phenobarbital) than in healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s14.p10",
        "sentence": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term @DRUG$ therapy (eg, phenytoin, @DRUG$, or phenobarbital) than in healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s14.p11",
        "sentence": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term @DRUG$ therapy (eg, phenytoin, carbamazepine, or @DRUG$) than in healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s14.p12",
        "sentence": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, @DRUG$, @DRUG$, or phenobarbital) than in healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s14.p13",
        "sentence": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, @DRUG$, carbamazepine, or @DRUG$) than in healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s14.p14",
        "sentence": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, @DRUG$, or @DRUG$) than in healthy volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s18.p0",
        "sentence": "When given concomitantly with @DRUG$, the @DRUG$ blood concentration should be followed and the tacrolimus dose may need to be adjusted.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s19.p0",
        "sentence": "Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when @DRUG$ was given concomitantly with @DRUG$ or spironolactone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s19.p1",
        "sentence": "Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when @DRUG$ was given concomitantly with indomethacin or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s19.p2",
        "sentence": "Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with @DRUG$ or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s3.p0",
        "sentence": "These effects have been observed with co-administration of @DRUG$ (a potent @DRUG$ inhibitor).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s4.p0",
        "sentence": "Caution should be used when @DRUG$ inhibitors are co-administered with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s8.p0",
        "sentence": "Grapefruit juice Co-administration of @DRUG$ with grapefruit juice resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half- life of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s9.p0",
        "sentence": "Cimetidine Co-administration of @DRUG$ with @DRUG$ (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of felodipine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s9.p1",
        "sentence": "Cimetidine Co-administration of @DRUG$ with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d316.s9.p2",
        "sentence": "Cimetidine Co-administration of felodipine with @DRUG$ (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d318.s0.p0",
        "sentence": "When administered concurrently, the following drugs may interact with @DRUG$: @DRUG$: may enhance the potential for renal toxicity, bronchospasm and hypotension.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d318.s12.p0",
        "sentence": "@DRUG$: @DRUG$-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d318.s12.p1",
        "sentence": "@DRUG$: amphotericin B-induced hypokalemia may enhance the curariform effect of @DRUG$ (e.g., tubocurarine).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d318.s12.p2",
        "sentence": "@DRUG$: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d318.s12.p3",
        "sentence": "Skeletal muscle relaxants: @DRUG$-induced hypokalemia may enhance the curariform effect of @DRUG$ (e.g., tubocurarine).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d318.s12.p4",
        "sentence": "Skeletal muscle relaxants: @DRUG$-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., @DRUG$).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d318.s12.p5",
        "sentence": "Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of @DRUG$ (e.g., @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d318.s14.p0",
        "sentence": "@DRUG$: acute pulmonary toxicity has been reported in patients receiving intravenous @DRUG$ and leukocyte transfusions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d318.s14.p1",
        "sentence": "@DRUG$: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d318.s14.p2",
        "sentence": "Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous @DRUG$ and @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d32.s0.p0",
        "sentence": "@DRUG$: Twelve healthy male volunteers were administered one 200-mg @DRUG$ capsule twice daily for 6 days.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d320.s5.p0",
        "sentence": "@DRUG$ e.g., @DRUG$;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d320.s6.p0",
        "sentence": "and @DRUG$ e.g., @DRUG$), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d320.s6.p1",
        "sentence": "and @DRUG$ e.g., verapamil), CYP1A2 inducers (@DRUG$) and CYP1A2 inhibitors (furafylline and clarithromycin).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d320.s6.p2",
        "sentence": "and @DRUG$ e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (@DRUG$ and clarithromycin).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d320.s6.p3",
        "sentence": "and @DRUG$ e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d320.s6.p4",
        "sentence": "and calcium channel antagonists e.g., @DRUG$), CYP1A2 inducers (@DRUG$) and CYP1A2 inhibitors (furafylline and clarithromycin).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d320.s6.p5",
        "sentence": "and calcium channel antagonists e.g., @DRUG$), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (@DRUG$ and clarithromycin).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d320.s6.p6",
        "sentence": "and calcium channel antagonists e.g., @DRUG$), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d320.s6.p7",
        "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (@DRUG$) and CYP1A2 inhibitors (@DRUG$ and clarithromycin).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d320.s6.p8",
        "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (@DRUG$) and CYP1A2 inhibitors (furafylline and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d320.s6.p9",
        "sentence": "and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (@DRUG$ and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d321.s1.p0",
        "sentence": "@DRUG$: In the fed state, @DRUG$ (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d321.s1.p1",
        "sentence": "@DRUG$: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of @DRUG$ by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d321.s1.p2",
        "sentence": "@DRUG$: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given @DRUG$ alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d321.s1.p3",
        "sentence": "Praziquantel: In the fed state, @DRUG$ (40 mg/kg) increased mean maximum plasma concentration and area under the curve of @DRUG$ by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d321.s1.p4",
        "sentence": "Praziquantel: In the fed state, @DRUG$ (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given @DRUG$ alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d321.s1.p5",
        "sentence": "Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of @DRUG$ by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given @DRUG$ alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s10.p0",
        "sentence": "@DRUG$: Coadministration of a single dose of @DRUG$ 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s10.p1",
        "sentence": "@DRUG$: Coadministration of a single dose of zaleplon 10 mg and multiple doses of @DRUG$ ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s10.p2",
        "sentence": "@DRUG$: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either @DRUG$ or venlafaxine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s10.p3",
        "sentence": "@DRUG$: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s10.p4",
        "sentence": "Venlafaxine: Coadministration of a single dose of @DRUG$ 10 mg and multiple doses of @DRUG$ ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s10.p5",
        "sentence": "Venlafaxine: Coadministration of a single dose of @DRUG$ 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either @DRUG$ or venlafaxine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s10.p6",
        "sentence": "Venlafaxine: Coadministration of a single dose of @DRUG$ 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s10.p7",
        "sentence": "Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of @DRUG$ ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either @DRUG$ or venlafaxine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s10.p8",
        "sentence": "Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of @DRUG$ ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s10.p9",
        "sentence": "Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either @DRUG$ or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s19.p0",
        "sentence": "Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of @DRUG$ because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, @DRUG$ and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s19.p1",
        "sentence": "Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of @DRUG$ because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and @DRUG$, account for only 9% of the urinary recovery of a zaleplon dose.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s19.p2",
        "sentence": "Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of @DRUG$ because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a @DRUG$ dose.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s19.p3",
        "sentence": "Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, @DRUG$ and @DRUG$, account for only 9% of the urinary recovery of a zaleplon dose.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s19.p4",
        "sentence": "Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, @DRUG$ and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a @DRUG$ dose.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s19.p5",
        "sentence": "Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and @DRUG$, account for only 9% of the urinary recovery of a @DRUG$ dose.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s22.p0",
        "sentence": "Other strong selective CYP3A4 inhibitors such as @DRUG$ can also be expected to increase the exposure of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d324.s26.p0",
        "sentence": "There is no pharmacokinetic interaction between @DRUG$ and @DRUG$ following the administration of a single dose (10 mg and 50 mg, respectively) of each drug.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s35.p0",
        "sentence": "@DRUG$: Multiple oral doses of @DRUG$ (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s35.p1",
        "sentence": "@DRUG$: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of @DRUG$ (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s35.p2",
        "sentence": "@DRUG$: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s35.p3",
        "sentence": "Warfarin: Multiple oral doses of @DRUG$ (20 mg q24h for 13 days) did not affect the pharmacokinetics of @DRUG$ (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s35.p4",
        "sentence": "Warfarin: Multiple oral doses of @DRUG$ (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d324.s35.p5",
        "sentence": "Warfarin: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of @DRUG$ (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d325.s13.p0",
        "sentence": "Administration of @DRUG$ to patients receiving @DRUG$ has been reported to lead to hypotension and bradycardia.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d325.s7.p0",
        "sentence": "@DRUG$ (such as @DRUG$) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d325.s7.p1",
        "sentence": "@DRUG$ (such as haloperidol) and @DRUG$ can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d325.s7.p2",
        "sentence": "@DRUG$ (such as haloperidol) and phenothiazines can suppress the @DRUG$rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d325.s7.p3",
        "sentence": "Butyrophenones (such as @DRUG$) and @DRUG$ can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d325.s7.p4",
        "sentence": "Butyrophenones (such as @DRUG$) and phenothiazines can suppress the @DRUG$rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d325.s7.p5",
        "sentence": "Butyrophenones (such as haloperidol) and @DRUG$ can suppress the @DRUG$rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d328.s22.p0",
        "sentence": "@DRUG$ (450 mg BID for 7 days) had no effect on @DRUG$ pharmacokinetics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s26.p0",
        "sentence": "@DRUG$ therapy should be monitored, particularly during the first few weeks, after initiating therapy with @DRUG$ in patients receiving warfarin or similar agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s26.p1",
        "sentence": "@DRUG$ therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving @DRUG$ or similar agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s26.p2",
        "sentence": "Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with @DRUG$ in patients receiving @DRUG$ or similar agents.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d328.s27.p0",
        "sentence": "@DRUG$ and @DRUG$: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s27.p1",
        "sentence": "@DRUG$ and Ketoconazole: @DRUG$ and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s27.p2",
        "sentence": "@DRUG$ and Ketoconazole: Ketoconazole and @DRUG$ are predominantly CYP 3A4 and 2C9 inhibitors, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s27.p3",
        "sentence": "Fluconazole and @DRUG$: @DRUG$ and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s27.p4",
        "sentence": "Fluconazole and @DRUG$: Ketoconazole and @DRUG$ are predominantly CYP 3A4 and 2C9 inhibitors, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s27.p5",
        "sentence": "Fluconazole and Ketoconazole: @DRUG$ and @DRUG$ are predominantly CYP 3A4 and 2C9 inhibitors, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s28.p0",
        "sentence": "Concomitant single dose administration of @DRUG$ 20 mg with multiple doses of @DRUG$ and fluconazole produced a significant increase in exposure of valdecoxib.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d328.s28.p1",
        "sentence": "Concomitant single dose administration of @DRUG$ 20 mg with multiple doses of ketoconazole and @DRUG$ produced a significant increase in exposure of valdecoxib.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d328.s28.p2",
        "sentence": "Concomitant single dose administration of @DRUG$ 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s28.p3",
        "sentence": "Concomitant single dose administration of valdecoxib 20 mg with multiple doses of @DRUG$ and @DRUG$ produced a significant increase in exposure of valdecoxib.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s28.p4",
        "sentence": "Concomitant single dose administration of valdecoxib 20 mg with multiple doses of @DRUG$ and fluconazole produced a significant increase in exposure of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s28.p5",
        "sentence": "Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and @DRUG$ produced a significant increase in exposure of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s38.p0",
        "sentence": "@DRUG$ steady state plasma concentrations (40 mg BID) were not affected significantly with multiple doses of @DRUG$ (40 mg QD).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s41.p0",
        "sentence": "However, because higher doses (up to 360 mg QD) of @DRUG$ are tolerated in Zollinger-Ellison (ZE) patients, no dose adjustment for @DRUG$ is recommended at current doses.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s6.p0",
        "sentence": "In a parallel group drug interaction study comparing the intravenous prodrug form of @DRUG$ at 40 mg BID (n=10) vs placebo (n=9), @DRUG$ had no effect on in vitro aspirin-mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s6.p1",
        "sentence": "In a parallel group drug interaction study comparing the intravenous prodrug form of @DRUG$ at 40 mg BID (n=10) vs placebo (n=9), valdecoxib had no effect on in vitro @DRUG$-mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s6.p2",
        "sentence": "In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at 40 mg BID (n=10) vs placebo (n=9), @DRUG$ had no effect on in vitro @DRUG$-mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d328.s9.p0",
        "sentence": "This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d329.s0.p0",
        "sentence": "When @DRUG$ is co-administered with @DRUG$ (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d329.s0.p1",
        "sentence": "When @DRUG$ is co-administered with probenecid (500 mg p.o. every 6 hours), @DRUG$ competes for active tubular secretion and reduces the renal clearance of ertapenem.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d329.s0.p2",
        "sentence": "When @DRUG$ is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d329.s0.p3",
        "sentence": "When ertapenem is co-administered with @DRUG$ (500 mg p.o. every 6 hours), @DRUG$ competes for active tubular secretion and reduces the renal clearance of ertapenem.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d329.s0.p4",
        "sentence": "When ertapenem is co-administered with @DRUG$ (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d329.s0.p5",
        "sentence": "When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), @DRUG$ competes for active tubular secretion and reduces the renal clearance of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d330.s5.p0",
        "sentence": "Oral @DRUG$ may enhance the effect of @DRUG$ in anticoagulants by decreasing vitamin K availability.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d330.s5.p1",
        "sentence": "Oral @DRUG$ may enhance the effect of coumarin in @DRUG$ by decreasing vitamin K availability.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d330.s5.p2",
        "sentence": "Oral neomycin sulfate may enhance the effect of @DRUG$ in @DRUG$ by decreasing vitamin K availability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d331.s4.p0",
        "sentence": "- @DRUG$: Pretreatment with @DRUG$ reduces both the natriuresis and hyperreninemia produced by bumetanide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d331.s4.p1",
        "sentence": "- @DRUG$: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d331.s4.p2",
        "sentence": "- Probenecid: Pretreatment with @DRUG$ reduces both the natriuresis and hyperreninemia produced by @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p0",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p1",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p2",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p3",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p4",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p5",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p6",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p7",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p8",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p9",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p10",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p11",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p12",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p13",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p14",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p15",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p16",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p17",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p18",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p19",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p20",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p21",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p22",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p23",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p24",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p25",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p26",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p27",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p28",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p29",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p30",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p31",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p32",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p33",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p34",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p35",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p36",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p37",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p38",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p39",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, antianxiety agents, the @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p40",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p41",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p42",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p43",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p44",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p45",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p46",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p47",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p48",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p49",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p50",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p51",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG-DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p52",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG-DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p53",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG$, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p54",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG$, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p55",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p56",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG-DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p57",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG$, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p58",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p59",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p60",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p61",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p62",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p63",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the @DRUG$, and by other anticonvulsant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p64",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d333.s7.p65",
        "sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the @DRUG$, and by other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s15.p0",
        "sentence": "Use of @DRUG$ with @DRUG$ (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d334.s15.p1",
        "sentence": "Use of @DRUG$ with potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d334.s15.p2",
        "sentence": "Use of @DRUG$ with potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d334.s15.p3",
        "sentence": "Use of @DRUG$ with potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d334.s15.p4",
        "sentence": "Use of @DRUG$ with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d334.s15.p5",
        "sentence": "Use of PRINIVIL with @DRUG$ (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s15.p6",
        "sentence": "Use of PRINIVIL with @DRUG$ (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s15.p7",
        "sentence": "Use of PRINIVIL with @DRUG$ (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s15.p8",
        "sentence": "Use of PRINIVIL with @DRUG$ (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s15.p9",
        "sentence": "Use of PRINIVIL with potassium-sparing diuretics (e.g., @DRUG$, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s15.p10",
        "sentence": "Use of PRINIVIL with potassium-sparing diuretics (e.g., @DRUG$, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s15.p11",
        "sentence": "Use of PRINIVIL with potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s15.p12",
        "sentence": "Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s15.p13",
        "sentence": "Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s15.p14",
        "sentence": "Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s4.p0",
        "sentence": "Studies with @DRUG$ in combination with @DRUG$ indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s4.p1",
        "sentence": "Studies with @DRUG$ in combination with diuretics indicate that the dose of the @DRUG$ can be reduced when it is given with a diuretic.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s4.p2",
        "sentence": "Studies with @DRUG$ in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s4.p3",
        "sentence": "Studies with ACE inhibitors in combination with @DRUG$ indicate that the dose of the @DRUG$ can be reduced when it is given with a diuretic.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s4.p4",
        "sentence": "Studies with ACE inhibitors in combination with @DRUG$ indicate that the dose of the ACE inhibitor can be reduced when it is given with a @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s4.p5",
        "sentence": "Studies with ACE inhibitors in combination with diuretics indicate that the dose of the @DRUG$ can be reduced when it is given with a @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d334.s9.p0",
        "sentence": "In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of @DRUG$ alone were compared to @DRUG$ given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s9.p1",
        "sentence": "In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of @DRUG$ alone were compared to PRINIVIL given concomitantly with @DRUG$, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s9.p2",
        "sentence": "In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of @DRUG$ alone were compared to PRINIVIL given concomitantly with indomethacin, the use of @DRUG$ was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s9.p3",
        "sentence": "In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to @DRUG$ given concomitantly with @DRUG$, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s9.p4",
        "sentence": "In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to @DRUG$ given concomitantly with indomethacin, the use of @DRUG$ was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d334.s9.p5",
        "sentence": "In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with @DRUG$, the use of @DRUG$ was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d335.s1.p0",
        "sentence": "Animal experience indicates that @DRUG$ prolongs the sleeping time after @DRUG$ or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d335.s1.p1",
        "sentence": "Animal experience indicates that @DRUG$ prolongs the sleeping time after hexobarbital or after @DRUG$, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d335.s1.p2",
        "sentence": "Animal experience indicates that @DRUG$ prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of @DRUG$, but does not exhibit monoamine oxidase inhibition.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d335.s1.p3",
        "sentence": "Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after @DRUG$ or after @DRUG$, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d335.s1.p4",
        "sentence": "Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after @DRUG$ or after ethyl alcohol, increases the inhibitory effects of @DRUG$, but does not exhibit monoamine oxidase inhibition.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d335.s1.p5",
        "sentence": "Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after @DRUG$, increases the inhibitory effects of @DRUG$, but does not exhibit monoamine oxidase inhibition.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d335.s3.p0",
        "sentence": "The actions of the @DRUG$ may be potentiated by @DRUG$, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d335.s3.p1",
        "sentence": "The actions of the @DRUG$ may be potentiated by barbiturates, @DRUG$, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d335.s3.p2",
        "sentence": "The actions of the @DRUG$ may be potentiated by barbiturates, narcotics, @DRUG$, monoamine oxidase inhibitors or other antidepressants.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d335.s3.p3",
        "sentence": "The actions of the @DRUG$ may be potentiated by barbiturates, narcotics, phenothiazines, @DRUG$ or other antidepressants.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d335.s3.p4",
        "sentence": "The actions of the @DRUG$ may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d335.s3.p5",
        "sentence": "The actions of the benzodiazepines may be potentiated by @DRUG$, @DRUG$, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d335.s3.p6",
        "sentence": "The actions of the benzodiazepines may be potentiated by @DRUG$, narcotics, @DRUG$, monoamine oxidase inhibitors or other antidepressants.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d335.s3.p7",
        "sentence": "The actions of the benzodiazepines may be potentiated by @DRUG$, narcotics, phenothiazines, @DRUG$ or other antidepressants.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d335.s3.p8",
        "sentence": "The actions of the benzodiazepines may be potentiated by @DRUG$, narcotics, phenothiazines, monoamine oxidase inhibitors or other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d335.s3.p9",
        "sentence": "The actions of the benzodiazepines may be potentiated by barbiturates, @DRUG$, @DRUG$, monoamine oxidase inhibitors or other antidepressants.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d335.s3.p10",
        "sentence": "The actions of the benzodiazepines may be potentiated by barbiturates, @DRUG$, phenothiazines, @DRUG$ or other antidepressants.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d335.s3.p11",
        "sentence": "The actions of the benzodiazepines may be potentiated by barbiturates, @DRUG$, phenothiazines, monoamine oxidase inhibitors or other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d335.s3.p12",
        "sentence": "The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, @DRUG$, @DRUG$ or other antidepressants.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d335.s3.p13",
        "sentence": "The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, @DRUG$, monoamine oxidase inhibitors or other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d335.s3.p14",
        "sentence": "The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, @DRUG$ or other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d338.s5.p0",
        "sentence": "@DRUG$: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of @DRUG$ to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d338.s5.p1",
        "sentence": "@DRUG$: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite @DRUG$ and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d338.s5.p2",
        "sentence": "@DRUG$: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other @DRUG$ is catalyzed by CYP3A.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d338.s5.p3",
        "sentence": "Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of @DRUG$ to the major circulating metabolite @DRUG$ and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d338.s5.p4",
        "sentence": "Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of @DRUG$ to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other @DRUG$ is catalyzed by CYP3A.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d338.s5.p5",
        "sentence": "Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite @DRUG$ and the metabolism of other @DRUG$ is catalyzed by CYP3A.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d338.s9.p0",
        "sentence": "Drug Interaction with @DRUG$: A multiple-dose study was conducted to assess the effect of @DRUG$ 20 mg BID on the pharmacokinetics of estazolam 2 mg QHS after seven days.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d338.s9.p1",
        "sentence": "Drug Interaction with @DRUG$: A multiple-dose study was conducted to assess the effect of fluoxetine 20 mg BID on the pharmacokinetics of @DRUG$ 2 mg QHS after seven days.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d338.s9.p2",
        "sentence": "Drug Interaction with Fluoxetine: A multiple-dose study was conducted to assess the effect of @DRUG$ 20 mg BID on the pharmacokinetics of @DRUG$ 2 mg QHS after seven days.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d339.s3.p0",
        "sentence": "Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using @DRUG$ but not with those using @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d34.s0.p0",
        "sentence": "Although acid-base and electrolyte disturbances were not reported in the clinical trials with @DRUG$, these disturbances have been reported with oral @DRUG$ and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d34.s0.p1",
        "sentence": "Although acid-base and electrolyte disturbances were not reported in the clinical trials with @DRUG$, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose @DRUG$ therapy).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d34.s0.p2",
        "sentence": "Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral @DRUG$ and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose @DRUG$ therapy).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d340.s22.p0",
        "sentence": "@DRUG$: Coadministration of @DRUG$ with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d340.s22.p1",
        "sentence": "@DRUG$: Coadministration of ketoconazole with @DRUG$ resulted in a 35% increase in nelfinavir plasma A.C.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d340.s22.p2",
        "sentence": "@DRUG$: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in @DRUG$ plasma A.C.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d340.s22.p3",
        "sentence": "Ketoconazole: Coadministration of @DRUG$ with @DRUG$ resulted in a 35% increase in nelfinavir plasma A.C.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d340.s22.p4",
        "sentence": "Ketoconazole: Coadministration of @DRUG$ with VIRACEPT resulted in a 35% increase in @DRUG$ plasma A.C.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d340.s22.p5",
        "sentence": "Ketoconazole: Coadministration of ketoconazole with @DRUG$ resulted in a 35% increase in @DRUG$ plasma A.C.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d340.s27.p0",
        "sentence": "A dose adjustment is not needed when @DRUG$ is administered with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d340.s31.p0",
        "sentence": "It is recommended that the dose of @DRUG$ be reduced to one-half the usual dose when administered with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d341.s1.p0",
        "sentence": "However, it was observed that the pharmacokinetics of @DRUG$  was unaltered by concomitant @DRUG$ in rheumatoid arthritis patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p0",
        "sentence": "This drug may interact with @DRUG$ or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p1",
        "sentence": "This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p2",
        "sentence": "This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p3",
        "sentence": "This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p4",
        "sentence": "This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p5",
        "sentence": "This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p6",
        "sentence": "This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p7",
        "sentence": "This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p8",
        "sentence": "This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p9",
        "sentence": "This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p10",
        "sentence": "This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p11",
        "sentence": "This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p12",
        "sentence": "This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p13",
        "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p14",
        "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p15",
        "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p16",
        "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p17",
        "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p18",
        "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p19",
        "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p20",
        "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p21",
        "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p22",
        "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p23",
        "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p24",
        "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p25",
        "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p26",
        "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d342.s0.p27",
        "sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p0",
        "sentence": "No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p1",
        "sentence": "No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, @DRUG$, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p2",
        "sentence": "No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, @DRUG$, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p3",
        "sentence": "No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, clofibrate, @DRUG$, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p4",
        "sentence": "No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, @DRUG$ (niacin), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p5",
        "sentence": "No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (@DRUG$), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p6",
        "sentence": "No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), @DRUG$, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p7",
        "sentence": "No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, @DRUG$ or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p8",
        "sentence": "No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p9",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, @DRUG$, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p10",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, @DRUG$, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p11",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, @DRUG$, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p12",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, methyldopa, @DRUG$ (niacin), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p13",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, methyldopa, nicotinic acid (@DRUG$), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p14",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), @DRUG$, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p15",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, @DRUG$ or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p16",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p17",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, @DRUG$, @DRUG$, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p18",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, @DRUG$, clofibrate, @DRUG$, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p19",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, @DRUG$, clofibrate, methyldopa, @DRUG$ (niacin), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p20",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, @DRUG$, clofibrate, methyldopa, nicotinic acid (@DRUG$), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p21",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, @DRUG$, clofibrate, methyldopa, nicotinic acid (niacin), @DRUG$, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p22",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, @DRUG$, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, @DRUG$ or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p23",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, @DRUG$, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p24",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, @DRUG$, @DRUG$, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p25",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, @DRUG$, methyldopa, @DRUG$ (niacin), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p26",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, @DRUG$, methyldopa, nicotinic acid (@DRUG$), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p27",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, @DRUG$, methyldopa, nicotinic acid (niacin), @DRUG$, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p28",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, @DRUG$, methyldopa, nicotinic acid (niacin), tolbutamide, @DRUG$ or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p29",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, @DRUG$, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p30",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, @DRUG$, @DRUG$ (niacin), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p31",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, @DRUG$, nicotinic acid (@DRUG$), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p32",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, @DRUG$, nicotinic acid (niacin), @DRUG$, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p33",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, @DRUG$, nicotinic acid (niacin), tolbutamide, @DRUG$ or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p34",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, @DRUG$, nicotinic acid (niacin), tolbutamide, phenytoin or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p35",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, @DRUG$ (@DRUG$), tolbutamide, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p36",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, @DRUG$ (niacin), @DRUG$, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p37",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, @DRUG$ (niacin), tolbutamide, @DRUG$ or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p38",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, @DRUG$ (niacin), tolbutamide, phenytoin or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p39",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (@DRUG$), @DRUG$, phenytoin or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p40",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (@DRUG$), tolbutamide, @DRUG$ or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p41",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (@DRUG$), tolbutamide, phenytoin or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p42",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), @DRUG$, @DRUG$ or warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p43",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), @DRUG$, phenytoin or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s13.p44",
        "sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, @DRUG$ or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s17.p0",
        "sentence": "@DRUG$ may also interfere with the absorption of oral @DRUG$ supplements and hydrocortisone.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d345.s17.p1",
        "sentence": "@DRUG$ may also interfere with the absorption of oral phosphate supplements and @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d345.s17.p2",
        "sentence": "Bile acid binding resins may also interfere with the absorption of oral @DRUG$ supplements and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s6.p0",
        "sentence": "However, in a follow-up study in normal subjects, single-dose administration of @DRUG$ and @DRUG$ and twice-a-day administration for 5 days of both agents did not affect the extent of propranolol absorption, but had a small yet statistically significant effect on its rate of absorption;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s6.p1",
        "sentence": "However, in a follow-up study in normal subjects, single-dose administration of @DRUG$ and propranolol and twice-a-day administration for 5 days of both agents did not affect the extent of @DRUG$ absorption, but had a small yet statistically significant effect on its rate of absorption;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d345.s6.p2",
        "sentence": "However, in a follow-up study in normal subjects, single-dose administration of colestipol hydrochloride and @DRUG$ and twice-a-day administration for 5 days of both agents did not affect the extent of @DRUG$ absorption, but had a small yet statistically significant effect on its rate of absorption;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d346.s4.p0",
        "sentence": "Patients taking @DRUG$ may not benefit from @DRUG$ containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d346.s4.p1",
        "sentence": "Patients taking @DRUG$ may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d346.s4.p2",
        "sentence": "Patients taking REVIA may not benefit from @DRUG$ containing medicines, such as cough and cold preparations, antidiarrheal preparations, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p0",
        "sentence": "Concomitant administration of @DRUG$ and @DRUG$, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p1",
        "sentence": "Concomitant administration of @DRUG$ and calcium carbonate, @DRUG$, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p2",
        "sentence": "Concomitant administration of @DRUG$ and calcium carbonate, cimetidine, @DRUG$, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p3",
        "sentence": "Concomitant administration of @DRUG$ and calcium carbonate, cimetidine, omeprazole, or an @DRUG$/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p4",
        "sentence": "Concomitant administration of @DRUG$ and calcium carbonate, cimetidine, omeprazole, or an estrogen/@DRUG$ oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p5",
        "sentence": "Concomitant administration of @DRUG$ and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral @DRUG$ produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p6",
        "sentence": "Concomitant administration of @DRUG$ and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of @DRUG$, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p7",
        "sentence": "Concomitant administration of FACTIVE and @DRUG$, @DRUG$, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p8",
        "sentence": "Concomitant administration of FACTIVE and @DRUG$, cimetidine, @DRUG$, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p9",
        "sentence": "Concomitant administration of FACTIVE and @DRUG$, cimetidine, omeprazole, or an @DRUG$/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p10",
        "sentence": "Concomitant administration of FACTIVE and @DRUG$, cimetidine, omeprazole, or an estrogen/@DRUG$ oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p11",
        "sentence": "Concomitant administration of FACTIVE and @DRUG$, cimetidine, omeprazole, or an estrogen/progesterone oral @DRUG$ produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p12",
        "sentence": "Concomitant administration of FACTIVE and @DRUG$, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of @DRUG$, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p13",
        "sentence": "Concomitant administration of FACTIVE and calcium carbonate, @DRUG$, @DRUG$, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p14",
        "sentence": "Concomitant administration of FACTIVE and calcium carbonate, @DRUG$, omeprazole, or an @DRUG$/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p15",
        "sentence": "Concomitant administration of FACTIVE and calcium carbonate, @DRUG$, omeprazole, or an estrogen/@DRUG$ oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p16",
        "sentence": "Concomitant administration of FACTIVE and calcium carbonate, @DRUG$, omeprazole, or an estrogen/progesterone oral @DRUG$ produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p17",
        "sentence": "Concomitant administration of FACTIVE and calcium carbonate, @DRUG$, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of @DRUG$, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p18",
        "sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, @DRUG$, or an @DRUG$/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p19",
        "sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, @DRUG$, or an estrogen/@DRUG$ oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p20",
        "sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, @DRUG$, or an estrogen/progesterone oral @DRUG$ produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p21",
        "sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, @DRUG$, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of @DRUG$, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p22",
        "sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an @DRUG$/@DRUG$ oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p23",
        "sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an @DRUG$/progesterone oral @DRUG$ produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p24",
        "sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an @DRUG$/progesterone oral contraceptive produced minor changes in the pharmacokinetics of @DRUG$, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p25",
        "sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/@DRUG$ oral @DRUG$ produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p26",
        "sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/@DRUG$ oral contraceptive produced minor changes in the pharmacokinetics of @DRUG$, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s1.p27",
        "sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral @DRUG$ produced minor changes in the pharmacokinetics of @DRUG$, which were considered to be without clinical significance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s2.p0",
        "sentence": "Concomitant administration of @DRUG$ with @DRUG$ resulted in a 45% increase in systemic exposure to gemifloxacin.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d347.s2.p1",
        "sentence": "Concomitant administration of @DRUG$ with probenecid resulted in a 45% increase in systemic exposure to @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d347.s2.p2",
        "sentence": "Concomitant administration of FACTIVE with @DRUG$ resulted in a 45% increase in systemic exposure to @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s3.p0",
        "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of @DRUG$ are not altered by @DRUG$, amphotericin B, mycophenolate, nelfinavir, or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s3.p1",
        "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of @DRUG$ are not altered by itraconazole, @DRUG$, mycophenolate, nelfinavir, or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s3.p2",
        "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of @DRUG$ are not altered by itraconazole, amphotericin B, @DRUG$, nelfinavir, or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s3.p3",
        "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of @DRUG$ are not altered by itraconazole, amphotericin B, mycophenolate, @DRUG$, or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s3.p4",
        "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of @DRUG$ are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s3.p5",
        "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by @DRUG$, @DRUG$, mycophenolate, nelfinavir, or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s3.p6",
        "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by @DRUG$, amphotericin B, @DRUG$, nelfinavir, or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s3.p7",
        "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by @DRUG$, amphotericin B, mycophenolate, @DRUG$, or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s3.p8",
        "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by @DRUG$, amphotericin B, mycophenolate, nelfinavir, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s3.p9",
        "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, @DRUG$, @DRUG$, nelfinavir, or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s3.p10",
        "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, @DRUG$, mycophenolate, @DRUG$, or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s3.p11",
        "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, @DRUG$, mycophenolate, nelfinavir, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s3.p12",
        "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, @DRUG$, @DRUG$, or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s3.p13",
        "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, @DRUG$, nelfinavir, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s3.p14",
        "sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, mycophenolate, @DRUG$, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s4.p0",
        "sentence": "@DRUG$ has no effect on the pharmacokinetics of @DRUG$, amphotericin B, or the active metabolite of mycophenolate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s4.p1",
        "sentence": "@DRUG$ has no effect on the pharmacokinetics of itraconazole, @DRUG$, or the active metabolite of mycophenolate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d350.s4.p2",
        "sentence": "CANCIDAS has no effect on the pharmacokinetics of @DRUG$, @DRUG$, or the active metabolite of mycophenolate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d352.s0.p0",
        "sentence": "@DRUG$ requirements (i.e., @DRUG$) may be altered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d352.s4.p0",
        "sentence": "Concurrent use of @DRUG$ may antagonize the anorectic effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d353.s0.p0",
        "sentence": "@DRUG$:Clinical evidence has shown that @DRUG$ can be formed with concurrent ingestion of acitretin and ethanol.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s0.p1",
        "sentence": "@DRUG$:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of @DRUG$ and ethanol.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s0.p2",
        "sentence": "@DRUG$:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s0.p3",
        "sentence": "Ethanol:Clinical evidence has shown that @DRUG$ can be formed with concurrent ingestion of @DRUG$ and ethanol.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s0.p4",
        "sentence": "Ethanol:Clinical evidence has shown that @DRUG$ can be formed with concurrent ingestion of acitretin and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s0.p5",
        "sentence": "Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of @DRUG$ and @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d353.s1.p0",
        "sentence": "@DRUG$: In a study of 7 healthy male volunteers, @DRUG$ treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s1.p1",
        "sentence": "@DRUG$: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of @DRUG$ (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s1.p2",
        "sentence": "@DRUG$: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a @DRUG$ similar to chlorpropamide) in 3 of the 7 subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s1.p3",
        "sentence": "@DRUG$: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to @DRUG$) in 3 of the 7 subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s1.p4",
        "sentence": "Glibenclamide: In a study of 7 healthy male volunteers, @DRUG$ treatment potentiated the blood glucose lowering effect of @DRUG$ (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d353.s1.p5",
        "sentence": "Glibenclamide: In a study of 7 healthy male volunteers, @DRUG$ treatment potentiated the blood glucose lowering effect of glibenclamide (a @DRUG$ similar to chlorpropamide) in 3 of the 7 subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s1.p6",
        "sentence": "Glibenclamide: In a study of 7 healthy male volunteers, @DRUG$ treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to @DRUG$) in 3 of the 7 subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s1.p7",
        "sentence": "Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of @DRUG$ (a @DRUG$ similar to chlorpropamide) in 3 of the 7 subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s1.p8",
        "sentence": "Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of @DRUG$ (a sulfonylurea similar to @DRUG$) in 3 of the 7 subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s1.p9",
        "sentence": "Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a @DRUG$ similar to @DRUG$) in 3 of the 7 subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s10.p0",
        "sentence": "@DRUG$: If @DRUG$ is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s10.p1",
        "sentence": "@DRUG$: If acitretin is given concurrently with @DRUG$, the protein binding of phenytoin may be reduced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s10.p2",
        "sentence": "@DRUG$: If acitretin is given concurrently with phenytoin, the protein binding of @DRUG$ may be reduced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s10.p3",
        "sentence": "Phenytoin: If @DRUG$ is given concurrently with @DRUG$, the protein binding of phenytoin may be reduced.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d353.s10.p4",
        "sentence": "Phenytoin: If @DRUG$ is given concurrently with phenytoin, the protein binding of @DRUG$ may be reduced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s10.p5",
        "sentence": "Phenytoin: If acitretin is given concurrently with @DRUG$, the protein binding of @DRUG$ may be reduced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s12.p0",
        "sentence": "@DRUG$ and oral @DRUG$: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s12.p1",
        "sentence": "@DRUG$ and oral retinoids: Concomitant administration of @DRUG$ and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s12.p2",
        "sentence": "@DRUG$ and oral retinoids: Concomitant administration of vitamin A and/or other oral @DRUG$ with acitretin must be avoided because of the risk of hypervitaminosis A.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s12.p3",
        "sentence": "@DRUG$ and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with @DRUG$ must be avoided because of the risk of hypervitaminosis A.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s12.p4",
        "sentence": "Vitamin A and oral @DRUG$: Concomitant administration of @DRUG$ and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s12.p5",
        "sentence": "Vitamin A and oral @DRUG$: Concomitant administration of vitamin A and/or other oral @DRUG$ with acitretin must be avoided because of the risk of hypervitaminosis A.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s12.p6",
        "sentence": "Vitamin A and oral @DRUG$: Concomitant administration of vitamin A and/or other oral retinoids with @DRUG$ must be avoided because of the risk of hypervitaminosis A.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s12.p7",
        "sentence": "Vitamin A and oral retinoids: Concomitant administration of @DRUG$ and/or other oral @DRUG$ with acitretin must be avoided because of the risk of hypervitaminosis A.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s12.p8",
        "sentence": "Vitamin A and oral retinoids: Concomitant administration of @DRUG$ and/or other oral retinoids with @DRUG$ must be avoided because of the risk of hypervitaminosis A.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d353.s12.p9",
        "sentence": "Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral @DRUG$ with @DRUG$ must be avoided because of the risk of hypervitaminosis A.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d353.s13.p0",
        "sentence": "Other: There appears to be no pharmacokinetic interaction between @DRUG$ and @DRUG$, digoxin, or glyburide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s13.p1",
        "sentence": "Other: There appears to be no pharmacokinetic interaction between @DRUG$ and cimetidine, @DRUG$, or glyburide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s13.p2",
        "sentence": "Other: There appears to be no pharmacokinetic interaction between @DRUG$ and cimetidine, digoxin, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s13.p3",
        "sentence": "Other: There appears to be no pharmacokinetic interaction between acitretin and @DRUG$, @DRUG$, or glyburide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s13.p4",
        "sentence": "Other: There appears to be no pharmacokinetic interaction between acitretin and @DRUG$, digoxin, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s13.p5",
        "sentence": "Other: There appears to be no pharmacokinetic interaction between acitretin and cimetidine, @DRUG$, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s2.p0",
        "sentence": "Repeating the study with 6 healthy male volunteers in the absence of @DRUG$ did not detect an effect of @DRUG$ on glucose tolerance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s8.p0",
        "sentence": "@DRUG$: An increased risk of hepatitis has been reported to result from combined use of @DRUG$ and etretinate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s8.p1",
        "sentence": "@DRUG$: An increased risk of hepatitis has been reported to result from combined use of methotrexate and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d353.s8.p2",
        "sentence": "Methotrexate: An increased risk of hepatitis has been reported to result from combined use of @DRUG$ and @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d355.s3.p0",
        "sentence": "In diabetic patients, the metabolic effects of @DRUG$ may decrease blood glucose and therefore, @DRUG$ requirements.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d356.s0.p0",
        "sentence": "When @DRUG$ HCl is administered concomitantly with an @DRUG$, the risk of hyperkalemia may be increased.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d358.s0.p0",
        "sentence": "Since @DRUG$ is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when @DRUG$ is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d358.s0.p1",
        "sentence": "Since @DRUG$ is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as @DRUG$ and erythromycin or inhibitors of CYP2C19 such as omeprazole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d358.s0.p2",
        "sentence": "Since @DRUG$ is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and @DRUG$ or inhibitors of CYP2C19 such as omeprazole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d358.s0.p3",
        "sentence": "Since @DRUG$ is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d358.s0.p4",
        "sentence": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when @DRUG$ is coadministered with inhibitors of C.P.A. such as @DRUG$ and erythromycin or inhibitors of CYP2C19 such as omeprazole.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d358.s0.p5",
        "sentence": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when @DRUG$ is coadministered with inhibitors of C.P.A. such as ketoconazole and @DRUG$ or inhibitors of CYP2C19 such as omeprazole.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d358.s0.p6",
        "sentence": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when @DRUG$ is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d358.s0.p7",
        "sentence": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as @DRUG$ and @DRUG$ or inhibitors of CYP2C19 such as omeprazole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d358.s0.p8",
        "sentence": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as @DRUG$ and erythromycin or inhibitors of CYP2C19 such as @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d358.s0.p9",
        "sentence": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and @DRUG$ or inhibitors of CYP2C19 such as @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d360.s2.p0",
        "sentence": "A possible interaction has been suggested with @DRUG$ and the herbal supplement St. Johns Wort based on some reports of oral @DRUG$ users experiencing breakthrough bleeding shortly after starting St. Johns Wort.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d362.s4.p0",
        "sentence": "In another drug interaction study, co-administration of orally inhaled @DRUG$ and oral @DRUG$, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d362.s4.p1",
        "sentence": "In another drug interaction study, co-administration of orally inhaled @DRUG$ and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of @DRUG$ by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d362.s4.p2",
        "sentence": "In another drug interaction study, co-administration of orally inhaled @DRUG$ and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of @DRUG$ remained unchanged.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d362.s4.p3",
        "sentence": "In another drug interaction study, co-administration of orally inhaled ciclesonide and oral @DRUG$, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of @DRUG$ by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d362.s4.p4",
        "sentence": "In another drug interaction study, co-administration of orally inhaled ciclesonide and oral @DRUG$, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of @DRUG$ remained unchanged.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d362.s4.p5",
        "sentence": "In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of @DRUG$ by approximately 3.6-fold at steady state, while levels of @DRUG$ remained unchanged.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d362.s5.p0",
        "sentence": "Therefore, @DRUG$ should be administered with caution with intranasal @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d363.s2.p0",
        "sentence": "Like @DRUG$, @DRUG$ does not predispose to premature ventricular arrhythmias in the presence of exogenously infused epinephrine in swine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d363.s2.p1",
        "sentence": "Like @DRUG$, desflurane does not predispose to premature ventricular arrhythmias in the presence of exogenously infused @DRUG$ in swine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d363.s2.p2",
        "sentence": "Like isoflurane, @DRUG$ does not predispose to premature ventricular arrhythmias in the presence of exogenously infused @DRUG$ in swine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s0.p0",
        "sentence": "Because @DRUG$ is metabolized by a variety of hepatic CYP drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s10.p0",
        "sentence": "Coadministration of @DRUG$ and strong CYP3A4 inhibitors, such as @DRUG$, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d364.s10.p1",
        "sentence": "Coadministration of @DRUG$ and strong CYP3A4 inhibitors, such as clarithromycin, @DRUG$, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d364.s10.p2",
        "sentence": "Coadministration of @DRUG$ and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, @DRUG$, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d364.s10.p3",
        "sentence": "Coadministration of @DRUG$ and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, @DRUG$, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d364.s10.p4",
        "sentence": "Coadministration of @DRUG$ and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and @DRUG$ has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d364.s10.p5",
        "sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as @DRUG$, @DRUG$, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s10.p6",
        "sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as @DRUG$, telithromycin, @DRUG$, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s10.p7",
        "sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as @DRUG$, telithromycin, protease inhibitors, @DRUG$, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s10.p8",
        "sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as @DRUG$, telithromycin, protease inhibitors, voriconazole, and @DRUG$ has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s10.p9",
        "sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, @DRUG$, @DRUG$, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s10.p10",
        "sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, @DRUG$, protease inhibitors, @DRUG$, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s10.p11",
        "sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, @DRUG$, protease inhibitors, voriconazole, and @DRUG$ has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s10.p12",
        "sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, @DRUG$, @DRUG$, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s10.p13",
        "sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, @DRUG$, voriconazole, and @DRUG$ has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s10.p14",
        "sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, @DRUG$, and @DRUG$ has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s15.p0",
        "sentence": "Although not studied with @DRUG$, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as @DRUG$, procainamide, and hydralazine.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d364.s15.p1",
        "sentence": "Although not studied with @DRUG$, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, @DRUG$, and hydralazine.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d364.s15.p2",
        "sentence": "Although not studied with @DRUG$, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d364.s15.p3",
        "sentence": "Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as @DRUG$, @DRUG$, and hydralazine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s15.p4",
        "sentence": "Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as @DRUG$, procainamide, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s15.p5",
        "sentence": "Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, @DRUG$, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s18.p0",
        "sentence": "A clinical interaction study was also conducted with @DRUG$ and the CYP3A4 substrate @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d364.s8.p0",
        "sentence": "@DRUG$ increased mean @DRUG$ plasma concentrations (AUC) by 29%.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d367.s3.p0",
        "sentence": "@DRUG$ has been administered without any evidence of an adverse drug interaction to patients receiving @DRUG$, beta-blocking agents, and nonsteroidal anti-inflammatory drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d367.s3.p1",
        "sentence": "@DRUG$ has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, @DRUG$s, and nonsteroidal anti-inflammatory drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d367.s3.p2",
        "sentence": "@DRUG$ has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, beta-blocking agents, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d367.s3.p3",
        "sentence": "Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving @DRUG$, @DRUG$s, and nonsteroidal anti-inflammatory drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d367.s3.p4",
        "sentence": "Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving @DRUG$, beta-blocking agents, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d367.s3.p5",
        "sentence": "Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, @DRUG$s, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d367.s4.p0",
        "sentence": "In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of @DRUG$ on day 1 of a four-day regimen of oral @DRUG$ (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d367.s4.p1",
        "sentence": "In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of @DRUG$ on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of @DRUG$ (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d367.s4.p2",
        "sentence": "In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of @DRUG$ on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d367.s4.p3",
        "sentence": "In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral @DRUG$ (400 mg twice daily) resulted in a 10% increase in mean AUC of @DRUG$ (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d367.s4.p4",
        "sentence": "In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral @DRUG$ (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d367.s4.p5",
        "sentence": "In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of @DRUG$ (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d368.s11.p0",
        "sentence": "@DRUG$ may prevent the urinary antiseptic effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d371.s1.p0",
        "sentence": "In vitro studies have shown that the metabolism of @DRUG$ may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as @DRUG$, terfenadine, ketoconazole, erythromycin, and troleandomycin.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d371.s1.p1",
        "sentence": "In vitro studies have shown that the metabolism of @DRUG$ may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, @DRUG$, ketoconazole, erythromycin, and troleandomycin.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d371.s1.p2",
        "sentence": "In vitro studies have shown that the metabolism of @DRUG$ may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, @DRUG$, erythromycin, and troleandomycin.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d371.s1.p3",
        "sentence": "In vitro studies have shown that the metabolism of @DRUG$ may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, @DRUG$, and troleandomycin.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d371.s1.p4",
        "sentence": "In vitro studies have shown that the metabolism of @DRUG$ may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d371.s1.p5",
        "sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as @DRUG$, @DRUG$, ketoconazole, erythromycin, and troleandomycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d371.s1.p6",
        "sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as @DRUG$, terfenadine, @DRUG$, erythromycin, and troleandomycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d371.s1.p7",
        "sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as @DRUG$, terfenadine, ketoconazole, @DRUG$, and troleandomycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d371.s1.p8",
        "sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as @DRUG$, terfenadine, ketoconazole, erythromycin, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d371.s1.p9",
        "sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, @DRUG$, @DRUG$, erythromycin, and troleandomycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d371.s1.p10",
        "sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, @DRUG$, ketoconazole, @DRUG$, and troleandomycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d371.s1.p11",
        "sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, @DRUG$, ketoconazole, erythromycin, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d371.s1.p12",
        "sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, @DRUG$, @DRUG$, and troleandomycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d371.s1.p13",
        "sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, @DRUG$, erythromycin, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d371.s1.p14",
        "sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, @DRUG$, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d373.s1.p0",
        "sentence": "Long Acting @DRUG$: @DRUG$ may be safely co-administered with nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d373.s1.p1",
        "sentence": "Long Acting @DRUG$: Nifedipine may be safely co-administered with @DRUG$, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d373.s1.p2",
        "sentence": "Long Acting Nitrates: @DRUG$ may be safely co-administered with @DRUG$, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d373.s13.p0",
        "sentence": "The effect may be mediated by the known inhibition of @DRUG$ on hepatic cytochrome P-450, the enzyme system probably responsible for the first-pass metabolism of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d376.s0.p0",
        "sentence": "May interact with addictive medications, especially @DRUG$ with habituating potential (prolonged concurrent use may increase the risk of habituation), @DRUG$ or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or ethinamate).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d376.s0.p1",
        "sentence": "May interact with addictive medications, especially @DRUG$ with habituating potential (prolonged concurrent use may increase the risk of habituation), alcohol or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d376.s0.p2",
        "sentence": "May interact with addictive medications, especially central nervous system (CNS) depressants with habituating potential (prolonged concurrent use may increase the risk of habituation), @DRUG$ or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d377.s0.p0",
        "sentence": "@DRUG$ potentiates other @DRUG$ such as succinylcholine or organophosphate and carbamate insecticides.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d377.s0.p1",
        "sentence": "@DRUG$ potentiates other cholinesterase inhibitors such as @DRUG$ or organophosphate and carbamate insecticides.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d377.s0.p2",
        "sentence": "@DRUG$ potentiates other cholinesterase inhibitors such as succinylcholine or @DRUG$s.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d377.s0.p3",
        "sentence": "@DRUG$ potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and @DRUG$s.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d377.s0.p4",
        "sentence": "Phospholine Iodide potentiates other @DRUG$ such as @DRUG$ or organophosphate and carbamate insecticides.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d377.s0.p5",
        "sentence": "Phospholine Iodide potentiates other @DRUG$ such as succinylcholine or @DRUG$s.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d377.s0.p6",
        "sentence": "Phospholine Iodide potentiates other @DRUG$ such as succinylcholine or organophosphate and @DRUG$s.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d377.s0.p7",
        "sentence": "Phospholine Iodide potentiates other cholinesterase inhibitors such as @DRUG$ or @DRUG$s.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d377.s0.p8",
        "sentence": "Phospholine Iodide potentiates other cholinesterase inhibitors such as @DRUG$ or organophosphate and @DRUG$s.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d377.s0.p9",
        "sentence": "Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or @DRUG-DRUG$s.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p0",
        "sentence": "It is, however, possible that concomitant use of other known @DRUG$ such as @DRUG$, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p1",
        "sentence": "It is, however, possible that concomitant use of other known @DRUG$ such as griseofulvin, @DRUG$, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p2",
        "sentence": "It is, however, possible that concomitant use of other known @DRUG$ such as griseofulvin, thiazide diuretics, @DRUG$, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p3",
        "sentence": "It is, however, possible that concomitant use of other known @DRUG$ such as griseofulvin, thiazide diuretics, sulfonylureas, @DRUG$, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p4",
        "sentence": "It is, however, possible that concomitant use of other known @DRUG$ such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, @DRUG$ and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p5",
        "sentence": "It is, however, possible that concomitant use of other known @DRUG$ such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p6",
        "sentence": "It is, however, possible that concomitant use of other known @DRUG$ such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p7",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as @DRUG$, @DRUG$, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p8",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as @DRUG$, thiazide diuretics, @DRUG$, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p9",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as @DRUG$, thiazide diuretics, sulfonylureas, @DRUG$, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p10",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as @DRUG$, thiazide diuretics, sulfonylureas, phenothiazines, @DRUG$ and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p11",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as @DRUG$, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p12",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as @DRUG$, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p13",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, @DRUG$, @DRUG$, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p14",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, @DRUG$, sulfonylureas, @DRUG$, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p15",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, @DRUG$, sulfonylureas, phenothiazines, @DRUG$ and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p16",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, @DRUG$, sulfonylureas, phenothiazines, sulfonamides and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p17",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, @DRUG$, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p18",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, @DRUG$, @DRUG$, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p19",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, @DRUG$, phenothiazines, @DRUG$ and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p20",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, @DRUG$, phenothiazines, sulfonamides and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p21",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, @DRUG$, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p22",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, @DRUG$, @DRUG$ and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p23",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, @DRUG$, sulfonamides and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p24",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, @DRUG$, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p25",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, @DRUG$ and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p26",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, @DRUG$ and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d379.s1.p27",
        "sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d380.s3.p0",
        "sentence": "Based on anecdotal reports, there may be an interaction between @DRUG$ and @DRUG$.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d380.s4.p0",
        "sentence": "There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of @DRUG$ and @DRUG$ by addicts.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d382.s10.p0",
        "sentence": "The oral @DRUG$ doses should be reduced by approximately 50% when coadministered with @DRUG$, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d382.s10.p1",
        "sentence": "The oral @DRUG$ doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of @DRUG$ similar to those obtained when it is given without Aprepitant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s10.p2",
        "sentence": "The oral @DRUG$ doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s10.p3",
        "sentence": "The oral dexamethasone doses should be reduced by approximately 50% when coadministered with @DRUG$, to achieve exposures of @DRUG$ similar to those obtained when it is given without Aprepitant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s10.p4",
        "sentence": "The oral dexamethasone doses should be reduced by approximately 50% when coadministered with @DRUG$, to achieve exposures of dexamethasone similar to those obtained when it is given without @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s10.p5",
        "sentence": "The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of @DRUG$ similar to those obtained when it is given without @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s16.p0",
        "sentence": "Although there was no effect of @DRUG$ on the plasma AUC of @DRUG$ determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s16.p1",
        "sentence": "Although there was no effect of @DRUG$ on the plasma AUC of R(+) or @DRUG$ determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s16.p2",
        "sentence": "Although there was no effect of @DRUG$ on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in @DRUG$ (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s16.p3",
        "sentence": "Although there was no effect of @DRUG$ on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s16.p4",
        "sentence": "Although there was no effect of Aprepitant on the plasma AUC of @DRUG-DRUG$ determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s16.p5",
        "sentence": "Although there was no effect of Aprepitant on the plasma AUC of @DRUG$ determined on Day 3, there was a 34% decrease in @DRUG$ (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s16.p6",
        "sentence": "Although there was no effect of Aprepitant on the plasma AUC of @DRUG$ determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s16.p7",
        "sentence": "Although there was no effect of Aprepitant on the plasma AUC of R(+) or @DRUG$ determined on Day 3, there was a 34% decrease in @DRUG$ (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s16.p8",
        "sentence": "Although there was no effect of Aprepitant on the plasma AUC of R(+) or @DRUG$ determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s16.p9",
        "sentence": "Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in @DRUG$ (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d382.s17.p0",
        "sentence": "In patients on chronic @DRUG$ therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of @DRUG$ with each chemotherapy cycle.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d382.s18.p0",
        "sentence": "@DRUG$: @DRUG$, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s18.p1",
        "sentence": "@DRUG$: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of @DRUG$ (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s18.p2",
        "sentence": "@DRUG$: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of @DRUG$ 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s18.p3",
        "sentence": "@DRUG$: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of @DRUG$ and on Days 4,8, and 15.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s18.p4",
        "sentence": "Tolbutamide: @DRUG$, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of @DRUG$ (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s18.p5",
        "sentence": "Tolbutamide: @DRUG$, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of @DRUG$ 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s18.p6",
        "sentence": "Tolbutamide: @DRUG$, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of @DRUG$ and on Days 4,8, and 15.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s18.p7",
        "sentence": "Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of @DRUG$ (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of @DRUG$ 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s18.p8",
        "sentence": "Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of @DRUG$ (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of @DRUG$ and on Days 4,8, and 15.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s18.p9",
        "sentence": "Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of @DRUG$ 500 mg was admini,stered orally prior to the administration of the 3-day regimen of @DRUG$ and on Days 4,8, and 15.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d382.s25.p0",
        "sentence": "@DRUG$ increased the AUC of @DRUG$ by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d382.s25.p1",
        "sentence": "@DRUG$ increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of @DRUG$ by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d382.s25.p2",
        "sentence": "@DRUG$ increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of @DRUG$ on Days 1 through 3.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s25.p3",
        "sentence": "Aprepitant increased the AUC of @DRUG$ by 25% on Day 4 and decreased the AUC of @DRUG$ by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s25.p4",
        "sentence": "Aprepitant increased the AUC of @DRUG$ by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of @DRUG$ on Days 1 through 3.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s25.p5",
        "sentence": "Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of @DRUG$ by 19% on Day 8 relative to the dosing of @DRUG$ on Days 1 through 3.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s30.p0",
        "sentence": "therefore, coadministration of @DRUG$ with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s34.p0",
        "sentence": "therefore, coadministration of @DRUG$ with drugs that strongly induce CYP3A4 activity (e.g., @DRUG$, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d382.s34.p1",
        "sentence": "therefore, coadministration of @DRUG$ with drugs that strongly induce CYP3A4 activity (e.g., rifampin, @DRUG$, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s34.p2",
        "sentence": "therefore, coadministration of @DRUG$ with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, @DRUG$) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d382.s34.p3",
        "sentence": "therefore, coadministration of @DRUG$ with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of @DRUG$ that may result in decreased efficacy of Aprepitant.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d382.s34.p4",
        "sentence": "therefore, coadministration of @DRUG$ with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s34.p5",
        "sentence": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., @DRUG$, @DRUG$, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s34.p6",
        "sentence": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., @DRUG$, carbamazepine, @DRUG$) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s34.p7",
        "sentence": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., @DRUG$, carbamazepine, phenytoin) may result in reduced plasma concentrations of @DRUG$ that may result in decreased efficacy of Aprepitant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s34.p8",
        "sentence": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., @DRUG$, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s34.p9",
        "sentence": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, @DRUG$, @DRUG$) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s34.p10",
        "sentence": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, @DRUG$, phenytoin) may result in reduced plasma concentrations of @DRUG$ that may result in decreased efficacy of Aprepitant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s34.p11",
        "sentence": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, @DRUG$, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s34.p12",
        "sentence": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, @DRUG$) may result in reduced plasma concentrations of @DRUG$ that may result in decreased efficacy of Aprepitant.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s34.p13",
        "sentence": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, @DRUG$) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s34.p14",
        "sentence": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of @DRUG$ that may result in decreased efficacy of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s43.p0",
        "sentence": "@DRUG$: Coadministration of once daily doses of @DRUG$, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s43.p1",
        "sentence": "@DRUG$: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with @DRUG$ 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s43.p2",
        "sentence": "@DRUG$: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both @DRUG$ and paroxetine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s43.p3",
        "sentence": "@DRUG$: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s43.p4",
        "sentence": "Paroxetine: Coadministration of once daily doses of @DRUG$, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with @DRUG$ 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d382.s43.p5",
        "sentence": "Paroxetine: Coadministration of once daily doses of @DRUG$, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both @DRUG$ and paroxetine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s43.p6",
        "sentence": "Paroxetine: Coadministration of once daily doses of @DRUG$, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s43.p7",
        "sentence": "Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with @DRUG$ 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both @DRUG$ and paroxetine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s43.p8",
        "sentence": "Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with @DRUG$ 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s43.p9",
        "sentence": "Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both @DRUG$ and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s5.p0",
        "sentence": "Coadministration of @DRUG$ with these drugs or other drugs that are known to be metabolized by CYP2C9, such as @DRUG$, may result in lower plasma concentrations of these drugs.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d382.s6.p0",
        "sentence": "@DRUG$ is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of @DRUG$ with digoxin in a clinical drug interaction study.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s6.p1",
        "sentence": "@DRUG$ is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with @DRUG$ in a clinical drug interaction study.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d382.s6.p2",
        "sentence": "Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of @DRUG$ with @DRUG$ in a clinical drug interaction study.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d387.s0.p0",
        "sentence": "Potential drug interactions for @DRUG$ include, increased sedation if @DRUG$ is combined with other CNS depressant drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d387.s0.p1",
        "sentence": "Potential drug interactions for @DRUG$ include, increased sedation if doxylamine is combined with other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d387.s0.p2",
        "sentence": "Potential drug interactions for doxylamine include, increased sedation if @DRUG$ is combined with other @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d388.s1.p0",
        "sentence": "Patients treated with @DRUG$ plus @DRUG$ should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p0",
        "sentence": "No significant interactions with @DRUG$, @DRUG$, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p1",
        "sentence": "No significant interactions with @DRUG$, hydrochlorothiazide, @DRUG$, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p2",
        "sentence": "No significant interactions with @DRUG$, hydrochlorothiazide, hydralazine, @DRUG$, oral contraceptives, tolbutamide, or warfarin have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p3",
        "sentence": "No significant interactions with @DRUG$, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral @DRUG$, tolbutamide, or warfarin have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p4",
        "sentence": "No significant interactions with @DRUG$, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, @DRUG$, or warfarin have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p5",
        "sentence": "No significant interactions with @DRUG$, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or @DRUG$ have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p6",
        "sentence": "No significant interactions with digoxin, @DRUG$, @DRUG$, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p7",
        "sentence": "No significant interactions with digoxin, @DRUG$, hydralazine, @DRUG$, oral contraceptives, tolbutamide, or warfarin have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p8",
        "sentence": "No significant interactions with digoxin, @DRUG$, hydralazine, sulfinpyrazone, oral @DRUG$, tolbutamide, or warfarin have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p9",
        "sentence": "No significant interactions with digoxin, @DRUG$, hydralazine, sulfinpyrazone, oral contraceptives, @DRUG$, or warfarin have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p10",
        "sentence": "No significant interactions with digoxin, @DRUG$, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or @DRUG$ have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p11",
        "sentence": "No significant interactions with digoxin, hydrochlorothiazide, @DRUG$, @DRUG$, oral contraceptives, tolbutamide, or warfarin have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p12",
        "sentence": "No significant interactions with digoxin, hydrochlorothiazide, @DRUG$, sulfinpyrazone, oral @DRUG$, tolbutamide, or warfarin have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p13",
        "sentence": "No significant interactions with digoxin, hydrochlorothiazide, @DRUG$, sulfinpyrazone, oral contraceptives, @DRUG$, or warfarin have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p14",
        "sentence": "No significant interactions with digoxin, hydrochlorothiazide, @DRUG$, sulfinpyrazone, oral contraceptives, tolbutamide, or @DRUG$ have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p15",
        "sentence": "No significant interactions with digoxin, hydrochlorothiazide, hydralazine, @DRUG$, oral @DRUG$, tolbutamide, or warfarin have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p16",
        "sentence": "No significant interactions with digoxin, hydrochlorothiazide, hydralazine, @DRUG$, oral contraceptives, @DRUG$, or warfarin have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p17",
        "sentence": "No significant interactions with digoxin, hydrochlorothiazide, hydralazine, @DRUG$, oral contraceptives, tolbutamide, or @DRUG$ have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p18",
        "sentence": "No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral @DRUG$, @DRUG$, or warfarin have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p19",
        "sentence": "No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral @DRUG$, tolbutamide, or @DRUG$ have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d388.s5.p20",
        "sentence": "No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, @DRUG$, or @DRUG$ have been observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d389.s1.p0",
        "sentence": "@DRUG$ prolong and intensify the anticholinergic effects of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d389.s3.p0",
        "sentence": "Effects of @DRUG$ are increased with @DRUG$ and beta adrenergic blockers.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d389.s3.p1",
        "sentence": "Effects of @DRUG$ are increased with MAO inhibitors and @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d389.s3.p2",
        "sentence": "Effects of sympathomimetics are increased with @DRUG$ and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s0.p0",
        "sentence": "Pharmacokinetic interaction studies with @DRUG$ in adults were conducted with @DRUG$, antipyrine, ketoconazole, erythromycin and azithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s0.p1",
        "sentence": "Pharmacokinetic interaction studies with @DRUG$ in adults were conducted with pseudoephedrine, @DRUG$, ketoconazole, erythromycin and azithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s0.p2",
        "sentence": "Pharmacokinetic interaction studies with @DRUG$ in adults were conducted with pseudoephedrine, antipyrine, @DRUG$, erythromycin and azithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s0.p3",
        "sentence": "Pharmacokinetic interaction studies with @DRUG$ in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, @DRUG$ and azithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s0.p4",
        "sentence": "Pharmacokinetic interaction studies with @DRUG$ in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s0.p5",
        "sentence": "Pharmacokinetic interaction studies with cetirizine in adults were conducted with @DRUG$, @DRUG$, ketoconazole, erythromycin and azithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s0.p6",
        "sentence": "Pharmacokinetic interaction studies with cetirizine in adults were conducted with @DRUG$, antipyrine, @DRUG$, erythromycin and azithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s0.p7",
        "sentence": "Pharmacokinetic interaction studies with cetirizine in adults were conducted with @DRUG$, antipyrine, ketoconazole, @DRUG$ and azithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s0.p8",
        "sentence": "Pharmacokinetic interaction studies with cetirizine in adults were conducted with @DRUG$, antipyrine, ketoconazole, erythromycin and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s0.p9",
        "sentence": "Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, @DRUG$, @DRUG$, erythromycin and azithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s0.p10",
        "sentence": "Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, @DRUG$, ketoconazole, @DRUG$ and azithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s0.p11",
        "sentence": "Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, @DRUG$, ketoconazole, erythromycin and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s0.p12",
        "sentence": "Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, @DRUG$, @DRUG$ and azithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s0.p13",
        "sentence": "Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, @DRUG$, erythromycin and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s0.p14",
        "sentence": "Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, @DRUG$ and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d393.s3.p0",
        "sentence": "The disposition of @DRUG$ was not altered by concomitant @DRUG$ administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s2.p0",
        "sentence": "@DRUG$: @DRUG$ is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s2.p1",
        "sentence": "@DRUG$: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s2.p2",
        "sentence": "Caffeine: @DRUG$ is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d395.s25.p0",
        "sentence": "Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when @DRUG$ or its derivatives and @DRUG$ are given concomitantly.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d395.s6.p0",
        "sentence": "@DRUG$: Elevated serum levels of @DRUG$ have been reported with concomitant use of cyclosporine with other members of the quinolone class.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s6.p1",
        "sentence": "@DRUG$: Elevated serum levels of cyclosporine have been reported with concomitant use of @DRUG$ with other members of the quinolone class.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s6.p2",
        "sentence": "@DRUG$: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s6.p3",
        "sentence": "Cyclosporine: Elevated serum levels of @DRUG$ have been reported with concomitant use of @DRUG$ with other members of the quinolone class.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s6.p4",
        "sentence": "Cyclosporine: Elevated serum levels of @DRUG$ have been reported with concomitant use of cyclosporine with other members of the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s6.p5",
        "sentence": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of @DRUG$ with other members of the @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d395.s8.p0",
        "sentence": "If signs and symptoms suggestive of @DRUG$ toxicity occur when @DRUG$ and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s8.p1",
        "sentence": "If signs and symptoms suggestive of @DRUG$ toxicity occur when enoxacin and @DRUG$ are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s8.p2",
        "sentence": "If signs and symptoms suggestive of @DRUG$ toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum @DRUG$ levels and adjust digoxin doses appropriately.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s8.p3",
        "sentence": "If signs and symptoms suggestive of @DRUG$ toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust @DRUG$ doses appropriately.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s8.p4",
        "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when @DRUG$ and @DRUG$ are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d395.s8.p5",
        "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when @DRUG$ and digoxin are given concomitantly, physicians are advised to obtain serum @DRUG$ levels and adjust digoxin doses appropriately.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s8.p6",
        "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when @DRUG$ and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust @DRUG$ doses appropriately.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s8.p7",
        "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and @DRUG$ are given concomitantly, physicians are advised to obtain serum @DRUG$ levels and adjust digoxin doses appropriately.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s8.p8",
        "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and @DRUG$ are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust @DRUG$ doses appropriately.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d395.s8.p9",
        "sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum @DRUG$ levels and adjust @DRUG$ doses appropriately.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p0",
        "sentence": "Patients receiving other @DRUG$, @DRUG$, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p1",
        "sentence": "Patients receiving other @DRUG$, antipsychotics, @DRUG$, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p2",
        "sentence": "Patients receiving other @DRUG$, antipsychotics, antianxiety agents, or other @DRUG$ (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p3",
        "sentence": "Patients receiving other @DRUG$, antipsychotics, antianxiety agents, or other CNS depressants (including @DRUG$) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p4",
        "sentence": "Patients receiving other @DRUG$, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with @DRUG$ and acetaminophen tablets may exhibit an additive CNS depression.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p5",
        "sentence": "Patients receiving other @DRUG$, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and @DRUG$ tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p6",
        "sentence": "Patients receiving other narcotic analgesics, @DRUG$, @DRUG$, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p7",
        "sentence": "Patients receiving other narcotic analgesics, @DRUG$, antianxiety agents, or other @DRUG$ (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p8",
        "sentence": "Patients receiving other narcotic analgesics, @DRUG$, antianxiety agents, or other CNS depressants (including @DRUG$) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p9",
        "sentence": "Patients receiving other narcotic analgesics, @DRUG$, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with @DRUG$ and acetaminophen tablets may exhibit an additive CNS depression.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p10",
        "sentence": "Patients receiving other narcotic analgesics, @DRUG$, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and @DRUG$ tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p11",
        "sentence": "Patients receiving other narcotic analgesics, antipsychotics, @DRUG$, or other @DRUG$ (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p12",
        "sentence": "Patients receiving other narcotic analgesics, antipsychotics, @DRUG$, or other CNS depressants (including @DRUG$) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p13",
        "sentence": "Patients receiving other narcotic analgesics, antipsychotics, @DRUG$, or other CNS depressants (including alcohol) concomitantly with @DRUG$ and acetaminophen tablets may exhibit an additive CNS depression.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p14",
        "sentence": "Patients receiving other narcotic analgesics, antipsychotics, @DRUG$, or other CNS depressants (including alcohol) concomitantly with hydrocodone and @DRUG$ tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p15",
        "sentence": "Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other @DRUG$ (including @DRUG$) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p16",
        "sentence": "Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other @DRUG$ (including alcohol) concomitantly with @DRUG$ and acetaminophen tablets may exhibit an additive CNS depression.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p17",
        "sentence": "Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other @DRUG$ (including alcohol) concomitantly with hydrocodone and @DRUG$ tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p18",
        "sentence": "Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including @DRUG$) concomitantly with @DRUG$ and acetaminophen tablets may exhibit an additive CNS depression.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p19",
        "sentence": "Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including @DRUG$) concomitantly with hydrocodone and @DRUG$ tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s0.p20",
        "sentence": "Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with @DRUG$ and @DRUG$ tablets may exhibit an additive CNS depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d396.s3.p0",
        "sentence": "The concurrent use of @DRUG$ with @DRUG$ may produce paralytic ileus.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d397.s10.p0",
        "sentence": "@DRUG$ has been reported to significantly alter the metabolism of nonsedating @DRUG$ terfenadine and astemizole when taken concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s10.p1",
        "sentence": "@DRUG$ has been reported to significantly alter the metabolism of nonsedating antihistamines @DRUG$ and astemizole when taken concomitantly.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d397.s10.p2",
        "sentence": "@DRUG$ has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and @DRUG$ when taken concomitantly.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d397.s10.p3",
        "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating @DRUG$ @DRUG$ and astemizole when taken concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s10.p4",
        "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating @DRUG$ terfenadine and @DRUG$ when taken concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s10.p5",
        "sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines @DRUG$ and @DRUG$ when taken concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s2.p0",
        "sentence": "Concomitant administration of @DRUG$ and @DRUG$ has been reported to result in elevated digoxin serum levels.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d397.s2.p1",
        "sentence": "Concomitant administration of @DRUG$ and digoxin has been reported to result in elevated @DRUG$ serum levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s2.p2",
        "sentence": "Concomitant administration of erythromycin and @DRUG$ has been reported to result in elevated @DRUG$ serum levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p0",
        "sentence": "There have been reports of interactions of @DRUG$ with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p1",
        "sentence": "There have been reports of interactions of @DRUG$ with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p2",
        "sentence": "There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p3",
        "sentence": "There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p4",
        "sentence": "There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p5",
        "sentence": "There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p6",
        "sentence": "There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p7",
        "sentence": "There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p8",
        "sentence": "There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p9",
        "sentence": "There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p10",
        "sentence": "There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p11",
        "sentence": "There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p12",
        "sentence": "There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p13",
        "sentence": "There have been reports of interactions of erythromycin with @DRUG$, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p14",
        "sentence": "There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p15",
        "sentence": "There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p16",
        "sentence": "There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p17",
        "sentence": "There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p18",
        "sentence": "There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p19",
        "sentence": "There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p20",
        "sentence": "There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p21",
        "sentence": "There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p22",
        "sentence": "There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p23",
        "sentence": "There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p24",
        "sentence": "There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p25",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p26",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p27",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p28",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p29",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p30",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p31",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p32",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p33",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p34",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p35",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p36",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p37",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p38",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p39",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p40",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p41",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p42",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p43",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p44",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p45",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p46",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p47",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p48",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p49",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p50",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p51",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p52",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p53",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p54",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p55",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p56",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p57",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p58",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p59",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p60",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p61",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p62",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p63",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p64",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p65",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p66",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p67",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p68",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p69",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p70",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p71",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p72",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p73",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p74",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p75",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p76",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p77",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p78",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p79",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p80",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p81",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, @DRUG$, valproate, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p82",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, @DRUG$, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p83",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, @DRUG$, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p84",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p85",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, @DRUG$, terfenadine, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p86",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, @DRUG$, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p87",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p88",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, @DRUG$, and astemizole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p89",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d397.s8.p90",
        "sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d40.s15.p0",
        "sentence": "Similarly, the effects of @DRUG$ on @DRUG$, valproic acid and sodium plasma valproate concentrations are unpredictable",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d40.s15.p1",
        "sentence": "Similarly, the effects of @DRUG$ on phenobarbital, @DRUG$ and sodium plasma valproate concentrations are unpredictable",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d40.s15.p2",
        "sentence": "Similarly, the effects of @DRUG$ on phenobarbital, valproic acid and sodium plasma @DRUG$ concentrations are unpredictable",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d40.s15.p3",
        "sentence": "Similarly, the effects of phenytoin on @DRUG$, @DRUG$ and sodium plasma valproate concentrations are unpredictable",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d40.s15.p4",
        "sentence": "Similarly, the effects of phenytoin on @DRUG$, valproic acid and sodium plasma @DRUG$ concentrations are unpredictable",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d40.s15.p5",
        "sentence": "Similarly, the effects of phenytoin on phenobarbital, @DRUG$ and sodium plasma @DRUG$ concentrations are unpredictable",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d40.s5.p0",
        "sentence": "The most significant drug interactions following administration of @DRUG$ are expected to occur with drugs that interact with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d400.s12.p0",
        "sentence": "Thus, when @DRUG$ and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d400.s12.p1",
        "sentence": "Thus, when @DRUG$ and lithium are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d400.s12.p2",
        "sentence": "Thus, when NSAIDs and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d400.s13.p0",
        "sentence": "@DRUG$: The effects of @DRUG$ and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d400.s13.p1",
        "sentence": "@DRUG$: The effects of warfarin and @DRUG$ on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d400.s13.p2",
        "sentence": "Warfarin: The effects of @DRUG$ and @DRUG$ on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d404.s10.p0",
        "sentence": "However, in vivo drug interaction studies of @DRUG$ with @DRUG$ have not been investigated.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d404.s4.p0",
        "sentence": "@DRUG$: @DRUG$ are known to induce hypercalcemia by the reduction of calcium excretion in urine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d404.s8.p0",
        "sentence": "@DRUG$: @DRUG$ may inhibit both synthetic and catabolic enzymes of vitamin D.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d404.s8.p1",
        "sentence": "@DRUG$: Ketoconazole may inhibit both synthetic and catabolic enzymes of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d404.s8.p2",
        "sentence": "Ketoconazole: @DRUG$ may inhibit both synthetic and catabolic enzymes of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d407.s1.p0",
        "sentence": "An immune response to @DRUG$ may interfere with subsequent diagnostic serum tests that utilize @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d409.s0.p0",
        "sentence": "Because the @DRUG$ have been shown to depress plasma prothrombin activity, patients who are on @DRUG$ therapy may require downward adjustment of their anticoagulant dosage.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d409.s0.p1",
        "sentence": "Because the @DRUG$ have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their @DRUG$ dosage.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d409.s0.p2",
        "sentence": "Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on @DRUG$ therapy may require downward adjustment of their @DRUG$ dosage.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s3.p0",
        "sentence": "@DRUG$: Although the results of a clinical study did not indicate a safe problem associated with the administration of @DRUG$  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s3.p1",
        "sentence": "@DRUG$: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (@DRUG$) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s3.p2",
        "sentence": "@DRUG$: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving @DRUG$, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s3.p3",
        "sentence": "@DRUG$: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that @DRUG$ may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s3.p4",
        "sentence": "@DRUG$: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of @DRUG$ by blocking the vasodilating property of epinephrine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s3.p5",
        "sentence": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of @DRUG$  (@DRUG$) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s3.p6",
        "sentence": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of @DRUG$  (dihydroergotamine mesylate) Injection, USP to subjects already receiving @DRUG$, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s3.p7",
        "sentence": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of @DRUG$  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that @DRUG$ may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s3.p8",
        "sentence": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of @DRUG$  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of @DRUG$ by blocking the vasodilating property of epinephrine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s3.p9",
        "sentence": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (@DRUG$) Injection, USP to subjects already receiving @DRUG$, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s3.p10",
        "sentence": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (@DRUG$) Injection, USP to subjects already receiving propranolol, there have been reports that @DRUG$ may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s3.p11",
        "sentence": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (@DRUG$) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of @DRUG$ by blocking the vasodilating property of epinephrine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s3.p12",
        "sentence": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving @DRUG$, there have been reports that @DRUG$ may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s3.p13",
        "sentence": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving @DRUG$, there have been reports that propranolol may potentiate the vasoconstrictive action of @DRUG$ by blocking the vasodilating property of epinephrine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s3.p14",
        "sentence": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that @DRUG$ may potentiate the vasoconstrictive action of @DRUG$ by blocking the vasodilating property of epinephrine.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d410.s4.p0",
        "sentence": "@DRUG$: @DRUG$ may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s4.p1",
        "sentence": "@DRUG$: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to @DRUG$ therapy.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s4.p2",
        "sentence": "Nicotine: @DRUG$ may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to @DRUG$ therapy.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d410.s7.p0",
        "sentence": "@DRUG$: Weakness hyperreflexia, and incoordination have been reported rarely when @DRUG$ have been co-administered with SSRIs (e. g.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s7.p1",
        "sentence": "@DRUG$: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with @DRUG$ (e. g.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d410.s7.p2",
        "sentence": "SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when @DRUG$ have been co-administered with @DRUG$ (e. g.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d411.s15.p0",
        "sentence": "@DRUG$ (123I and 131I), @DRUG$: Uptake of radiolabeled ions may be decreased.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p0",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p1",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p2",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p3",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p4",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p5",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p6",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p7",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p8",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p9",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p10",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p11",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p12",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p13",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p14",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p15",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p16",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p17",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p18",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p19",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p20",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p21",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p22",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p23",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p24",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p25",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p26",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p27",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p28",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p29",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p30",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p31",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p32",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p33",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p34",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p35",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p36",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p37",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p38",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p39",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p40",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p41",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p42",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p43",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p44",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p45",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p46",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p47",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p48",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p49",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p50",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p51",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p52",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p53",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p54",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p55",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p56",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p57",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p58",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p59",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p60",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p61",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p62",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p63",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p64",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p65",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p66",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p67",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p68",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p69",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p70",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p71",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p72",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p73",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p74",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p75",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p76",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p77",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p78",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p79",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p80",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p81",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p82",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p83",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p84",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p85",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p86",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p87",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p88",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p89",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p90",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p91",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p92",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p93",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p94",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p95",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p96",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p97",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p98",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p99",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p100",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p101",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p102",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p103",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p104",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p105",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p106",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p107",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p108",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p109",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p110",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p111",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p112",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p113",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p114",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p115",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p116",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p117",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p118",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p119",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p120",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p121",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p122",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p123",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p124",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p125",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p126",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p127",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p128",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p129",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p130",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p131",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p132",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p133",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p134",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p135",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p136",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p137",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p138",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p139",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p140",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p141",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p142",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p143",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, @DRUG$, phenytoin, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p144",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, @DRUG$, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p145",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, @DRUG$, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p146",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p147",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, @DRUG$, salicylates, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p148",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, @DRUG$, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p149",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p150",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, @DRUG$, tamoxifen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p151",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s3.p152",
        "sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p0",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p1",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p2",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p3",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p4",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p5",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p6",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p7",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p8",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p9",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p10",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p11",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p12",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p13",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p14",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p15",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p16",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p17",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p18",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p19",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p20",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p21",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p22",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p23",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p24",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p25",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p26",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p27",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p28",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p29",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p30",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p31",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p32",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p33",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p34",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p35",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p36",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p37",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p38",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p39",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p40",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p41",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p42",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p43",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p44",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p45",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p46",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p47",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p48",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p49",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p50",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p51",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p52",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p53",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p54",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p55",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p56",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p57",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p58",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p59",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p60",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p61",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p62",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p63",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p64",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p65",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p66",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p67",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p68",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p69",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p70",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p71",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p72",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p73",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p74",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p75",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p76",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p77",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p78",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p79",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p80",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p81",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p82",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p83",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p84",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p85",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p86",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p87",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p88",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p89",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p90",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p91",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p92",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p93",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p94",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p95",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p96",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p97",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p98",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p99",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p100",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p101",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p102",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p103",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p104",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p105",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p106",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p107",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p108",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p109",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p110",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p111",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p112",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p113",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p114",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p115",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p116",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p117",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p118",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p119",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p120",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p121",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p122",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p123",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p124",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p125",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p126",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p127",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p128",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p129",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p130",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p131",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p132",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p133",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p134",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p135",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p136",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p137",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p138",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p139",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p140",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p141",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p142",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p143",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p144",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p145",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p146",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p147",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p148",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p149",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p150",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p151",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p152",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p153",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p154",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p155",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p156",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p157",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p158",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p159",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p160",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p161",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p162",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p163",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p164",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p165",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p166",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p167",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p168",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p169",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p170",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p171",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p172",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p173",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p174",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p175",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p176",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p177",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p178",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p179",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p180",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p181",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p182",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p183",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p184",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p185",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p186",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p187",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p188",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p189",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p190",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p191",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p192",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p193",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p194",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p195",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p196",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p197",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p198",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p199",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p200",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p201",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p202",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p203",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p204",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p205",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p206",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p207",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p208",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p209",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p210",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p211",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p212",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p213",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p214",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p215",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p216",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p217",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p218",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p219",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p220",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p221",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p222",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p223",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p224",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p225",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p226",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p227",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p228",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p229",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p230",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p231",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p232",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p233",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p234",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p235",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p236",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p237",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p238",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p239",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p240",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p241",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p242",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p243",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p244",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p245",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p246",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p247",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p248",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p249",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p250",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p251",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p252",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p253",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p254",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p255",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p256",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p257",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p258",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p259",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p260",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p261",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p262",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p263",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p264",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p265",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p266",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p267",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p268",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p269",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p270",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p271",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p272",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p273",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p274",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p275",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p276",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p277",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p278",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p279",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p280",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p281",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p282",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p283",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p284",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p285",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p286",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p287",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p288",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p289",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p290",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p291",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p292",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p293",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p294",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p295",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p296",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p297",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p298",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p299",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p300",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p301",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p302",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p303",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p304",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p305",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p306",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p307",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p308",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p309",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p310",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p311",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p312",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p313",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p314",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p315",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p316",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p317",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p318",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p319",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p320",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p321",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p322",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p323",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p324",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p325",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p326",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p327",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p328",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p329",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p330",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p331",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p332",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p333",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p334",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p335",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p336",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p337",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p338",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p339",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p340",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p341",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p342",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p343",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p344",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p345",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p346",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p347",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p348",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p349",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p350",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p351",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p352",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p353",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p354",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p355",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p356",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p357",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p358",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p359",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p360",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p361",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p362",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p363",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p364",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p365",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p366",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p367",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p368",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p369",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p370",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p371",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p372",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p373",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p374",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p375",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p376",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p377",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p378",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p379",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p380",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p381",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p382",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p383",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p384",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p385",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p386",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p387",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p388",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p389",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p390",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p391",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p392",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p393",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p394",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p395",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p396",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p397",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p398",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p399",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p400",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p401",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p402",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p403",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p404",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p405",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p406",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p407",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p408",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p409",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p410",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p411",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p412",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p413",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p414",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p415",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p416",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p417",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p418",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p419",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p420",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p421",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p422",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p423",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p424",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p425",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p426",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p427",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p428",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p429",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p430",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p431",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p432",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p433",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p434",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p435",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p436",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p437",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p438",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p439",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p440",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p441",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p442",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p443",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p444",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p445",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p446",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p447",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p448",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p449",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p450",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p451",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p452",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p453",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p454",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p455",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p456",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p457",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p458",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p459",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p460",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p461",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p462",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p463",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p464",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p465",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p466",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p467",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p468",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p469",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p470",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p471",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p472",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p473",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p474",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p475",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p476",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p477",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p478",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p479",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p480",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p481",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p482",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p483",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p484",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p485",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p486",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p487",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p488",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p489",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p490",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p491",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p492",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p493",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p494",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p495",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p496",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p497",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p498",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p499",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p500",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p501",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p502",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p503",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p504",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p505",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p506",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p507",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p508",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p509",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p510",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p511",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p512",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p513",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p514",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p515",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p516",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p517",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p518",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p519",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p520",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p521",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p522",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p523",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p524",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p525",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p526",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p527",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p528",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p529",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p530",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p531",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p532",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p533",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p534",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p535",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p536",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p537",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p538",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p539",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p540",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p541",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p542",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p543",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p544",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p545",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p546",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p547",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p548",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p549",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p550",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p551",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p552",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p553",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p554",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p555",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, @DRUG$, sulfonylureas, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p556",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p557",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p558",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, @DRUG$, thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p559",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s4.p560",
        "sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d411.s7.p0",
        "sentence": "@DRUG$ (Oral): The hypoprothrombinemic effect of @DRUG$ may be potentiated, apparently by increased catabloism of vitamin K-dependent clotting factors.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d412.s17.p0",
        "sentence": "When patients being treated with @DRUG$ have a positive urine test for @DRUG$ using these techniques confirmation should be made by using more specific methods such as a gas chromatographic-mass spectrometer technique.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d413.s20.p0",
        "sentence": "@DRUG$: @DRUG$s plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d413.s20.p1",
        "sentence": "@DRUG$: Chlorpropamides plasma half-life may be prolonged by @DRUG$, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d413.s20.p2",
        "sentence": "@DRUG$: Chlorpropamides plasma half-life may be prolonged by allopurinol, since @DRUG$ and chlorpropamide may compete for excretion in the renal tubule.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d413.s20.p3",
        "sentence": "@DRUG$: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and @DRUG$ may compete for excretion in the renal tubule.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d413.s20.p4",
        "sentence": "Chlorpropamide: @DRUG$s plasma half-life may be prolonged by @DRUG$, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d413.s20.p5",
        "sentence": "Chlorpropamide: @DRUG$s plasma half-life may be prolonged by allopurinol, since @DRUG$ and chlorpropamide may compete for excretion in the renal tubule.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d413.s20.p6",
        "sentence": "Chlorpropamide: @DRUG$s plasma half-life may be prolonged by allopurinol, since allopurinol and @DRUG$ may compete for excretion in the renal tubule.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d413.s20.p7",
        "sentence": "Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by @DRUG$, since @DRUG$ and chlorpropamide may compete for excretion in the renal tubule.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d413.s20.p8",
        "sentence": "Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by @DRUG$, since allopurinol and @DRUG$ may compete for excretion in the renal tubule.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d413.s20.p9",
        "sentence": "Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since @DRUG$ and @DRUG$ may compete for excretion in the renal tubule.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d415.s11.p0",
        "sentence": "During concomitant therapy with @DRUG$, the patient should be observed closely for signs of renal failure, as well as to assure @DRUG$ efficacy.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d415.s12.p0",
        "sentence": "@DRUG$: @DRUG$ produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d415.s12.p1",
        "sentence": "@DRUG$: Ibuprofen produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d415.s12.p2",
        "sentence": "@DRUG$: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance in a study of eleven normal volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d415.s12.p3",
        "sentence": "Lithium: @DRUG$ produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d415.s12.p4",
        "sentence": "Lithium: @DRUG$ produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance in a study of eleven normal volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d415.s12.p5",
        "sentence": "Lithium: Ibuprofen produced an elevation of plasma @DRUG$ levels and a reduction in renal @DRUG$ clearance in a study of eleven normal volunteers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d415.s15.p0",
        "sentence": "Thus, when @DRUG$ and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d415.s15.p1",
        "sentence": "Thus, when @DRUG$ and lithium are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d415.s15.p2",
        "sentence": "Thus, when ibuprofen and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d415.s3.p0",
        "sentence": "Single dose bioavailability studies in normal volunteers have failed to wshow an effect of @DRUG$ on @DRUG$ blood levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d415.s9.p0",
        "sentence": "@DRUG$: Clinical studies, as well as random observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and thiazides in some patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d415.s9.p1",
        "sentence": "@DRUG$: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d415.s9.p2",
        "sentence": "@DRUG$: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d415.s9.p3",
        "sentence": "Furosemide: Clinical studies, as well as random observations, have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d415.s9.p4",
        "sentence": "Furosemide: Clinical studies, as well as random observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d415.s9.p5",
        "sentence": "Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d416.s3.p0",
        "sentence": "Therefore, patients receiving @DRUG$ will have erroneously low ERPF and Tm @DRUG$ values.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d417.s0.p0",
        "sentence": "@DRUG$ should not be administered concomitantly with potent @DRUG$ such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d417.s0.p1",
        "sentence": "@DRUG$ should not be administered concomitantly with potent loop diuretics such as @DRUG$ and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d417.s0.p2",
        "sentence": "@DRUG$ should not be administered concomitantly with potent loop diuretics such as furosemide and @DRUG$ as the potential for ototoxicity is enhanced by the combination.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d417.s0.p3",
        "sentence": "Netilmicin should not be administered concomitantly with potent @DRUG$ such as @DRUG$ and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d417.s0.p4",
        "sentence": "Netilmicin should not be administered concomitantly with potent @DRUG$ such as furosemide and @DRUG$ as the potential for ototoxicity is enhanced by the combination.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d417.s0.p5",
        "sentence": "Netilmicin should not be administered concomitantly with potent loop diuretics such as @DRUG$ and @DRUG$ as the potential for ototoxicity is enhanced by the combination.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d419.s0.p0",
        "sentence": "The concurrent administration of @DRUG$ and @DRUG$ increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d419.s0.p1",
        "sentence": "The concurrent administration of @DRUG$ and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving @DRUG$ alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d419.s0.p2",
        "sentence": "The concurrent administration of allopurinol and @DRUG$ increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving @DRUG$ alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p0",
        "sentence": "In patients taking @DRUG$, @DRUG$, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p1",
        "sentence": "In patients taking @DRUG$, nifedipine, @DRUG$, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p2",
        "sentence": "In patients taking @DRUG$, nifedipine, diltiazem, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p3",
        "sentence": "In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p4",
        "sentence": "In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p5",
        "sentence": "In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p6",
        "sentence": "In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p7",
        "sentence": "In patients taking furosemide, @DRUG$, @DRUG$, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p8",
        "sentence": "In patients taking furosemide, @DRUG$, diltiazem, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p9",
        "sentence": "In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p10",
        "sentence": "In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p11",
        "sentence": "In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p12",
        "sentence": "In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p13",
        "sentence": "In patients taking furosemide, nifedipine, @DRUG$, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p14",
        "sentence": "In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p15",
        "sentence": "In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p16",
        "sentence": "In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p17",
        "sentence": "In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p18",
        "sentence": "In patients taking furosemide, nifedipine, diltiazem, @DRUG$, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p19",
        "sentence": "In patients taking furosemide, nifedipine, diltiazem, @DRUG$, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p20",
        "sentence": "In patients taking furosemide, nifedipine, diltiazem, @DRUG$, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p21",
        "sentence": "In patients taking furosemide, nifedipine, diltiazem, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p22",
        "sentence": "In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, @DRUG$, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p23",
        "sentence": "In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, @DRUG$, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p24",
        "sentence": "In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p25",
        "sentence": "In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, @DRUG$, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p26",
        "sentence": "In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s4.p27",
        "sentence": "In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s5.p0",
        "sentence": "Clearance of @DRUG$ decreased by about 27% when @DRUG$ was administered intravenously concomitantly with atenolol.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s5.p1",
        "sentence": "Clearance of @DRUG$ decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d42.s5.p2",
        "sentence": "Clearance of hydrodolasetron decreased by about 27% when @DRUG$ was administered intravenously concomitantly with @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d420.s12.p0",
        "sentence": "Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using @DRUG$, but not with those using @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s3.p0",
        "sentence": "If @DRUG$ are required during @DRUG$ therapy, OMNICEF should be taken at least 2 hours before or after the antacid.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s3.p1",
        "sentence": "If @DRUG$ are required during OMNICEF therapy, @DRUG$ should be taken at least 2 hours before or after the antacid.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s3.p2",
        "sentence": "If @DRUG$ are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s3.p3",
        "sentence": "If antacids are required during @DRUG$ therapy, @DRUG$ should be taken at least 2 hours before or after the antacid.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s3.p4",
        "sentence": "If antacids are required during @DRUG$ therapy, OMNICEF should be taken at least 2 hours before or after the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s3.p5",
        "sentence": "If antacids are required during OMNICEF therapy, @DRUG$ should be taken at least 2 hours before or after the @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p0",
        "sentence": "@DRUG$ and Foods Fortified With @DRUG$ Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p1",
        "sentence": "@DRUG$ and Foods Fortified With Iron Concomitant administration of @DRUG$ with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p2",
        "sentence": "@DRUG$ and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic @DRUG$ containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p3",
        "sentence": "@DRUG$ and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental @DRUG$ (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p4",
        "sentence": "@DRUG$ and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or @DRUG$ supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p5",
        "sentence": "@DRUG$ and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental @DRUG$ reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p6",
        "sentence": "Iron Supplements and Foods Fortified With @DRUG$ Concomitant administration of @DRUG$ with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p7",
        "sentence": "Iron Supplements and Foods Fortified With @DRUG$ Concomitant administration of cefdinir with a therapeutic @DRUG$ containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p8",
        "sentence": "Iron Supplements and Foods Fortified With @DRUG$ Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental @DRUG$ (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p9",
        "sentence": "Iron Supplements and Foods Fortified With @DRUG$ Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or @DRUG$ supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p10",
        "sentence": "Iron Supplements and Foods Fortified With @DRUG$ Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental @DRUG$ reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p11",
        "sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of @DRUG$ with a therapeutic @DRUG$ containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p12",
        "sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of @DRUG$ with a therapeutic iron supplement containing 60 mg of elemental @DRUG$ (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p13",
        "sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of @DRUG$ with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or @DRUG$ supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p14",
        "sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of @DRUG$ with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental @DRUG$ reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p15",
        "sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic @DRUG$ containing 60 mg of elemental @DRUG$ (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p16",
        "sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic @DRUG$ containing 60 mg of elemental iron (as FeSO4) or @DRUG$ supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p17",
        "sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic @DRUG$ containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental @DRUG$ reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p18",
        "sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental @DRUG$ (as FeSO4) or @DRUG$ supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p19",
        "sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental @DRUG$ (as FeSO4) or vitamins supplemented with 10 mg of elemental @DRUG$ reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s5.p20",
        "sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or @DRUG$ supplemented with 10 mg of elemental @DRUG$ reduced extent of absorption by 80% and 31%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s6.p0",
        "sentence": "If @DRUG$ are required during @DRUG$ therapy, OMNICEF should be taken at least 2 hours before or after the supplement.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d420.s6.p1",
        "sentence": "If @DRUG$ are required during OMNICEF therapy, @DRUG$ should be taken at least 2 hours before or after the supplement.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d420.s6.p2",
        "sentence": "If iron supplements are required during @DRUG$ therapy, @DRUG$ should be taken at least 2 hours before or after the supplement.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d422.s3.p0",
        "sentence": "@DRUG$ concentrations were equivocally higher when given with @DRUG$, but this is not likely to be clinically important.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d422.s4.p0",
        "sentence": "When @DRUG$ and @DRUG$ were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d422.s4.p1",
        "sentence": "When @DRUG$ and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in @DRUG$ blood levels at some time points.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d422.s4.p2",
        "sentence": "When digoxin and @DRUG$ were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in @DRUG$ blood levels at some time points.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d423.s3.p0",
        "sentence": "At least 3 weeks should elapse between discontinuation of @DRUG$ and initiation of treatment with a @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d423.s6.p0",
        "sentence": "@DRUG$ should not be administered with other @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d424.s3.p0",
        "sentence": "@DRUG$: Coadministration of @DRUG$ and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d424.s3.p1",
        "sentence": "@DRUG$: Coadministration of rifampin and @DRUG$ Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d424.s3.p2",
        "sentence": "@DRUG$: Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma @DRUG$ concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d424.s3.p3",
        "sentence": "Rifampin: Coadministration of @DRUG$ and @DRUG$ Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d424.s3.p4",
        "sentence": "Rifampin: Coadministration of @DRUG$ and MEPRON Suspension results in a significant decrease in average steady- state plasma @DRUG$ concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d424.s3.p5",
        "sentence": "Rifampin: Coadministration of rifampin and @DRUG$ Suspension results in a significant decrease in average steady- state plasma @DRUG$ concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d424.s6.p0",
        "sentence": "No interaction trials have been conducted with @DRUG$ and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d425.s5.p0",
        "sentence": "Therefore, intake of supplemental @DRUG$ should not exceed 1000 micrograms ( g, sometimes mcg) per day to prevent @DRUG$ from masking symptoms of vitamin B12 deficiency.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s1.p0",
        "sentence": "Due to a theoretical risk of a pharmacodynamic interaction, use of @DRUG$-containing or @DRUG$ (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s1.p1",
        "sentence": "Due to a theoretical risk of a pharmacodynamic interaction, use of @DRUG$-containing or ergot-type medications (like @DRUG$ or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s1.p2",
        "sentence": "Due to a theoretical risk of a pharmacodynamic interaction, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s1.p3",
        "sentence": "Due to a theoretical risk of a pharmacodynamic interaction, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d426.s1.p4",
        "sentence": "Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or @DRUG$ (like @DRUG$ or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s1.p5",
        "sentence": "Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or @DRUG$) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s1.p6",
        "sentence": "Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d426.s1.p7",
        "sentence": "Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like @DRUG$ or @DRUG$) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s1.p8",
        "sentence": "Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like @DRUG$ or methysergide) and @DRUG$ within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d426.s1.p9",
        "sentence": "Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and @DRUG$ within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p0",
        "sentence": "@DRUG$ (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p1",
        "sentence": "@DRUG$ (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p2",
        "sentence": "@DRUG$ (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p3",
        "sentence": "@DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p4",
        "sentence": "@DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p5",
        "sentence": "@DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p6",
        "sentence": "Selective serotonin reuptake inhibitors (@DRUG$) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p7",
        "sentence": "Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p8",
        "sentence": "Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p9",
        "sentence": "Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p10",
        "sentence": "Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p11",
        "sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p12",
        "sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p13",
        "sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p14",
        "sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p15",
        "sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p16",
        "sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p17",
        "sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p18",
        "sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p19",
        "sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d426.s3.p20",
        "sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d427.s0.p0",
        "sentence": "Elevated plasma levels of @DRUG$ have been reported with concomitant @DRUG$ use.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d427.s1.p0",
        "sentence": "There have been reports of @DRUG$-related side effects in patients on concomitant therapy with @DRUG$ and theophylline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d427.s1.p1",
        "sentence": "There have been reports of @DRUG$-related side effects in patients on concomitant therapy with quinolones and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d427.s1.p2",
        "sentence": "There have been reports of theophylline-related side effects in patients on concomitant therapy with @DRUG$ and @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d427.s11.p0",
        "sentence": "and @DRUG$ , (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d427.s11.p1",
        "sentence": "and @DRUG$ , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of @DRUG$, resulting in systemic levels considerably lower than desired.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d427.s11.p2",
        "sentence": "and Videx , (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of @DRUG$, resulting in systemic levels considerably lower than desired.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d427.s13.p0",
        "sentence": "Elevated serum levels of @DRUG$ have been reported with the concomitant use of some @DRUG$ and cyclosporine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d427.s13.p1",
        "sentence": "Elevated serum levels of @DRUG$ have been reported with the concomitant use of some quinolones and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d427.s13.p2",
        "sentence": "Elevated serum levels of cyclosporine have been reported with the concomitant use of some @DRUG$ and @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d427.s7.p0",
        "sentence": "@DRUG$ interferes with the therapeutic action of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d427.s8.p0",
        "sentence": "@DRUG$ containing @DRUG$, aluminum, or calcium;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d427.s8.p1",
        "sentence": "@DRUG$ containing magnesium, @DRUG$, or calcium;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d427.s8.p2",
        "sentence": "@DRUG$ containing magnesium, aluminum, or @DRUG$;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d427.s8.p3",
        "sentence": "Antacids containing @DRUG$, @DRUG$, or calcium;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d427.s8.p4",
        "sentence": "Antacids containing @DRUG$, aluminum, or @DRUG$;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d427.s8.p5",
        "sentence": "Antacids containing magnesium, @DRUG$, or @DRUG$;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d429.s2.p0",
        "sentence": "@DRUG$: @DRUG$ can inhibit the metabolism of chloroquine, increasing its plasma level.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d429.s2.p1",
        "sentence": "@DRUG$: Cimetidine can inhibit the metabolism of @DRUG$, increasing its plasma level.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d429.s2.p2",
        "sentence": "Cimetidine: @DRUG$ can inhibit the metabolism of @DRUG$, increasing its plasma level.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d429.s4.p0",
        "sentence": "@DRUG$: In a study of healthy volunteers, @DRUG$ significantly reduced the bioavailability of ampicillin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d429.s4.p1",
        "sentence": "@DRUG$: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d429.s4.p2",
        "sentence": "Ampicillin: In a study of healthy volunteers, @DRUG$ significantly reduced the bioavailability of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d43.s15.p0",
        "sentence": "To avoid this interaction, @DRUG$ or @DRUG$ should be given 1 hour prior to dosing with VIDEX.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s15.p1",
        "sentence": "To avoid this interaction, @DRUG$ or indinavir should be given 1 hour prior to dosing with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d43.s15.p2",
        "sentence": "To avoid this interaction, delavirdine or @DRUG$ should be given 1 hour prior to dosing with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d43.s7.p0",
        "sentence": "A 21 (17)% decrease in the steady-state AUC of @DRUG$ was observed when @DRUG$ was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s7.p1",
        "sentence": "A 21 (17)% decrease in the steady-state AUC of @DRUG$ was observed when VIDEX was administered 2 hours prior to @DRUG$, but not when the two drugs were administered simultaneously (n = 12).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s7.p2",
        "sentence": "A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when @DRUG$ was administered 2 hours prior to @DRUG$, but not when the two drugs were administered simultaneously (n = 12).",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p0",
        "sentence": "@DRUG$s: @DRUG$ should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p1",
        "sentence": "@DRUG$s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with @DRUG$ because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p2",
        "sentence": "@DRUG$s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of @DRUG$ are decreased when administered with antacids containing magnesium, calcium, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p3",
        "sentence": "@DRUG$s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with @DRUG$ containing magnesium, calcium, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p4",
        "sentence": "@DRUG$s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing @DRUG$, calcium, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p5",
        "sentence": "@DRUG$s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, @DRUG$, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p6",
        "sentence": "@DRUG$s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p7",
        "sentence": "Quinolone Antibiotics: @DRUG$ should be administered at least 2 hours after or 6 hours before dosing with @DRUG$ because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p8",
        "sentence": "Quinolone Antibiotics: @DRUG$ should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of @DRUG$ are decreased when administered with antacids containing magnesium, calcium, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p9",
        "sentence": "Quinolone Antibiotics: @DRUG$ should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with @DRUG$ containing magnesium, calcium, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p10",
        "sentence": "Quinolone Antibiotics: @DRUG$ should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing @DRUG$, calcium, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p11",
        "sentence": "Quinolone Antibiotics: @DRUG$ should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, @DRUG$, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p12",
        "sentence": "Quinolone Antibiotics: @DRUG$ should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p13",
        "sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with @DRUG$ because plasma concentrations of @DRUG$ are decreased when administered with antacids containing magnesium, calcium, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p14",
        "sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with @DRUG$ because plasma concentrations of ciprofloxacin are decreased when administered with @DRUG$ containing magnesium, calcium, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p15",
        "sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with @DRUG$ because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing @DRUG$, calcium, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p16",
        "sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with @DRUG$ because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, @DRUG$, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p17",
        "sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with @DRUG$ because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p18",
        "sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of @DRUG$ are decreased when administered with @DRUG$ containing magnesium, calcium, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p19",
        "sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of @DRUG$ are decreased when administered with antacids containing @DRUG$, calcium, or aluminum.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p20",
        "sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of @DRUG$ are decreased when administered with antacids containing magnesium, @DRUG$, or aluminum.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p21",
        "sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of @DRUG$ are decreased when administered with antacids containing magnesium, calcium, or @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p22",
        "sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with @DRUG$ containing @DRUG$, calcium, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p23",
        "sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with @DRUG$ containing magnesium, @DRUG$, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p24",
        "sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with @DRUG$ containing magnesium, calcium, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p25",
        "sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing @DRUG$, @DRUG$, or aluminum.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p26",
        "sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing @DRUG$, calcium, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d43.s8.p27",
        "sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, @DRUG$, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s15.p0",
        "sentence": "In order to maintain @DRUG$ levels, limit adverse experiences, and achieve the @DRUG$ dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s15.p1",
        "sentence": "In order to maintain @DRUG$ levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a @DRUG$ dose reduction of approximately 40% was necessary for eight of these 10 subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s15.p2",
        "sentence": "In order to maintain phenytoin levels, limit adverse experiences, and achieve the @DRUG$ dose of 3600 mg/day, a @DRUG$ dose reduction of approximately 40% was necessary for eight of these 10 subjects.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d434.s16.p0",
        "sentence": "In a controlled clinical trial, a 20% reduction of the @DRUG$ dose at the initiation of @DRUG$  therapy resulted in phenytoin levels comparable to those prior to Felbatol  administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s16.p1",
        "sentence": "In a controlled clinical trial, a 20% reduction of the @DRUG$ dose at the initiation of Felbatol  therapy resulted in @DRUG$ levels comparable to those prior to Felbatol  administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s16.p2",
        "sentence": "In a controlled clinical trial, a 20% reduction of the @DRUG$ dose at the initiation of Felbatol  therapy resulted in phenytoin levels comparable to those prior to @DRUG$  administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s16.p3",
        "sentence": "In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of @DRUG$  therapy resulted in @DRUG$ levels comparable to those prior to Felbatol  administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s16.p4",
        "sentence": "In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of @DRUG$  therapy resulted in phenytoin levels comparable to those prior to @DRUG$  administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s16.p5",
        "sentence": "In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol  therapy resulted in @DRUG$ levels comparable to those prior to @DRUG$  administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s21.p0",
        "sentence": "In clinical trials, similar changes in @DRUG$ and @DRUG$ were seen.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s27.p0",
        "sentence": "The ratios of the AUCs of unbound @DRUG$ to the AUCs of the total @DRUG$ were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol , respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s27.p1",
        "sentence": "The ratios of the AUCs of unbound @DRUG$ to the AUCs of the total valproate were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of @DRUG$ , respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s27.p2",
        "sentence": "The ratios of the AUCs of unbound valproate to the AUCs of the total @DRUG$ were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of @DRUG$ , respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s36.p0",
        "sentence": "Effects of @DRUG$ on @DRUG$  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s36.p1",
        "sentence": "Effects of @DRUG$ on Felbatol  The coadministration of @DRUG$ (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s36.p2",
        "sentence": "Effects of @DRUG$ on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at @DRUG$ daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s36.p3",
        "sentence": "Effects of Erythromycin on @DRUG$  The coadministration of @DRUG$ (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s36.p4",
        "sentence": "Effects of Erythromycin on @DRUG$  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at @DRUG$ daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d434.s36.p5",
        "sentence": "Effects of Erythromycin on Felbatol  The coadministration of @DRUG$ (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at @DRUG$ daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d437.s13.p0",
        "sentence": "Laboratory Tests: The combination of @DRUG$ and low-dose @DRUG$ has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d437.s5.p0",
        "sentence": "@DRUG$ steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d437.s8.p0",
        "sentence": "@DRUG$ steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d438.s11.p0",
        "sentence": "@DRUG$: The mean steady-state trough serum @DRUG$ concentrations prior to and during concomitant gabapentin administration (400 mg TID;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d438.s11.p1",
        "sentence": "@DRUG$: The mean steady-state trough serum valproic acid concentrations prior to and during concomitant @DRUG$ administration (400 mg TID;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d438.s11.p2",
        "sentence": "Valproic Acid: The mean steady-state trough serum @DRUG$ concentrations prior to and during concomitant @DRUG$ administration (400 mg TID;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d438.s27.p0",
        "sentence": "@DRUG$ pharmacokinetic parameter values were not affected by administration of @DRUG$  2 hours after morphine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d438.s27.p1",
        "sentence": "@DRUG$ pharmacokinetic parameter values were not affected by administration of Neurontin  2 hours after @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d438.s27.p2",
        "sentence": "Morphine pharmacokinetic parameter values were not affected by administration of @DRUG$  2 hours after @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d438.s29.p0",
        "sentence": "@DRUG$: In the presence of @DRUG$ at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d438.s29.p1",
        "sentence": "@DRUG$: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of @DRUG$ fell by 14% and creatinine clearance fell by 10%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d438.s29.p2",
        "sentence": "Cimetidine: In the presence of @DRUG$ at 300 mg QID (N=12) the mean apparent oral clearance of @DRUG$ fell by 14% and creatinine clearance fell by 10%.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d438.s32.p0",
        "sentence": "The effect of @DRUG$ on @DRUG$ was not evaluated.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d438.s35.p0",
        "sentence": "The Cmax of @DRUG$ was 13% higher when it was coadministered with @DRUG$;",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d438.s39.p0",
        "sentence": "It is recommended that @DRUG$ be taken at least 2 hours following @DRUG$ administration.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d438.s43.p0",
        "sentence": "Drug/Laboratory Tests Interactions Because false positive readings were reported with the Ames N-Multistix SG dipstick test for urinary protein when @DRUG$ was added to other @DRUG$, the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d439.s0.p0",
        "sentence": "@DRUG$ may accentuate the electrolyte loss associated with @DRUG$ therapy.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d440.s13.p0",
        "sentence": "However, since @DRUG$, @DRUG$, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s13.p1",
        "sentence": "However, since @DRUG$, NSAIDs, and @DRUG$ are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s13.p2",
        "sentence": "However, since @DRUG$, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of @DRUG$ or NSAIDs with Ibandronate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s13.p3",
        "sentence": "However, since @DRUG$, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or @DRUG$ with Ibandronate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s13.p4",
        "sentence": "However, since @DRUG$, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s13.p5",
        "sentence": "However, since aspirin, @DRUG$, and @DRUG$ are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s13.p6",
        "sentence": "However, since aspirin, @DRUG$, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of @DRUG$ or NSAIDs with Ibandronate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s13.p7",
        "sentence": "However, since aspirin, @DRUG$, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or @DRUG$ with Ibandronate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s13.p8",
        "sentence": "However, since aspirin, @DRUG$, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s13.p9",
        "sentence": "However, since aspirin, NSAIDs, and @DRUG$ are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of @DRUG$ or NSAIDs with Ibandronate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s13.p10",
        "sentence": "However, since aspirin, NSAIDs, and @DRUG$ are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or @DRUG$ with Ibandronate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s13.p11",
        "sentence": "However, since aspirin, NSAIDs, and @DRUG$ are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s13.p12",
        "sentence": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of @DRUG$ or @DRUG$ with Ibandronate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s13.p13",
        "sentence": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of @DRUG$ or NSAIDs with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d440.s13.p14",
        "sentence": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or @DRUG$ with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d440.s4.p0",
        "sentence": "Of over 3500 patients enrolled in the @DRUG$ osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily @DRUG$ and PPIs).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s4.p1",
        "sentence": "Of over 3500 patients enrolled in the @DRUG$ osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2 blockers and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s4.p2",
        "sentence": "Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily @DRUG$ and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d440.s7.p0",
        "sentence": "Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with @DRUG$ 150 mg once monthly was similar to that in patients treated with @DRUG$ 2.5 mg once daily.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d441.s5.p0",
        "sentence": "@DRUG$: Co-administration of @DRUG$ and serotonergic agents was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d441.s5.p1",
        "sentence": "@DRUG$: Co-administration of linezolid and @DRUG$ was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d441.s5.p2",
        "sentence": "Serotonergic Agents: Co-administration of @DRUG$ and @DRUG$ was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d441.s6.p0",
        "sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of @DRUG$ and @DRUG$, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d441.s6.p1",
        "sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of @DRUG$ and serotonergic agents, including @DRUG$ such as selective serotonin reuptake inhibitors (SSRIs), have been reported.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d441.s6.p2",
        "sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of @DRUG$ and serotonergic agents, including antidepressants such as @DRUG$ (SSRIs), have been reported.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d441.s6.p3",
        "sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of @DRUG$ and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (@DRUG$), have been reported.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d441.s6.p4",
        "sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and @DRUG$, including @DRUG$ such as selective serotonin reuptake inhibitors (SSRIs), have been reported.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d441.s6.p5",
        "sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and @DRUG$, including antidepressants such as @DRUG$ (SSRIs), have been reported.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d441.s6.p6",
        "sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and @DRUG$, including antidepressants such as selective serotonin reuptake inhibitors (@DRUG$), have been reported.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d441.s6.p7",
        "sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including @DRUG$ such as @DRUG$ (SSRIs), have been reported.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d441.s6.p8",
        "sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including @DRUG$ such as selective serotonin reuptake inhibitors (@DRUG$), have been reported.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d441.s6.p9",
        "sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as @DRUG$ (@DRUG$), have been reported.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d441.s7.p0",
        "sentence": "Patients who are treated with @DRUG$ and concomitant @DRUG$ should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d442.s0.p0",
        "sentence": "Increases in prothrombin time have been noted in patients receiving long- term @DRUG$ therapy after @DRUG$ was initiated.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d443.s4.p0",
        "sentence": "@DRUG$ Agents: @DRUG$ is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d443.s4.p1",
        "sentence": "@DRUG$ Agents: Aspirin is contraindicated in patients who are hypersensitive to @DRUG$ agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d443.s4.p2",
        "sentence": "Nonsteroidal Antiinflammatory Agents: @DRUG$ is contraindicated in patients who are hypersensitive to @DRUG$ agents.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d448.s1.p0",
        "sentence": "Concomitant use of @DRUG$ with @DRUG$, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d448.s1.p1",
        "sentence": "Concomitant use of @DRUG$ with alcohol, @DRUG$, barbiturates, or other central nervous system depressants may have an additive effect.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d448.s1.p2",
        "sentence": "Concomitant use of @DRUG$ with alcohol, tricyclic antidepressants, @DRUG$, or other central nervous system depressants may have an additive effect.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d448.s1.p3",
        "sentence": "Concomitant use of @DRUG$ with alcohol, tricyclic antidepressants, barbiturates, or other @DRUG$ may have an additive effect.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d448.s1.p4",
        "sentence": "Concomitant use of antihistamines with @DRUG$, @DRUG$, barbiturates, or other central nervous system depressants may have an additive effect.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d448.s1.p5",
        "sentence": "Concomitant use of antihistamines with @DRUG$, tricyclic antidepressants, @DRUG$, or other central nervous system depressants may have an additive effect.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d448.s1.p6",
        "sentence": "Concomitant use of antihistamines with @DRUG$, tricyclic antidepressants, barbiturates, or other @DRUG$ may have an additive effect.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d448.s1.p7",
        "sentence": "Concomitant use of antihistamines with alcohol, @DRUG$, @DRUG$, or other central nervous system depressants may have an additive effect.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d448.s1.p8",
        "sentence": "Concomitant use of antihistamines with alcohol, @DRUG$, barbiturates, or other @DRUG$ may have an additive effect.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d448.s1.p9",
        "sentence": "Concomitant use of antihistamines with alcohol, tricyclic antidepressants, @DRUG$, or other @DRUG$ may have an additive effect.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d448.s4.p0",
        "sentence": "@DRUG$ may also interact with @DRUG$.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d448.s6.p0",
        "sentence": "@DRUG$ increase the rate of absorption of @DRUG$, while kaolin decreases it.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d448.s6.p1",
        "sentence": "@DRUG$ increase the rate of absorption of pseudoephedrine, while @DRUG$ decreases it.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d448.s6.p2",
        "sentence": "Antacids increase the rate of absorption of @DRUG$, while @DRUG$ decreases it.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d449.s1.p0",
        "sentence": "@DRUG$, @DRUG$, cimetidine (consider Xanax dose reduction).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d449.s1.p1",
        "sentence": "@DRUG$, fluvoxamine, @DRUG$ (consider Xanax dose reduction).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d449.s1.p2",
        "sentence": "@DRUG$, fluvoxamine, cimetidine (consider @DRUG$ dose reduction).",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d449.s1.p3",
        "sentence": "Nafazodone, @DRUG$, @DRUG$ (consider Xanax dose reduction).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d449.s1.p4",
        "sentence": "Nafazodone, @DRUG$, cimetidine (consider @DRUG$ dose reduction).",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d449.s1.p5",
        "sentence": "Nafazodone, fluvoxamine, @DRUG$ (consider @DRUG$ dose reduction).",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d45.s1.p0",
        "sentence": "Other @DRUG$ (including @DRUG$) used in combination with anakinra may also result in similar toxicities.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d45.s1.p1",
        "sentence": "Other @DRUG$ (including REMICADE) used in combination with @DRUG$ may also result in similar toxicities.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d45.s1.p2",
        "sentence": "Other TNFa-blocking agents (including @DRUG$) used in combination with @DRUG$ may also result in similar toxicities.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d45.s8.p0",
        "sentence": "Serum @DRUG$ concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including @DRUG$, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d45.s8.p1",
        "sentence": "Serum @DRUG$ concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, @DRUG$ (metronidazole or ciprofloxacin) and aminosalicylates.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d45.s8.p2",
        "sentence": "Serum @DRUG$ concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, antibiotics (@DRUG$ or ciprofloxacin) and aminosalicylates.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d45.s8.p3",
        "sentence": "Serum @DRUG$ concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, antibiotics (metronidazole or @DRUG$) and aminosalicylates.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d45.s8.p4",
        "sentence": "Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including @DRUG$, @DRUG$ (metronidazole or ciprofloxacin) and aminosalicylates.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d45.s8.p5",
        "sentence": "Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including @DRUG$, antibiotics (@DRUG$ or ciprofloxacin) and aminosalicylates.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d45.s8.p6",
        "sentence": "Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including @DRUG$, antibiotics (metronidazole or @DRUG$) and aminosalicylates.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d45.s8.p7",
        "sentence": "Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, @DRUG$ (@DRUG$ or ciprofloxacin) and aminosalicylates.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d45.s8.p8",
        "sentence": "Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, @DRUG$ (metronidazole or @DRUG$) and aminosalicylates.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d45.s8.p9",
        "sentence": "Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, antibiotics (@DRUG$ or @DRUG$) and aminosalicylates.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d450.s10.p0",
        "sentence": "Concomitant use of @DRUG$ and @DRUG$ increases the risk of cardiac arrhythmias.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d450.s5.p0",
        "sentence": "@DRUG$ and @DRUG$, by decreasing gut motility, may increase digoxin absorption.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d450.s5.p1",
        "sentence": "@DRUG$ and diphenoxylate, by decreasing gut motility, may increase @DRUG$ absorption.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d450.s5.p2",
        "sentence": "Propantheline and @DRUG$, by decreasing gut motility, may increase @DRUG$ absorption.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d454.s4.p0",
        "sentence": "- Concomitant use of @DRUG$ may reduce the efficacy of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d455.s10.p0",
        "sentence": "These include @DRUG$, @DRUG$, and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s10.p1",
        "sentence": "These include @DRUG$, cholestyramine, and some @DRUG$ (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s10.p2",
        "sentence": "These include @DRUG$, cholestyramine, and some antibiotics (e.g. @DRUG$, rifamipicin, ampicillin and chloramphenicol).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s10.p3",
        "sentence": "These include @DRUG$, cholestyramine, and some antibiotics (e.g. erythromycin, rifamipicin, @DRUG$ and chloramphenicol).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s10.p4",
        "sentence": "These include @DRUG$, cholestyramine, and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s10.p5",
        "sentence": "These include probenecid, @DRUG$, and some @DRUG$ (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s10.p6",
        "sentence": "These include probenecid, @DRUG$, and some antibiotics (e.g. @DRUG$, rifamipicin, ampicillin and chloramphenicol).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s10.p7",
        "sentence": "These include probenecid, @DRUG$, and some antibiotics (e.g. erythromycin, rifamipicin, @DRUG$ and chloramphenicol).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s10.p8",
        "sentence": "These include probenecid, @DRUG$, and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s10.p9",
        "sentence": "These include probenecid, cholestyramine, and some @DRUG$ (e.g. @DRUG$, rifamipicin, ampicillin and chloramphenicol).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s10.p10",
        "sentence": "These include probenecid, cholestyramine, and some @DRUG$ (e.g. erythromycin, rifamipicin, @DRUG$ and chloramphenicol).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s10.p11",
        "sentence": "These include probenecid, cholestyramine, and some @DRUG$ (e.g. erythromycin, rifamipicin, ampicillin and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s10.p12",
        "sentence": "These include probenecid, cholestyramine, and some antibiotics (e.g. @DRUG$, rifamipicin, @DRUG$ and chloramphenicol).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s10.p13",
        "sentence": "These include probenecid, cholestyramine, and some antibiotics (e.g. @DRUG$, rifamipicin, ampicillin and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s10.p14",
        "sentence": "These include probenecid, cholestyramine, and some antibiotics (e.g. erythromycin, rifamipicin, @DRUG$ and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s11.p0",
        "sentence": "No interaction with the @DRUG$ @DRUG$ was shown in a single-dose study with entacapone without coadministered levodopa/dopa-decarboxylase inhibitor.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s11.p1",
        "sentence": "No interaction with the @DRUG$ imipramine was shown in a single-dose study with @DRUG$ without coadministered levodopa/dopa-decarboxylase inhibitor.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s11.p2",
        "sentence": "No interaction with the @DRUG$ imipramine was shown in a single-dose study with entacapone without coadministered @DRUG$/dopa-decarboxylase inhibitor.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s11.p3",
        "sentence": "No interaction with the @DRUG$ imipramine was shown in a single-dose study with entacapone without coadministered levodopa/@DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s11.p4",
        "sentence": "No interaction with the tricyclic antidepressant @DRUG$ was shown in a single-dose study with @DRUG$ without coadministered levodopa/dopa-decarboxylase inhibitor.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s11.p5",
        "sentence": "No interaction with the tricyclic antidepressant @DRUG$ was shown in a single-dose study with entacapone without coadministered @DRUG$/dopa-decarboxylase inhibitor.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s11.p6",
        "sentence": "No interaction with the tricyclic antidepressant @DRUG$ was shown in a single-dose study with entacapone without coadministered levodopa/@DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s11.p7",
        "sentence": "No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with @DRUG$ without coadministered @DRUG$/dopa-decarboxylase inhibitor.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s11.p8",
        "sentence": "No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with @DRUG$ without coadministered levodopa/@DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d455.s11.p9",
        "sentence": "No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered @DRUG$/@DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d456.s6.p0",
        "sentence": "Other CYP3A4 inducers include, but are not limited to, @DRUG$, @DRUG$, phenytoin, carbamazepine, phenobarbital and St. Johns Wort.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d456.s6.p1",
        "sentence": "Other CYP3A4 inducers include, but are not limited to, @DRUG$, rifapentine, @DRUG$, carbamazepine, phenobarbital and St. Johns Wort.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d456.s6.p2",
        "sentence": "Other CYP3A4 inducers include, but are not limited to, @DRUG$, rifapentine, phenytoin, @DRUG$, phenobarbital and St. Johns Wort.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d456.s6.p3",
        "sentence": "Other CYP3A4 inducers include, but are not limited to, @DRUG$, rifapentine, phenytoin, carbamazepine, @DRUG$ and St. Johns Wort.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d456.s6.p4",
        "sentence": "Other CYP3A4 inducers include, but are not limited to, rifabutin, @DRUG$, @DRUG$, carbamazepine, phenobarbital and St. Johns Wort.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d456.s6.p5",
        "sentence": "Other CYP3A4 inducers include, but are not limited to, rifabutin, @DRUG$, phenytoin, @DRUG$, phenobarbital and St. Johns Wort.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d456.s6.p6",
        "sentence": "Other CYP3A4 inducers include, but are not limited to, rifabutin, @DRUG$, phenytoin, carbamazepine, @DRUG$ and St. Johns Wort.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d456.s6.p7",
        "sentence": "Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, @DRUG$, @DRUG$, phenobarbital and St. Johns Wort.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d456.s6.p8",
        "sentence": "Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, @DRUG$, carbamazepine, @DRUG$ and St. Johns Wort.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d456.s6.p9",
        "sentence": "Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, phenytoin, @DRUG$, @DRUG$ and St. Johns Wort.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p0",
        "sentence": "@DRUG$ may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p1",
        "sentence": "@DRUG$ may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p2",
        "sentence": "@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p3",
        "sentence": "@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p4",
        "sentence": "@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p5",
        "sentence": "@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, @DRUG$, and beta blockers.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p6",
        "sentence": "@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p7",
        "sentence": "Barbiturates may decrease the effectiveness of oral @DRUG$, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p8",
        "sentence": "Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p9",
        "sentence": "Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p10",
        "sentence": "Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p11",
        "sentence": "Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, corticosteroids, @DRUG$, and beta blockers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p12",
        "sentence": "Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p13",
        "sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p14",
        "sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p15",
        "sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p16",
        "sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, corticosteroids, @DRUG$, and beta blockers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p17",
        "sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p18",
        "sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, @DRUG$, corticosteroids, anticoagulants, and beta blockers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p19",
        "sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, @DRUG$, anticoagulants, and beta blockers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p20",
        "sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, @DRUG$, and beta blockers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p21",
        "sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p22",
        "sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, @DRUG$, anticoagulants, and beta blockers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p23",
        "sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, @DRUG$, and beta blockers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p24",
        "sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p25",
        "sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, @DRUG$, @DRUG$, and beta blockers.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p26",
        "sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d457.s0.p27",
        "sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, @DRUG$, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d458.s10.p0",
        "sentence": "@DRUG$ tablets may alter the metabolism of @DRUG$, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d458.s10.p1",
        "sentence": "@DRUG$ tablets may alter the metabolism of cyclosporine, @DRUG$, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d458.s10.p2",
        "sentence": "@DRUG$ tablets may alter the metabolism of cyclosporine, tacrolimus, and @DRUG$, resulting in elevated plasma concentrations of the latter drugs.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d458.s10.p3",
        "sentence": "Ketoconazole tablets may alter the metabolism of @DRUG$, @DRUG$, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d458.s10.p4",
        "sentence": "Ketoconazole tablets may alter the metabolism of @DRUG$, tacrolimus, and @DRUG$, resulting in elevated plasma concentrations of the latter drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d458.s10.p5",
        "sentence": "Ketoconazole tablets may alter the metabolism of cyclosporine, @DRUG$, and @DRUG$, resulting in elevated plasma concentrations of the latter drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d458.s20.p0",
        "sentence": "In simultaneous treatment with @DRUG$ and @DRUG$, the anticoagulant effect should be carefully titrated and monitored.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d458.s30.p0",
        "sentence": "Also, there were no clinically significant differences in adverse events when @DRUG$ was administered with or without @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d46.s15.p0",
        "sentence": "- @DRUG$: Generally should not be given with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p0",
        "sentence": "Certain drugs, including @DRUG$ (@DRUG$), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p1",
        "sentence": "Certain drugs, including @DRUG$ (NSAIDs), @DRUG$, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p2",
        "sentence": "Certain drugs, including @DRUG$ (NSAIDs), salicylates, @DRUG$, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p3",
        "sentence": "Certain drugs, including @DRUG$ (NSAIDs), salicylates, monoamine oxidase inhibitors, and @DRUG$ may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p4",
        "sentence": "Certain drugs, including @DRUG$ (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p5",
        "sentence": "Certain drugs, including @DRUG$ (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p6",
        "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (@DRUG$), @DRUG$, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p7",
        "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (@DRUG$), salicylates, @DRUG$, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p8",
        "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (@DRUG$), salicylates, monoamine oxidase inhibitors, and @DRUG$ may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p9",
        "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (@DRUG$), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p10",
        "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (@DRUG$), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p11",
        "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), @DRUG$, @DRUG$, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p12",
        "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), @DRUG$, monoamine oxidase inhibitors, and @DRUG$ may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p13",
        "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), @DRUG$, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p14",
        "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), @DRUG$, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p15",
        "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, @DRUG$, and @DRUG$ may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p16",
        "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, @DRUG$, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p17",
        "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, @DRUG$, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p18",
        "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and @DRUG$ may potentiate the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p19",
        "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and @DRUG$ may potentiate the hypoglycemic action of Starlix and other oral @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s14.p20",
        "sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of @DRUG$ and other oral @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s15.p0",
        "sentence": "Certain drugs including @DRUG$, @DRUG$, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s15.p1",
        "sentence": "Certain drugs including @DRUG$, corticosteroids, @DRUG$, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s15.p2",
        "sentence": "Certain drugs including @DRUG$, corticosteroids, thyroid products, and @DRUG$ may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s15.p3",
        "sentence": "Certain drugs including @DRUG$, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s15.p4",
        "sentence": "Certain drugs including @DRUG$, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s15.p5",
        "sentence": "Certain drugs including thiazides, @DRUG$, @DRUG$, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s15.p6",
        "sentence": "Certain drugs including thiazides, @DRUG$, thyroid products, and @DRUG$ may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s15.p7",
        "sentence": "Certain drugs including thiazides, @DRUG$, thyroid products, and sympathomimetics may reduce the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s15.p8",
        "sentence": "Certain drugs including thiazides, @DRUG$, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s15.p9",
        "sentence": "Certain drugs including thiazides, corticosteroids, @DRUG$, and @DRUG$ may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s15.p10",
        "sentence": "Certain drugs including thiazides, corticosteroids, @DRUG$, and sympathomimetics may reduce the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s15.p11",
        "sentence": "Certain drugs including thiazides, corticosteroids, @DRUG$, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s15.p12",
        "sentence": "Certain drugs including thiazides, corticosteroids, thyroid products, and @DRUG$ may reduce the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s15.p13",
        "sentence": "Certain drugs including thiazides, corticosteroids, thyroid products, and @DRUG$ may reduce the hypoglycemic action of Starlix and other oral @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d460.s15.p14",
        "sentence": "Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of @DRUG$ and other oral @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s7.p0",
        "sentence": "@DRUG$: When healthy subjects were administered @DRUG$ 120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s7.p1",
        "sentence": "@DRUG$: When healthy subjects were administered Starlix 120 mg three times daily before meals for four days in combination with a single dose of @DRUG$ 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d460.s7.p2",
        "sentence": "Warfarin: When healthy subjects were administered @DRUG$ 120 mg three times daily before meals for four days in combination with a single dose of @DRUG$ 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d461.s0.p0",
        "sentence": "Additive depressant effect when used with general @DRUG$, @DRUG$, antianxiety drugs, hypnotics, alcohol, and other opiate analgesics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d461.s0.p1",
        "sentence": "Additive depressant effect when used with general @DRUG$, sedatives, @DRUG$, hypnotics, alcohol, and other opiate analgesics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d461.s0.p2",
        "sentence": "Additive depressant effect when used with general @DRUG$, sedatives, antianxiety drugs, @DRUG$, alcohol, and other opiate analgesics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d461.s0.p3",
        "sentence": "Additive depressant effect when used with general @DRUG$, sedatives, antianxiety drugs, hypnotics, @DRUG$, and other opiate analgesics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d461.s0.p4",
        "sentence": "Additive depressant effect when used with general @DRUG$, sedatives, antianxiety drugs, hypnotics, alcohol, and other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d461.s0.p5",
        "sentence": "Additive depressant effect when used with general anesthetics, @DRUG$, @DRUG$, hypnotics, alcohol, and other opiate analgesics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d461.s0.p6",
        "sentence": "Additive depressant effect when used with general anesthetics, @DRUG$, antianxiety drugs, @DRUG$, alcohol, and other opiate analgesics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d461.s0.p7",
        "sentence": "Additive depressant effect when used with general anesthetics, @DRUG$, antianxiety drugs, hypnotics, @DRUG$, and other opiate analgesics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d461.s0.p8",
        "sentence": "Additive depressant effect when used with general anesthetics, @DRUG$, antianxiety drugs, hypnotics, alcohol, and other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d461.s0.p9",
        "sentence": "Additive depressant effect when used with general anesthetics, sedatives, @DRUG$, @DRUG$, alcohol, and other opiate analgesics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d461.s0.p10",
        "sentence": "Additive depressant effect when used with general anesthetics, sedatives, @DRUG$, hypnotics, @DRUG$, and other opiate analgesics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d461.s0.p11",
        "sentence": "Additive depressant effect when used with general anesthetics, sedatives, @DRUG$, hypnotics, alcohol, and other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d461.s0.p12",
        "sentence": "Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs, @DRUG$, @DRUG$, and other opiate analgesics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d461.s0.p13",
        "sentence": "Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs, @DRUG$, alcohol, and other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d461.s0.p14",
        "sentence": "Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs, hypnotics, @DRUG$, and other @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d463.s5.p0",
        "sentence": "In vitro, @DRUG$ does not displace tightly bound drugs like @DRUG$, propranolol, and warfarin from serum proteins.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d463.s5.p1",
        "sentence": "In vitro, @DRUG$ does not displace tightly bound drugs like phenytoin, @DRUG$, and warfarin from serum proteins.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d463.s5.p2",
        "sentence": "In vitro, @DRUG$ does not displace tightly bound drugs like phenytoin, propranolol, and @DRUG$ from serum proteins.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d463.s5.p3",
        "sentence": "In vitro, buspirone does not displace tightly bound drugs like @DRUG$, @DRUG$, and warfarin from serum proteins.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d463.s5.p4",
        "sentence": "In vitro, buspirone does not displace tightly bound drugs like @DRUG$, propranolol, and @DRUG$ from serum proteins.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d463.s5.p5",
        "sentence": "In vitro, buspirone does not displace tightly bound drugs like phenytoin, @DRUG$, and @DRUG$ from serum proteins.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s0.p0",
        "sentence": "Drug Interaction with @DRUG$ and @DRUG$ Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s0.p1",
        "sentence": "Drug Interaction with @DRUG$ and Ketoconazole @DRUG$ has been shown to exhibit minimal (ca. 5%) metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s0.p2",
        "sentence": "Drug Interaction with Erythromycin and @DRUG$ @DRUG$ has been shown to exhibit minimal (ca. 5%) metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p0",
        "sentence": "Drug Interactions with @DRUG$ Administration of 120 mg of @DRUG$ (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p1",
        "sentence": "Drug Interactions with @DRUG$ Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an @DRUG$ and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p2",
        "sentence": "Drug Interactions with @DRUG$ Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and @DRUG$ containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p3",
        "sentence": "Drug Interactions with @DRUG$ Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing @DRUG$ (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p4",
        "sentence": "Drug Interactions with @DRUG$ Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (@DRUG$ ) decreased fexofenadine AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p5",
        "sentence": "Drug Interactions with @DRUG$ Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased @DRUG$ AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p6",
        "sentence": "Drug Interactions with Antacids Administration of 120 mg of @DRUG$ (2 x 60 mg capsule) within 15 minutes of an @DRUG$ and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p7",
        "sentence": "Drug Interactions with Antacids Administration of 120 mg of @DRUG$ (2 x 60 mg capsule) within 15 minutes of an aluminum and @DRUG$ containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p8",
        "sentence": "Drug Interactions with Antacids Administration of 120 mg of @DRUG$ (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing @DRUG$ (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p9",
        "sentence": "Drug Interactions with Antacids Administration of 120 mg of @DRUG$ (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (@DRUG$ ) decreased fexofenadine AUC by 41% and cmax by 43%.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p10",
        "sentence": "Drug Interactions with Antacids Administration of 120 mg of @DRUG$ (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased @DRUG$ AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p11",
        "sentence": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an @DRUG$ and @DRUG$ containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p12",
        "sentence": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an @DRUG$ and magnesium containing @DRUG$ (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p13",
        "sentence": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an @DRUG$ and magnesium containing antacid (@DRUG$ ) decreased fexofenadine AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p14",
        "sentence": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an @DRUG$ and magnesium containing antacid (Maalox ) decreased @DRUG$ AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p15",
        "sentence": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and @DRUG$ containing @DRUG$ (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p16",
        "sentence": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and @DRUG$ containing antacid (@DRUG$ ) decreased fexofenadine AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p17",
        "sentence": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and @DRUG$ containing antacid (Maalox ) decreased @DRUG$ AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p18",
        "sentence": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing @DRUG$ (@DRUG$ ) decreased fexofenadine AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p19",
        "sentence": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing @DRUG$ (Maalox ) decreased @DRUG$ AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s19.p20",
        "sentence": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (@DRUG$ ) decreased @DRUG$ AUC by 41% and cmax by 43%.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s27.p0",
        "sentence": "Therefore, to maximize the effects of @DRUG$, it is recommended that @DRUG$ should be taken with water",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d466.s5.p0",
        "sentence": "The findings of these studies are summarized in the following table: Effects on steady-state @DRUG$ pharmacokinetics after 7 days of co-administration with @DRUG$ 120 mg every 12 hours (two times the recommended twice daily dose) in healthy volunteers (n=24)",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d467.s2.p0",
        "sentence": "On the basis of the metabolism of @DRUG$ by cytochrome P450 3A4, @DRUG$, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d467.s2.p1",
        "sentence": "On the basis of the metabolism of @DRUG$ by cytochrome P450 3A4, ketoconazole, @DRUG$, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d467.s2.p2",
        "sentence": "On the basis of the metabolism of @DRUG$ by cytochrome P450 3A4, ketoconazole, itraconazole, @DRUG$, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d467.s2.p3",
        "sentence": "On the basis of the metabolism of @DRUG$ by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, @DRUG$, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d467.s2.p4",
        "sentence": "On the basis of the metabolism of @DRUG$ by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma @DRUG$ concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d467.s2.p5",
        "sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, @DRUG$, @DRUG$, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d467.s2.p6",
        "sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, @DRUG$, itraconazole, @DRUG$, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d467.s2.p7",
        "sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, @DRUG$, itraconazole, erythromycin, @DRUG$, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d467.s2.p8",
        "sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, @DRUG$, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma @DRUG$ concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d467.s2.p9",
        "sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, @DRUG$, @DRUG$, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d467.s2.p10",
        "sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, @DRUG$, erythromycin, @DRUG$, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d467.s2.p11",
        "sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, @DRUG$, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma @DRUG$ concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d467.s2.p12",
        "sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, @DRUG$, @DRUG$, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d467.s2.p13",
        "sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, @DRUG$, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma @DRUG$ concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d467.s2.p14",
        "sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, @DRUG$, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma @DRUG$ concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d467.s3.p0",
        "sentence": "Furthermore, @DRUG$, @DRUG$, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d467.s3.p1",
        "sentence": "Furthermore, @DRUG$, phenytoin, @DRUG$, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d467.s3.p2",
        "sentence": "Furthermore, @DRUG$, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma @DRUG$ concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d467.s3.p3",
        "sentence": "Furthermore, rifampin, @DRUG$, @DRUG$, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d467.s3.p4",
        "sentence": "Furthermore, rifampin, @DRUG$, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma @DRUG$ concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d467.s3.p5",
        "sentence": "Furthermore, rifampin, phenytoin, @DRUG$, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma @DRUG$ concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d468.s4.p0",
        "sentence": "@DRUG$: Some @DRUG$ may increase the concentration of digitalis preparations in the blood.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d468.s4.p1",
        "sentence": "@DRUG$: Some calcium blockers may increase the concentration of @DRUG$ in the blood.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d468.s4.p2",
        "sentence": "Digoxin: Some @DRUG$ may increase the concentration of @DRUG$ in the blood.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d468.s8.p0",
        "sentence": "@DRUG$: Concomitant administration of @DRUG$ and cyclosporine levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d468.s8.p1",
        "sentence": "@DRUG$: Concomitant administration of nicardipine and @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d468.s8.p2",
        "sentence": "Cyclosporine: Concomitant administration of @DRUG$ and @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d468.s9.p0",
        "sentence": "Plasma concentrations of @DRUG$ should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d47.s3.p0",
        "sentence": "In addition, the beneficial effects of @DRUG$ in Parkinsons disease have been reported to be reversed by @DRUG$ and papaverine.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d47.s3.p1",
        "sentence": "In addition, the beneficial effects of @DRUG$ in Parkinsons disease have been reported to be reversed by phenytoin and @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d47.s3.p2",
        "sentence": "In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by @DRUG$ and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d47.s7.p0",
        "sentence": "Although @DRUG$ may increase the bioavailability of @DRUG$ by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d47.s7.p1",
        "sentence": "Although @DRUG$ may increase the bioavailability of levodopa by increasing gastric emptying, @DRUG$ may also adversely affect disease control by its dopamine receptor antagonistic properties.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d47.s7.p2",
        "sentence": "Although metoclopramide may increase the bioavailability of @DRUG$ by increasing gastric emptying, @DRUG$ may also adversely affect disease control by its dopamine receptor antagonistic properties.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d476.s7.p0",
        "sentence": "There was no effect of @DRUG$ on prothrombin time in patients on stable doses of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d477.s2.p0",
        "sentence": "@DRUG$ may decrease the hypotensive effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d478.s5.p0",
        "sentence": "If concomitant treatment with @DRUG$ and an @DRUG$ is clinically warranted, appropriate observation of the patient is advised.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p0",
        "sentence": "@DRUG$/@DRUG$: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p1",
        "sentence": "@DRUG$/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by @DRUG$ or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p2",
        "sentence": "@DRUG$/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or @DRUG$ (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p3",
        "sentence": "@DRUG$/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, @DRUG$ and omeprazole) is likely to reduce dasatinib exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p4",
        "sentence": "@DRUG$/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and @DRUG$) is likely to reduce dasatinib exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p5",
        "sentence": "@DRUG$/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce @DRUG$ exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p6",
        "sentence": "H2 Blockers/@DRUG$: Long-term suppression of gastric acid secretion by @DRUG$ or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p7",
        "sentence": "H2 Blockers/@DRUG$: Long-term suppression of gastric acid secretion by H2 blockers or @DRUG$ (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p8",
        "sentence": "H2 Blockers/@DRUG$: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, @DRUG$ and omeprazole) is likely to reduce dasatinib exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p9",
        "sentence": "H2 Blockers/@DRUG$: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and @DRUG$) is likely to reduce dasatinib exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p10",
        "sentence": "H2 Blockers/@DRUG$: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce @DRUG$ exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p11",
        "sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by @DRUG$ or @DRUG$ (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p12",
        "sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by @DRUG$ or proton pump inhibitors (eg, @DRUG$ and omeprazole) is likely to reduce dasatinib exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p13",
        "sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by @DRUG$ or proton pump inhibitors (eg, famotidine and @DRUG$) is likely to reduce dasatinib exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p14",
        "sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by @DRUG$ or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce @DRUG$ exposure.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p15",
        "sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or @DRUG$ (eg, @DRUG$ and omeprazole) is likely to reduce dasatinib exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p16",
        "sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or @DRUG$ (eg, famotidine and @DRUG$) is likely to reduce dasatinib exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p17",
        "sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or @DRUG$ (eg, famotidine and omeprazole) is likely to reduce @DRUG$ exposure.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p18",
        "sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, @DRUG$ and @DRUG$) is likely to reduce dasatinib exposure.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p19",
        "sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, @DRUG$ and omeprazole) is likely to reduce @DRUG$ exposure.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d48.s11.p20",
        "sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and @DRUG$) is likely to reduce @DRUG$ exposure.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d48.s12.p0",
        "sentence": "The concomitant use of @DRUG$ or @DRUG$ with SPRYCEL is not recommended.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s12.p1",
        "sentence": "The concomitant use of @DRUG$ or proton pump inhibitors with @DRUG$ is not recommended.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d48.s12.p2",
        "sentence": "The concomitant use of H2 blockers or @DRUG$ with @DRUG$ is not recommended.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d48.s14.p0",
        "sentence": "Drugs that may have their plasma concentration altered by @DRUG$ CYP3A4 Substrates: @DRUG$ is a time-dependent inhibitor of CYP3A4.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s2.p0",
        "sentence": "In patients receiving treatment with @DRUG$, close monitoring for toxicity and a @DRUG$ dose reduction should be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d48.s8.p0",
        "sentence": "@DRUG$: Nonclinical data demonstrate that the solubility of @DRUG$ is pH dependent.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d480.s21.p0",
        "sentence": "@DRUG$ produced only minor changes in the levels of @DRUG$ and its metabolites.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d480.s23.p0",
        "sentence": "Therefore, such combined treatment should be approached with caution and patients should be monitored closely when @DRUG$ is combined with these drugs, particularly with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d480.s26.p0",
        "sentence": "Such individuals are referred to as poor metabolizers of drugs such as @DRUG$, @DRUG$, the tricyclic antidepressants, and clozapine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d480.s26.p1",
        "sentence": "Such individuals are referred to as poor metabolizers of drugs such as @DRUG$, dextromethorphan, the @DRUG$, and clozapine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d480.s26.p2",
        "sentence": "Such individuals are referred to as poor metabolizers of drugs such as @DRUG$, dextromethorphan, the tricyclic antidepressants, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d480.s26.p3",
        "sentence": "Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, @DRUG$, the @DRUG$, and clozapine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d480.s26.p4",
        "sentence": "Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, @DRUG$, the tricyclic antidepressants, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d480.s26.p5",
        "sentence": "Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, the @DRUG$, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d480.s29.p0",
        "sentence": "Concomitant use of @DRUG$ with other drugs metabolized by cytochrome P450 2D6 may require lower doses than usually prescribed for either @DRUG$ or the other drug.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d480.s9.p0",
        "sentence": "@DRUG$ may potentiate the hypotensive effects of @DRUG$ and the anticholinergic effects of atropine-type drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d480.s9.p1",
        "sentence": "@DRUG$ may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of @DRUG$-type drugs.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d480.s9.p2",
        "sentence": "Clozapine may potentiate the hypotensive effects of @DRUG$ and the anticholinergic effects of @DRUG$-type drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d482.s1.p0",
        "sentence": "Talk to your doctor if you are taking certain @DRUG$ such as @DRUG$, clarithromycin or azithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d482.s1.p1",
        "sentence": "Talk to your doctor if you are taking certain @DRUG$ such as erythromycin, @DRUG$ or azithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d482.s1.p2",
        "sentence": "Talk to your doctor if you are taking certain @DRUG$ such as erythromycin, clarithromycin or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d482.s1.p3",
        "sentence": "Talk to your doctor if you are taking certain antibiotics such as @DRUG$, @DRUG$ or azithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d482.s1.p4",
        "sentence": "Talk to your doctor if you are taking certain antibiotics such as @DRUG$, clarithromycin or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d482.s1.p5",
        "sentence": "Talk to your doctor if you are taking certain antibiotics such as erythromycin, @DRUG$ or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d483.s4.p0",
        "sentence": "As with other @DRUG$, high concentrations of @DRUG$ may interfere with measurement of serum and urine creatinine levels by Jaffe  reaction and produce false increases in the levels of creatinine reported.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s10.p0",
        "sentence": "@DRUG$: Combination @DRUG$ may increase or decrease the effects of coumarin derivatives.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s10.p1",
        "sentence": "@DRUG$: Combination hormonal contraceptives may increase or decrease the effects of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s10.p2",
        "sentence": "Anticoagulants: Combination @DRUG$ may increase or decrease the effects of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p0",
        "sentence": "@DRUG$ (@DRUG$, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p1",
        "sentence": "@DRUG$ (carbamazepine, @DRUG$, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p2",
        "sentence": "@DRUG$ (carbamazepine, felbamate, @DRUG$, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p3",
        "sentence": "@DRUG$ (carbamazepine, felbamate, phenobarbital, @DRUG$, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p4",
        "sentence": "@DRUG$ (carbamazepine, felbamate, phenobarbital, phenytoin, @DRUG$): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p5",
        "sentence": "@DRUG$ (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of @DRUG$ and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p6",
        "sentence": "@DRUG$ (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some @DRUG$, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p7",
        "sentence": "Anticonvulsants (@DRUG$, @DRUG$, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p8",
        "sentence": "Anticonvulsants (@DRUG$, felbamate, @DRUG$, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p9",
        "sentence": "Anticonvulsants (@DRUG$, felbamate, phenobarbital, @DRUG$, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p10",
        "sentence": "Anticonvulsants (@DRUG$, felbamate, phenobarbital, phenytoin, @DRUG$): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p11",
        "sentence": "Anticonvulsants (@DRUG$, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of @DRUG$ and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p12",
        "sentence": "Anticonvulsants (@DRUG$, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some @DRUG$, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p13",
        "sentence": "Anticonvulsants (carbamazepine, @DRUG$, @DRUG$, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p14",
        "sentence": "Anticonvulsants (carbamazepine, @DRUG$, phenobarbital, @DRUG$, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p15",
        "sentence": "Anticonvulsants (carbamazepine, @DRUG$, phenobarbital, phenytoin, @DRUG$): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p16",
        "sentence": "Anticonvulsants (carbamazepine, @DRUG$, phenobarbital, phenytoin, topiramate): Increase the metabolism of @DRUG$ and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p17",
        "sentence": "Anticonvulsants (carbamazepine, @DRUG$, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some @DRUG$, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p18",
        "sentence": "Anticonvulsants (carbamazepine, felbamate, @DRUG$, @DRUG$, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p19",
        "sentence": "Anticonvulsants (carbamazepine, felbamate, @DRUG$, phenytoin, @DRUG$): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p20",
        "sentence": "Anticonvulsants (carbamazepine, felbamate, @DRUG$, phenytoin, topiramate): Increase the metabolism of @DRUG$ and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p21",
        "sentence": "Anticonvulsants (carbamazepine, felbamate, @DRUG$, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some @DRUG$, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p22",
        "sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, @DRUG$, @DRUG$): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p23",
        "sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, @DRUG$, topiramate): Increase the metabolism of @DRUG$ and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p24",
        "sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, @DRUG$, topiramate): Increase the metabolism of ethinyl estradiol and/or some @DRUG$, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p25",
        "sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, @DRUG$): Increase the metabolism of @DRUG$ and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p26",
        "sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, @DRUG$): Increase the metabolism of ethinyl estradiol and/or some @DRUG$, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s12.p27",
        "sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of @DRUG$ and/or some @DRUG$, leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s2.p0",
        "sentence": "@DRUG$: May increase plasma concentration of @DRUG$, possibly by inhibiting conjugation.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s23.p0",
        "sentence": "@DRUG$: @DRUG$ may induce the metabolism of combination hormonal contraceptives causing menstrual changes;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s23.p1",
        "sentence": "@DRUG$: Griseofulvin may induce the metabolism of @DRUG$ causing menstrual changes;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s23.p2",
        "sentence": "Griseofulvin: @DRUG$ may induce the metabolism of @DRUG$ causing menstrual changes;",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s3.p0",
        "sentence": "Combination @DRUG$ may also decrease the plasma concentration of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s31.p0",
        "sentence": "@DRUG$: @DRUG$ may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s31.p1",
        "sentence": "@DRUG$: Ethinyl estradiol may inhibit the metabolism of @DRUG$, leading to increased plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s31.p2",
        "sentence": "Prednisolone: @DRUG$ may inhibit the metabolism of @DRUG$, leading to increased plasma concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s36.p0",
        "sentence": "@DRUG$: @DRUG$ increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s36.p1",
        "sentence": "@DRUG$: Rifampin increases the metabolism of @DRUG$ and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s36.p2",
        "sentence": "@DRUG$: Rifampin increases the metabolism of ethinyl estradiol and some @DRUG$ (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s36.p3",
        "sentence": "@DRUG$: Rifampin increases the metabolism of ethinyl estradiol and some progestins (@DRUG$) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s36.p4",
        "sentence": "Rifampin: @DRUG$ increases the metabolism of @DRUG$ and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s36.p5",
        "sentence": "Rifampin: @DRUG$ increases the metabolism of ethinyl estradiol and some @DRUG$ (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s36.p6",
        "sentence": "Rifampin: @DRUG$ increases the metabolism of ethinyl estradiol and some progestins (@DRUG$) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s36.p7",
        "sentence": "Rifampin: Rifampin increases the metabolism of @DRUG$ and some @DRUG$ (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s36.p8",
        "sentence": "Rifampin: Rifampin increases the metabolism of @DRUG$ and some progestins (@DRUG$) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s36.p9",
        "sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some @DRUG$ (@DRUG$) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s39.p0",
        "sentence": "@DRUG$: @DRUG$ may increase the serum concentration of selegiline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s39.p1",
        "sentence": "@DRUG$: Combination hormonal contraceptives may increase the serum concentration of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d485.s39.p2",
        "sentence": "Selegiline: @DRUG$ may increase the serum concentration of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d485.s6.p0",
        "sentence": "@DRUG$: May increase CYP metabolism of @DRUG$ leading to possible decrease in contraceptive effectiveness.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d486.s0.p0",
        "sentence": "No drug interaction studies have been conducted for @DRUG$, however the use of orally administered @DRUG$ could, theoretically, interfere with the release of mesalamine in the colon.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d486.s0.p1",
        "sentence": "No drug interaction studies have been conducted for @DRUG$, however the use of orally administered antibiotics could, theoretically, interfere with the release of @DRUG$ in the colon.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d486.s0.p2",
        "sentence": "No drug interaction studies have been conducted for COLAZAL, however the use of orally administered @DRUG$ could, theoretically, interfere with the release of @DRUG$ in the colon.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d487.s1.p0",
        "sentence": "Drugs that induce hepatic enzymes such as @DRUG$, @DRUG$ and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d487.s1.p1",
        "sentence": "Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and @DRUG$ may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d487.s1.p2",
        "sentence": "Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and rifampin may increase the clearance of @DRUG$ and may require increases in corticosteroid dose to achieve the desired response.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d487.s1.p3",
        "sentence": "Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in @DRUG$ dose to achieve the desired response.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d487.s1.p4",
        "sentence": "Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$ and @DRUG$ may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d487.s1.p5",
        "sentence": "Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$ and rifampin may increase the clearance of @DRUG$ and may require increases in corticosteroid dose to achieve the desired response.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d487.s1.p6",
        "sentence": "Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$ and rifampin may increase the clearance of corticosteroids and may require increases in @DRUG$ dose to achieve the desired response.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d487.s1.p7",
        "sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and @DRUG$ may increase the clearance of @DRUG$ and may require increases in corticosteroid dose to achieve the desired response.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d487.s1.p8",
        "sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and @DRUG$ may increase the clearance of corticosteroids and may require increases in @DRUG$ dose to achieve the desired response.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d487.s1.p9",
        "sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of @DRUG$ and may require increases in @DRUG$ dose to achieve the desired response.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d487.s6.p0",
        "sentence": "@DRUG$ should be used cautiously in conjunction with @DRUG$ in patients suffering from hypopro-thrombinemia.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d487.s8.p0",
        "sentence": "There are reports of enhanced as well as diminished effects of @DRUG$ when given concurrently with @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d488.s4.p0",
        "sentence": "Thus in order to avoid bleeding, reduced dosage of @DRUG$ is recommended during treatment with @DRUG$ (human).",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d489.s1.p0",
        "sentence": "Concomitant administration of @DRUG$ with the oral @DRUG$ warfarin has been shown not to potentiate the anticoagulant effect of warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s1.p1",
        "sentence": "Concomitant administration of @DRUG$ with the oral anticoagulant @DRUG$ has been shown not to potentiate the anticoagulant effect of warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s1.p2",
        "sentence": "Concomitant administration of @DRUG$ with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s1.p3",
        "sentence": "Concomitant administration of Kerlone with the oral @DRUG$ @DRUG$ has been shown not to potentiate the anticoagulant effect of warfarin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s1.p4",
        "sentence": "Concomitant administration of Kerlone with the oral @DRUG$ warfarin has been shown not to potentiate the anticoagulant effect of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s1.p5",
        "sentence": "Concomitant administration of Kerlone with the oral anticoagulant @DRUG$ has been shown not to potentiate the anticoagulant effect of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s2.p0",
        "sentence": "Catecholamine-depleting drugs (e.g., @DRUG$) may have an additive effect when given with @DRUG$ agents.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d489.s4.p0",
        "sentence": "Should it be decided to discontinue therapy in patients receiving @DRUG$ and @DRUG$ concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d489.s4.p1",
        "sentence": "Should it be decided to discontinue therapy in patients receiving @DRUG$ and clonidine concurrently, the @DRUG$ should be discontinued slowly over several days before the gradual withdrawal of clonidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s4.p2",
        "sentence": "Should it be decided to discontinue therapy in patients receiving @DRUG$ and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s4.p3",
        "sentence": "Should it be decided to discontinue therapy in patients receiving beta-blockers and @DRUG$ concurrently, the @DRUG$ should be discontinued slowly over several days before the gradual withdrawal of clonidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s4.p4",
        "sentence": "Should it be decided to discontinue therapy in patients receiving beta-blockers and @DRUG$ concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s4.p5",
        "sentence": "Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the @DRUG$ should be discontinued slowly over several days before the gradual withdrawal of @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d489.s7.p0",
        "sentence": "Hypotension was more likely to occur if the @DRUG$ were a @DRUG$, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s7.p1",
        "sentence": "Hypotension was more likely to occur if the @DRUG$ were a dihydropyridine derivative, e.g., @DRUG$, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s7.p2",
        "sentence": "Hypotension was more likely to occur if the @DRUG$ were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either @DRUG$ or diltiazem.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s7.p3",
        "sentence": "Hypotension was more likely to occur if the @DRUG$ were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s7.p4",
        "sentence": "Hypotension was more likely to occur if the calcium antagonist were a @DRUG$, e.g., @DRUG$, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s7.p5",
        "sentence": "Hypotension was more likely to occur if the calcium antagonist were a @DRUG$, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either @DRUG$ or diltiazem.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s7.p6",
        "sentence": "Hypotension was more likely to occur if the calcium antagonist were a @DRUG$, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s7.p7",
        "sentence": "Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., @DRUG$, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either @DRUG$ or diltiazem.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s7.p8",
        "sentence": "Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., @DRUG$, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s7.p9",
        "sentence": "Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either @DRUG$ or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s8.p0",
        "sentence": "Risk of Anaphylactic Reaction: Although it is known that patients on @DRUG$ may be refractory to @DRUG$ in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d489.s8.p1",
        "sentence": "Risk of Anaphylactic Reaction: Although it is known that patients on @DRUG$ may be refractory to epinephrine in the treatment of anaphylactic shock, @DRUG$ can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d489.s8.p2",
        "sentence": "Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to @DRUG$ in the treatment of anaphylactic shock, @DRUG$ can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d493.s4.p0",
        "sentence": "Therefore the, combination of @DRUG$ with other @DRUG$, including HUMIRA, may also result i n similar toxicities.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d493.s4.p1",
        "sentence": "Therefore the, combination of @DRUG$ with other TNF-blocking agents, including @DRUG$, may also result i n similar toxicities.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d493.s4.p2",
        "sentence": "Therefore the, combination of anakinra with other @DRUG$, including @DRUG$, may also result i n similar toxicities.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d495.s0.p0",
        "sentence": "Tablet If a patient receiving @DRUG$ is also taking @DRUG$, the effect of clonidine may be reduced, thus necessitating an increase in dosage.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d495.s0.p1",
        "sentence": "Tablet If a patient receiving @DRUG$ is also taking tricyclic antidepressants, the effect of @DRUG$ may be reduced, thus necessitating an increase in dosage.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d495.s0.p2",
        "sentence": "Tablet If a patient receiving clonidine hydrochloride is also taking @DRUG$, the effect of @DRUG$ may be reduced, thus necessitating an increase in dosage.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d495.s5.p0",
        "sentence": "The effects of @DRUG$ on @DRUG$s analgesic actions are not known.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d497.s2.p0",
        "sentence": "However, in patients treated with oral @DRUG$, rare instances of drug interactions have occurred with high-dose @DRUG$ therapy.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d498.s2.p0",
        "sentence": "Local and some general @DRUG$, @DRUG$ and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all, in patients with myasthenia gravis;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d499.s17.p0",
        "sentence": "Because prostaglandina play an important role in hemostasis and @DRUG$ has an effect on platelet function as well, concurent therapy with @DRUG$ and warfarin requires close monitoring of patients on both drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d499.s17.p1",
        "sentence": "Because prostaglandina play an important role in hemostasis and @DRUG$ has an effect on platelet function as well, concurent therapy with ketoprofen and @DRUG$ requires close monitoring of patients on both drugs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d499.s17.p2",
        "sentence": "Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with @DRUG$ and @DRUG$ requires close monitoring of patients on both drugs.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d499.s3.p0",
        "sentence": "@DRUG$: Concomitant administration of @DRUG$ and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d499.s3.p1",
        "sentence": "@DRUG$: Concomitant administration of magnesium hydroxide and @DRUG$ does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d499.s3.p2",
        "sentence": "@DRUG$: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of @DRUG$ administered as Orudis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d499.s3.p3",
        "sentence": "@DRUG$: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d499.s3.p4",
        "sentence": "Antacids: Concomitant administration of @DRUG$ and @DRUG$ does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d499.s3.p5",
        "sentence": "Antacids: Concomitant administration of @DRUG$ and aluminum hydroxide does not interfere with the rate or extent of the absorption of @DRUG$ administered as Orudis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d499.s3.p6",
        "sentence": "Antacids: Concomitant administration of @DRUG$ and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d499.s3.p7",
        "sentence": "Antacids: Concomitant administration of magnesium hydroxide and @DRUG$ does not interfere with the rate or extent of the absorption of @DRUG$ administered as Orudis.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d499.s3.p8",
        "sentence": "Antacids: Concomitant administration of magnesium hydroxide and @DRUG$ does not interfere with the rate or extent of the absorption of ketoprofen administered as @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d499.s3.p9",
        "sentence": "Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of @DRUG$ administered as @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s12.p0",
        "sentence": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most @DRUG$ (SSRIs, many @DRUG$), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s12.p1",
        "sentence": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most @DRUG$ (SSRIs, many tricyclics), @DRUG$, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s12.p2",
        "sentence": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most @DRUG$ (SSRIs, many tricyclics), beta-blockers, @DRUG$, and antipsychotics are metabolized by the CYP2D6 isoenzyme.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s12.p3",
        "sentence": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most @DRUG$ (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and @DRUG$ are metabolized by the CYP2D6 isoenzyme.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s12.p4",
        "sentence": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many @DRUG$), @DRUG$, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s12.p5",
        "sentence": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many @DRUG$), beta-blockers, @DRUG$, and antipsychotics are metabolized by the CYP2D6 isoenzyme.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s12.p6",
        "sentence": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many @DRUG$), beta-blockers, antiarrhythmics, and @DRUG$ are metabolized by the CYP2D6 isoenzyme.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s12.p7",
        "sentence": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), @DRUG$, @DRUG$, and antipsychotics are metabolized by the CYP2D6 isoenzyme.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s12.p8",
        "sentence": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), @DRUG$, antiarrhythmics, and @DRUG$ are metabolized by the CYP2D6 isoenzyme.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s12.p9",
        "sentence": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, @DRUG$, and @DRUG$ are metabolized by the CYP2D6 isoenzyme.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s19.p0",
        "sentence": "@DRUG$: Studies in animals demonstrate that the acute toxicity of @DRUG$ is enhanced by the MAO inhibitor phenelzine .",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s19.p1",
        "sentence": "@DRUG$: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the @DRUG$ phenelzine .",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s19.p2",
        "sentence": "@DRUG$: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor @DRUG$ .",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s19.p3",
        "sentence": "MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of @DRUG$ is enhanced by the @DRUG$ phenelzine .",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s19.p4",
        "sentence": "MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of @DRUG$ is enhanced by the MAO inhibitor @DRUG$ .",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d5.s19.p5",
        "sentence": "MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the @DRUG$ @DRUG$ .",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s3.p0",
        "sentence": "Therefore, the potential exists for a drug interaction between @DRUG$ and drugs that affect the CYP2B6 isoenzyme (e.g., @DRUG$ and cyclophosphamide).",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d5.s3.p1",
        "sentence": "Therefore, the potential exists for a drug interaction between @DRUG$ and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and @DRUG$).",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d5.s3.p2",
        "sentence": "Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., @DRUG$ and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s6.p0",
        "sentence": "Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of @DRUG$, the pharmacokinetics of @DRUG$ and hydroxybupropion were unaffected.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s6.p1",
        "sentence": "Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of @DRUG$, the pharmacokinetics of bupropion and @DRUG$ were unaffected.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s6.p2",
        "sentence": "Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of @DRUG$ and @DRUG$ were unaffected.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d5.s7.p0",
        "sentence": "However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of @DRUG$ and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d500.s1.p0",
        "sentence": "Since bacteriostatic drugs may interfere with the bactericidal action of @DRUG$, it is advisable to avoid giving @DRUG$ in conjunction with penicillin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d500.s1.p1",
        "sentence": "Since bacteriostatic drugs may interfere with the bactericidal action of @DRUG$, it is advisable to avoid giving tetracyclines in conjunction with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d500.s1.p2",
        "sentence": "Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving @DRUG$ in conjunction with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d500.s6.p0",
        "sentence": "Concurrent use of @DRUG$ may render oral @DRUG$ less effective.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d501.s6.p0",
        "sentence": "However, appropriate monitoring of blood glucose should be performed when initiating @DRUG$ in diabetic patients and @DRUG$ dosage should be adjusted if needed.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d503.s2.p0",
        "sentence": "If @DRUG$ is given concomitantly with @DRUG$, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d503.s2.p1",
        "sentence": "If @DRUG$ is given concomitantly with opioids, the @DRUG$ dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d503.s2.p2",
        "sentence": "If @DRUG$ is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because @DRUG$ amplifies the therapeutic actions and side-effects of opioids massively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d503.s2.p3",
        "sentence": "If @DRUG$ is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of @DRUG$ massively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d503.s2.p4",
        "sentence": "If chlorprothixene is given concomitantly with @DRUG$, the @DRUG$ dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d503.s2.p5",
        "sentence": "If chlorprothixene is given concomitantly with @DRUG$, the opioid dose should be reduced (by approx. 50%), because @DRUG$ amplifies the therapeutic actions and side-effects of opioids massively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d503.s2.p6",
        "sentence": "If chlorprothixene is given concomitantly with @DRUG$, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of @DRUG$ massively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d503.s2.p7",
        "sentence": "If chlorprothixene is given concomitantly with opioids, the @DRUG$ dose should be reduced (by approx. 50%), because @DRUG$ amplifies the therapeutic actions and side-effects of opioids massively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d503.s2.p8",
        "sentence": "If chlorprothixene is given concomitantly with opioids, the @DRUG$ dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of @DRUG$ massively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d503.s2.p9",
        "sentence": "If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because @DRUG$ amplifies the therapeutic actions and side-effects of @DRUG$ massively.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d505.s2.p0",
        "sentence": "@DRUG$: @DRUG$ has been reported to increase the plasma levels and cardiovascular effects of adenosine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d505.s2.p1",
        "sentence": "@DRUG$: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d505.s2.p2",
        "sentence": "Adenosine: @DRUG$ has been reported to increase the plasma levels and cardiovascular effects of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d506.s2.p0",
        "sentence": "Other @DRUG$ (eg, @DRUG$, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s2.p1",
        "sentence": "Other @DRUG$ (eg, quinidine, @DRUG$, lidocaine, propranolol) have occasionally been used concurrently with Norpace.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s2.p2",
        "sentence": "Other @DRUG$ (eg, quinidine, procainamide, @DRUG$, propranolol) have occasionally been used concurrently with Norpace.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s2.p3",
        "sentence": "Other @DRUG$ (eg, quinidine, procainamide, lidocaine, @DRUG$) have occasionally been used concurrently with Norpace.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s2.p4",
        "sentence": "Other @DRUG$ (eg, quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s2.p5",
        "sentence": "Other antiarrhythmic drugs (eg, @DRUG$, @DRUG$, lidocaine, propranolol) have occasionally been used concurrently with Norpace.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s2.p6",
        "sentence": "Other antiarrhythmic drugs (eg, @DRUG$, procainamide, @DRUG$, propranolol) have occasionally been used concurrently with Norpace.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s2.p7",
        "sentence": "Other antiarrhythmic drugs (eg, @DRUG$, procainamide, lidocaine, @DRUG$) have occasionally been used concurrently with Norpace.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s2.p8",
        "sentence": "Other antiarrhythmic drugs (eg, @DRUG$, procainamide, lidocaine, propranolol) have occasionally been used concurrently with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s2.p9",
        "sentence": "Other antiarrhythmic drugs (eg, quinidine, @DRUG$, @DRUG$, propranolol) have occasionally been used concurrently with Norpace.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s2.p10",
        "sentence": "Other antiarrhythmic drugs (eg, quinidine, @DRUG$, lidocaine, @DRUG$) have occasionally been used concurrently with Norpace.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s2.p11",
        "sentence": "Other antiarrhythmic drugs (eg, quinidine, @DRUG$, lidocaine, propranolol) have occasionally been used concurrently with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s2.p12",
        "sentence": "Other antiarrhythmic drugs (eg, quinidine, procainamide, @DRUG$, @DRUG$) have occasionally been used concurrently with Norpace.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s2.p13",
        "sentence": "Other antiarrhythmic drugs (eg, quinidine, procainamide, @DRUG$, propranolol) have occasionally been used concurrently with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s2.p14",
        "sentence": "Other antiarrhythmic drugs (eg, quinidine, procainamide, lidocaine, @DRUG$) have occasionally been used concurrently with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s5.p0",
        "sentence": "Concomitant administration of @DRUG$ and @DRUG$ resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d506.s5.p1",
        "sentence": "Concomitant administration of @DRUG$ and quinidine resulted in slight increases in plasma @DRUG$ levels and slight decreases in plasma quinidine levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s5.p2",
        "sentence": "Concomitant administration of @DRUG$ and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s5.p3",
        "sentence": "Concomitant administration of Norpace and @DRUG$ resulted in slight increases in plasma @DRUG$ levels and slight decreases in plasma quinidine levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s5.p4",
        "sentence": "Concomitant administration of Norpace and @DRUG$ resulted in slight increases in plasma disopyramide levels and slight decreases in plasma @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s5.p5",
        "sentence": "Concomitant administration of Norpace and quinidine resulted in slight increases in plasma @DRUG$ levels and slight decreases in plasma @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d506.s6.p0",
        "sentence": "@DRUG$ does not increase serum @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d507.s5.p0",
        "sentence": "@DRUG$ (@DRUG$,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d507.s5.p1",
        "sentence": "@DRUG$ (nadolol,porpranolol,@DRUG$) may exacerbate rebound hypertension when guanfacine is withdrawn.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d507.s5.p2",
        "sentence": "@DRUG$ (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when @DRUG$ is withdrawn.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d507.s5.p3",
        "sentence": "Noncardioselective beta-blockers (@DRUG$,porpranolol,@DRUG$) may exacerbate rebound hypertension when guanfacine is withdrawn.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d507.s5.p4",
        "sentence": "Noncardioselective beta-blockers (@DRUG$,porpranolol,timolol) may exacerbate rebound hypertension when @DRUG$ is withdrawn.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d507.s5.p5",
        "sentence": "Noncardioselective beta-blockers (nadolol,porpranolol,@DRUG$) may exacerbate rebound hypertension when @DRUG$ is withdrawn.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d507.s7.p0",
        "sentence": "The gradual withdrawal of @DRUG$ or a @DRUG$ could be substituted.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d508.s3.p0",
        "sentence": "Because @DRUG$, @DRUG$, or Activase may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d508.s3.p1",
        "sentence": "Because @DRUG$, aspirin, or @DRUG$ may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d508.s3.p2",
        "sentence": "Because heparin, @DRUG$, or @DRUG$ may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s19.p0",
        "sentence": "@DRUG$: Coadministration of @DRUG$ (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s19.p1",
        "sentence": "@DRUG$: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with @DRUG$ (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s19.p2",
        "sentence": "@DRUG$: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both @DRUG$ and its active metabolite, dehydro-aripiprazole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s19.p3",
        "sentence": "@DRUG$: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s19.p4",
        "sentence": "Carbamazepine: Coadministration of @DRUG$ (200 mg BID), a potent CYP3A4 inducer, with @DRUG$ (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d509.s19.p5",
        "sentence": "Carbamazepine: Coadministration of @DRUG$ (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both @DRUG$ and its active metabolite, dehydro-aripiprazole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s19.p6",
        "sentence": "Carbamazepine: Coadministration of @DRUG$ (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s19.p7",
        "sentence": "Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with @DRUG$ (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both @DRUG$ and its active metabolite, dehydro-aripiprazole.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s19.p8",
        "sentence": "Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with @DRUG$ (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s19.p9",
        "sentence": "Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both @DRUG$ and its active metabolite, @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s8.p0",
        "sentence": "Inhibitors of CYP3A4 (eg, @DRUG$) or CYP2D6 (eg, @DRUG$, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s8.p1",
        "sentence": "Inhibitors of CYP3A4 (eg, @DRUG$) or CYP2D6 (eg, quinidine, @DRUG$, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s8.p2",
        "sentence": "Inhibitors of CYP3A4 (eg, @DRUG$) or CYP2D6 (eg, quinidine, fluoxetine, or @DRUG$) can inhibit aripiprazole elimination and cause increased blood levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s8.p3",
        "sentence": "Inhibitors of CYP3A4 (eg, @DRUG$) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit @DRUG$ elimination and cause increased blood levels.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d509.s8.p4",
        "sentence": "Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, @DRUG$, @DRUG$, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s8.p5",
        "sentence": "Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, @DRUG$, fluoxetine, or @DRUG$) can inhibit aripiprazole elimination and cause increased blood levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s8.p6",
        "sentence": "Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, @DRUG$, fluoxetine, or paroxetine) can inhibit @DRUG$ elimination and cause increased blood levels.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d509.s8.p7",
        "sentence": "Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, @DRUG$, or @DRUG$) can inhibit aripiprazole elimination and cause increased blood levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d509.s8.p8",
        "sentence": "Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, @DRUG$, or paroxetine) can inhibit @DRUG$ elimination and cause increased blood levels.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d509.s8.p9",
        "sentence": "Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or @DRUG$) can inhibit @DRUG$ elimination and cause increased blood levels.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d510.s0.p0",
        "sentence": "The concurrent use of @DRUG$ Injection with other @DRUG$ or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d510.s0.p1",
        "sentence": "The concurrent use of @DRUG$ Injection with other anticholinergics or medications with anticholinergic activity, such as @DRUG$, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d510.s0.p2",
        "sentence": "The concurrent use of @DRUG$ Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, @DRUG$, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d510.s0.p3",
        "sentence": "The concurrent use of @DRUG$ Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or @DRUG$, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d510.s0.p4",
        "sentence": "The concurrent use of Robinul Injection with other @DRUG$ or medications with anticholinergic activity, such as @DRUG$, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d510.s0.p5",
        "sentence": "The concurrent use of Robinul Injection with other @DRUG$ or medications with anticholinergic activity, such as phenothiazines, @DRUG$, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d510.s0.p6",
        "sentence": "The concurrent use of Robinul Injection with other @DRUG$ or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or @DRUG$, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d510.s0.p7",
        "sentence": "The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as @DRUG$, @DRUG$, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d510.s0.p8",
        "sentence": "The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as @DRUG$, antiparkinson drugs, or @DRUG$, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d510.s0.p9",
        "sentence": "The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, @DRUG$, or @DRUG$, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d514.s3.p0",
        "sentence": "Ironically, @DRUG$ are often used in the treatment of @DRUG$ addiction while they cause much more severe withdrawal symptoms.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s16.p0",
        "sentence": "Interaction between @DRUG$ and @DRUG$ has not been studied.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s20.p0",
        "sentence": "@DRUG$ is unlikely to have a significant effect on @DRUG$ metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p0",
        "sentence": "@DRUG$ and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p1",
        "sentence": "@DRUG$ and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p2",
        "sentence": "@DRUG$ and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p3",
        "sentence": "@DRUG$ and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p4",
        "sentence": "@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p5",
        "sentence": "@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p6",
        "sentence": "@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p7",
        "sentence": "@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p8",
        "sentence": "Antacids and @DRUG$: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p9",
        "sentence": "Antacids and @DRUG$: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p10",
        "sentence": "Antacids and @DRUG$: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p11",
        "sentence": "Antacids and @DRUG$: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p12",
        "sentence": "Antacids and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p13",
        "sentence": "Antacids and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p14",
        "sentence": "Antacids and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p15",
        "sentence": "Antacids and sucralfate: @DRUG$ and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p16",
        "sentence": "Antacids and sucralfate: @DRUG$ and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p17",
        "sentence": "Antacids and sucralfate: @DRUG$ and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p18",
        "sentence": "Antacids and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p19",
        "sentence": "Antacids and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p20",
        "sentence": "Antacids and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p21",
        "sentence": "Antacids and sucralfate: Sucralfate and @DRUG$ containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p22",
        "sentence": "Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p23",
        "sentence": "Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p24",
        "sentence": "Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p25",
        "sentence": "Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p26",
        "sentence": "Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p27",
        "sentence": "Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p28",
        "sentence": "Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p29",
        "sentence": "Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p30",
        "sentence": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p31",
        "sentence": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p32",
        "sentence": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p33",
        "sentence": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p34",
        "sentence": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d516.s3.p35",
        "sentence": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d52.s1.p0",
        "sentence": "Concomitant treatment with @DRUG$ (@DRUG$) and drugs that affect platelet function may also increase the risk of bleeding.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p0",
        "sentence": "- a @DRUG$ such as @DRUG$ (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p1",
        "sentence": "- a @DRUG$ such as propranolol (@DRUG$), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p2",
        "sentence": "- a @DRUG$ such as propranolol (Inderal), @DRUG$ (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p3",
        "sentence": "- a @DRUG$ such as propranolol (Inderal), atenolol (@DRUG$), acebutolol (Sectral), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p4",
        "sentence": "- a @DRUG$ such as propranolol (Inderal), atenolol (Tenormin), @DRUG$ (Sectral), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p5",
        "sentence": "- a @DRUG$ such as propranolol (Inderal), atenolol (Tenormin), acebutolol (@DRUG$), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p6",
        "sentence": "- a @DRUG$ such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), @DRUG$ (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p7",
        "sentence": "- a @DRUG$ such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (@DRUG$), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p8",
        "sentence": "- a beta-blocker such as @DRUG$ (@DRUG$), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p9",
        "sentence": "- a beta-blocker such as @DRUG$ (Inderal), @DRUG$ (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p10",
        "sentence": "- a beta-blocker such as @DRUG$ (Inderal), atenolol (@DRUG$), acebutolol (Sectral), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p11",
        "sentence": "- a beta-blocker such as @DRUG$ (Inderal), atenolol (Tenormin), @DRUG$ (Sectral), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p12",
        "sentence": "- a beta-blocker such as @DRUG$ (Inderal), atenolol (Tenormin), acebutolol (@DRUG$), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p13",
        "sentence": "- a beta-blocker such as @DRUG$ (Inderal), atenolol (Tenormin), acebutolol (Sectral), @DRUG$ (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p14",
        "sentence": "- a beta-blocker such as @DRUG$ (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (@DRUG$), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p15",
        "sentence": "- a beta-blocker such as propranolol (@DRUG$), @DRUG$ (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p16",
        "sentence": "- a beta-blocker such as propranolol (@DRUG$), atenolol (@DRUG$), acebutolol (Sectral), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p17",
        "sentence": "- a beta-blocker such as propranolol (@DRUG$), atenolol (Tenormin), @DRUG$ (Sectral), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p18",
        "sentence": "- a beta-blocker such as propranolol (@DRUG$), atenolol (Tenormin), acebutolol (@DRUG$), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p19",
        "sentence": "- a beta-blocker such as propranolol (@DRUG$), atenolol (Tenormin), acebutolol (Sectral), @DRUG$ (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p20",
        "sentence": "- a beta-blocker such as propranolol (@DRUG$), atenolol (Tenormin), acebutolol (Sectral), metoprolol (@DRUG$), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p21",
        "sentence": "- a beta-blocker such as propranolol (Inderal), @DRUG$ (@DRUG$), acebutolol (Sectral), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p22",
        "sentence": "- a beta-blocker such as propranolol (Inderal), @DRUG$ (Tenormin), @DRUG$ (Sectral), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p23",
        "sentence": "- a beta-blocker such as propranolol (Inderal), @DRUG$ (Tenormin), acebutolol (@DRUG$), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p24",
        "sentence": "- a beta-blocker such as propranolol (Inderal), @DRUG$ (Tenormin), acebutolol (Sectral), @DRUG$ (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p25",
        "sentence": "- a beta-blocker such as propranolol (Inderal), @DRUG$ (Tenormin), acebutolol (Sectral), metoprolol (@DRUG$), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p26",
        "sentence": "- a beta-blocker such as propranolol (Inderal), atenolol (@DRUG$), @DRUG$ (Sectral), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p27",
        "sentence": "- a beta-blocker such as propranolol (Inderal), atenolol (@DRUG$), acebutolol (@DRUG$), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p28",
        "sentence": "- a beta-blocker such as propranolol (Inderal), atenolol (@DRUG$), acebutolol (Sectral), @DRUG$ (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p29",
        "sentence": "- a beta-blocker such as propranolol (Inderal), atenolol (@DRUG$), acebutolol (Sectral), metoprolol (@DRUG$), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p30",
        "sentence": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), @DRUG$ (@DRUG$), metoprolol (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p31",
        "sentence": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), @DRUG$ (Sectral), @DRUG$ (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p32",
        "sentence": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), @DRUG$ (Sectral), metoprolol (@DRUG$), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p33",
        "sentence": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (@DRUG$), @DRUG$ (Lopressor), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p34",
        "sentence": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (@DRUG$), metoprolol (@DRUG$), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d521.s5.p35",
        "sentence": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), @DRUG$ (@DRUG$), and others;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s10.p0",
        "sentence": "Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving @DRUG$ concomitantly with other @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d522.s11.p0",
        "sentence": "In addition, most @DRUG$ are contraindicated in patients receiving @DRUG$ therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d522.s15.p0",
        "sentence": "@DRUG$ or @DRUG$: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s15.p1",
        "sentence": "@DRUG$ or H 2 receptor antagonists: When @DRUG$ is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s15.p2",
        "sentence": "@DRUG$ or H 2 receptor antagonists: When dirithromycin is administered immediately following @DRUG$ or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s15.p3",
        "sentence": "@DRUG$ or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or @DRUG$, the absorption of dirithromycin is slightly enhanced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s15.p4",
        "sentence": "@DRUG$ or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of @DRUG$ is slightly enhanced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s15.p5",
        "sentence": "Antacids or @DRUG$: When @DRUG$ is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s15.p6",
        "sentence": "Antacids or @DRUG$: When dirithromycin is administered immediately following @DRUG$ or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s15.p7",
        "sentence": "Antacids or @DRUG$: When dirithromycin is administered immediately following antacids or @DRUG$, the absorption of dirithromycin is slightly enhanced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s15.p8",
        "sentence": "Antacids or @DRUG$: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of @DRUG$ is slightly enhanced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s15.p9",
        "sentence": "Antacids or H 2 receptor antagonists: When @DRUG$ is administered immediately following @DRUG$ or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d522.s15.p10",
        "sentence": "Antacids or H 2 receptor antagonists: When @DRUG$ is administered immediately following antacids or @DRUG$, the absorption of dirithromycin is slightly enhanced.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d522.s15.p11",
        "sentence": "Antacids or H 2 receptor antagonists: When @DRUG$ is administered immediately following antacids or H 2 -receptor antagonists, the absorption of @DRUG$ is slightly enhanced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s15.p12",
        "sentence": "Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following @DRUG$ or @DRUG$, the absorption of dirithromycin is slightly enhanced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s15.p13",
        "sentence": "Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following @DRUG$ or H 2 -receptor antagonists, the absorption of @DRUG$ is slightly enhanced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s15.p14",
        "sentence": "Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or @DRUG$, the absorption of @DRUG$ is slightly enhanced.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s23.p0",
        "sentence": "@DRUG$: Concurrent use of @DRUG$ and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s23.p1",
        "sentence": "@DRUG$: Concurrent use of erythromycin and @DRUG$ or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s23.p2",
        "sentence": "@DRUG$: Concurrent use of erythromycin and ergotamine or @DRUG$ has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s23.p3",
        "sentence": "Ergotamine: Concurrent use of @DRUG$ and @DRUG$ or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d522.s23.p4",
        "sentence": "Ergotamine: Concurrent use of @DRUG$ and ergotamine or @DRUG$ has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d522.s23.p5",
        "sentence": "Ergotamine: Concurrent use of erythromycin and @DRUG$ or @DRUG$ has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s5.p0",
        "sentence": "in one man, the C max of @DRUG$ was 8.1 ng/mL with @DRUG$ alone and 7.2 ng/mL with terfenadine plus dirithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s5.p1",
        "sentence": "in one man, the C max of @DRUG$ was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with @DRUG$ plus dirithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s5.p2",
        "sentence": "in one man, the C max of @DRUG$ was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s5.p3",
        "sentence": "in one man, the C max of terfenadine was 8.1 ng/mL with @DRUG$ alone and 7.2 ng/mL with @DRUG$ plus dirithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s5.p4",
        "sentence": "in one man, the C max of terfenadine was 8.1 ng/mL with @DRUG$ alone and 7.2 ng/mL with terfenadine plus @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d522.s5.p5",
        "sentence": "in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with @DRUG$ plus @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d523.s16.p0",
        "sentence": "The adverse experience profile seen with @DRUG$ was similar to that seen with @DRUG$ tablets.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d523.s2.p0",
        "sentence": "SIDE EFFECTS (@DRUG$) The most common adverse reaction during treatment with @DRUG$ is transient drowsiness (10-63%).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d525.s5.p0",
        "sentence": "@DRUG$ doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release @DRUG$ (sustained-release nifedipine) with no clinically significant adverse interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d525.s5.p1",
        "sentence": "@DRUG$ doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release @DRUG$) with no clinically significant adverse interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d525.s5.p2",
        "sentence": "Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release @DRUG$ (sustained-release @DRUG$) with no clinically significant adverse interactions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d526.s18.p0",
        "sentence": "Observe the patient for possible diminished effect of @DRUG$ and increase the @DRUG$ dosage accordingly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d526.s4.p0",
        "sentence": "@DRUG$ enhanced possibility of arrhythmias or @DRUG$ toxicity associated with hypokalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d527.s3.p0",
        "sentence": "@DRUG$, @DRUG$, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d527.s3.p1",
        "sentence": "@DRUG$, clonidine, @DRUG$ salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d527.s3.p2",
        "sentence": "@DRUG$, clonidine, lithium salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of insulin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d527.s3.p3",
        "sentence": "@DRUG$, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d527.s3.p4",
        "sentence": "Beta-blockers, @DRUG$, @DRUG$ salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d527.s3.p5",
        "sentence": "Beta-blockers, @DRUG$, lithium salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of insulin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d527.s3.p6",
        "sentence": "Beta-blockers, @DRUG$, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d527.s3.p7",
        "sentence": "Beta-blockers, clonidine, @DRUG$ salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of insulin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d527.s3.p8",
        "sentence": "Beta-blockers, clonidine, @DRUG$ salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d527.s3.p9",
        "sentence": "Beta-blockers, clonidine, lithium salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d527.s5.p0",
        "sentence": "In addition, under the influence of sympatholytic medicinal products such as @DRUG$, @DRUG$, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d527.s5.p1",
        "sentence": "In addition, under the influence of sympatholytic medicinal products such as @DRUG$, clonidine, @DRUG$, and reserpine, the signs of hypoglycemia may be reduced or absent.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d527.s5.p2",
        "sentence": "In addition, under the influence of sympatholytic medicinal products such as @DRUG$, clonidine, guanethidine, and @DRUG$, the signs of hypoglycemia may be reduced or absent.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d527.s5.p3",
        "sentence": "In addition, under the influence of sympatholytic medicinal products such as beta-blockers, @DRUG$, @DRUG$, and reserpine, the signs of hypoglycemia may be reduced or absent.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d527.s5.p4",
        "sentence": "In addition, under the influence of sympatholytic medicinal products such as beta-blockers, @DRUG$, guanethidine, and @DRUG$, the signs of hypoglycemia may be reduced or absent.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d527.s5.p5",
        "sentence": "In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, @DRUG$, and @DRUG$, the signs of hypoglycemia may be reduced or absent.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p0",
        "sentence": "@DRUG$, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p1",
        "sentence": "@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p2",
        "sentence": "@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p3",
        "sentence": "@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p4",
        "sentence": "@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p5",
        "sentence": "@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p6",
        "sentence": "Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p7",
        "sentence": "Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p8",
        "sentence": "Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p9",
        "sentence": "Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p10",
        "sentence": "Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p11",
        "sentence": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p12",
        "sentence": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p13",
        "sentence": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p14",
        "sentence": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p15",
        "sentence": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p16",
        "sentence": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p17",
        "sentence": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p18",
        "sentence": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p19",
        "sentence": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s12.p20",
        "sentence": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d529.s19.p0",
        "sentence": "Although there was a slight reduction in blood sugar concentrations during concomitant administration of @DRUG$ and @DRUG$, there were no signs or symptoms of hypoglycemia.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d529.s2.p0",
        "sentence": "@DRUG$: @DRUG$ like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s2.p1",
        "sentence": "@DRUG$: Flurbiprofen like other @DRUG$, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s2.p2",
        "sentence": "@DRUG$: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving @DRUG$, and serious clinical bleeding has been reported.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s2.p3",
        "sentence": "Anticoagulants: @DRUG$ like other @DRUG$, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s2.p4",
        "sentence": "Anticoagulants: @DRUG$ like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving @DRUG$, and serious clinical bleeding has been reported.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d529.s2.p5",
        "sentence": "Anticoagulants: Flurbiprofen like other @DRUG$, has been shown to affect bleeding parameters in patients receiving @DRUG$, and serious clinical bleeding has been reported.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d529.s6.p0",
        "sentence": "Concurrent use of @DRUG$ and @DRUG$ is therefore not recommended.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d529.s7.p0",
        "sentence": "@DRUG$: The effect of @DRUG$ on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s7.p1",
        "sentence": "@DRUG$: The effect of flurbiprofen on blood pressure response to @DRUG$ and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s7.p2",
        "sentence": "@DRUG$: The effect of flurbiprofen on blood pressure response to propranolol and @DRUG$ was evaluated in men with mild uncomplicated hypertension (n = 10).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s7.p3",
        "sentence": "Beta-adrenergic Blocking Agents: The effect of @DRUG$ on blood pressure response to @DRUG$ and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s7.p4",
        "sentence": "Beta-adrenergic Blocking Agents: The effect of @DRUG$ on blood pressure response to propranolol and @DRUG$ was evaluated in men with mild uncomplicated hypertension (n = 10).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s7.p5",
        "sentence": "Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to @DRUG$ and @DRUG$ was evaluated in men with mild uncomplicated hypertension (n = 10).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s8.p0",
        "sentence": "@DRUG$ pretreatment attenuated the hypotensive effect of a single dose of @DRUG$ but not atenolol.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d529.s8.p1",
        "sentence": "@DRUG$ pretreatment attenuated the hypotensive effect of a single dose of propranolol but not @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d529.s8.p2",
        "sentence": "Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of @DRUG$ but not @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d53.s14.p0",
        "sentence": "@DRUG$ or @DRUG$ acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d53.s8.p0",
        "sentence": "Co-administration with @DRUG$ or @DRUG$ had a modest effect on the pharmacokinetics of azithromycin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d53.s8.p1",
        "sentence": "Co-administration with @DRUG$ or fluconazole had a modest effect on the pharmacokinetics of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d53.s8.p2",
        "sentence": "Co-administration with efavirenz or @DRUG$ had a modest effect on the pharmacokinetics of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d531.s1.p0",
        "sentence": "Other compounds that are substrates of CYP3A4 may have decreased plasma concentrations when coadministered with @DRUG$ (@DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s10.p0",
        "sentence": "@DRUG$: @DRUG$ GI Motility Agents Anti-Migraine Antifungal",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s10.p1",
        "sentence": "@DRUG$: Benzodiazepines GI Motility Agents @DRUG$ Antifungal",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s10.p2",
        "sentence": "@DRUG$: Benzodiazepines GI Motility Agents Anti-Migraine @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s10.p3",
        "sentence": "Antihistamines: @DRUG$ GI Motility Agents @DRUG$ Antifungal",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s10.p4",
        "sentence": "Antihistamines: @DRUG$ GI Motility Agents Anti-Migraine @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s10.p5",
        "sentence": "Antihistamines: Benzodiazepines GI Motility Agents @DRUG$ @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s11.p0",
        "sentence": "@DRUG$ @DRUG$, triazolam cisapride ergot derivatives voriconazole",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s11.p1",
        "sentence": "@DRUG$ midazolam, @DRUG$ cisapride ergot derivatives voriconazole",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s11.p2",
        "sentence": "@DRUG$ midazolam, triazolam @DRUG$ ergot derivatives voriconazole",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s11.p3",
        "sentence": "@DRUG$ midazolam, triazolam cisapride ergot derivatives @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s11.p4",
        "sentence": "astemizole @DRUG$, @DRUG$ cisapride ergot derivatives voriconazole",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s11.p5",
        "sentence": "astemizole @DRUG$, triazolam @DRUG$ ergot derivatives voriconazole",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s11.p6",
        "sentence": "astemizole @DRUG$, triazolam cisapride ergot derivatives @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s11.p7",
        "sentence": "astemizole midazolam, @DRUG$ @DRUG$ ergot derivatives voriconazole",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s11.p8",
        "sentence": "astemizole midazolam, @DRUG$ cisapride ergot derivatives @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s11.p9",
        "sentence": "astemizole midazolam, triazolam @DRUG$ ergot derivatives @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s19.p0",
        "sentence": "When coadministered with @DRUG$ in treatment-naive patients, the recommended dose of @DRUG$ is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s19.p1",
        "sentence": "When coadministered with @DRUG$ in treatment-naive patients, the recommended dose of atazanavir is 300 mg with @DRUG$ 100 mg and SUSTIVA 600 mg (all once daily).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s19.p2",
        "sentence": "When coadministered with @DRUG$ in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and @DRUG$ 600 mg (all once daily).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s19.p3",
        "sentence": "When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of @DRUG$ is 300 mg with @DRUG$ 100 mg and SUSTIVA 600 mg (all once daily).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s19.p4",
        "sentence": "When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of @DRUG$ is 300 mg with ritonavir 100 mg and @DRUG$ 600 mg (all once daily).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s19.p5",
        "sentence": "When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with @DRUG$ 100 mg and @DRUG$ 600 mg (all once daily).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s31.p0",
        "sentence": "Alternatives to @DRUG$, such as @DRUG$, should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s45.p0",
        "sentence": "Coadministration in HIV-infected individuals with a history of injection drug use resulted in decreased plasma levels of @DRUG$ and signs of @DRUG$ withdrawal.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s5.p0",
        "sentence": "Drugs which induce CYP3A4 activity (eg, @DRUG$, @DRUG$, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s5.p1",
        "sentence": "Drugs which induce CYP3A4 activity (eg, @DRUG$, rifampin, @DRUG$) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s5.p2",
        "sentence": "Drugs which induce CYP3A4 activity (eg, @DRUG$, rifampin, rifabutin) would be expected to increase the clearance of @DRUG$ resulting in lowered plasma concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d531.s5.p3",
        "sentence": "Drugs which induce CYP3A4 activity (eg, phenobarbital, @DRUG$, @DRUG$) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s5.p4",
        "sentence": "Drugs which induce CYP3A4 activity (eg, phenobarbital, @DRUG$, rifabutin) would be expected to increase the clearance of @DRUG$ resulting in lowered plasma concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d531.s5.p5",
        "sentence": "Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, @DRUG$) would be expected to increase the clearance of @DRUG$ resulting in lowered plasma concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d531.s56.p0",
        "sentence": "Consider doubling the @DRUG$ dose in regimens where @DRUG$ is given 2 or 3 times a week.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s74.p0",
        "sentence": "@DRUG$: @DRUG$ Phenobarbital Carbamazepine",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s74.p1",
        "sentence": "@DRUG$: Phenytoin @DRUG$ Carbamazepine",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s74.p2",
        "sentence": "@DRUG$: Phenytoin Phenobarbital @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s74.p3",
        "sentence": "Anticonvulsants: @DRUG$ @DRUG$ Carbamazepine",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s74.p4",
        "sentence": "Anticonvulsants: @DRUG$ Phenobarbital @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s74.p5",
        "sentence": "Anticonvulsants: Phenytoin @DRUG$ @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s78.p0",
        "sentence": "Drug interaction studies with @DRUG$ and these @DRUG$ have not been conducted.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s78.p1",
        "sentence": "Drug interaction studies with @DRUG$ and these imidazole and @DRUG$ have not been conducted.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s78.p2",
        "sentence": "Drug interaction studies with SUSTIVA and these @DRUG-DRUG$ have not been conducted.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p0",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p1",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p2",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p3",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p4",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p5",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, @DRUG$, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p6",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, @DRUG$, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p7",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p8",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p9",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p10",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p11",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p12",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p13",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p14",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p15",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, @DRUG$, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p16",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, @DRUG$, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p17",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p18",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p19",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p20",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p21",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p22",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p23",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, @DRUG$, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p24",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, @DRUG$, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p25",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, @DRUG$, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p26",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p27",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p28",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p29",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p30",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, @DRUG$, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p31",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, @DRUG$, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p32",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, @DRUG$, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p33",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, @DRUG$, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p34",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p35",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p36",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p37",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p38",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, @DRUG$, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p39",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, @DRUG$, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p40",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, @DRUG$, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p41",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p42",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p43",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p44",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p45",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, @DRUG$, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p46",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, fluconazole, @DRUG$, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p47",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p48",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p49",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, fluconazole, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p50",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p51",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, @DRUG$, @DRUG$, lorazepam, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p52",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, @DRUG$, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p53",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, @DRUG$, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p54",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, @DRUG$, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p55",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, @DRUG$, lamivudine, lorazepam, nelfinavir, paroxetine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p56",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, @DRUG$, @DRUG$, nelfinavir, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p57",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, @DRUG$, lorazepam, @DRUG$, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p58",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, @DRUG$, lorazepam, nelfinavir, @DRUG$, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p59",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, @DRUG$, lorazepam, nelfinavir, paroxetine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p60",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, @DRUG$, paroxetine, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p61",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, @DRUG$, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p62",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p63",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, @DRUG$, and zidovudine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p64",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d531.s90.p65",
        "sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, @DRUG$, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d533.s0.p0",
        "sentence": "Effects of Other Drugs on @DRUG$ Based on in-vitro studies, @DRUG$ is metabolized by CYP 3A4.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d533.s3.p0",
        "sentence": "Co-administration of @DRUG$ resulted in about a 50% increase in @DRUG$ Cmax and AUC after multiple dosing.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d533.s6.p0",
        "sentence": "Effects of @DRUG$ on Other Drugs @DRUG$ does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and CYP 3A) or induce CYP 3A4.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s4.p0",
        "sentence": "@DRUG$ (e. g., @DRUG$) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s4.p1",
        "sentence": "@DRUG$ (e. g., charcoal) and @DRUG$ containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s4.p2",
        "sentence": "@DRUG$ (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., @DRUG$, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s4.p3",
        "sentence": "@DRUG$ (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, @DRUG$) may reduce the effect of Acarbose and should not be taken concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s4.p4",
        "sentence": "@DRUG$ (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of @DRUG$ and should not be taken concomitantly.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d536.s4.p5",
        "sentence": "Intestinal adsorbents (e. g., @DRUG$) and @DRUG$ containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s4.p6",
        "sentence": "Intestinal adsorbents (e. g., @DRUG$) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., @DRUG$, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s4.p7",
        "sentence": "Intestinal adsorbents (e. g., @DRUG$) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, @DRUG$) may reduce the effect of Acarbose and should not be taken concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s4.p8",
        "sentence": "Intestinal adsorbents (e. g., @DRUG$) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of @DRUG$ and should not be taken concomitantly.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d536.s4.p9",
        "sentence": "Intestinal adsorbents (e. g., charcoal) and @DRUG$ containing carbohydrate-splitting enzymes (e. g., @DRUG$, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s4.p10",
        "sentence": "Intestinal adsorbents (e. g., charcoal) and @DRUG$ containing carbohydrate-splitting enzymes (e. g., amylase, @DRUG$) may reduce the effect of Acarbose and should not be taken concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s4.p11",
        "sentence": "Intestinal adsorbents (e. g., charcoal) and @DRUG$ containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of @DRUG$ and should not be taken concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s4.p12",
        "sentence": "Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., @DRUG$, @DRUG$) may reduce the effect of Acarbose and should not be taken concomitantly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s4.p13",
        "sentence": "Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., @DRUG$, pancreatin) may reduce the effect of @DRUG$ and should not be taken concomitantly.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d536.s4.p14",
        "sentence": "Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, @DRUG$) may reduce the effect of @DRUG$ and should not be taken concomitantly.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d536.s6.p0",
        "sentence": "Studies in healthy volunteers have shown that @DRUG$ has no effect on either the pharmacokinetics or pharmacodynamics of @DRUG$, nifedipine, propranolol, or ranitidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s6.p1",
        "sentence": "Studies in healthy volunteers have shown that @DRUG$ has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, @DRUG$, propranolol, or ranitidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s6.p2",
        "sentence": "Studies in healthy volunteers have shown that @DRUG$ has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, @DRUG$, or ranitidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s6.p3",
        "sentence": "Studies in healthy volunteers have shown that @DRUG$ has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s6.p4",
        "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of @DRUG$, @DRUG$, propranolol, or ranitidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s6.p5",
        "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of @DRUG$, nifedipine, @DRUG$, or ranitidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s6.p6",
        "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of @DRUG$, nifedipine, propranolol, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s6.p7",
        "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, @DRUG$, @DRUG$, or ranitidine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s6.p8",
        "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, @DRUG$, propranolol, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s6.p9",
        "sentence": "Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, @DRUG$, or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s8.p0",
        "sentence": "@DRUG$ may affect @DRUG$ bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s8.p1",
        "sentence": "@DRUG$ may affect digoxin bioavailabillty and may require dose adjustment of @DRUG$ by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s8.p2",
        "sentence": "@DRUG$ may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max @DRUG$ by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s8.p3",
        "sentence": "@DRUG$ may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of @DRUG$ by 9% (90% confidence limit: 19% decrease to 2% increase).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s8.p4",
        "sentence": "Acarbose may affect @DRUG$ bioavailabillty and may require dose adjustment of @DRUG$ by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s8.p5",
        "sentence": "Acarbose may affect @DRUG$ bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max @DRUG$ by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s8.p6",
        "sentence": "Acarbose may affect @DRUG$ bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of @DRUG$ by 9% (90% confidence limit: 19% decrease to 2% increase).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s8.p7",
        "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of @DRUG$ by 16% (90% confidence interval: 8-23%), decrease mean C max @DRUG$ by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s8.p8",
        "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of @DRUG$ by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of @DRUG$ by 9% (90% confidence limit: 19% decrease to 2% increase).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d536.s8.p9",
        "sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max @DRUG$ by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of @DRUG$ by 9% (90% confidence limit: 19% decrease to 2% increase).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d538.s0.p0",
        "sentence": "Known drug interactions include @DRUG$, @DRUG$, and alcohol.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d538.s0.p1",
        "sentence": "Known drug interactions include @DRUG$, tranquilizers, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d538.s0.p2",
        "sentence": "Known drug interactions include barbiturates, @DRUG$, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d54.s10.p0",
        "sentence": "Therefore, 4 to 5 hours should elapse between administration of @DRUG$ and @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d54.s11.p0",
        "sentence": "@DRUG$, Oral @DRUG$: Estrogens tend to increase serum thyroxine-binding globulin (TBg).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d54.s11.p1",
        "sentence": "@DRUG$, Oral Contraceptives: @DRUG$ tend to increase serum thyroxine-binding globulin (TBg).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d54.s11.p2",
        "sentence": "Estrogen, Oral @DRUG$: @DRUG$ tend to increase serum thyroxine-binding globulin (TBg).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d54.s12.p0",
        "sentence": "In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free @DRUG$ may be decreased when @DRUG$ are started thus increasing thyroid requirements.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d54.s12.p1",
        "sentence": "In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free @DRUG$ may be decreased when estrogens are started thus increasing @DRUG$ requirements.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d54.s12.p2",
        "sentence": "In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when @DRUG$ are started thus increasing @DRUG$ requirements.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d54.s19.p0",
        "sentence": "@DRUG$: When administered to patients on a @DRUG$, this parenteral anesthetic may cause hypertension and tachycardia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d54.s19.p1",
        "sentence": "@DRUG$: When administered to patients on a thyroid preparation, this parenteral @DRUG$ may cause hypertension and tachycardia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d54.s19.p2",
        "sentence": "Ketamine: When administered to patients on a @DRUG$, this parenteral @DRUG$ may cause hypertension and tachycardia.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d54.s27.p0",
        "sentence": "Pregnancy @DRUG$ and @DRUG$-containing oral contraceptives increase TBg concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d54.s27.p1",
        "sentence": "Pregnancy @DRUG$ and estrogen-containing oral @DRUG$ increase TBg concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d54.s27.p2",
        "sentence": "Pregnancy estrogens and @DRUG$-containing oral @DRUG$ increase TBg concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p0",
        "sentence": "The following agents may increase certain actions or side effects of @DRUG$. @DRUG$ antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p1",
        "sentence": "The following agents may increase certain actions or side effects of @DRUG$. amantadine @DRUG$ of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p2",
        "sentence": "The following agents may increase certain actions or side effects of @DRUG$. amantadine antiarrhythmic agents of class (e.g. @DRUG$), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p3",
        "sentence": "The following agents may increase certain actions or side effects of @DRUG$. amantadine antiarrhythmic agents of class (e.g. quinidine), @DRUG$ antipsychotic agents (e.g. phenothiazines), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p4",
        "sentence": "The following agents may increase certain actions or side effects of @DRUG$. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines @DRUG$ (e.g. phenothiazines), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p5",
        "sentence": "The following agents may increase certain actions or side effects of @DRUG$. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. @DRUG$), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p6",
        "sentence": "The following agents may increase certain actions or side effects of @DRUG$. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p7",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. @DRUG$ @DRUG$ of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p8",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. @DRUG$ antiarrhythmic agents of class (e.g. @DRUG$), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p9",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. @DRUG$ antiarrhythmic agents of class (e.g. quinidine), @DRUG$ antipsychotic agents (e.g. phenothiazines), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p10",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. @DRUG$ antiarrhythmic agents of class (e.g. quinidine), antihistamines @DRUG$ (e.g. phenothiazines), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p11",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. @DRUG$ antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. @DRUG$), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p12",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. @DRUG$ antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p13",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine @DRUG$ of class (e.g. @DRUG$), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p14",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine @DRUG$ of class (e.g. quinidine), @DRUG$ antipsychotic agents (e.g. phenothiazines), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p15",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine @DRUG$ of class (e.g. quinidine), antihistamines @DRUG$ (e.g. phenothiazines), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p16",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine @DRUG$ of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. @DRUG$), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p17",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine @DRUG$ of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p18",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. @DRUG$), @DRUG$ antipsychotic agents (e.g. phenothiazines), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p19",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. @DRUG$), antihistamines @DRUG$ (e.g. phenothiazines), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p20",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. @DRUG$), antihistamines antipsychotic agents (e.g. @DRUG$), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p21",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. @DRUG$), antihistamines antipsychotic agents (e.g. phenothiazines), @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p22",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), @DRUG$ @DRUG$ (e.g. phenothiazines), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p23",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), @DRUG$ antipsychotic agents (e.g. @DRUG$), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p24",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), @DRUG$ antipsychotic agents (e.g. phenothiazines), @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p25",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines @DRUG$ (e.g. @DRUG$), benzodiazepines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p26",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines @DRUG$ (e.g. phenothiazines), @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d543.s0.p27",
        "sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. @DRUG$), @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d544.s0.p0",
        "sentence": "No dose adjustment is necessary when @DRUG$ is added to triple-immunosuppression regimens including @DRUG$, corticosteroids, and either azathioprine or mycophenolate mofetil.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d544.s0.p1",
        "sentence": "No dose adjustment is necessary when @DRUG$ is added to triple-immunosuppression regimens including cyclosporine, @DRUG$, and either azathioprine or mycophenolate mofetil.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d544.s0.p2",
        "sentence": "No dose adjustment is necessary when @DRUG$ is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either @DRUG$ or mycophenolate mofetil.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d544.s0.p3",
        "sentence": "No dose adjustment is necessary when @DRUG$ is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either azathioprine or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d544.s0.p4",
        "sentence": "No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including @DRUG$, @DRUG$, and either azathioprine or mycophenolate mofetil.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d544.s0.p5",
        "sentence": "No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including @DRUG$, corticosteroids, and either @DRUG$ or mycophenolate mofetil.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d544.s0.p6",
        "sentence": "No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including @DRUG$, corticosteroids, and either azathioprine or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d544.s0.p7",
        "sentence": "No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine, @DRUG$, and either @DRUG$ or mycophenolate mofetil.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d544.s0.p8",
        "sentence": "No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine, @DRUG$, and either azathioprine or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d544.s0.p9",
        "sentence": "No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either @DRUG$ or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d546.s0.p0",
        "sentence": "Drug Interactions with @DRUG$: Concomitant use of @DRUG$ with beta-blockers should be avoided.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d546.s0.p1",
        "sentence": "Drug Interactions with @DRUG$: Concomitant use of fenoldopam with @DRUG$ should be avoided.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d546.s0.p2",
        "sentence": "Drug Interactions with Beta-Blockers: Concomitant use of @DRUG$ with @DRUG$ should be avoided.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d546.s2.p0",
        "sentence": "Drug Interactions, General: Although there have been no formal interaction studies, intravenous @DRUG$ has been administered safely with drugs such as @DRUG$ and sublingual nitroglycerin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d546.s2.p1",
        "sentence": "Drug Interactions, General: Although there have been no formal interaction studies, intravenous @DRUG$ has been administered safely with drugs such as digitalis and sublingual @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d546.s2.p2",
        "sentence": "Drug Interactions, General: Although there have been no formal interaction studies, intravenous fenoldopam has been administered safely with drugs such as @DRUG$ and sublingual @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d547.s2.p0",
        "sentence": "@DRUG$ Reversible increases in serum @DRUG$ concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d547.s2.p1",
        "sentence": "@DRUG$ Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of @DRUG$ with ACE inhibitors, and with some angiotensin II receptor antagonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d547.s2.p2",
        "sentence": "@DRUG$ Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with @DRUG$, and with some angiotensin II receptor antagonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d547.s2.p3",
        "sentence": "@DRUG$ Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d547.s2.p4",
        "sentence": "Lithium Reversible increases in serum @DRUG$ concentrations and toxicity have been reported during concomitant administration of @DRUG$ with ACE inhibitors, and with some angiotensin II receptor antagonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d547.s2.p5",
        "sentence": "Lithium Reversible increases in serum @DRUG$ concentrations and toxicity have been reported during concomitant administration of lithium with @DRUG$, and with some angiotensin II receptor antagonists.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d547.s2.p6",
        "sentence": "Lithium Reversible increases in serum @DRUG$ concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d547.s2.p7",
        "sentence": "Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of @DRUG$ with @DRUG$, and with some angiotensin II receptor antagonists.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d547.s2.p8",
        "sentence": "Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of @DRUG$ with ACE inhibitors, and with some @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d547.s2.p9",
        "sentence": "Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with @DRUG$, and with some @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d547.s3.p0",
        "sentence": "An increase in serum @DRUG$ concentration has been reported during concomitant administration of @DRUG$ with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d547.s3.p1",
        "sentence": "An increase in serum @DRUG$ concentration has been reported during concomitant administration of lithium with @DRUG$, so careful monitoring of serum lithium levels is recommended during concomitant use.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d547.s3.p2",
        "sentence": "An increase in serum @DRUG$ concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum @DRUG$ levels is recommended during concomitant use.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d547.s3.p3",
        "sentence": "An increase in serum lithium concentration has been reported during concomitant administration of @DRUG$ with @DRUG$, so careful monitoring of serum lithium levels is recommended during concomitant use.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d547.s3.p4",
        "sentence": "An increase in serum lithium concentration has been reported during concomitant administration of @DRUG$ with ATACAND, so careful monitoring of serum @DRUG$ levels is recommended during concomitant use.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d547.s3.p5",
        "sentence": "An increase in serum lithium concentration has been reported during concomitant administration of lithium with @DRUG$, so careful monitoring of serum @DRUG$ levels is recommended during concomitant use.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d548.s0.p0",
        "sentence": "Potential for Other Drugs to Affect @DRUG$: Both CYP1A2 and CYP2D6 are responsible for @DRUG$ metabolism.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d548.s10.p0",
        "sentence": "Plasma @DRUG$ concentrations may need to be monitored and the dose of the @DRUG$ may need to be reduced if a TCA is co-administered with Duloxetine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d548.s10.p1",
        "sentence": "Plasma @DRUG$ concentrations may need to be monitored and the dose of the TCA may need to be reduced if a @DRUG$ is co-administered with Duloxetine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d548.s10.p2",
        "sentence": "Plasma @DRUG$ concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d548.s10.p3",
        "sentence": "Plasma TCA concentrations may need to be monitored and the dose of the @DRUG$ may need to be reduced if a @DRUG$ is co-administered with Duloxetine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d548.s10.p4",
        "sentence": "Plasma TCA concentrations may need to be monitored and the dose of the @DRUG$ may need to be reduced if a TCA is co-administered with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d548.s10.p5",
        "sentence": "Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a @DRUG$ is co-administered with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d548.s11.p0",
        "sentence": "Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of @DRUG$, @DRUG$ and thioridazine should not be co-administered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d548.s11.p1",
        "sentence": "Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of @DRUG$, Duloxetine and @DRUG$ should not be co-administered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d548.s11.p2",
        "sentence": "Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, @DRUG$ and @DRUG$ should not be co-administered.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d548.s22.p0",
        "sentence": "It is unknown whether the concomitant administration of @DRUG$ affects @DRUG$ absorption.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d548.s3.p0",
        "sentence": "Inhibitors of CYP2D6: Because CYP2D6 is involved in @DRUG$ metabolism, concomitant use of @DRUG$ with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d548.s3.p1",
        "sentence": "Inhibitors of CYP2D6: Because CYP2D6 is involved in @DRUG$ metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d548.s3.p2",
        "sentence": "Inhibitors of CYP2D6: Because CYP2D6 is involved in duloxetine metabolism, concomitant use of @DRUG$ with potent inhibitors of CYP2D6 may result in higher concentrations of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d548.s4.p0",
        "sentence": "@DRUG$ (20 mg QD) increased the concentration of @DRUG$ (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d548.s4.p1",
        "sentence": "@DRUG$ (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d548.s4.p2",
        "sentence": "Paroxetine (20 mg QD) increased the concentration of @DRUG$ (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d549.s4.p0",
        "sentence": "Intravenous infusion of @DRUG$ had no effect on the pharmacokinetics of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d550.s2.p0",
        "sentence": "@DRUG$: Co-administration of a single dose of intravenously administered @DRUG$ (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d550.s2.p1",
        "sentence": "@DRUG$: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of @DRUG$ administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d550.s2.p2",
        "sentence": "H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered @DRUG$ (20 mg) reduced the oral absorption of a single 400 mg dose of @DRUG$ administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d550.s3.p0",
        "sentence": "Although the clinical significance is not known, it is not recommended that @DRUG$ be taken concomitantly with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d551.s2.p0",
        "sentence": "@DRUG$  decreased the Cmax and AUC of sustained-release @DRUG$ (Calan SR ) by approximately 31% and 11%, respectively.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d551.s2.p1",
        "sentence": "@DRUG$  decreased the Cmax and AUC of sustained-release verapamil (@DRUG$ ) by approximately 31% and 11%, respectively.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d551.s2.p2",
        "sentence": "WelChol  decreased the Cmax and AUC of sustained-release @DRUG$ (@DRUG$ ) by approximately 31% and 11%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d551.s4.p0",
        "sentence": "In clinical studies, coadministration of @DRUG$  with @DRUG$, lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d551.s4.p1",
        "sentence": "In clinical studies, coadministration of @DRUG$  with atorvastatin, @DRUG$, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d551.s4.p2",
        "sentence": "In clinical studies, coadministration of @DRUG$  with atorvastatin, lovastatin, or @DRUG$ did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d551.s4.p3",
        "sentence": "In clinical studies, coadministration of @DRUG$  with atorvastatin, lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d551.s4.p4",
        "sentence": "In clinical studies, coadministration of WelChol  with @DRUG$, @DRUG$, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d551.s4.p5",
        "sentence": "In clinical studies, coadministration of WelChol  with @DRUG$, lovastatin, or @DRUG$ did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d551.s4.p6",
        "sentence": "In clinical studies, coadministration of WelChol  with @DRUG$, lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d551.s4.p7",
        "sentence": "In clinical studies, coadministration of WelChol  with atorvastatin, @DRUG$, or @DRUG$ did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d551.s4.p8",
        "sentence": "In clinical studies, coadministration of WelChol  with atorvastatin, @DRUG$, or simvastatin did not interfere with the lipid-lowering activity of the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d551.s4.p9",
        "sentence": "In clinical studies, coadministration of WelChol  with atorvastatin, lovastatin, or @DRUG$ did not interfere with the lipid-lowering activity of the @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d554.s0.p0",
        "sentence": "Certain @DRUG$, @DRUG$, cyclosporine, diuretic, foscarnet, and vaccines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d554.s0.p1",
        "sentence": "Certain @DRUG$, cisplatin, @DRUG$, diuretic, foscarnet, and vaccines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d554.s0.p2",
        "sentence": "Certain @DRUG$, cisplatin, cyclosporine, @DRUG$, foscarnet, and vaccines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d554.s0.p3",
        "sentence": "Certain @DRUG$, cisplatin, cyclosporine, diuretic, @DRUG$, and vaccines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d554.s0.p4",
        "sentence": "Certain @DRUG$, cisplatin, cyclosporine, diuretic, foscarnet, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d554.s0.p5",
        "sentence": "Certain antibiotic, @DRUG$, @DRUG$, diuretic, foscarnet, and vaccines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d554.s0.p6",
        "sentence": "Certain antibiotic, @DRUG$, cyclosporine, @DRUG$, foscarnet, and vaccines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d554.s0.p7",
        "sentence": "Certain antibiotic, @DRUG$, cyclosporine, diuretic, @DRUG$, and vaccines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d554.s0.p8",
        "sentence": "Certain antibiotic, @DRUG$, cyclosporine, diuretic, foscarnet, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d554.s0.p9",
        "sentence": "Certain antibiotic, cisplatin, @DRUG$, @DRUG$, foscarnet, and vaccines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d554.s0.p10",
        "sentence": "Certain antibiotic, cisplatin, @DRUG$, diuretic, @DRUG$, and vaccines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d554.s0.p11",
        "sentence": "Certain antibiotic, cisplatin, @DRUG$, diuretic, foscarnet, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d554.s0.p12",
        "sentence": "Certain antibiotic, cisplatin, cyclosporine, @DRUG$, @DRUG$, and vaccines.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d554.s0.p13",
        "sentence": "Certain antibiotic, cisplatin, cyclosporine, @DRUG$, foscarnet, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d554.s0.p14",
        "sentence": "Certain antibiotic, cisplatin, cyclosporine, diuretic, @DRUG$, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s10.p0",
        "sentence": "@DRUG$ at 400 mg daily (the maximum approved prescription dose) co-administered with @DRUG$ (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d558.s10.p1",
        "sentence": "@DRUG$ at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase @DRUG$ Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s10.p2",
        "sentence": "Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with @DRUG$ (500 mcg BID) for 7 days has been shown to increase @DRUG$ Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s14.p0",
        "sentence": "In patients receiving @DRUG$ alone, @DRUG$ AUC increased by 27% and Cmax by 21%.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p0",
        "sentence": "Inhibitors of this isoenzyme (e.g., @DRUG$, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p1",
        "sentence": "Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p2",
        "sentence": "Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p3",
        "sentence": "Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p4",
        "sentence": "Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p5",
        "sentence": "Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p6",
        "sentence": "Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p7",
        "sentence": "Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p8",
        "sentence": "Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p9",
        "sentence": "Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p10",
        "sentence": "Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p11",
        "sentence": "Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p12",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p13",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p14",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p15",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p16",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p17",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p18",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p19",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p20",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p21",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p22",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p23",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p24",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p25",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p26",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p27",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p28",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p29",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p30",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p31",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p32",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p33",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p34",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p35",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p36",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p37",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p38",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p39",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p40",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p41",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p42",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p43",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p44",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p45",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p46",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p47",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p48",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p49",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p50",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p51",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p52",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p53",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p54",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p55",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p56",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p57",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p58",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p59",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p60",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p61",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p62",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p63",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p64",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p65",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p66",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p67",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p68",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p69",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p70",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p71",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p72",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p73",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p74",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p75",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p76",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s25.p77",
        "sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase @DRUG$ levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s33.p0",
        "sentence": "In addition, studies in healthy volunteers have shown that @DRUG$ does not affect the pharmacokinetics or pharmacodynamics of @DRUG$, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s33.p1",
        "sentence": "In addition, studies in healthy volunteers have shown that @DRUG$ does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of @DRUG$ (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s33.p2",
        "sentence": "In addition, studies in healthy volunteers have shown that @DRUG$ does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), @DRUG$, theophylline, or oral contraceptives.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s33.p3",
        "sentence": "In addition, studies in healthy volunteers have shown that @DRUG$ does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, @DRUG$, or oral contraceptives.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s33.p4",
        "sentence": "In addition, studies in healthy volunteers have shown that @DRUG$ does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s33.p5",
        "sentence": "In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of @DRUG$, or the pharmacokinetics of @DRUG$ (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s33.p6",
        "sentence": "In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of @DRUG$, or the pharmacokinetics of propranolol (40 mg twice daily), @DRUG$, theophylline, or oral contraceptives.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s33.p7",
        "sentence": "In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of @DRUG$, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, @DRUG$, or oral contraceptives.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s33.p8",
        "sentence": "In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of @DRUG$, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s33.p9",
        "sentence": "In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of @DRUG$ (40 mg twice daily), @DRUG$, theophylline, or oral contraceptives.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s33.p10",
        "sentence": "In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of @DRUG$ (40 mg twice daily), phenytoin, @DRUG$, or oral contraceptives.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s33.p11",
        "sentence": "In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of @DRUG$ (40 mg twice daily), phenytoin, theophylline, or oral @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s33.p12",
        "sentence": "In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), @DRUG$, @DRUG$, or oral contraceptives.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s33.p13",
        "sentence": "In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), @DRUG$, theophylline, or oral @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s33.p14",
        "sentence": "In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, @DRUG$, or oral @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d558.s37.p0",
        "sentence": "The mean clearances of @DRUG$ were 16% and 15% lower in patients on @DRUG$ and inhibitors of tubular organic cation transport, respectively.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d558.s8.p0",
        "sentence": "In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of @DRUG$ with @DRUG$ was associated with a higher occurrence of torsade de pointes.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d559.s0.p0",
        "sentence": "The CNS effects of @DRUG$ may be enhanced by @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d561.s3.p0",
        "sentence": "@DRUG$ Supplements and @DRUG$ Lotensin can attenuate potassium loss caused by thiazide diuretics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s3.p1",
        "sentence": "@DRUG$ Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s3.p2",
        "sentence": "Potassium Supplements and @DRUG$ Lotensin can attenuate potassium loss caused by @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d561.s4.p0",
        "sentence": "@DRUG$ (@DRUG$, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s4.p1",
        "sentence": "@DRUG$ (spironolactone, @DRUG$, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s4.p2",
        "sentence": "@DRUG$ (spironolactone, amiloride, @DRUG$, and others) or potassium supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s4.p3",
        "sentence": "@DRUG$ (spironolactone, amiloride, triamterene, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s4.p4",
        "sentence": "Potassium-sparing diuretics (@DRUG$, @DRUG$, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s4.p5",
        "sentence": "Potassium-sparing diuretics (@DRUG$, amiloride, @DRUG$, and others) or potassium supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s4.p6",
        "sentence": "Potassium-sparing diuretics (@DRUG$, amiloride, triamterene, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s4.p7",
        "sentence": "Potassium-sparing diuretics (spironolactone, @DRUG$, @DRUG$, and others) or potassium supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s4.p8",
        "sentence": "Potassium-sparing diuretics (spironolactone, @DRUG$, triamterene, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s4.p9",
        "sentence": "Potassium-sparing diuretics (spironolactone, amiloride, @DRUG$, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s6.p0",
        "sentence": "Oral @DRUG$ Interaction studies with @DRUG$ and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s6.p1",
        "sentence": "Oral @DRUG$ Interaction studies with warfarin and @DRUG$ failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s6.p2",
        "sentence": "Oral @DRUG$ Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s6.p3",
        "sentence": "Oral Anticoagulants Interaction studies with @DRUG$ and @DRUG$ failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s6.p4",
        "sentence": "Oral Anticoagulants Interaction studies with @DRUG$ and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d561.s6.p5",
        "sentence": "Oral Anticoagulants Interaction studies with warfarin and @DRUG$ failed to identify any clinically important effects on the serum concentrations or clinical effects of these @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d562.s10.p0",
        "sentence": "Seizures have been reported in patients taking another @DRUG$ and the @DRUG$ fenbufen concurrently.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d562.s10.p1",
        "sentence": "Seizures have been reported in patients taking another @DRUG$ and the nonsteroidal anti-inflammatory drug @DRUG$ concurrently.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d562.s10.p2",
        "sentence": "Seizures have been reported in patients taking another quinolone class antimicrobial and the @DRUG$ @DRUG$ concurrently.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d564.s0.p0",
        "sentence": "The administration of local @DRUG$ containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d564.s0.p1",
        "sentence": "The administration of local @DRUG$ containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d564.s0.p2",
        "sentence": "The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving @DRUG$ or tricyclic antidepressants may produce severe, prolonged hypertension.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d564.s0.p3",
        "sentence": "The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d564.s0.p4",
        "sentence": "The administration of local anesthetic solutions containing @DRUG$ or @DRUG$ to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d564.s0.p5",
        "sentence": "The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving @DRUG$ or tricyclic antidepressants may produce severe, prolonged hypertension.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d564.s0.p6",
        "sentence": "The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d564.s0.p7",
        "sentence": "The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving @DRUG$ or tricyclic antidepressants may produce severe, prolonged hypertension.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d564.s0.p8",
        "sentence": "The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d564.s0.p9",
        "sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$ or @DRUG$ may produce severe, prolonged hypertension.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d564.s1.p0",
        "sentence": "@DRUG$ and @DRUG$ may reduce or reverse the pressor effect of epinephrine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d564.s1.p1",
        "sentence": "@DRUG$ and butyrophenones may reduce or reverse the pressor effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d564.s1.p2",
        "sentence": "Phenothiazines and @DRUG$ may reduce or reverse the pressor effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d565.s14.p0",
        "sentence": "The effect may be mediated by @DRUG$s known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d565.s15.p0",
        "sentence": "Patients currently receiving @DRUG$ therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d565.s20.p0",
        "sentence": "Since there have been conflicting results regarding the effect of @DRUG$ levels, it is recommended that @DRUG$ levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d565.s20.p1",
        "sentence": "Since there have been conflicting results regarding the effect of @DRUG$ levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing @DRUG$ therapy to avoid possible over- or under-digitalization.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d565.s20.p2",
        "sentence": "Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that @DRUG$ levels be monitored when initiating, adjusting, and discontinuing @DRUG$ therapy to avoid possible over- or under-digitalization.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d565.s33.p0",
        "sentence": "Studies showed that @DRUG$ increased the AUC of @DRUG$ and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d565.s33.p1",
        "sentence": "Studies showed that @DRUG$ increased the AUC of midazolam and @DRUG$ by 3-4 fold and the Cmax by 2-fold, compared to placebo.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d565.s33.p2",
        "sentence": "Studies showed that diltiazem increased the AUC of @DRUG$ and @DRUG$ by 3-4 fold and the Cmax by 2-fold, compared to placebo.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d565.s35.p0",
        "sentence": "These pharmacokinetic effects seen during @DRUG$ coadministration can result in increased clinical effects (e.g., prolonged sodation)of both @DRUG$ and triazolam.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d565.s35.p1",
        "sentence": "These pharmacokinetic effects seen during @DRUG$ coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d565.s35.p2",
        "sentence": "These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both @DRUG$ and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d565.s9.p0",
        "sentence": "In vitro, @DRUG$ appears to be displaced from its binding sites by @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d566.s4.p0",
        "sentence": "When @DRUG$ @DRUG$ is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d566.s4.p1",
        "sentence": "When @DRUG$ resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of @DRUG$ should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d566.s4.p2",
        "sentence": "When cholestyramine @DRUG$ is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of @DRUG$ should be considered.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d566.s5.p0",
        "sentence": "SINCE @DRUG$ @DRUG$ MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d566.s5.p1",
        "sentence": "SINCE @DRUG$ RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER @DRUG$ RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d566.s5.p2",
        "sentence": "SINCE @DRUG$ RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE @DRUG$ (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d566.s5.p3",
        "sentence": "SINCE CHOLESTYRAMINE @DRUG$ MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER @DRUG$ RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d566.s5.p4",
        "sentence": "SINCE CHOLESTYRAMINE @DRUG$ MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE @DRUG$ (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d566.s5.p5",
        "sentence": "SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER @DRUG$ @DRUG$ (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d567.s13.p0",
        "sentence": "@DRUG$s: In a small clinical trial in which @DRUG$ was administered to warfarin treated patients, no effect on prothrombin time was detected.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d567.s13.p1",
        "sentence": "@DRUG$s: In a small clinical trial in which lovastatin was administered to @DRUG$ treated patients, no effect on prothrombin time was detected.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d567.s13.p2",
        "sentence": "Coumarin Anticoagulants: In a small clinical trial in which @DRUG$ was administered to @DRUG$ treated patients, no effect on prothrombin time was detected.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d567.s15.p0",
        "sentence": "Also, bleeding and/or increased prothrombin time have been reported in a few patients taking @DRUG$s concomitantly with @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d567.s16.p0",
        "sentence": "It is recommended that in patients taking @DRUG$, prothrombin time be determined before starting @DRUG$ and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d567.s19.p0",
        "sentence": "@DRUG$ therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s11.p0",
        "sentence": "Nevertheless, plasma @DRUG$ levels should be monitored with appropriate adjustment to the @DRUG$ dose in accordance with standard clinical practice.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s13.p0",
        "sentence": "@DRUG$ and @DRUG$ - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s13.p1",
        "sentence": "@DRUG$ and Celexa - In a controlled study, a single dose of @DRUG$ 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s13.p2",
        "sentence": "@DRUG$ and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic @DRUG$ 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s13.p3",
        "sentence": "@DRUG$ and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to @DRUG$ given alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s13.p4",
        "sentence": "Pimozide and @DRUG$ - In a controlled study, a single dose of @DRUG$ 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s13.p5",
        "sentence": "Pimozide and @DRUG$ - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic @DRUG$ 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s13.p6",
        "sentence": "Pimozide and @DRUG$ - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to @DRUG$ given alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s13.p7",
        "sentence": "Pimozide and Celexa - In a controlled study, a single dose of @DRUG$ 2 mg co-administered with racemic @DRUG$ 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d568.s13.p8",
        "sentence": "Pimozide and Celexa - In a controlled study, a single dose of @DRUG$ 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to @DRUG$ given alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s13.p9",
        "sentence": "Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic @DRUG$ 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to @DRUG$ given alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s19.p0",
        "sentence": "The effect of @DRUG$ on the pharmacokinetics of @DRUG$ was not evaluated.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s22.p0",
        "sentence": "@DRUG$ - Combined administration of racemic @DRUG$ (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s22.p1",
        "sentence": "@DRUG$ - Combined administration of racemic citalopram (40 mg/day for 14 days) and @DRUG$ (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s22.p2",
        "sentence": "@DRUG$ - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of @DRUG$, a CYP3A4 substrate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s22.p3",
        "sentence": "Carbamazepine - Combined administration of racemic @DRUG$ (40 mg/day for 14 days) and @DRUG$ (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s22.p4",
        "sentence": "Carbamazepine - Combined administration of racemic @DRUG$ (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of @DRUG$, a CYP3A4 substrate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s22.p5",
        "sentence": "Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and @DRUG$ (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of @DRUG$, a CYP3A4 substrate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s28.p0",
        "sentence": "However, coadministration of @DRUG$ (20 mg) and @DRUG$ (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s28.p1",
        "sentence": "However, coadministration of @DRUG$ (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s28.p2",
        "sentence": "However, coadministration of escitalopram (20 mg) and @DRUG$ (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s29.p0",
        "sentence": "Because @DRUG$ is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease @DRUG$ clearance.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s37.p0",
        "sentence": "Coadministration of @DRUG$ and @DRUG$ had no clinically significant effects on blood pressure or heart rate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s5.p0",
        "sentence": "Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of @DRUG$ that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an @DRUG$ or aspirin potentiated the risk of bleeding.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d568.s5.p1",
        "sentence": "Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of @DRUG$ that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or @DRUG$ potentiated the risk of bleeding.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d568.s5.p2",
        "sentence": "Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an @DRUG$ or @DRUG$ potentiated the risk of bleeding.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s7.p0",
        "sentence": "@DRUG$ - In subjects who had received 21 days of 40 mg/day racemic @DRUG$, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s7.p1",
        "sentence": "@DRUG$ - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day @DRUG$ for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s7.p2",
        "sentence": "@DRUG$ - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in @DRUG$ AUC and Cmax of 43% and 39%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s7.p3",
        "sentence": "Cimetidine - In subjects who had received 21 days of 40 mg/day racemic @DRUG$, combined administration of 400 mg/day @DRUG$ for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d568.s7.p4",
        "sentence": "Cimetidine - In subjects who had received 21 days of 40 mg/day racemic @DRUG$, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in @DRUG$ AUC and Cmax of 43% and 39%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d568.s7.p5",
        "sentence": "Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day @DRUG$ for 8 days resulted in an increase in @DRUG$ AUC and Cmax of 43% and 39%, respectively.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d57.s0.p0",
        "sentence": "In vitro mixing of an @DRUG$ with beta-lactamtype @DRUG$ (penicillins or cephalosporins) may result in a significant mutual inactivation.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d57.s0.p1",
        "sentence": "In vitro mixing of an @DRUG$ with beta-lactamtype antibiotics (@DRUG$ or cephalosporins) may result in a significant mutual inactivation.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d57.s0.p2",
        "sentence": "In vitro mixing of an @DRUG$ with beta-lactamtype antibiotics (penicillins or @DRUG$) may result in a significant mutual inactivation.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d57.s0.p3",
        "sentence": "In vitro mixing of an aminoglycoside with beta-lactamtype @DRUG$ (@DRUG$ or cephalosporins) may result in a significant mutual inactivation.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d57.s0.p4",
        "sentence": "In vitro mixing of an aminoglycoside with beta-lactamtype @DRUG$ (penicillins or @DRUG$) may result in a significant mutual inactivation.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d57.s0.p5",
        "sentence": "In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (@DRUG$ or @DRUG$) may result in a significant mutual inactivation.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d571.s4.p0",
        "sentence": "Patients on oral @DRUG$ receiving @DRUG$ treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d571.s4.p1",
        "sentence": "Patients on oral @DRUG$ receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d571.s4.p2",
        "sentence": "Patients on oral antidiabetic agents receiving @DRUG$ treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d6.s2.p0",
        "sentence": "If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of @DRUG$ than when @DRUG$ or nitrous oxide with a balanced technique are used.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d6.s2.p1",
        "sentence": "If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of @DRUG$ than when halothane or @DRUG$ with a balanced technique are used.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d6.s2.p2",
        "sentence": "If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when @DRUG$ or @DRUG$ with a balanced technique are used.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d60.s0.p0",
        "sentence": "Administration of 0.1-mg/kg (2 x ED95) @DRUG$ at 10% or 95% recovery following an intubating dose of @DRUG$ (1 mg/kg) produced  95% neuromuscular block.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d60.s1.p0",
        "sentence": "The time to onset of maximum block following @DRUG$ is approximately 2 minutes faster with prior administration of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d60.s14.p0",
        "sentence": "While the effects of chronic @DRUG$ or @DRUG$ therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d60.s14.p1",
        "sentence": "While the effects of chronic @DRUG$ or carbamazepine therapy on the action of @DRUG$ are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d60.s14.p2",
        "sentence": "While the effects of chronic phenytoin or @DRUG$ therapy on the action of @DRUG$ are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d60.s4.p0",
        "sentence": "The use of @DRUG$ before @DRUG$ to attenuate some of the side effects of succinylcholine has not been studied.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d60.s4.p1",
        "sentence": "The use of @DRUG$ before succinylcholine to attenuate some of the side effects of @DRUG$ has not been studied.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d60.s4.p2",
        "sentence": "The use of NIMBEX before @DRUG$ to attenuate some of the side effects of @DRUG$ has not been studied.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p0",
        "sentence": "@DRUG$ such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p1",
        "sentence": "@DRUG$ such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p2",
        "sentence": "@DRUG$ such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p3",
        "sentence": "@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p4",
        "sentence": "@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p5",
        "sentence": "@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p6",
        "sentence": "@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p7",
        "sentence": "@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p8",
        "sentence": "@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p9",
        "sentence": "@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p10",
        "sentence": "@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p11",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p12",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p13",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p14",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p15",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p16",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p17",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p18",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p19",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p20",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p21",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p22",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p23",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p24",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p25",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p26",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p27",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p28",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p29",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p30",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p31",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p32",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p33",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p34",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p35",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p36",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p37",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p38",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p39",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p40",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p41",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p42",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p43",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p44",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p45",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p46",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p47",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p48",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p49",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p50",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p51",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p52",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p53",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p54",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p55",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p56",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p57",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p58",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p59",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p60",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p61",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p62",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p63",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p64",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d63.s0.p65",
        "sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with @DRUG$ may increase the chance of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d64.s3.p0",
        "sentence": "For example, since @DRUG$ may reduce the gastrointestinal absorption of both the oral @DRUG$ and vitamin K, the net effects are unpredictable.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d64.s3.p1",
        "sentence": "For example, since @DRUG$ may reduce the gastrointestinal absorption of both the oral anticoagulants and @DRUG$, the net effects are unpredictable.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d64.s3.p2",
        "sentence": "For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral @DRUG$ and @DRUG$, the net effects are unpredictable.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d64.s88.p0",
        "sentence": "Oral @DRUG$ may potentiate the hypoglycemic action of @DRUG$, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d64.s88.p1",
        "sentence": "Oral @DRUG$ may potentiate the hypoglycemic action of hypoglycemic agents, eg, @DRUG$ and chlorpropamide, by inhibiting their metabolism in the liver.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d64.s88.p2",
        "sentence": "Oral @DRUG$ may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and @DRUG$, by inhibiting their metabolism in the liver.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d64.s88.p3",
        "sentence": "Oral anticoagulants may potentiate the hypoglycemic action of @DRUG$, eg, @DRUG$ and chlorpropamide, by inhibiting their metabolism in the liver.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d64.s88.p4",
        "sentence": "Oral anticoagulants may potentiate the hypoglycemic action of @DRUG$, eg, tolbutamide and @DRUG$, by inhibiting their metabolism in the liver.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d64.s88.p5",
        "sentence": "Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, @DRUG$ and @DRUG$, by inhibiting their metabolism in the liver.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d64.s89.p0",
        "sentence": "Because oral @DRUG$ may interfere with the hepatic metabolism of @DRUG$, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d64.s89.p1",
        "sentence": "Because oral @DRUG$ may interfere with the hepatic metabolism of phenytoin, toxic levels of the @DRUG$ may occur when an oral anticoagulant and phenytoin are administered concurrently.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d64.s89.p2",
        "sentence": "Because oral @DRUG$ may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral @DRUG$ and phenytoin are administered concurrently.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d64.s89.p3",
        "sentence": "Because oral @DRUG$ may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and @DRUG$ are administered concurrently.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d64.s89.p4",
        "sentence": "Because oral anticoagulants may interfere with the hepatic metabolism of @DRUG$, toxic levels of the @DRUG$ may occur when an oral anticoagulant and phenytoin are administered concurrently.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d64.s89.p5",
        "sentence": "Because oral anticoagulants may interfere with the hepatic metabolism of @DRUG$, toxic levels of the anticonvulsant may occur when an oral @DRUG$ and phenytoin are administered concurrently.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d64.s89.p6",
        "sentence": "Because oral anticoagulants may interfere with the hepatic metabolism of @DRUG$, toxic levels of the anticonvulsant may occur when an oral anticoagulant and @DRUG$ are administered concurrently.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d64.s89.p7",
        "sentence": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the @DRUG$ may occur when an oral @DRUG$ and phenytoin are administered concurrently.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d64.s89.p8",
        "sentence": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the @DRUG$ may occur when an oral anticoagulant and @DRUG$ are administered concurrently.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d64.s89.p9",
        "sentence": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral @DRUG$ and @DRUG$ are administered concurrently.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d64.s91.p0",
        "sentence": "The beneficial effects on arterial thrombus formation from combined therapy with @DRUG-DRUG$ must be weighed against an increased risk of inducing hemorrhage.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d64.s93.p0",
        "sentence": "Drug/Laboratory Test Interferences: @DRUG$ and @DRUG$, including anisindione, or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d64.s93.p1",
        "sentence": "Drug/Laboratory Test Interferences: @DRUG$ and indanedione anticoagulants, including @DRUG$, or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d64.s93.p2",
        "sentence": "Drug/Laboratory Test Interferences: Dicumarol and @DRUG$, including @DRUG$, or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d65.s0.p0",
        "sentence": "@DRUG$ preparations are incompatible with @DRUG$ preparations.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d68.s3.p0",
        "sentence": "Coadministration of @DRUG$ did not have effects on either the safety or efficacy of @DRUG$ in the clinical trials.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d69.s0.p0",
        "sentence": "Use of @DRUG$ in a patient who has previously received @DRUG$ increases the risk of cardiotoxicity.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d69.s1.p0",
        "sentence": "@DRUG$ should not be used in patients who have previously received the recommended maximum cumulative doses of @DRUG$ or Cerubidine.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d69.s1.p1",
        "sentence": "@DRUG$ should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d69.s1.p2",
        "sentence": "Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of @DRUG$ or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d69.s2.p0",
        "sentence": "@DRUG$ used concurrently with @DRUG$ may also result in increased cardiotoxicity.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d7.s0.p0",
        "sentence": "The rate of metabolism and the leukopenic activity of @DRUG$ reportedly are increased by chronic administration of high doses of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d7.s2.p0",
        "sentence": "@DRUG$ treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d70.s11.p0",
        "sentence": "The potential effects of @DRUG$ on the fertility of male animals were not studied but in a 6-month toxicology study, male rats treated with intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days, or 10 mg/rat/15 days @DRUG$ showed a loss of spermatozoa from the seminiferous tubules, seminiferous tubular atrophy, and degenerative changes in the epididymides.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d73.s0.p0",
        "sentence": "Catecholamine-depleting drugs (eg, @DRUG$) may have an additive effect when given with @DRUG$s.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d73.s2.p0",
        "sentence": "@DRUG$ may also have an additive effect when given with @DRUG$ .",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d74.s3.p0",
        "sentence": "For this reason the dose of @DRUG$ should be restricted and an @DRUG$ administered as appropriate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d75.s6.p0",
        "sentence": "No clinically relevant pharmacokinetic interactions between @DRUG$ and @DRUG$ were observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d76.s1.p0",
        "sentence": "In patients receiving another @DRUG$ in combination with @DRUG$ (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d76.s1.p1",
        "sentence": "In patients receiving another @DRUG$ in combination with monoamine oxidase inhibitors (@DRUG$), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d76.s1.p2",
        "sentence": "In patients receiving another serotonin reuptake inhibitor drug in combination with @DRUG$ (@DRUG$), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d76.s10.p0",
        "sentence": "Although it has not been definitively demonstrated that @DRUG$ is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of @DRUG$ with alprazolam.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d76.s10.p1",
        "sentence": "Although it has not been definitively demonstrated that @DRUG$ is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d76.s10.p2",
        "sentence": "Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of @DRUG$ with @DRUG$.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d76.s14.p0",
        "sentence": "@DRUG$: When @DRUG$ (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d76.s14.p1",
        "sentence": "@DRUG$: When fluvoxamine maleate (100 mg qd) and @DRUG$ (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d76.s14.p2",
        "sentence": "@DRUG$: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of @DRUG$ were approximately twice those observed when alprazolam was administered alone;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d76.s14.p3",
        "sentence": "@DRUG$: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when @DRUG$ was administered alone;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d76.s14.p4",
        "sentence": "Alprazolam: When @DRUG$ (100 mg qd) and @DRUG$ (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d76.s14.p5",
        "sentence": "Alprazolam: When @DRUG$ (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of @DRUG$ were approximately twice those observed when alprazolam was administered alone;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d76.s14.p6",
        "sentence": "Alprazolam: When @DRUG$ (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when @DRUG$ was administered alone;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d76.s14.p7",
        "sentence": "Alprazolam: When fluvoxamine maleate (100 mg qd) and @DRUG$ (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of @DRUG$ were approximately twice those observed when alprazolam was administered alone;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d76.s14.p8",
        "sentence": "Alprazolam: When fluvoxamine maleate (100 mg qd) and @DRUG$ (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when @DRUG$ was administered alone;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d76.s14.p9",
        "sentence": "Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of @DRUG$ were approximately twice those observed when @DRUG$ was administered alone;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d76.s20.p0",
        "sentence": "Because @DRUG$ reduces the clearance of both @DRUG$ and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d76.s20.p1",
        "sentence": "Because @DRUG$ reduces the clearance of both diazepam and its active metabolite, @DRUG$, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d76.s20.p2",
        "sentence": "Because fluvoxamine reduces the clearance of both @DRUG$ and its active metabolite, @DRUG$, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d76.s28.p0",
        "sentence": "Therefore, if @DRUG$ is co-administered with @DRUG$, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d76.s28.p1",
        "sentence": "Therefore, if @DRUG$ is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of @DRUG$ should to monitored.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d76.s28.p2",
        "sentence": "Therefore, if theophylline is co-administered with @DRUG$, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of @DRUG$ should to monitored.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d77.s16.p0",
        "sentence": "The extent to which @DRUG$-@DRUG$ interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-DrugBank.d77.s16.p1",
        "sentence": "The extent to which @DRUG$-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the @DRUG$ involved.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d77.s16.p2",
        "sentence": "The extent to which SSRI-@DRUG$ interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the @DRUG$ involved.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p0",
        "sentence": "Administration of @DRUG$ with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p1",
        "sentence": "Administration of @DRUG$ with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p2",
        "sentence": "Administration of @DRUG$ with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p3",
        "sentence": "Administration of @DRUG$ with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p4",
        "sentence": "Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p5",
        "sentence": "Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p6",
        "sentence": "Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p7",
        "sentence": "Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p8",
        "sentence": "Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p9",
        "sentence": "Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p10",
        "sentence": "Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p11",
        "sentence": "Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p12",
        "sentence": "Administration of quinolones with @DRUG$ containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p13",
        "sentence": "Administration of quinolones with @DRUG$ containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p14",
        "sentence": "Administration of quinolones with @DRUG$ containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p15",
        "sentence": "Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p16",
        "sentence": "Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p17",
        "sentence": "Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p18",
        "sentence": "Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p19",
        "sentence": "Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p20",
        "sentence": "Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p21",
        "sentence": "Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p22",
        "sentence": "Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p23",
        "sentence": "Administration of quinolones with antacids containing @DRUG$, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p24",
        "sentence": "Administration of quinolones with antacids containing @DRUG$, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p25",
        "sentence": "Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p26",
        "sentence": "Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p27",
        "sentence": "Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p28",
        "sentence": "Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p29",
        "sentence": "Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p30",
        "sentence": "Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p31",
        "sentence": "Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p32",
        "sentence": "Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p33",
        "sentence": "Administration of quinolones with antacids containing aluminum, @DRUG$, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p34",
        "sentence": "Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p35",
        "sentence": "Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p36",
        "sentence": "Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p37",
        "sentence": "Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p38",
        "sentence": "Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p39",
        "sentence": "Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p40",
        "sentence": "Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p41",
        "sentence": "Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p42",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p43",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p44",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p45",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p46",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p47",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p48",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p49",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p50",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p51",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p52",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p53",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p54",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p55",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p56",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p57",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p58",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p59",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p60",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p61",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p62",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p63",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p64",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p65",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p66",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p67",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p68",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p69",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p70",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p71",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p72",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p73",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p74",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p75",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p76",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s1.p77",
        "sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s19.p0",
        "sentence": "@DRUG$ (@DRUG$): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s19.p1",
        "sentence": "@DRUG$ (NSAIDs): The concomitant administration of a @DRUG$ with a quinolone may increase the risks of CNS stimulation and convulsions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s19.p2",
        "sentence": "@DRUG$ (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a @DRUG$ may increase the risks of CNS stimulation and convulsions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s19.p3",
        "sentence": "Nonsteroidal Anti-inflammatory Drugs (@DRUG$): The concomitant administration of a @DRUG$ with a quinolone may increase the risks of CNS stimulation and convulsions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s19.p4",
        "sentence": "Nonsteroidal Anti-inflammatory Drugs (@DRUG$): The concomitant administration of a nonsteroidal anti inflammatory drug with a @DRUG$ may increase the risks of CNS stimulation and convulsions.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s19.p5",
        "sentence": "Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a @DRUG$ with a @DRUG$ may increase the risks of CNS stimulation and convulsions.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d78.s6.p0",
        "sentence": "@DRUG$: @DRUG$ is a competitive inhibitor of the metabolism of theophylline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s6.p1",
        "sentence": "@DRUG$: Grepafloxacin is a competitive inhibitor of the metabolism of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s6.p2",
        "sentence": "Theophylline: @DRUG$ is a competitive inhibitor of the metabolism of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d78.s7.p0",
        "sentence": "Serum @DRUG$ concentrations increase when @DRUG$ is initiated in a patient maintained on theophylline.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s7.p1",
        "sentence": "Serum @DRUG$ concentrations increase when grepafloxacin is initiated in a patient maintained on @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s7.p2",
        "sentence": "Serum theophylline concentrations increase when @DRUG$ is initiated in a patient maintained on @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d78.s8.p0",
        "sentence": "When initiating a multi-day course of @DRUG$ in a patient maintained on @DRUG$, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s8.p1",
        "sentence": "When initiating a multi-day course of @DRUG$ in a patient maintained on theophylline, the @DRUG$ maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s8.p2",
        "sentence": "When initiating a multi-day course of @DRUG$ in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of @DRUG$ and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s8.p3",
        "sentence": "When initiating a multi-day course of @DRUG$ in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum @DRUG$ concentrations should be initiated as a guide to further dosage adjustments.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s8.p4",
        "sentence": "When initiating a multi-day course of grepafloxacin in a patient maintained on @DRUG$, the @DRUG$ maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s8.p5",
        "sentence": "When initiating a multi-day course of grepafloxacin in a patient maintained on @DRUG$, the theophylline maintenance dose should be halved for the period of concurrent use of @DRUG$ and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s8.p6",
        "sentence": "When initiating a multi-day course of grepafloxacin in a patient maintained on @DRUG$, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum @DRUG$ concentrations should be initiated as a guide to further dosage adjustments.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s8.p7",
        "sentence": "When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the @DRUG$ maintenance dose should be halved for the period of concurrent use of @DRUG$ and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d78.s8.p8",
        "sentence": "When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the @DRUG$ maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum @DRUG$ concentrations should be initiated as a guide to further dosage adjustments.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d78.s8.p9",
        "sentence": "When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of @DRUG$ and monitoring of serum @DRUG$ concentrations should be initiated as a guide to further dosage adjustments.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d79.s0.p0",
        "sentence": "The absorption of @DRUG$ may be affected by the simultaneous administration of indigestion remedies, @DRUG$ or zinc supplements.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d79.s0.p1",
        "sentence": "The absorption of @DRUG$ may be affected by the simultaneous administration of indigestion remedies, iron or @DRUG$ supplements.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d79.s0.p2",
        "sentence": "The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, @DRUG$ or @DRUG$ supplements.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d8.s3.p0",
        "sentence": "Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d8.s3.p1",
        "sentence": "Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of @DRUG$ with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d8.s3.p2",
        "sentence": "Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with @DRUG$ can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d8.s3.p3",
        "sentence": "Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d8.s3.p4",
        "sentence": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of @DRUG$ with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d8.s3.p5",
        "sentence": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of erythromycin with @DRUG$ can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d8.s3.p6",
        "sentence": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of erythromycin with ALFENTA can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d8.s3.p7",
        "sentence": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of @DRUG$ with @DRUG$ can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d8.s3.p8",
        "sentence": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of @DRUG$ with ALFENTA can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d8.s3.p9",
        "sentence": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with @DRUG$ can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d81.s1.p0",
        "sentence": "@DRUG$: A study in normal healthy volunteers has shown that concomitant administration of @DRUG$  (isradipine) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d81.s1.p1",
        "sentence": "@DRUG$: A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  (@DRUG$) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d81.s1.p2",
        "sentence": "@DRUG$: A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  (isradipine) and @DRUG$ does not result in altered pharmacoktnetics of either drug.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d81.s1.p3",
        "sentence": "Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of @DRUG$  (@DRUG$) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d81.s1.p4",
        "sentence": "Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of @DRUG$  (isradipine) and @DRUG$ does not result in altered pharmacoktnetics of either drug.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d81.s1.p5",
        "sentence": "Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  (@DRUG$) and @DRUG$ does not result in altered pharmacoktnetics of either drug.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d81.s15.p0",
        "sentence": "Even though such interactions have not been seen in clinical studies with @DRUG$  (@DRUG$), an increased volume of circulating fluids might be required if such an interaction were to occur.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d81.s9.p0",
        "sentence": "@DRUG$: In a study in healthy volunteers, a six-day course of @DRUG$ at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d81.s9.p1",
        "sentence": "@DRUG$: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of @DRUG$ resulted in a reduction in isradipine levels to below detectable limits.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d81.s9.p2",
        "sentence": "@DRUG$: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in @DRUG$ levels to below detectable limits.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d81.s9.p3",
        "sentence": "Rifampicin: In a study in healthy volunteers, a six-day course of @DRUG$ at 600 mg/day followed by a single 5 mg dose of @DRUG$ resulted in a reduction in isradipine levels to below detectable limits.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d81.s9.p4",
        "sentence": "Rifampicin: In a study in healthy volunteers, a six-day course of @DRUG$ at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in @DRUG$ levels to below detectable limits.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d81.s9.p5",
        "sentence": "Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of @DRUG$ resulted in a reduction in @DRUG$ levels to below detectable limits.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d82.s0.p0",
        "sentence": "In normal volunteers receiving @DRUG$, the administration of @DRUG$ decreased the renal clearance and significantly increased the plasma levels of indomethacin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d82.s0.p1",
        "sentence": "In normal volunteers receiving @DRUG$, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d82.s0.p2",
        "sentence": "In normal volunteers receiving indomethacin, the administration of @DRUG$ decreased the renal clearance and significantly increased the plasma levels of @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d82.s1.p0",
        "sentence": "In some patients, combined use of @DRUG$ and @DRUG$ has been associated with fatal gastrointestinal hemorrhage.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d82.s12.p0",
        "sentence": "Caution should be used if @DRUG$ is administered simultaneously with @DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d82.s16.p0",
        "sentence": "Capsules @DRUG$ 50 mg t.i.d. produced a clinically relevant elevation of plasma @DRUG$ and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d82.s16.p1",
        "sentence": "Capsules @DRUG$ 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal @DRUG$ clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d82.s16.p2",
        "sentence": "Capsules @DRUG$ 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma @DRUG$ concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d82.s16.p3",
        "sentence": "Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma @DRUG$ and reduction in renal @DRUG$ clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d82.s16.p4",
        "sentence": "Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma @DRUG$ and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma @DRUG$ concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d82.s16.p5",
        "sentence": "Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal @DRUG$ clearance in psychiatric patients and normal subjects with steady state plasma @DRUG$ concentrations.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d82.s24.p0",
        "sentence": "Therefore, when @DRUG$ and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d82.s28.p0",
        "sentence": "It has been reported that the addition of @DRUG$ to a maintenance schedule of @DRUG$ resulted in reversible acute renal failure in two of four healthy volunteers.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d82.s29.p0",
        "sentence": "@DRUG$ and @DRUG$ should not be administered together.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d82.s30.p0",
        "sentence": "@DRUG$ and @DRUG$ each may be associated with increased serum potassium levels.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d82.s31.p0",
        "sentence": "The potential effects of @DRUG$ and @DRUG$ on potassium kinetics and renal function should be considered when these agents are administered concurrently.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d82.s32.p0",
        "sentence": "Most of the above effects concerning @DRUG$ have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d82.s4.p0",
        "sentence": "The concomitant use of @DRUG$ with other @DRUG$ is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d82.s8.p0",
        "sentence": "Caution should be exercised when @DRUG$ and @DRUG$ are administered concomitantly.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d83.s0.p0",
        "sentence": "Patients on @DRUG$ therapy may require dosage adjustment of the anticoagulant during and after @DRUG$ therapy.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d84.s2.p0",
        "sentence": "In healthy volunteers, @DRUG$ had no effect on the pharmacokinetics of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d85.s8.p0",
        "sentence": "Inhibition of renal @DRUG$ clearance leading to increases in plasma @DRUG$ concentrations has also been reported.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d87.s16.p0",
        "sentence": "Drugs that inhibit cytochrome P450IID6, such as @DRUG$ , might increase the plasma concentrations of @DRUG$ in patients that are on chronic flecainide therapy;",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d87.s16.p1",
        "sentence": "Drugs that inhibit cytochrome P450IID6, such as @DRUG$ , might increase the plasma concentrations of flecainide in patients that are on chronic @DRUG$ therapy;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d87.s16.p2",
        "sentence": "Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of @DRUG$ in patients that are on chronic @DRUG$ therapy;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d87.s19.p0",
        "sentence": "Because both of these drugs have negative inotropic properties and the effects of coadministration with @DRUG$ are unknown, neither @DRUG$ nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d87.s19.p1",
        "sentence": "Because both of these drugs have negative inotropic properties and the effects of coadministration with @DRUG$ are unknown, neither disopyramide nor @DRUG$ should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d87.s19.p2",
        "sentence": "Because both of these drugs have negative inotropic properties and the effects of coadministration with @DRUG$ are unknown, neither disopyramide nor verapamil should be administered concurrently with @DRUG$ unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d87.s19.p3",
        "sentence": "Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither @DRUG$ nor @DRUG$ should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d87.s19.p4",
        "sentence": "Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither @DRUG$ nor verapamil should be administered concurrently with @DRUG$ unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d87.s19.p5",
        "sentence": "Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor @DRUG$ should be administered concurrently with @DRUG$ unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d87.s20.p0",
        "sentence": "There has been too little experience with the coadministration of @DRUG$ with @DRUG$ or diltiazem to recommend concomitant use.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d87.s20.p1",
        "sentence": "There has been too little experience with the coadministration of @DRUG$ with nifedipine or @DRUG$ to recommend concomitant use.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d87.s20.p2",
        "sentence": "There has been too little experience with the coadministration of TAMBOCOR with @DRUG$ or @DRUG$ to recommend concomitant use.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d87.s4.p0",
        "sentence": "In this formal interaction study, @DRUG$ and @DRUG$ were each found to have negative inotropic effects;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d87.s7.p0",
        "sentence": "In @DRUG$ clinical trials, patients who were receiving @DRUG$ concurrently did not experience an increased incidence of side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d87.s8.p0",
        "sentence": "Nevertheless, the possibility of additive negative inotropic effects of @DRUG$ and @DRUG$ should be recognized.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d88.s2.p0",
        "sentence": "there was no effect on the 3 major metabolites (@DRUG$, @DRUG$ and FBAL).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d88.s2.p1",
        "sentence": "there was no effect on the 3 major metabolites (@DRUG$, 5-FU and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d88.s2.p2",
        "sentence": "there was no effect on the 3 major metabolites (5-DFUR, @DRUG$ and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d89.s4.p0",
        "sentence": "@DRUG$ administered concurrently with @DRUG$ reduced the urine volume in 4 healthy volunteers.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p0",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p2",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p3",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p4",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p5",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p6",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p7",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p8",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p9",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p10",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p11",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p12",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p13",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p14",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p15",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p16",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p17",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p18",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p19",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p20",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p21",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p22",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p23",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p24",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p25",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p26",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p27",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p28",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p29",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p30",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p31",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p32",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p33",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p34",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p35",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p36",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p37",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p38",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p39",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p40",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p41",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p42",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p43",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p44",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p45",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p46",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p47",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p48",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p49",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p50",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p51",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p52",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p53",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p54",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p55",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p56",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p57",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p58",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p59",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p60",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p61",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p62",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p63",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p64",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p65",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p66",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p67",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p68",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p69",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p70",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p71",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p72",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p73",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p74",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p75",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p76",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p77",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p78",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p79",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p80",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p81",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p82",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p83",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p84",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p85",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p86",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p87",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p88",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p89",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p90",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p91",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p92",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p93",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p94",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p95",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p96",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p97",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p98",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p99",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p100",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p101",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p102",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p103",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p104",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p105",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p106",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p107",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p108",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p109",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p110",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p111",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p112",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p113",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p114",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p115",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p116",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p117",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p118",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p119",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p120",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p121",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p122",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p123",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p124",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p125",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p126",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p127",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p128",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p129",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p130",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p131",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p132",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p133",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p134",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p135",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p136",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p137",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p138",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p139",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p140",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p141",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p142",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p143",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p144",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p145",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p146",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p147",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p148",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p149",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p150",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p151",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p152",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p153",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p154",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p155",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p156",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p157",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p158",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p159",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p160",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p161",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p162",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p163",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p164",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p165",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p166",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p167",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p168",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p169",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p170",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p171",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p172",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p173",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p174",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p175",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p176",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p177",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p178",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p179",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p180",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p181",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p182",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p183",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p184",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p185",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p186",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p187",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p188",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p189",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p190",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p191",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p192",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p193",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p194",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p195",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p196",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p197",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p198",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p199",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p200",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p201",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p202",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p203",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p204",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p205",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p206",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p207",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p208",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p209",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p210",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p211",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p212",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p213",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p214",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p215",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p216",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p217",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p218",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p219",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p220",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p221",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p222",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p223",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p224",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p225",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p226",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p227",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p228",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p229",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p230",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p231",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p232",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p233",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p234",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p235",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p236",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p237",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p238",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p239",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p240",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p241",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p242",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p243",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p244",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p245",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p246",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p247",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p248",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p249",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p250",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p251",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p252",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p253",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p254",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p255",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p256",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p257",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p258",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p259",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p260",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p261",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p262",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p263",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p264",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p265",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p266",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p267",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p268",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p269",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p270",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p271",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p272",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p273",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p274",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p275",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p276",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p277",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p278",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p279",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p280",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p281",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p282",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p283",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p284",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p285",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p286",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p287",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p288",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p289",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p290",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p291",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p292",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p293",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p294",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p295",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p296",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p297",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p298",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p299",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p300",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p301",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p302",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p303",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p304",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p305",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p306",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p307",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p308",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p309",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p310",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p311",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p312",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p313",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p314",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p315",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p316",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p317",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p318",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p319",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p320",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p321",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p322",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p323",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p324",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p325",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p326",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p327",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p328",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p329",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p330",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p331",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p332",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p333",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p334",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p335",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p336",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p337",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p338",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p339",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p340",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p341",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p342",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p343",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p344",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p345",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p346",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p347",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p348",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p349",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p350",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p351",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p352",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p353",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p354",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p355",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p356",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p357",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p358",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p359",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p360",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p361",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p362",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p363",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p364",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p365",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p366",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p367",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p368",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p369",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p370",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p371",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p372",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p373",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p374",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p375",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p376",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p377",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p378",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p379",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p380",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p381",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p382",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p383",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p384",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p385",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p386",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p387",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p388",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p389",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p390",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p391",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p392",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p393",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p394",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p395",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p396",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p397",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p398",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p399",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p400",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p401",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p402",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p403",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p404",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p405",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p406",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p407",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p408",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p409",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p410",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p411",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p412",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p413",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p414",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p415",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p416",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p417",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p418",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p419",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p420",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p421",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p422",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p423",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p424",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p425",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p426",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p427",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p428",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p429",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p430",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p431",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p432",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p433",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p434",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p435",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p436",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p437",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p438",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p439",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p440",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p441",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p442",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p443",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p444",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p445",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p446",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p447",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p448",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p449",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p450",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p451",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p452",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p453",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p454",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p455",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p456",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p457",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p458",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p459",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p460",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p461",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p462",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p463",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p464",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p465",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p466",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p467",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p468",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p469",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p470",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p471",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p472",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p473",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p474",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p475",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p476",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p477",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p478",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p479",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p480",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p481",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p482",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p483",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p484",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p485",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p486",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p487",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p488",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p489",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p490",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p491",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p492",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p493",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p494",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p495",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p496",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p497",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p498",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p499",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p500",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p501",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p502",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p503",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p504",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p505",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p506",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p507",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p508",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p509",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p510",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p511",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p512",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p513",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p514",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p515",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p516",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p517",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p518",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p519",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p520",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p521",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p522",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p523",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p524",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p525",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p526",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p527",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p528",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p529",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p530",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p531",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p532",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p533",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p534",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p535",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p536",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p537",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p538",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p539",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p540",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p541",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p542",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p543",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p544",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p545",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p546",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p547",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p548",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p549",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p550",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p551",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p552",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p553",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p554",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p555",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p556",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p557",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p558",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p559",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p560",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p561",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p562",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p563",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p564",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p565",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p566",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p567",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p568",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p569",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p570",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p571",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p572",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p573",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p574",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p575",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p576",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p577",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p578",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p579",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p580",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p581",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p582",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p583",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p584",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p585",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p586",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p587",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p588",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p589",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p590",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p591",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p592",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p593",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p594",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p595",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p596",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p597",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p598",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p599",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p600",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p601",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p602",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p603",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p604",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p605",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p606",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p607",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p608",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p609",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p610",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p611",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p612",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p613",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p614",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p615",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p616",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p617",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p618",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p619",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p620",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p621",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p622",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p623",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p624",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p625",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p626",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p627",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p628",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p629",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p630",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p631",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p632",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p633",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p634",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p635",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p636",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p637",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p638",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p639",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p640",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p641",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p642",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p643",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p644",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p645",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p646",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p647",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p648",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p649",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p650",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p651",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p652",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p653",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p654",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p655",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p656",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p657",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p658",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p659",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p660",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p661",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p662",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p663",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p664",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p665",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p666",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p667",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p668",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p669",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p670",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p671",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p672",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p673",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p674",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p675",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p676",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p677",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p678",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p679",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p680",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p681",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p682",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p683",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p684",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p685",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p686",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p687",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p688",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p689",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p690",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p691",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p692",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p693",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p694",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p695",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p696",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p697",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p698",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p699",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p700",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p701",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p702",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p703",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p704",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p705",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p706",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p707",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p708",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p709",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p710",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p711",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p712",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p713",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p714",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p715",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p716",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p717",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p718",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p719",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p720",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p721",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p722",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p723",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p724",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p725",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p726",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p727",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p728",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p729",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p730",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p731",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p732",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p733",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p734",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p735",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p736",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p737",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p738",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p739",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p740",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p741",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p742",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p743",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p744",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p745",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p746",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p747",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p748",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p749",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p750",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p751",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p752",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p753",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p754",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p755",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p756",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p757",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p758",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p759",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p760",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p761",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p762",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p763",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p764",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p765",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p766",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p767",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p768",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p769",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p770",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p771",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p772",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p773",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p774",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p775",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p776",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p777",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p778",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p779",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p780",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p781",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p782",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p783",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p784",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p785",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p786",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p787",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p788",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p789",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p790",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p791",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p792",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p793",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p794",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p795",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p796",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p797",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p798",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p799",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p800",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p801",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p802",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p803",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p804",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p805",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p806",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p807",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p808",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p809",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p810",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p811",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p812",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p813",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p814",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p815",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p816",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p817",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p818",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p819",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p820",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p821",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p822",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p823",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p824",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p825",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p826",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p827",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p828",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p829",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p830",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p831",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p832",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p833",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p834",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p835",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p836",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p837",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p838",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p839",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p840",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p841",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p842",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p843",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p844",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p845",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p846",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p847",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p848",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p849",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p850",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p851",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p852",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p853",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p854",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p855",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p856",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p857",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p858",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p859",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p860",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p861",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p862",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p863",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p864",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p865",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p866",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p867",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p868",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p869",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p870",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p871",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p872",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p873",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p874",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p875",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p876",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p877",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p878",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p879",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p880",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p881",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p882",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p883",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p884",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p885",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p886",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p887",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p888",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p889",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p890",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p891",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p892",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p893",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p894",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p895",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p896",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p897",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p898",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p899",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p900",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p901",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p902",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p903",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p904",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p905",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p906",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p907",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p908",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p909",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p910",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p911",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p912",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p913",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p914",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p915",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p916",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p917",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p918",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p919",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p920",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p921",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p922",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p923",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p924",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p925",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p926",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p927",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p928",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p929",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p930",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p931",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p932",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p933",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p934",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p935",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p936",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p937",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p938",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p939",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p940",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p941",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p942",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p943",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p944",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p945",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p946",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p947",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p948",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p949",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p950",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p951",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p952",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p953",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p954",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p955",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p956",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p957",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p958",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p959",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p960",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p961",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p962",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p963",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p964",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p965",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p966",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p967",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p968",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p969",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p970",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p971",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p972",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p973",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p974",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p975",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p976",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p977",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p978",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p979",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p980",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p981",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p982",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p983",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p984",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p985",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p986",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p987",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p988",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p989",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p990",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p991",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p992",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p993",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p994",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p995",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p996",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p997",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p998",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p999",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1000",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1001",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1002",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1003",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1004",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1005",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1006",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1007",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1008",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1009",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1010",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1011",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1012",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1013",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1014",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1015",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1016",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1017",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1018",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1019",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1020",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1021",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1022",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1023",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1024",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1025",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1026",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1027",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1028",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1029",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, @DRUG$(5) , ziprasidone, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1030",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1031",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1032",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , @DRUG$, and zonisamide.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1033",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s11.p1034",
        "sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s14.p0",
        "sentence": "Pharmacological/Pharmacodynamic Interactions with @DRUG$ Concomitant administration of @DRUG$ and lithium may increase the risk of neurotoxic side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s14.p1",
        "sentence": "Pharmacological/Pharmacodynamic Interactions with @DRUG$ Concomitant administration of carbamazepine and @DRUG$ may increase the risk of neurotoxic side effects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d94.s14.p2",
        "sentence": "Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of @DRUG$ and @DRUG$ may increase the risk of neurotoxic side effects.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-DrugBank.d97.s20.p0",
        "sentence": "@DRUG$: @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d97.s21.p0",
        "sentence": "May lead to loss of virologic response and possible resistance to @DRUG$ or to the class of @DRUG$ or other coadministered antiretroviral agents.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d97.s21.p1",
        "sentence": "May lead to loss of virologic response and possible resistance to @DRUG$ or to the class of protease inhibitors or other coadministered @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d97.s21.p2",
        "sentence": "May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of @DRUG$ or other coadministered @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d97.s26.p0",
        "sentence": "Combinations of these drugs have not been studied and coadministration of @DRUG$ and @DRUG$ is not recommended.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d97.s41.p0",
        "sentence": "Increasing the @DRUG$ dose to 1000 mg every 8 hours does not compensate for the increased @DRUG$ metabolism due to efavirenz.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d97.s41.p1",
        "sentence": "Increasing the @DRUG$ dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d97.s41.p2",
        "sentence": "Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased @DRUG$ metabolism due to @DRUG$.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-DrugBank.d97.s68.p0",
        "sentence": "@DRUG$ concentration   @DRUG$ concentration",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d97.s70.p0",
        "sentence": "@DRUG$: @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d97.s73.p0",
        "sentence": "@DRUG$: @DRUG$, tacrolimus, sirolimus",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d97.s73.p1",
        "sentence": "@DRUG$: cyclosporine, @DRUG$, sirolimus",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d97.s73.p2",
        "sentence": "@DRUG$: cyclosporine, tacrolimus, @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d97.s73.p3",
        "sentence": "Immunosuppressants: @DRUG$, @DRUG$, sirolimus",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d97.s73.p4",
        "sentence": "Immunosuppressants: @DRUG$, tacrolimus, @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d97.s73.p5",
        "sentence": "Immunosuppressants: cyclosporine, @DRUG$, @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d97.s78.p0",
        "sentence": "Dose reduction of @DRUG$ to 600 mg every 8 hours is recommended when administering @DRUG$ concurrently.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d97.s8.p0",
        "sentence": "@DRUG$: @DRUG$",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d97.s93.p0",
        "sentence": "@DRUG$ dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant @DRUG$ therapy.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-DrugBank.d99.s18.p0",
        "sentence": "and @DRUG$ When @DRUG$ is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s18.p1",
        "sentence": "and @DRUG$ When amitriptyline HCl is given with @DRUG$ agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s18.p2",
        "sentence": "and @DRUG$ When amitriptyline HCl is given with anticholinergic agents or @DRUG$ drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s18.p3",
        "sentence": "and @DRUG$ When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including @DRUG$ combined with local anesthetics, close supervision and careful adjustment of dosages are required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s18.p4",
        "sentence": "and @DRUG$ When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local @DRUG$, close supervision and careful adjustment of dosages are required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s18.p5",
        "sentence": "and disulfiram When @DRUG$ is given with @DRUG$ agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s18.p6",
        "sentence": "and disulfiram When @DRUG$ is given with anticholinergic agents or @DRUG$ drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s18.p7",
        "sentence": "and disulfiram When @DRUG$ is given with anticholinergic agents or sympathomimetic drugs, including @DRUG$ combined with local anesthetics, close supervision and careful adjustment of dosages are required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s18.p8",
        "sentence": "and disulfiram When @DRUG$ is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local @DRUG$, close supervision and careful adjustment of dosages are required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s18.p9",
        "sentence": "and disulfiram When amitriptyline HCl is given with @DRUG$ agents or @DRUG$ drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s18.p10",
        "sentence": "and disulfiram When amitriptyline HCl is given with @DRUG$ agents or sympathomimetic drugs, including @DRUG$ combined with local anesthetics, close supervision and careful adjustment of dosages are required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s18.p11",
        "sentence": "and disulfiram When amitriptyline HCl is given with @DRUG$ agents or sympathomimetic drugs, including epinephrine combined with local @DRUG$, close supervision and careful adjustment of dosages are required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s18.p12",
        "sentence": "and disulfiram When amitriptyline HCl is given with anticholinergic agents or @DRUG$ drugs, including @DRUG$ combined with local anesthetics, close supervision and careful adjustment of dosages are required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s18.p13",
        "sentence": "and disulfiram When amitriptyline HCl is given with anticholinergic agents or @DRUG$ drugs, including epinephrine combined with local @DRUG$, close supervision and careful adjustment of dosages are required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s18.p14",
        "sentence": "and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including @DRUG$ combined with local @DRUG$, close supervision and careful adjustment of dosages are required.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s2.p0",
        "sentence": "Poor metabolizers have higher than expected plasma concentrations of @DRUG$ (@DRUG$) when given usual doses.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s7.p0",
        "sentence": "@DRUG$) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s7.p1",
        "sentence": "@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s7.p2",
        "sentence": "@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ propafenone and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s7.p3",
        "sentence": "@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s7.p4",
        "sentence": "@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s7.p5",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, @DRUG$, and the Type 1C antiarrhythmics propafenone and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s7.p6",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the @DRUG$ propafenone and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s7.p7",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s7.p8",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics propafenone and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s7.p9",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the @DRUG$ propafenone and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s7.p10",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics @DRUG$ and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s7.p11",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s7.p12",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ @DRUG$ and flecainide).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s7.p13",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ propafenone and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s7.p14",
        "sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and @DRUG$).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s8.p0",
        "sentence": "While all the selective @DRUG$ (@DRUG$), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s8.p1",
        "sentence": "While all the selective @DRUG$ (SSRIs), e.g., @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s8.p2",
        "sentence": "While all the selective @DRUG$ (SSRIs), e.g., fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s8.p3",
        "sentence": "While all the selective @DRUG$ (SSRIs), e.g., fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s8.p4",
        "sentence": "While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s8.p5",
        "sentence": "While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s8.p6",
        "sentence": "While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s8.p7",
        "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s8.p8",
        "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-DrugBank.d99.s8.p9",
        "sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, @DRUG$, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d102.s3.p0",
        "sentence": "injection of vehicle (corn oil, 0.1 mL/day), @DRUG$ (10 microg/kg/day or 4 mg/kg/day) and/or @DRUG$ (20 mg/kg/day), for eight days.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s1.p0",
        "sentence": "Two different types of therapy with @DRUG$ are used: physiological oral @DRUG$ supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s1.p1",
        "sentence": "Two different types of therapy with @DRUG$ are used: physiological oral magnesium supplementation which is totally atoxic since it palliates @DRUG$ deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s1.p2",
        "sentence": "Two different types of therapy with @DRUG$ are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the @DRUG$ intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s1.p3",
        "sentence": "Two different types of therapy with @DRUG$ are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological @DRUG$ therapy which may induce toxicity since it creates iatrogenic magnesium overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s1.p4",
        "sentence": "Two different types of therapy with @DRUG$ are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic @DRUG$ overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s1.p5",
        "sentence": "Two different types of therapy with magnesium are used: physiological oral @DRUG$ supplementation which is totally atoxic since it palliates @DRUG$ deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s1.p6",
        "sentence": "Two different types of therapy with magnesium are used: physiological oral @DRUG$ supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the @DRUG$ intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s1.p7",
        "sentence": "Two different types of therapy with magnesium are used: physiological oral @DRUG$ supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological @DRUG$ therapy which may induce toxicity since it creates iatrogenic magnesium overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s1.p8",
        "sentence": "Two different types of therapy with magnesium are used: physiological oral @DRUG$ supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic @DRUG$ overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s1.p9",
        "sentence": "Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates @DRUG$ deficiencies by simply normalizing the @DRUG$ intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s1.p10",
        "sentence": "Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates @DRUG$ deficiencies by simply normalizing the magnesium intake and pharmacological @DRUG$ therapy which may induce toxicity since it creates iatrogenic magnesium overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s1.p11",
        "sentence": "Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates @DRUG$ deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic @DRUG$ overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s1.p12",
        "sentence": "Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the @DRUG$ intake and pharmacological @DRUG$ therapy which may induce toxicity since it creates iatrogenic magnesium overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s1.p13",
        "sentence": "Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the @DRUG$ intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic @DRUG$ overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s1.p14",
        "sentence": "Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological @DRUG$ therapy which may induce toxicity since it creates iatrogenic @DRUG$ overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s15.p0",
        "sentence": "Lastly local use of the mucocutaneous and cytoprotective properties of @DRUG$ is still valid, in @DRUG$ and for preservation of transplants particularly.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s6.p0",
        "sentence": "Specific and aspecific treatments of @DRUG$ depletion are tricky using for example @DRUG$, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s6.p1",
        "sentence": "Specific and aspecific treatments of @DRUG$ depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of @DRUG$, physiological doses of vitamin D and of selenium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s6.p2",
        "sentence": "Specific and aspecific treatments of @DRUG$ depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of @DRUG$ and of selenium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s6.p3",
        "sentence": "Specific and aspecific treatments of @DRUG$ depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s6.p4",
        "sentence": "Specific and aspecific treatments of magnesium depletion are tricky using for example @DRUG$, pharmacological doses of @DRUG$, physiological doses of vitamin D and of selenium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s6.p5",
        "sentence": "Specific and aspecific treatments of magnesium depletion are tricky using for example @DRUG$, pharmacological doses of vitamin B6, physiological doses of @DRUG$ and of selenium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s6.p6",
        "sentence": "Specific and aspecific treatments of magnesium depletion are tricky using for example @DRUG$, pharmacological doses of vitamin B6, physiological doses of vitamin D and of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s6.p7",
        "sentence": "Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of @DRUG$, physiological doses of @DRUG$ and of selenium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s6.p8",
        "sentence": "Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of @DRUG$, physiological doses of vitamin D and of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d103.s6.p9",
        "sentence": "Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of @DRUG$ and of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d104.s8.p0",
        "sentence": "In order to examine some molecular mechanisms of @DRUG$-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with @DRUG$, DCG-IV, and L-CCG-1 was carried out.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d104.s8.p3",
        "sentence": "In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with @DRUG$, @DRUG$, and L-CCG-1 was carried out.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d104.s8.p4",
        "sentence": "In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with @DRUG$, DCG-IV, and @DRUG$ was carried out.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d104.s8.p5",
        "sentence": "In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, @DRUG$, and @DRUG$ was carried out.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d105.s1.p0",
        "sentence": "Two studies were conducted in HIV-infected subjects to assess the potential for @DRUG$ to interact with @DRUG$ and dideoxyinosine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d105.s1.p1",
        "sentence": "Two studies were conducted in HIV-infected subjects to assess the potential for @DRUG$ to interact with zidovudine and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d105.s1.p2",
        "sentence": "Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with @DRUG$ and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d105.s4.p0",
        "sentence": "Subjects treated with 200 mg of @DRUG$ twice daily for 21 days received 1200 mg of @DRUG$ or an equivalent amount of placebo/day for Days 8 to 21.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d109.s1.p0",
        "sentence": "The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, @DRUG$, at steady state on the pharmacokinetics of @DRUG$ following a single dose in healthy subjects.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d11.s4.p0",
        "sentence": "This article looks at five commonly used @DRUG$ in turn (@DRUG$, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d11.s4.p1",
        "sentence": "This article looks at five commonly used @DRUG$ in turn (corticosteroids, @DRUG$, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d11.s4.p2",
        "sentence": "This article looks at five commonly used @DRUG$ in turn (corticosteroids, cyclosporin, @DRUG$, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d11.s4.p3",
        "sentence": "This article looks at five commonly used @DRUG$ in turn (corticosteroids, cyclosporin, azathioprine, @DRUG$, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d11.s4.p4",
        "sentence": "This article looks at five commonly used @DRUG$ in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, @DRUG$), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d11.s4.p5",
        "sentence": "This article looks at five commonly used immunosuppressive drugs in turn (@DRUG$, @DRUG$, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d11.s4.p6",
        "sentence": "This article looks at five commonly used immunosuppressive drugs in turn (@DRUG$, cyclosporin, @DRUG$, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d11.s4.p7",
        "sentence": "This article looks at five commonly used immunosuppressive drugs in turn (@DRUG$, cyclosporin, azathioprine, @DRUG$, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d11.s4.p8",
        "sentence": "This article looks at five commonly used immunosuppressive drugs in turn (@DRUG$, cyclosporin, azathioprine, methotrexate, @DRUG$), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d11.s4.p9",
        "sentence": "This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, @DRUG$, @DRUG$, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d11.s4.p10",
        "sentence": "This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, @DRUG$, azathioprine, @DRUG$, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d11.s4.p11",
        "sentence": "This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, @DRUG$, azathioprine, methotrexate, @DRUG$), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d11.s4.p12",
        "sentence": "This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, @DRUG$, @DRUG$, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d11.s4.p13",
        "sentence": "This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, @DRUG$, methotrexate, @DRUG$), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d11.s4.p14",
        "sentence": "This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, @DRUG$, @DRUG$), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d110.s0.p0",
        "sentence": "@DRUG$ (@DRUG$) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d110.s0.p1",
        "sentence": "@DRUG$ (18-MC) and @DRUG$: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d110.s0.p2",
        "sentence": "18-Methoxycoronaridine (@DRUG$) and @DRUG$: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d110.s10.p0",
        "sentence": "both compounds attenuate @DRUG$-induced locomotion in @DRUG$-experienced rats.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d110.s15.p0",
        "sentence": "Both @DRUG$ and @DRUG$ are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d110.s15.p1",
        "sentence": "Both @DRUG$ and ibogaine are sequestered in fat and, like @DRUG$, 18-MC probably has an active metabolite.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d110.s15.p2",
        "sentence": "Both @DRUG$ and ibogaine are sequestered in fat and, like ibogaine, @DRUG$ probably has an active metabolite.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d110.s15.p3",
        "sentence": "Both 18-MC and @DRUG$ are sequestered in fat and, like @DRUG$, 18-MC probably has an active metabolite.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d110.s15.p4",
        "sentence": "Both 18-MC and @DRUG$ are sequestered in fat and, like ibogaine, @DRUG$ probably has an active metabolite.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d110.s15.p5",
        "sentence": "Both 18-MC and ibogaine are sequestered in fat and, like @DRUG$, @DRUG$ probably has an active metabolite.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d110.s4.p0",
        "sentence": "Both @DRUG$ and @DRUG$ ameliorate opioid withdrawal signs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d110.s4.p1",
        "sentence": "Both @DRUG$ and 18-MC ameliorate @DRUG$ withdrawal signs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d110.s4.p2",
        "sentence": "Both ibogaine and @DRUG$ ameliorate @DRUG$ withdrawal signs.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d110.s9.p0",
        "sentence": "@DRUG$ attenuates, but @DRUG$ potentiates, the acute locomotor effects of morphine;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d110.s9.p1",
        "sentence": "@DRUG$ attenuates, but 18-MC potentiates, the acute locomotor effects of @DRUG$;",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d110.s9.p2",
        "sentence": "Ibogaine attenuates, but @DRUG$ potentiates, the acute locomotor effects of @DRUG$;",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d111.s10.p0",
        "sentence": "@DRUG$ decreased the binding of @DRUG$ by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L;",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-MedLine.d112.s1.p0",
        "sentence": "The effect of @DRUG$ on the steady-state pharmacokinetics of @DRUG$ was evaluated in a randomized, double-blind study.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d114.s6.p0",
        "sentence": "In contrast, in isolated single pancreatic acinar cells, @DRUG$ had no effect on @DRUG$-induced responses.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d115.s14.p0",
        "sentence": "However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between @DRUG-DRUG$.",
        "gold": "DDI-advise"
    },
    {
        "index": "DDI-MedLine.d115.s5.p0",
        "sentence": "@DRUG$ regimens consisted of two @DRUG$ and one protease inhibitor.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d115.s5.p1",
        "sentence": "@DRUG$ regimens consisted of two reverse transcriptase inhibitors and one @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d115.s5.p2",
        "sentence": "Antiretroviral regimens consisted of two @DRUG$ and one @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d116.s1.p0",
        "sentence": "The drug interaction between @DRUG$ and @DRUG$ is not well known.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-MedLine.d116.s3.p0",
        "sentence": "The concomitant administration of @DRUG$ and @DRUG$ resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-MedLine.d116.s3.p1",
        "sentence": "The concomitant administration of @DRUG$ and warfarin resulted in the need for an unusually high maintenance dose of @DRUG$ (20 mg per day) in order to produce a therapeutic effect.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d116.s3.p2",
        "sentence": "The concomitant administration of rifampin and @DRUG$ resulted in the need for an unusually high maintenance dose of @DRUG$ (20 mg per day) in order to produce a therapeutic effect.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s0.p0",
        "sentence": "@DRUG$: mammalian target of @DRUG$ inhibitor to prevent kidney rejection.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s2.p0",
        "sentence": "@DRUG$ works differently from the @DRUG$ currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s2.p1",
        "sentence": "@DRUG$ works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of @DRUG$ does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s2.p2",
        "sentence": "@DRUG$ works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with @DRUG$ or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s2.p3",
        "sentence": "@DRUG$ works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s2.p4",
        "sentence": "Sirolimus works differently from the @DRUG$ currently available, and except for increased lipid levels, the adverse reaction profile of @DRUG$ does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s2.p5",
        "sentence": "Sirolimus works differently from the @DRUG$ currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with @DRUG$ or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s2.p6",
        "sentence": "Sirolimus works differently from the @DRUG$ currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s2.p7",
        "sentence": "Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of @DRUG$ does not appear to overlap to any great extent with that associated with @DRUG$ or tacrolimus.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s2.p8",
        "sentence": "Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of @DRUG$ does not appear to overlap to any great extent with that associated with cyclosporine or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s2.p9",
        "sentence": "Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with @DRUG$ or @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s3.p0",
        "sentence": "While additional research is needed, the initial clinical data in kidney recipients suggest that @DRUG$, in combination with @DRUG$ or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s3.p1",
        "sentence": "While additional research is needed, the initial clinical data in kidney recipients suggest that @DRUG$, in combination with cyclosporine or @DRUG$, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s3.p2",
        "sentence": "While additional research is needed, the initial clinical data in kidney recipients suggest that @DRUG$, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in @DRUG$ or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s3.p3",
        "sentence": "While additional research is needed, the initial clinical data in kidney recipients suggest that @DRUG$, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or @DRUG$ dosage, and permit steroid withdrawal (Kelly, 1999).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s3.p4",
        "sentence": "While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with @DRUG$ or @DRUG$, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s3.p5",
        "sentence": "While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with @DRUG$ or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in @DRUG$ or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s3.p6",
        "sentence": "While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with @DRUG$ or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or @DRUG$ dosage, and permit steroid withdrawal (Kelly, 1999).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s3.p7",
        "sentence": "While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or @DRUG$, might have the potential to reduce the frequency of rejection episodes, permit reductions in @DRUG$ or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s3.p8",
        "sentence": "While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or @DRUG$, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or @DRUG$ dosage, and permit steroid withdrawal (Kelly, 1999).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d118.s3.p9",
        "sentence": "While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in @DRUG$ or @DRUG$ dosage, and permit steroid withdrawal (Kelly, 1999).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d12.s3.p0",
        "sentence": "@DRUG$ at 10(-10) M or @DRUG$ at about 3 X 10(-9) M inhibits proliferation stimulated by EGF.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d12.s3.p1",
        "sentence": "@DRUG$ at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d12.s3.p2",
        "sentence": "Dexamethasone at 10(-10) M or @DRUG$ at about 3 X 10(-9) M inhibits proliferation stimulated by @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d120.s4.p0",
        "sentence": "@DRUG$ was more potent in lysing human red blood cells, whereas @DRUG$ was more potent in inhibiting yeast cell growth;",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d122.s1.p0",
        "sentence": "Many people use both @DRUG$ and @DRUG$ (i.e., cigarettes and other tobacco products).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d124.s0.p0",
        "sentence": "Lack of interaction between @DRUG$ and @DRUG$: pharmacokinetics and drug disposition.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d124.s2.p0",
        "sentence": "This decrease in absorption results in a 36% and 50% lower AUC for @DRUG$ and @DRUG$, respectively, which could cause clinical failures.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d125.s1.p0",
        "sentence": "The biochemical toxicology of @DRUG$, a known metabolite of the major ingredient of the pesticide @DRUG$ (1,3-difluoro-2-propanol), was investigated in vivo and in vitro.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d125.s1.p1",
        "sentence": "The biochemical toxicology of @DRUG$, a known metabolite of the major ingredient of the pesticide Gliftor (@DRUG$), was investigated in vivo and in vitro.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d125.s1.p2",
        "sentence": "The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide @DRUG$ (@DRUG$), was investigated in vivo and in vitro.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d125.s2.p0",
        "sentence": "Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted @DRUG$ to @DRUG$ in vitro.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d125.s3.p0",
        "sentence": "Administration of @DRUG$ (100 mg kg(-1) body weight) to rats in vivo resulted in @DRUG$ synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d128.s10.p0",
        "sentence": "On the other hand, the enhanced secretion of colonic fluid by @DRUG$, given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of @DRUG$ in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d13.s7.p0",
        "sentence": "On the basis of the estimated number of regular users of intravenous @DRUG$ in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and @DRUG$ addicts.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d130.s4.p0",
        "sentence": "@DRUG$ was administered over the last two hours of the @DRUG$ infusion.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d130.s6.p0",
        "sentence": "Comparison of @DRUG$ pharmacokinetics in patients treated with 202.5 mg/m2 plus @DRUG$ to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d130.s6.p1",
        "sentence": "Comparison of @DRUG$ pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without @DRUG$ indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d130.s6.p2",
        "sentence": "Comparison of @DRUG$ pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d130.s6.p3",
        "sentence": "Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus @DRUG$ to those in patients treated with 100 mg/m2 without @DRUG$ indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d130.s6.p4",
        "sentence": "Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus @DRUG$ to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d130.s6.p5",
        "sentence": "Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without @DRUG$ indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d131.s4.p0",
        "sentence": "On the contrary, @DRUG$ and @DRUG$ were agonists in induction of analgesia.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d131.s5.p0",
        "sentence": "It is concluded that @DRUG$ modulates in an opposite way the function of the enkephalinergic neurons and the central action of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d132.s0.p0",
        "sentence": "The emerging roles of @DRUG$ in @DRUG$ therapy.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d132.s10.p0",
        "sentence": "@DRUG$ has demonstrated superiority over @DRUG$ in nucleoside-experienced patients, although combining these 2 agents may represent the best approach in these circumstances.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d132.s5.p0",
        "sentence": "A smaller 24-week study has suggested @DRUG$ may be superior to the @DRUG$ nelfinavir.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d132.s5.p1",
        "sentence": "A smaller 24-week study has suggested @DRUG$ may be superior to the PI @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d132.s5.p2",
        "sentence": "A smaller 24-week study has suggested nevirapine may be superior to the @DRUG$ @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d134.s1.p0",
        "sentence": "An intravenous dose of 50 mg @DRUG$ was in respect of competitive suppression of organs actively concentrating @DRUG$ as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d134.s1.p1",
        "sentence": "An intravenous dose of 50 mg @DRUG$ was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d134.s1.p2",
        "sentence": "An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating @DRUG$ as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d134.s2.p0",
        "sentence": "An intravenous injection of @DRUG$ given later also produces a complete and immediately beginning depletion of @DRUG$ already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-MedLine.d135.s5.p0",
        "sentence": "Acute dosing with @DRUG$ failed to alter the behavioral effects of @DRUG$ in either procedure even when tested up to doses that produced pharmacological effects alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d137.s1.p0",
        "sentence": "AIMS/HYPOTHESIS: There is evidence that @DRUG$ and @DRUG$ cause renal and ocular vasodilation.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d140.s13.p0",
        "sentence": "@DRUG$ doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered @DRUG$ dose level (P = .13, .82, and .76, respectively).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d140.s15.p0",
        "sentence": "For a 4-fold range of @DRUG$ doses there were no differential effects on @DRUG$ dosing or pharmacokinetics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p0",
        "sentence": "[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p1",
        "sentence": "[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p2",
        "sentence": "[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p3",
        "sentence": "[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p4",
        "sentence": "[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p5",
        "sentence": "[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for @DRUG$ in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p6",
        "sentence": "[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p7",
        "sentence": "[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p8",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p9",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p10",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p11",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p12",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for @DRUG$ in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p13",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p14",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p15",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p16",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p17",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p18",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for @DRUG$ in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p19",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p20",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p21",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p22",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p23",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for @DRUG$ in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p24",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p25",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p26",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p27",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for @DRUG$ in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p28",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p29",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p30",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for @DRUG$ in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p31",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for apomorphine in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p32",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p33",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for @DRUG$ in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p34",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for @DRUG$ in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s0.p35",
        "sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s1.p0",
        "sentence": "After prolonged administration of @DRUG$ the displacing effect of @DRUG$, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s1.p1",
        "sentence": "After prolonged administration of @DRUG$ the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on @DRUG$ binding.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d15.s1.p2",
        "sentence": "After prolonged administration of neuroleptics the displacing effect of @DRUG$, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on @DRUG$ binding.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d16.s0.p0",
        "sentence": "Interaction of @DRUG$ and @DRUG$ in rats.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-MedLine.d17.s0.p0",
        "sentence": "In vitro interaction of @DRUG$ and @DRUG$ in placental vessels.",
        "gold": "DDI-int"
    },
    {
        "index": "DDI-MedLine.d17.s1.p0",
        "sentence": "The interaction of @DRUG$ and synthetic @DRUG$ on placental vessels was studied in vitro.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d17.s3.p0",
        "sentence": "In seven experiments reactions to @DRUG$ and @DRUG$ were PGF2alpha.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d17.s3.p1",
        "sentence": "In seven experiments reactions to @DRUG$ and oxytocin were @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d17.s3.p2",
        "sentence": "In seven experiments reactions to norepinephrine and @DRUG$ were @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d17.s4.p0",
        "sentence": "@DRUG$ produced significantly increased vasoconstriction after a single administration of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d18.s1.p0",
        "sentence": "The effect of a @DRUG$ extract from bovine lung, @DRUG$, on the dissolution rate of aerosol particles of budesonide was determined.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d18.s1.p1",
        "sentence": "The effect of a @DRUG$ extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of @DRUG$ was determined.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d18.s1.p2",
        "sentence": "The effect of a pulmonary surfactant extract from bovine lung, @DRUG$, on the dissolution rate of aerosol particles of @DRUG$ was determined.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d18.s6.p0",
        "sentence": "@DRUG$ increased the extent of dissolution of @DRUG$ in proportion to the added concentration, which was also verified by equilibrium solubilization studies.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d2.s0.p0",
        "sentence": "Failure of @DRUG$ to modify @DRUG$ induced hypertension in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d2.s3.p0",
        "sentence": "@DRUG$ has no effect on the blood pressure or metabolic responses to @DRUG$ in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d21.s11.p0",
        "sentence": "@DRUG$ neutralized the increase of glycemia induced by oral @DRUG$ overload.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d21.s8.p0",
        "sentence": "An oral @DRUG$ overload of 1 ml of a 50% @DRUG$ solution was given to rats and blood glucose was determined after 30, 60 and 90 min.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d21.s9.p0",
        "sentence": "@DRUG$ and @DRUG$ did not change fasting or overload glycemia.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d23.s2.p0",
        "sentence": "Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d23.s2.p1",
        "sentence": "Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or droperidol but not after administration of fentayl alone or after pentobarbital.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d23.s2.p2",
        "sentence": "Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, ketamine, or @DRUG$ but not after administration of fentayl alone or after pentobarbital.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d23.s2.p3",
        "sentence": "Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of @DRUG$ alone or after pentobarbital.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d23.s2.p4",
        "sentence": "Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d23.s2.p5",
        "sentence": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, @DRUG$, or droperidol but not after administration of fentayl alone or after pentobarbital.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d23.s2.p6",
        "sentence": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or @DRUG$ but not after administration of fentayl alone or after pentobarbital.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d23.s2.p7",
        "sentence": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or droperidol but not after administration of @DRUG$ alone or after pentobarbital.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d23.s2.p8",
        "sentence": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or droperidol but not after administration of fentayl alone or after @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d23.s2.p9",
        "sentence": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or @DRUG$ but not after administration of fentayl alone or after pentobarbital.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d23.s2.p10",
        "sentence": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or droperidol but not after administration of @DRUG$ alone or after pentobarbital.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d23.s2.p11",
        "sentence": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or droperidol but not after administration of fentayl alone or after @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d23.s2.p12",
        "sentence": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or @DRUG$ but not after administration of @DRUG$ alone or after pentobarbital.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d23.s2.p13",
        "sentence": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or @DRUG$ but not after administration of fentayl alone or after @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d23.s2.p14",
        "sentence": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of @DRUG$ alone or after @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d25.s0.p0",
        "sentence": "Rhabdomyolysis secondary to a drug interaction between @DRUG$ and @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d27.s0.p0",
        "sentence": "[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that @DRUG$ (1 mg/kg) removes the antiedematous action of @DRUG$, phenazepam, phenibut and amizyl and reduces the action of phentolamine.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d27.s0.p1",
        "sentence": "[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that @DRUG$ (1 mg/kg) removes the antiedematous action of diazepam, @DRUG$, phenibut and amizyl and reduces the action of phentolamine.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d27.s0.p2",
        "sentence": "[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that @DRUG$ (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, @DRUG$ and amizyl and reduces the action of phentolamine.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d27.s0.p3",
        "sentence": "[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that @DRUG$ (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and @DRUG$ and reduces the action of phentolamine.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d27.s0.p4",
        "sentence": "[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that @DRUG$ (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d27.s0.p5",
        "sentence": "[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of @DRUG$, @DRUG$, phenibut and amizyl and reduces the action of phentolamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d27.s0.p6",
        "sentence": "[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of @DRUG$, phenazepam, @DRUG$ and amizyl and reduces the action of phentolamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d27.s0.p7",
        "sentence": "[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of @DRUG$, phenazepam, phenibut and @DRUG$ and reduces the action of phentolamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d27.s0.p8",
        "sentence": "[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of @DRUG$, phenazepam, phenibut and amizyl and reduces the action of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d27.s0.p9",
        "sentence": "[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, @DRUG$, @DRUG$ and amizyl and reduces the action of phentolamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d27.s0.p10",
        "sentence": "[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, @DRUG$, phenibut and @DRUG$ and reduces the action of phentolamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d27.s0.p11",
        "sentence": "[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, @DRUG$, phenibut and amizyl and reduces the action of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d27.s0.p12",
        "sentence": "[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, @DRUG$ and @DRUG$ and reduces the action of phentolamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d27.s0.p13",
        "sentence": "[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, @DRUG$ and amizyl and reduces the action of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d27.s0.p14",
        "sentence": "[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and @DRUG$ and reduces the action of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d28.s7.p0",
        "sentence": "The @DRUG$ (@DRUG$ and pioglitazone), a new class of oral antidiabetic agents, are \"insulin sensitizers\"",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d28.s7.p1",
        "sentence": "The @DRUG$ (rosiglitazone and @DRUG$), a new class of oral antidiabetic agents, are \"insulin sensitizers\"",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d28.s7.p2",
        "sentence": "The @DRUG$ (rosiglitazone and pioglitazone), a new class of oral @DRUG$, are \"insulin sensitizers\"",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d28.s7.p3",
        "sentence": "The thiazolidinediones (@DRUG$ and @DRUG$), a new class of oral antidiabetic agents, are \"insulin sensitizers\"",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d28.s7.p4",
        "sentence": "The thiazolidinediones (@DRUG$ and pioglitazone), a new class of oral @DRUG$, are \"insulin sensitizers\"",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d28.s7.p5",
        "sentence": "The thiazolidinediones (rosiglitazone and @DRUG$), a new class of oral @DRUG$, are \"insulin sensitizers\"",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d3.s1.p0",
        "sentence": "The objective of this study was to determine if there is a pharmacokinetic interaction when @DRUG$ is given with @DRUG$ or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d3.s1.p1",
        "sentence": "The objective of this study was to determine if there is a pharmacokinetic interaction when @DRUG$ is given with rifabutin or @DRUG$ and to determine the effects of these drugs on the erythromycin breath test (ERMBT).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d3.s1.p2",
        "sentence": "The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with @DRUG$ or @DRUG$ and to determine the effects of these drugs on the erythromycin breath test (ERMBT).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d3.s13.p0",
        "sentence": "@DRUG$ markedly increases the metabolic clearance of @DRUG$, and coadministration is contraindicated.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-MedLine.d3.s14.p0",
        "sentence": "@DRUG$ significantly decreases clearance of @DRUG$ and 25-O-desacetylrifabutin, and the combination is poorly tolerated.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-MedLine.d3.s14.p1",
        "sentence": "@DRUG$ significantly decreases clearance of rifabutin and @DRUG$, and the combination is poorly tolerated.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-MedLine.d3.s14.p2",
        "sentence": "Amprenavir significantly decreases clearance of @DRUG$ and @DRUG$, and the combination is poorly tolerated.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d3.s6.p0",
        "sentence": "@DRUG$ did not significantly affect @DRUG$'s pharmacokinetics.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d30.s1.p0",
        "sentence": "The behavioral effects of the stereoisomers of @DRUG$ (@DRUG$) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d30.s1.p1",
        "sentence": "The behavioral effects of the stereoisomers of @DRUG$ (NANM) were compared with those of @DRUG$ (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d30.s1.p2",
        "sentence": "The behavioral effects of the stereoisomers of @DRUG$ (NANM) were compared with those of phencyclidine (@DRUG$) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d30.s1.p3",
        "sentence": "The behavioral effects of the stereoisomers of N-allylnormetazocine (@DRUG$) were compared with those of @DRUG$ (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d30.s1.p4",
        "sentence": "The behavioral effects of the stereoisomers of N-allylnormetazocine (@DRUG$) were compared with those of phencyclidine (@DRUG$) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d30.s1.p5",
        "sentence": "The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of @DRUG$ (@DRUG$) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d34.s11.p0",
        "sentence": "Because of the low dietary @DRUG$ concentration as compared to the @DRUG$ contents of the diets, no effect of cobalt on iron absorption and excretion occurred.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d34.s11.p1",
        "sentence": "Because of the low dietary @DRUG$ concentration as compared to the iron contents of the diets, no effect of @DRUG$ on iron absorption and excretion occurred.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d34.s11.p2",
        "sentence": "Because of the low dietary @DRUG$ concentration as compared to the iron contents of the diets, no effect of cobalt on @DRUG$ absorption and excretion occurred.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d34.s11.p3",
        "sentence": "Because of the low dietary cobalt concentration as compared to the @DRUG$ contents of the diets, no effect of @DRUG$ on iron absorption and excretion occurred.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d34.s11.p4",
        "sentence": "Because of the low dietary cobalt concentration as compared to the @DRUG$ contents of the diets, no effect of cobalt on @DRUG$ absorption and excretion occurred.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d34.s11.p5",
        "sentence": "Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of @DRUG$ on @DRUG$ absorption and excretion occurred.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d34.s9.p0",
        "sentence": "Consequently, the effect of @DRUG$ on the retention of @DRUG$ was lower than on absorption.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-MedLine.d38.s2.p0",
        "sentence": "However, the effects of stress and @DRUG$ on the subjective and behavioral effects of @DRUG$ have not been well studied in humans.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d38.s8.p0",
        "sentence": "However, @DRUG$ pretreatment did not affect any of the physiological, behavioral, or subjective effects of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d39.s1.p0",
        "sentence": "We examined the effect of exogenous @DRUG$ on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli @DRUG$ in male rats and the deaths due to nonlethal and lethal doses of endotoxin.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d39.s1.p1",
        "sentence": "We examined the effect of exogenous @DRUG$ on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d39.s1.p2",
        "sentence": "We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli @DRUG$ in male rats and the deaths due to nonlethal and lethal doses of @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d42.s4.p0",
        "sentence": "METHODS: Clinical studies, case reports, and commentaries and editorials concerning @DRUG$ published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms @DRUG$, Viagra, and erectile dysfunction.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d42.s4.p1",
        "sentence": "METHODS: Clinical studies, case reports, and commentaries and editorials concerning @DRUG$ published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, @DRUG$, and erectile dysfunction.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d42.s4.p2",
        "sentence": "METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms @DRUG$, @DRUG$, and erectile dysfunction.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d44.s2.p0",
        "sentence": "In this study, the effects of @DRUG$ upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day @DRUG$ or placebo for 1-month.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d44.s6.p0",
        "sentence": "@DRUG$ elicited 62% enhancement of post-@DRUG$ lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d45.s5.p0",
        "sentence": "Twelve strains of Staphylococcus aureus (a frequent cause of infection in @DRUG$, but not in @DRUG$ and tripelennamine, addicts) were completely inhibited by the drug combination.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d45.s5.p1",
        "sentence": "Twelve strains of Staphylococcus aureus (a frequent cause of infection in @DRUG$, but not in pentazocine and @DRUG$, addicts) were completely inhibited by the drug combination.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d45.s5.p2",
        "sentence": "Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in @DRUG$ and @DRUG$, addicts) were completely inhibited by the drug combination.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d46.s1.p0",
        "sentence": "STUDY OBJECTIVE: To evaluate the effect of @DRUG$ on the pharmacokinetics and cardiovascular safety of @DRUG$ at steady state in healthy men.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d46.s9.p0",
        "sentence": "and phase 3 (days 45-52): @DRUG$ 10 mg 4 times/day (days 45-51) plus @DRUG$ 20 mg/day (days 45-52).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d47.s3.p0",
        "sentence": "Moreover, its activity was enhanced when it was combined with either @DRUG$ or @DRUG$ with 90% parasite reduction at the highest concentration tested.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s0.p0",
        "sentence": "Repeated oral administration of @DRUG$ in sheep: interactions of @DRUG$ with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s0.p1",
        "sentence": "Repeated oral administration of @DRUG$ in sheep: interactions of coumaphos with @DRUG$, trichlorfon, and phenobarbital sodium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s0.p2",
        "sentence": "Repeated oral administration of @DRUG$ in sheep: interactions of coumaphos with bishydroxycoumarin, @DRUG$, and phenobarbital sodium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s0.p3",
        "sentence": "Repeated oral administration of @DRUG$ in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s0.p4",
        "sentence": "Repeated oral administration of coumaphos in sheep: interactions of @DRUG$ with @DRUG$, trichlorfon, and phenobarbital sodium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s0.p5",
        "sentence": "Repeated oral administration of coumaphos in sheep: interactions of @DRUG$ with bishydroxycoumarin, @DRUG$, and phenobarbital sodium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s0.p6",
        "sentence": "Repeated oral administration of coumaphos in sheep: interactions of @DRUG$ with bishydroxycoumarin, trichlorfon, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s0.p7",
        "sentence": "Repeated oral administration of coumaphos in sheep: interactions of coumaphos with @DRUG$, @DRUG$, and phenobarbital sodium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s0.p8",
        "sentence": "Repeated oral administration of coumaphos in sheep: interactions of coumaphos with @DRUG$, trichlorfon, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s0.p9",
        "sentence": "Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, @DRUG$, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s1.p0",
        "sentence": "Interactions between treatments with @DRUG$, @DRUG$ (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s1.p1",
        "sentence": "Interactions between treatments with @DRUG$, bishydroxycoumarin (an @DRUG$), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s1.p2",
        "sentence": "Interactions between treatments with @DRUG$, bishydroxycoumarin (an anticoagulant), @DRUG$ (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s1.p3",
        "sentence": "Interactions between treatments with @DRUG$, bishydroxycoumarin (an anticoagulant), trichlorfon (an @DRUG$), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s1.p4",
        "sentence": "Interactions between treatments with @DRUG$, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and @DRUG$ (an inducer of microsomal enzymes) were investigated in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s1.p5",
        "sentence": "Interactions between treatments with coumaphos, @DRUG$ (an @DRUG$), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s1.p6",
        "sentence": "Interactions between treatments with coumaphos, @DRUG$ (an anticoagulant), @DRUG$ (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s1.p7",
        "sentence": "Interactions between treatments with coumaphos, @DRUG$ (an anticoagulant), trichlorfon (an @DRUG$), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s1.p8",
        "sentence": "Interactions between treatments with coumaphos, @DRUG$ (an anticoagulant), trichlorfon (an organophosphorous compound), and @DRUG$ (an inducer of microsomal enzymes) were investigated in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s1.p9",
        "sentence": "Interactions between treatments with coumaphos, bishydroxycoumarin (an @DRUG$), @DRUG$ (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s1.p10",
        "sentence": "Interactions between treatments with coumaphos, bishydroxycoumarin (an @DRUG$), trichlorfon (an @DRUG$), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s1.p11",
        "sentence": "Interactions between treatments with coumaphos, bishydroxycoumarin (an @DRUG$), trichlorfon (an organophosphorous compound), and @DRUG$ (an inducer of microsomal enzymes) were investigated in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s1.p12",
        "sentence": "Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), @DRUG$ (an @DRUG$), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s1.p13",
        "sentence": "Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), @DRUG$ (an organophosphorous compound), and @DRUG$ (an inducer of microsomal enzymes) were investigated in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d5.s1.p14",
        "sentence": "Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an @DRUG$), and @DRUG$ (an inducer of microsomal enzymes) were investigated in sheep.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d51.s3.p0",
        "sentence": "The anxiogenic effects of @DRUG$ were reduced by pretreatment with @DRUG$, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d51.s3.p1",
        "sentence": "The anxiogenic effects of @DRUG$ were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by @DRUG$ (CPA), an A1-selective agonist.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d51.s3.p2",
        "sentence": "The anxiogenic effects of @DRUG$ were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (@DRUG$), an A1-selective agonist.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d51.s3.p3",
        "sentence": "The anxiogenic effects of theophylline were reduced by pretreatment with @DRUG$, an A2-selective agonist, but not by @DRUG$ (CPA), an A1-selective agonist.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d51.s3.p4",
        "sentence": "The anxiogenic effects of theophylline were reduced by pretreatment with @DRUG$, an A2-selective agonist, but not by N6-cyclopentyladenosine (@DRUG$), an A1-selective agonist.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d51.s3.p5",
        "sentence": "The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by @DRUG$ (@DRUG$), an A1-selective agonist.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d53.s3.p0",
        "sentence": "In the experiments reported here, we examined the interactions between @DRUG$ and the @DRUG$ 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d53.s3.p1",
        "sentence": "In the experiments reported here, we examined the interactions between @DRUG$ and the antiestrogen @DRUG$ (TAM), which also induces apoptosis in MCF-7 cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d53.s3.p2",
        "sentence": "In the experiments reported here, we examined the interactions between @DRUG$ and the antiestrogen 4-hydroxytamoxifen (@DRUG$), which also induces apoptosis in MCF-7 cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d53.s3.p3",
        "sentence": "In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the @DRUG$ @DRUG$ (TAM), which also induces apoptosis in MCF-7 cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d53.s3.p4",
        "sentence": "In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the @DRUG$ 4-hydroxytamoxifen (@DRUG$), which also induces apoptosis in MCF-7 cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d53.s3.p5",
        "sentence": "In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen @DRUG$ (@DRUG$), which also induces apoptosis in MCF-7 cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d53.s4.p0",
        "sentence": "Our data suggest that @DRUG$ significantly potentiates the reduction in cell number induced by @DRUG$ alone.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d54.s2.p0",
        "sentence": "Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of @DRUG$ on these components may help to trace pathways which are affected by @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d54.s3.p0",
        "sentence": "In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, @DRUG$ (2.0 g/kg), @DRUG$ (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d54.s3.p1",
        "sentence": "In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, @DRUG$ (2.0 g/kg), physostigmine (0.6 mg/kg) or @DRUG$ (15.0 mg/kg) on separate days.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d54.s3.p2",
        "sentence": "In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), @DRUG$ (0.6 mg/kg) or @DRUG$ (15.0 mg/kg) on separate days.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d54.s8.p0",
        "sentence": "@DRUG$ pretreatment augmented the depressant effect of @DRUG$ on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d54.s8.p1",
        "sentence": "@DRUG$ pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating @DRUG$'s influence on components P2 and P3.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d54.s8.p2",
        "sentence": "Physostigmine pretreatment augmented the depressant effect of @DRUG$ on the early components P1 and N1, while attenuating @DRUG$'s influence on components P2 and P3.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d55.s4.p0",
        "sentence": "Careful observations on hepatotoxicity are suggested when @DRUG$ is prescribed with @DRUG$.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d57.s2.p0",
        "sentence": "Those for which effectiveness is reported includes @DRUG$, @DRUG$, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p1",
        "sentence": "Those for which effectiveness is reported includes @DRUG$, hydroxyzine, @DRUG$, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p2",
        "sentence": "Those for which effectiveness is reported includes @DRUG$, hydroxyzine, orphenadrine, @DRUG$, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p3",
        "sentence": "Those for which effectiveness is reported includes @DRUG$, hydroxyzine, orphenadrine, pyrilamine, @DRUG$, promethazine, methdilazine, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p4",
        "sentence": "Those for which effectiveness is reported includes @DRUG$, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, @DRUG$, methdilazine, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p5",
        "sentence": "Those for which effectiveness is reported includes @DRUG$, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, @DRUG$, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p6",
        "sentence": "Those for which effectiveness is reported includes @DRUG$, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p7",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, @DRUG$, @DRUG$, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p8",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, @DRUG$, orphenadrine, @DRUG$, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p9",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, @DRUG$, orphenadrine, pyrilamine, @DRUG$, promethazine, methdilazine, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p10",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, @DRUG$, orphenadrine, pyrilamine, phenyltoloxamine, @DRUG$, methdilazine, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p11",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, @DRUG$, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, @DRUG$, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p12",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, @DRUG$, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p13",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, @DRUG$, @DRUG$, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p14",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, @DRUG$, pyrilamine, @DRUG$, promethazine, methdilazine, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p15",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, @DRUG$, pyrilamine, phenyltoloxamine, @DRUG$, methdilazine, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p16",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, @DRUG$, pyrilamine, phenyltoloxamine, promethazine, @DRUG$, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p17",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, @DRUG$, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p18",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, @DRUG$, @DRUG$, promethazine, methdilazine, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p19",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, @DRUG$, phenyltoloxamine, @DRUG$, methdilazine, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p20",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, @DRUG$, phenyltoloxamine, promethazine, @DRUG$, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p21",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, @DRUG$, phenyltoloxamine, promethazine, methdilazine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p22",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, @DRUG$, @DRUG$, methdilazine, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p23",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, @DRUG$, promethazine, @DRUG$, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p24",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, @DRUG$, promethazine, methdilazine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p25",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, @DRUG$, @DRUG$, and tripelennamine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p26",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, @DRUG$, methdilazine, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d57.s2.p27",
        "sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, @DRUG$, and @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s3.p0",
        "sentence": "In this study we investigated the effect of @DRUG$ on high threshold voltage-dependent Ca(2+) channel subtypes using their @DRUG$ nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s3.p1",
        "sentence": "In this study we investigated the effect of @DRUG$ on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers @DRUG$ (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s3.p2",
        "sentence": "In this study we investigated the effect of @DRUG$ on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), @DRUG$ (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s3.p3",
        "sentence": "In this study we investigated the effect of @DRUG$ on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or @DRUG$ (P-type) in bovine chromaffin cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s3.p4",
        "sentence": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their @DRUG$ @DRUG$ (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s3.p5",
        "sentence": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their @DRUG$ nimodipine (L-type), @DRUG$ (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s3.p6",
        "sentence": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their @DRUG$ nimodipine (L-type), omega-conotoxin GVIA (N-type), or @DRUG$ (P-type) in bovine chromaffin cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s3.p7",
        "sentence": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers @DRUG$ (L-type), @DRUG$ (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s3.p8",
        "sentence": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers @DRUG$ (L-type), omega-conotoxin GVIA (N-type), or @DRUG$ (P-type) in bovine chromaffin cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s3.p9",
        "sentence": "In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), @DRUG$ (N-type), or @DRUG$ (P-type) in bovine chromaffin cells.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s7.p0",
        "sentence": "These data suggest that @DRUG$ are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an @DRUG$-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s7.p1",
        "sentence": "These data suggest that @DRUG$ are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an @DRUG$-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s7.p2",
        "sentence": "These data suggest that @DRUG$ are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and @DRUG$/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s7.p3",
        "sentence": "These data suggest that @DRUG$ are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/@DRUG$/omega-agatoxin VIA-resistant (presumptive Q-type) channel.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s7.p4",
        "sentence": "These data suggest that @DRUG$ are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/@DRUG$-resistant (presumptive Q-type) channel.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s7.p5",
        "sentence": "These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an @DRUG$-sensitive (N-type) channel, an @DRUG$-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s7.p6",
        "sentence": "These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an @DRUG$-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and @DRUG$/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s7.p7",
        "sentence": "These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an @DRUG$-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/@DRUG$/omega-agatoxin VIA-resistant (presumptive Q-type) channel.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s7.p8",
        "sentence": "These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an @DRUG$-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/@DRUG$-resistant (presumptive Q-type) channel.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s7.p9",
        "sentence": "These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an @DRUG$-sensitive (P-type) channel and @DRUG$/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s7.p10",
        "sentence": "These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an @DRUG$-sensitive (P-type) channel and nimodipine/@DRUG$/omega-agatoxin VIA-resistant (presumptive Q-type) channel.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s7.p11",
        "sentence": "These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an @DRUG$-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/@DRUG$-resistant (presumptive Q-type) channel.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s7.p12",
        "sentence": "These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and @DRUG$/@DRUG$/omega-agatoxin VIA-resistant (presumptive Q-type) channel.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s7.p13",
        "sentence": "These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and @DRUG$/omega-conotoxin GVIA/@DRUG$-resistant (presumptive Q-type) channel.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d58.s7.p14",
        "sentence": "These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/@DRUG$/@DRUG$-resistant (presumptive Q-type) channel.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d60.s2.p0",
        "sentence": "The serum concentration of @DRUG$ increased dramatically from 16.6 to 49.1 microg/mL when @DRUG$ was coadministered, although the daily dosage of phenytoin and other drugs had not changed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d60.s2.p1",
        "sentence": "The serum concentration of @DRUG$ increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of @DRUG$ and other drugs had not changed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d60.s2.p2",
        "sentence": "The serum concentration of @DRUG$ increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other @DRUG$ had not changed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d60.s2.p3",
        "sentence": "The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when @DRUG$ was coadministered, although the daily dosage of @DRUG$ and other drugs had not changed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d60.s2.p4",
        "sentence": "The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when @DRUG$ was coadministered, although the daily dosage of phenytoin and other @DRUG$ had not changed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d60.s2.p5",
        "sentence": "The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of @DRUG$ and other @DRUG$ had not changed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d60.s3.p0",
        "sentence": "During @DRUG$ and fluvoxamine treatment, ataxia, a typical side effect of @DRUG$, was observed.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d61.s3.p0",
        "sentence": "The pharmacokinetic variables for @DRUG$ were determined after a 1.0 mg intravenous dose of @DRUG$ in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d61.s3.p1",
        "sentence": "The pharmacokinetic variables for @DRUG$ were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral @DRUG$, 400 mg daily for 3 weeks.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d61.s3.p2",
        "sentence": "The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of @DRUG$ in each subject, before and after oral @DRUG$, 400 mg daily for 3 weeks.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d62.s4.p0",
        "sentence": "Using in situ hybridization, we observed that @DRUG$ caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist @DRUG$ but not by an atypical neuroleptic clozapine.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d62.s4.p1",
        "sentence": "Using in situ hybridization, we observed that @DRUG$ caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an @DRUG$ clozapine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d62.s4.p2",
        "sentence": "Using in situ hybridization, we observed that @DRUG$ caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d62.s4.p3",
        "sentence": "Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist @DRUG$ but not by an @DRUG$ clozapine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d62.s4.p4",
        "sentence": "Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist @DRUG$ but not by an atypical neuroleptic @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d62.s4.p5",
        "sentence": "Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an @DRUG$ @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d63.s0.p0",
        "sentence": "Differential actions of intrathecal @DRUG$ on blocking the tail-flick inhibition induced by intraventricular @DRUG$ and morphine in rats.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d63.s0.p1",
        "sentence": "Differential actions of intrathecal @DRUG$ on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and @DRUG$ in rats.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d63.s0.p2",
        "sentence": "Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular @DRUG$ and @DRUG$ in rats.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d63.s5.p0",
        "sentence": "On the other hand, intrathecal @DRUG$ (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular @DRUG$ (40 micrograms).",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d66.s1.p0",
        "sentence": "The present work involved the administration of both @DRUG$ and @DRUG$ to groups of rats, followed by determination of the homocysteine excretion rate in urine.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d68.s3.p0",
        "sentence": "Possible extrarenal mechanisms of action of @DRUG$ on @DRUG$ and iodamide transport were also examined.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d68.s3.p1",
        "sentence": "Possible extrarenal mechanisms of action of @DRUG$ on verografine and @DRUG$ transport were also examined.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d68.s3.p2",
        "sentence": "Possible extrarenal mechanisms of action of cimetidine on @DRUG$ and @DRUG$ transport were also examined.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d7.s4.p0",
        "sentence": "With combined use, clinicians should be aware, when @DRUG$ is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum @DRUG$ concentrations.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d73.s4.p0",
        "sentence": "@DRUG$, like @DRUG$, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d73.s4.p1",
        "sentence": "@DRUG$, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by @DRUG$ pretreatment.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d73.s4.p2",
        "sentence": "Methamphetamine, like @DRUG$, produced depletions of striatal dopamine but these actions were potentiated by @DRUG$ pretreatment.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d75.s3.p0",
        "sentence": "The percentage of neurons hyperpolarized by @DRUG-DRUG$ was significantly reduced when 1% but not <",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d75.s3.p1",
        "sentence": "The percentage of neurons hyperpolarized by @DRUG-DRUG$ was significantly reduced when 1% but not <",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d75.s3.p2",
        "sentence": "The percentage of neurons hyperpolarized by mu-, @DRUG-DRUG$ was significantly reduced when 1% but not <",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d76.s8.p0",
        "sentence": "@DRUG$ at 1% (m/v) in the presence of free @DRUG$ had no significant effect on the R-value of NaFlu compared to NaCMC alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d76.s8.p1",
        "sentence": "@DRUG$ at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of @DRUG$ compared to NaCMC alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d76.s8.p2",
        "sentence": "@DRUG$ at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to @DRUG$ alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d76.s8.p3",
        "sentence": "NaCMC at 1% (m/v) in the presence of free @DRUG$ had no significant effect on the R-value of @DRUG$ compared to NaCMC alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d76.s8.p4",
        "sentence": "NaCMC at 1% (m/v) in the presence of free @DRUG$ had no significant effect on the R-value of NaFlu compared to @DRUG$ alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d76.s8.p5",
        "sentence": "NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of @DRUG$ compared to @DRUG$ alone.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d79.s1.p0",
        "sentence": "Concurrent administration of @DRUG$ and @DRUG$ significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-MedLine.d79.s1.p1",
        "sentence": "Concurrent administration of @DRUG$ and didanosine significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after didanosine administration indinavir may be given safely.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d79.s1.p2",
        "sentence": "Concurrent administration of @DRUG$ and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after @DRUG$ administration indinavir may be given safely.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d79.s1.p3",
        "sentence": "Concurrent administration of @DRUG$ and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration @DRUG$ may be given safely.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d79.s1.p4",
        "sentence": "Concurrent administration of indinavir and @DRUG$ significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after didanosine administration indinavir may be given safely.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d79.s1.p5",
        "sentence": "Concurrent administration of indinavir and @DRUG$ significantly reduces the level of exposure to indinavir, but it is unclear how soon after @DRUG$ administration indinavir may be given safely.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d79.s1.p6",
        "sentence": "Concurrent administration of indinavir and @DRUG$ significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration @DRUG$ may be given safely.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d79.s1.p7",
        "sentence": "Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after @DRUG$ administration indinavir may be given safely.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d79.s1.p8",
        "sentence": "Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after didanosine administration @DRUG$ may be given safely.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d79.s1.p9",
        "sentence": "Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after @DRUG$ administration @DRUG$ may be given safely.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d79.s3.p0",
        "sentence": "Median gastric pH was significantly higher when @DRUG$ was taken after @DRUG$ administration;",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-MedLine.d82.s1.p0",
        "sentence": "The intestinal absorption of @DRUG$(@DRUG$) has been investigated in the chick by means of the in situ ligated duodenal loop technique.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d83.s15.p0",
        "sentence": "Pharmacoeconomic analyses indicate that @DRUG$ does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d83.s6.p0",
        "sentence": "In contrast, preliminary results from an 8-week controlled study suggested @DRUG$ 2 to 6 mg/day was superior to @DRUG$ 5 to 20 mg/day against positive and anxiety/depressive symptoms (p < 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d84.s4.p0",
        "sentence": "The antimicrobial combinations of @DRUG$ with four @DRUG$ resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d86.s0.p0",
        "sentence": "Pharmacokinetic interaction between single oral doses of @DRUG$ and @DRUG$ in healthy volunteers.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-MedLine.d86.s2.p0",
        "sentence": "Several clinically important interactions have previously been reported for other @DRUG$ that are metabolized by the same enzyme and for @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d86.s5.p0",
        "sentence": "RESULTS: The geometric mean (90% confidence interval) whole blood @DRUG$ area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with @DRUG$ coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.",
        "gold": "DDI-mechanism"
    },
    {
        "index": "DDI-MedLine.d86.s5.p1",
        "sentence": "RESULTS: The geometric mean (90% confidence interval) whole blood @DRUG$ area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of @DRUG$ decreased slightly, from 79 to 67 hours.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d86.s5.p2",
        "sentence": "RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with @DRUG$ coadministration, whereas the mean elimination half-life of @DRUG$ decreased slightly, from 79 to 67 hours.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d89.s0.p0",
        "sentence": "Therapeutic drug monitoring can avoid iatrogenic alterations caused by @DRUG$ (MDP)-@DRUG$ interaction.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d89.s8.p0",
        "sentence": "The data presented here demonstrate that with serial pharmacokinetic dosing of @DRUG$, the iatrogenic alteration caused by @DRUG$ therapy can be avoided.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d90.s1.p0",
        "sentence": "Evoked hind limb digital extensor tension (hoof twitch) was maintained at 40% of baseline for 1 h by @DRUG$ infusion in 7 horses anaesthetised with @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d90.s11.p0",
        "sentence": "It was concluded that, although @DRUG$ did augment the neuromuscular blockade of @DRUG$, the effect was minimal.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d93.s6.p0",
        "sentence": "The 20% v/v solution of @DRUG$ was prepared in water from a stock solution of 95% @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d94.s12.p0",
        "sentence": "The uptake inhibitors @DRUG$ and @DRUG$ (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d94.s12.p1",
        "sentence": "The uptake inhibitors @DRUG$ and desipramine (3 mumol/liter) potentiated the positive inotropic effects of @DRUG$ in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d94.s12.p2",
        "sentence": "The uptake inhibitors cocaine and @DRUG$ (3 mumol/liter) potentiated the positive inotropic effects of @DRUG$ in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.",
        "gold": "DDI-effect"
    },
    {
        "index": "DDI-MedLine.d94.s13.p0",
        "sentence": "Radioligand binding experiments using the uptake inhibitor hydrogen-3 @DRUG$ revealed a significant decrease by approximately 30% in @DRUG$ uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05).",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d95.s4.p0",
        "sentence": "@DRUG$ (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with @DRUG$ (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d95.s4.p1",
        "sentence": "@DRUG$ (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or @DRUG$ (125 mmol/l) from both lean and dietary-obese rats.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d95.s4.p2",
        "sentence": "Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with @DRUG$ (8 micromol/l) or @DRUG$ (125 mmol/l) from both lean and dietary-obese rats.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d95.s9.p0",
        "sentence": "This study indicates that: (a) the maximal effects of @DRUG$ on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of @DRUG$ in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d98.s0.p0",
        "sentence": "Behavioral responses to repeated @DRUG$ exposure in mice selectively bred for differential sensitivity to @DRUG$.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d99.s8.p0",
        "sentence": "Plasma was analyzed for @DRUG$, and urine was analyzed for @DRUG$ and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d99.s8.p1",
        "sentence": "Plasma was analyzed for @DRUG$, and urine was analyzed for tolbutamide and its two metabolites, @DRUG$ and carboxytolbutamide by means of HPLC.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d99.s8.p2",
        "sentence": "Plasma was analyzed for @DRUG$, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and @DRUG$ by means of HPLC.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d99.s8.p3",
        "sentence": "Plasma was analyzed for tolbutamide, and urine was analyzed for @DRUG$ and its two metabolites, @DRUG$ and carboxytolbutamide by means of HPLC.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d99.s8.p4",
        "sentence": "Plasma was analyzed for tolbutamide, and urine was analyzed for @DRUG$ and its two metabolites, 4-hydroxytolbutamide and @DRUG$ by means of HPLC.",
        "gold": "DDI-false"
    },
    {
        "index": "DDI-MedLine.d99.s8.p5",
        "sentence": "Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, @DRUG$ and @DRUG$ by means of HPLC.",
        "gold": "DDI-false"
    }
]